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Abstract 
The generation and spread of misfolded protein aggregates is common to all 
Protein Misfolding Diseases (PMDs) including but not limited to Alzheimer’s, 
Parkinson’s and Prion disease. Yet despite this common feature, the early 
mechanisms underpinning the apparent perturbation in protein handling and 
processing in such conditions remain poorly understood. Research in our lab 
has previously shown protein misfolding may be seeded and supported in 
different ways in the brain. Mice homozygous for the P101L mutation in murine 
PrP (101LL) are capable of supporting protein misfolding and amyloid plaque 
formation after challenge with pre-formed PrP fibrils and wild type mice of the 
same genetic background do not, and appear to be capable of curtailing this 
accumulation of abnormal protein in vivo. Thus, both mouse lines provided 
ideal tools to investigate early cellular and molecular responses to abnormal 
PrP fibril challenge. PMDs occur in vivo with a regional dependant progression 
however; such investigations are more amenable to controlled initiation and 
visualisation in vitro. Therefore, primary neuronal hippocampal cell cultures 
were generated from each line (101LL and WT) and were thoroughly assessed 
at the cellular level. Comparative molecular analysis of these cultures and in 
vivo hippocampal tissue from both WT and 101LL lines was carried out and 
transcriptome analysis confirmed a broadly comparable global expression 
profile at a basal level between in vivo, in vitro and genotype. Interestingly, this 
suggests that the genotype specific differential protein misfolding responses 
are therefore likely to be the result of regulatory cascades initiated after 
inoculation. To examine this at the cellular level, cultures were then challenged 
with fluorescently labelled recombinant PrP fibrils. 
 
Fibrils were directly interacting with PrPC on neuronal surfaces but did not 
cause neurotoxicity. However, post-synaptic marker PSD-95 was significantly 
reduced in 101LL cultures suggestive that 101LL neurons were more 
susceptible to fibril insult than WT. Microglial cells were activated post             
fibril challenge in both genotypes. This generic response was possibly to limit 
neuronal damage and promote fibril degradation through phagocytosis.  
iv 
 
Transcriptome analyses supported these observations and showed an 
increase in expression of genes associated with phagocytosis was occurring 
after fibril challenge in both genotypes. Hypertrophic astrocytes and an 
increase in expression of genes associated with astrocyte differentiation and 
development was only evident in WT fibril-challenged cultures indicating 
differential glial responses were occurring between genotypes. Intracellular 
labelling showed localisation with endosomes and lysosomes in WT cells 
indicating an endolysosomal pathway was operative however; localisation in 
101LL cells was primarily in endosomes indicating an impairment in abnormal 
protein degradation pathways was occurring in 101LL fibril-challenged 
cultures. Transcriptomic analysis identified reduced gene expression of 
lysosomal associated genes Laptm5 and Ctsz in 101LL fibril-challenged 
cultures, supporting endolysosomal processing was reduced in this genotype. 
Additional transcriptomic profiles obtained post-fibril challenge showed an 
increase in gene expression in WT cultures associated with endocytosis, 
macrophage engulfment, immune and defence response and ER-associated 
misfolded protein catabolic processes none of which were induced in 101LL 
fibril-challenged cultures. These analyses suggest a dysfunction of multiple 
mechanisms may be associated with an inability to clear misfolded protein. 
 
These data provide key information on pathways and cellular mechanisms 
involved in either clearance of misfolded protein or initiation of amyloid 
formation. Identifying these pathways will provide a number of possible test 
targets with the potential of impacting diagnosis and/or intervention in PMD’s 
such as AD, PD and prions. 
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Lay Summary 
Protein misfolding in the brain can lead to its accumulation into structures 
referred to as amyloid plaques. These plaques are a hallmark of many 
neurodegenerative diseases including but not limited Alzheimer’s, Parkinson’s 
and Prion (BSE/Mad Cow) diseases. However, the formation of amyloid 
plaques are still poorly understood. To provide more insights into this poorly 
understood area a number of objectives were carried out as listed below.  
1) To model the brain, cells from living brain tissue were obtained and were 
kept living and functional in dishes. This is known as primary neuronal 
culturing. These cultures provided easily accessible models for looking at 
protein misfolding. Such primary cultures were made from two different types 
of mouse brain, one which is susceptible to protein misfolding (here called 
101LL), and another which is not (here called WT). Thus, a comparison would 
provide ideal models for studying protein misfolding interactions with cells. 
 
2) To initiate protein misfolding in our cell cultures we need to add a “seed” 
(here called fibrils - a collection of artificially produced misfolded protein) which 
once added to the cells will encourage other protein from the cell to interact 
and accumulate around the fibril thereby “growing” a plaque. Thus, fibrils were 
made and were labelled with a fluorescent marker to allow visualisation of 
fibrils once added to primary cell cultures.  
 
3) By doing this in both WT and 101LL cultures the following questions can be 
addressed; how do the fibrils get into the cells, where they go, how do they 
change and importantly how does the composition (the molecular recipe) of 
the cell change in response? 
 
The data generated in this thesis enhances our understanding and knowledge 
of amyloid plaque formation, distribution and the cellular responses, which are 
important for helping and hindering this process. Such knowledge will be 
essential for the development of potential therapeutics for treatment of 
misfolded protein diseases. 
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1.1 Protein Misfolding Diseases (PMDs) 
 
Proteins are essential constituents of cells and tissues in all living organisms 
and correct formation and confirmation of these complex macromolecules is 
essential. Protein folding involves multiple chaperone systems where 
dysfunction in any of these pathways can provide many opportunities for error 
(Valastyan and Lindquist 2014). The mechanisms by which failures occur in 
protein quality systems remain elusive however, factors such as defective or 
incomplete translation, post-translational misfolding, mutations, environmental 
or intracellular stressors can all result in the generation of misfolded abnormal 
protein (Gregersen and Bross 2010). Misfolding of a protein jeopardises its 
biological function, and failure to degrade such abnormal protein 
conformations encourages the formation of aggregates resistant to biological 
clearance resulting in the triggering of a cascade of events leading eventually 
to disease (Soto 2003).  
 
Protein misfolding diseases (PMDs) such as Alzheimer’s disease (AD), 
Parkinson’s disease (PD), Huntington’s disease (HD) and transmissible 
spongiform encephalopathies (TSEs) or prions are a broad group of 
neurodegenerative disorders associated with the accumulation of abnormally 
folded proteins in the brain (Knowles, Vendruscolo, and Dobson 2014; Braak 
et al. 2003; Caughey and Lansbury 2003; Forloni et al. 2002; Bucciantini et al. 
2002; Lazarov et al. 2002). These abnormal aggregates are common to all 
PMDs and once formed, encourage further misfolding of the native host 
protein, eventually leading to neurotoxicity in the brain. Additionally, these 
aggregates can accumulate in specific areas of the brain for example, in one 
form of prion disease (Gerstmann-Sträussler-Scheinker disease) and AD, the 
hippocampus and cerebral cortex are commonly targeted areas (Knowles, 
Vendruscolo, and Dobson 2014; Caughey and Lansbury 2003; Bucciantini et 
al. 2002; Braak, Braak, and Bohl 1993). It has recently been proposed that AD 
and several other neurodegenerative diseases may spread through a cross 
seeding mechanism or a “prion-like” mechanism.  
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The cross seeding mechanism proposes that seeds composed of one protein 
can accelerate a second misfolding process in an unrelated protein (Morales 
et al. 2010). The term “prion-like” refers to the introduction of a misfolded 
protein seed, which acts as a template for the conversion, and misfolding of 
the normal host protein present resulting in the cell-to-cell spread of protein 
aggregation in the tissue. Evidence supporting these “prion-like” mechanisms 
comes from studies using pre-formed amyloid seeds from AD patients as 
inoculum which were shown to accelerate plaque formation in the brains of 
amyloid precursor protein (APP) mice (Meyer-Luehmann et al. 2006). Similar 
results were observed in models of PD (Oueslati, Ximerakis, and Vekrellis 
2014) and Amyotrophic Lateral Sclerosis (ALS) (Ayers et al. 2016). Converse 
to these studies there is no epidemiological data or documentation to suggest 
neurodegenerative disorders such as AD, PD or ALS diseases are actually 
infectious and only TSE diseases appear to be transmissible (Irwin et al. 2013; 
Peters, Ghasemi, and Brown 2015). 
 
The actual role of protein aggregates in neurodegenerative diseases is 
unclear, and early mechanisms involved in abnormal protein processing are 
poorly understood (Moreno-Gonzalez and Soto 2011). Due to this lack of 
understanding it is widely debated whether abnormal protein deposits are toxic 
to neurons or if they are generated as a protective mechanism to sequester 
smaller soluble forms of misfolded protein (Wolfe and Cyr 2011; Treusch, Cyr, 
and Lindquist 2009; Haass and Selkoe 2007). These soluble assemblies of 
misfolded protein which have a high β-sheet content are referred to as 
oligomers (Winner, Kohl, and Gage 2011; Simoneau et al. 2007; Quist et al. 
2005; Kristiansen et al. 2005; Mucke et al. 2000; Lue et al. 1999; McLean et 
al. 1999; Kuo et al. 1996), and can cause interference with normal cellular 
functions (Wolfe and Cyr 2011). For example low molecular weight oligomers 
have been detected in the brains of AD patients (Gong et al. 2003; Roher et 
al. 1996) and in the lysates of cultured cells expressing the amyloid β (Aβ) 
protein precursor (Walsh et al. 2000).  
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Transgenic mice (overexpressing human mutant APP and a triple human tau 
mutation) develop deficits in cognitive impairment and cell function well before 
the significant accumulation of amyloid plaques, suggesting the severity of 
cognitive impairment in AD correlates with the abundance of small oligomers 
rather than with amyloid burden (DaRocha-Souto et al. 2011). Our group, 
however, has shown that oligomeric forms of misfolded protein inoculated into 
the brains of mice have no neurotoxic effect on the brain (Barron et al. 2016), 
highlighting the fact that the relationship between misfolded protein and 
neurotoxicity is still poorly understood. Thus, further investigation of these 
“prion-like” molecular mechanisms, and interactions in the initiation and 
possible misfolded protein spread, will be carried out here using well-
characterised prion models. This will provide valuable information on 
pathological mechanisms that may be shared by the most common forms of 
neurodegeneration, and so facilitate the development of new therapeutics.  
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1.2 TSEs and PrP protein 
 
1.2.1 TSE Diseases 
 
TSE’s are infectious, fatal neurodegenerative diseases, which include 
Gerstmann-Sträussler-Scheinker (GSS), Creutzfeldt Jacob disease (CJD), 
Fatal Familial Insomnia (FFI) in humans and scrapie and Bovine Spongiform 
Encephalopathy (BSE) in animals (Table 1.1). It has been proposed that TSE 
diseases can be infectious, genetic or sporadic (Wechselberger et al. 2002; 
Harris 1999; Prusiner 1998; Prusiner 1993) and the disease pathology has 
been shown to involve the conversion of the normal cellular prion protein 
(PrPC) to an insoluble aggregated isoform (PrPSc) (Prusiner 1996). Sporadic 
CJD represents the most frequent type of human prion disease (85%) with a 
worldwide incidence of 1-2 cases per million per year and genetic prion 
diseases caused by mutations in the prion protein represent 10-15% (Gelpi et 
al. 2015). Additionally, the PRNP polymorphic residue at codon 129 (ATG-
methionine to GTG-valine, M129V) has been studied extensively in the prion 
field where 129 homozygosity is considered a risk factor for human prion 
disease (Bishop et al. 2009). Interestingly, variations in genotype frequencies 
in relation to geographical region occur for example MM and MV frequencies 
are approximately 40-50% in most countries however in Japan frequencies of 
MM are 92% and MV 8% (Bishop et al. 2009). The prion hypothesis predicts 
that PrPSc alone is the infectious agent of TSE, and is able to seed the 
conversion of the host glycoprotein PrPC to produce additional protease-
resistant forms during disease (Prusiner 1982). These abnormal forms of 
protein aggregates exist in tissue in the form of amyloid deposits (Ross and 
Poirier 2004).  
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The mechanisms involved in PrPC to PrPSc conversion are poorly understood 
and may involve several intracellular compartments associated with the 
endolysosomal system and the Trans-Golgi network (TGN) (Beranger et al. 
2002; Magalhaes et al. 2002; Borchelt, Taraboulos, and Prusiner 1992; 
Taraboulos et al. 1992; Caughey et al. 1991), recycling endosomes 
(Marijanovic et al. 2009) and multivesicular body vesicles (MVBs) (Yim et al. 
2015). Additionally, conversion may also occur at the plasma membrane 
(Goold et al. 2011) or even at lipid raft transmembrane domains (Rouvinski et 
al. 2014; Taylor and Hooper 2006). 
 
TSE Disease Affected Species 
Gerstmann-Sträussler-Scheinker (GSS) Human 
Creutzfeldt-Jakob Disease (CJD) Human 
Kuru Human 
Bovine Spongiform Encephalopathy (BSE) Cattle 
Scrapie Sheep and goats 
Chronic Wasting Disease (CWD) Deer, Elk and Moose 
Feline Spongiform Encephalopathy (FSE) Cats 
 
Table 1.1: TSE diseases are found across multiple species.  
 
TSEs are characterised by lengthy asymptomatic incubation periods that can 
proceed into clinical symptoms, which include behavioural changes, cognitive 
impairment and insomnia. TSE studies involving mice clinical progression 
signs include tremor, ataxia, rigidity of tail and loss of condition. 
Neuropathological profiling including examining vacuolation of the brain, 
gliosis, synaptic degradation, abnormal deposition of misfolded PrP and 
neuronal loss are all quantified post-mortem to determine disease progression. 
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1.2.2 Normal Cellular PrP (PrPC) 
 
PrPC is a cellular 38kDa glycoprotein encoded by the PRNP gene on the short 
arm of chromosome 20 in humans and Prnp on chromosome 2 in mice (Figure 
1.1). Full length PrPC is expressed most abundantly in the brain with the 
highest levels in neurons (Westergard, Christensen, and Harris 2007; 
Bendheim et al. 1992). However, PrPC is also detectable in spleen, liver, 
kidney, heart, testes, gastrointestinal tract and blood platelets (MacGregor 
2001; Li et al. 2000).  
 
A 
 
 
 
B 
 
 
 
Figure 1.1: Schematic illustrations of WT mouse Prnp and PrP protein. (A) 
Prnp gene retains 3 exons, with the open reading frame (ORF) in exon 3. 
Adapted from (Shmerling et al. 1998; Moore et al. 1995). (B) Schematic 
diagram of murine PrPC adapted from (Gill et al. 2000; Moore et al. 1999). 
 
 
Murine PrPC is a 253 amino acid protein with a biosynthetic pathway that is 
similar to that of other membrane-bound and secreted proteins including 
synthesis in the rough endoplasmic reticulum (ER), followed by transportation 
to the Golgi, on its way to the cell surface (Harris 2003).  
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Within the ER, PrPC undergoes several post-translational modifications 
including cleavage of the N-terminal signal peptide, addition of N-linked 
oligosaccharide chains at two sites (180 and 196) where differential 
glycosylation results in un-, mono-, or di-glycosylated states of PrPC being 
produced (Xanthopoulos et al. 2009), formation of a single disulphide bond, 
and attachment of the glycosylphosphatidylinositol (GPI) anchor following 
cleavage of the C-terminal hydrophobic peptide (Harris 2003; Haraguchi et al. 
1989; Turk et al. 1988; Stahl et al. 1987). PrPC locates to the outer leaflet of 
the lipid bilayer in regions rich in cholesterol within the cell membrane known 
as lipid rafts, where the protein is anchored via its GPI anchor present at the 
carboxyl-terminus (Harris 2003; Stahl et al. 1993; Taraboulos et al. 1995). 
PrPC structure consists of a flexible N-terminal, random coil region that is 
unstructured and contains five copies of an octapeptide repeat region (Figure 
1.1). The C-terminal globular domain of PrPC is comprised of three α-helices 
which make up 42% of the protein, and only 3% β-sheet structure (Pan et al. 
1993). α-helixes 2 and 3 are stabilised by the presence of a disulphide bond 
that forms between cysteine residues at amino acids 179 and 214 in murine 
PrPC (Riesner 2003). Recycling of PrPC occurs via an endocytic pathway, 
where the protein is transported back into the cell by endosomes via multiple 
mechanisms that involve clathrin-coated pits and caveolae (Taylor and Hooper 
2006; Peters et al. 2003). After internalisation, which can be influenced by the 
GPI anchor of PrPC (Kaneko et al. 1997), into early endosomes, it is either 
recycled back to the plasma membrane via recycling endosomes or is routed 
to the lysosomes for degradation via late endosome/multivesicular bodies 
(Campana, Sarnataro, and Zurzolo 2005). The structures of human, murine, 
bovine and hamster PrPC as determined by Nuclear Magnetic Resonance 
(NMR) are remarkably similar (Wüthrich and Riek 2001). 
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Figure 1.2: Structure of murine recombinant PrP as determined by NMR.         
C-terminal domain (121-231) comprises most structured region with three        
α-helices and two β-strands. Amino acids (23-120) make up the random coil of 
the protein. Sourced from (Riek et al. 1997).  
 
 
1.2.3 Function of Cellular PrP (PrPC) 
 
The cellular isoform PrPC is expressed most abundantly in the brain (Zomosa-
Signoret et al. 2007). Early in embryogenesis (D9) it is evident that mouse 
brains express PrPC mRNA and as development continues, the level of PrP 
mRNA increases (Manson et al. 1992). In the adult murine central nervous 
system, PrPC and its mRNA are widely distributed with specific concentrations 
in neocortical, hippocampal and spinal cord neurons (Kretzschmar et al. 1986). 
Despite extensive research, the precise function of PrPC is not yet known. 
Proposed roles include cell signalling, formation and maintenance of 
synapses, promotion of neuronal growth and survival, protection against 
oxidative stress and involvement in cellular uptake or binding of copper ions 
(Brown 2003). Other studies suggest that PrPC plays an important role in the 
modulation of neuronal survival, both in vivo (Harris 2003; Walz et al. 1999) 
and in vitro (Chiarini et al. 2002; Kuwahara et al. 1999) supported by 
experimental data showing that PrPC is a specific receptor for the C-terminal 
domain of the γ-1 chain of extracellular matrix laminin. After binding to the 
laminin γ-1 chain neuronal growth is promoted through an unknown 
intercellular signaling pathway (Graner, Mercadante, et al. 2000a; Graner, 
Mercadante, Zanata, Martins, et al. 2000).  
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Interestingly both the 37kDa laminin receptor precursor and the 67kDa laminin 
receptor have also been identified as endocytic receptors for PrPC on the cell 
surface that mediate the internalisation and recycling of PrPC through clathrin 
coated pits (Gauczynski et al. 2001; Rieger et al. 1997). PrPC was also shown 
to be involved in the fyn kinase pathway where the protein binds to the Neural 
Cell Adhesion Molecule (NCAM) promoting recruitment of NCAM to lipid-rafts 
which also promoted neurite outgrowth further supporting a role for PrPC in 
neuronal survival (Santuccione et al. 2005). Other studies have demonstrated 
interactions between PrPC and cell-surface stress inducible protein 1 (STI1) 
which mediates neurogenesis and neuroprotection of hippocampal neurons 
(Zanata et al. 2002). This protective effect was shown to be dependent on the 
cAMP/protein kinase A (PKA) signalling pathway where PrPC was described 
to function as a trophic receptor (Chiarini et al. 2002).  
 
PrP null mice (Prnp-/-) have a grossly normal neurological phenotype, however, 
they do have subtle abnormalities in synaptic transmission, hippocampal 
morphology, circadian rhythms, cognition and seizure threshold (Zomosa-
Signoret et al. 2007). Prnp-/- mice are resistant to scrapie infection (Manson, 
Clarke, Hooper, et al. 1994; Bueler et al. 1993; Prusiner 1993) indicating an 
essential role for the presence of normal cellular PrPC to establish TSE 
disease. Furthermore, sub-passage studies of Prnp-/- mouse brain into wild-
type CD-1 mice indicated no transmission of asymptomatic disease 
demonstrating that the infectious agent had not been replicated during the 
primary passage (Prusiner 1993). Additionally heterozygous mice (Prnp-/+) 
were shown to have enhanced resistance to disease, with extended incubation 
periods to clinical disease indicating a dose-dependent effect of Prnp 
expression. The heterozygous expression of Prnp-/+ did not affect the 
distribution of either TSE associated vacuolation or PrPSc deposition observed 
at the clinical stage of the disease (Manson, Clarke, McBride, et al. 1994). The 
level of PrPC expression therefore influences the length of incubation period in 
a dose-dependent manner and thus, it can be concluded that the host PrPC is 
required to support TSE infection. Other studies demonstrated Prnp-/- mice to 
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be more resistant to the neurotoxic effect of Aβ oligomers than WT mice in 
both in vivo and in vitro models (Kudo et al. 2012). They found that blocking 
Aβ/ PrPC binding using anti-PrP antibody or competitive PrP peptide rescues 
Aβ oligomer-induced neuronal cell death suggesting PrPC is an essential co-
factor in mediating Aβ oligomer neurotoxicity. Conversely, PrPC was shown to 
be capable of binding and detoxifying Aβ oligomers (Biasini et al. 2011). 
Collectively these data demonstrate a role for PrPC in Aβ oligomer-induced 
neurotoxicity however; the precise mechanisms remain to be fully elucidated. 
 
1.2.4 Prion Hypothesis 
 
Many hypotheses have been put forward to explain the disease mechanisms 
of TSEs. However over-time, and in correlation with numerous key 
observations carried out in the TSE scientific field, the prion hypothesis 
proposed by Stanley Prusiner has become the most accepted paradigm (Kuhn 
1996; Prusiner 1982). This hypothesis states that the transmissible agent in 
TSE disease is a misfolded protein called a “prion”, a term derived from its 
description as being a proteinaceous infectious particle, which is able to 
reproduce itself in the apparent absence of nucleic acid (Legname et al. 2004; 
Prusiner 1998). The infectious agent according to Prusiner’s hypothesis is 
composed largely, if not exclusively, of a single kind of protein molecule named 
the protease-resistant, conformationally altered prion protein (PrPSc) which is 
resistant to inactivation by most procedures that modify nucleic acids (Prusiner 
1982). This abnormal form of protein acts as the infectious agent in TSE 
disease, catalysing the conversion of the normal cellular PrPC into the 
misfolded PrPSc form. Other key observations in support of this hypothesis 
included analysis of PrPSc concentrations in relation to titre of infection whereby 
results demonstrated that the majority of PrPSc was found in sucrose fractions 
with the highest infectivity titre (McKinley, Bolton, and Prusiner 1983). 
Furthermore, scrapie-associated fibrils (SAF), with amyloid-like properties 
identified from murine and hamster TSE models were found to be associated 
with infectivity (Hilmert and Diringer 1984; Merz et al. 1981). Post-mortem 
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analysis of tissue from infected animals using anti-SAF (Scrapie-associated 
fibril) antibodies also displayed accumulation of disease-associated PrP 
deposition in the brain (Farquhar, Somerville, and Ritchie 1989; McBride, 
Bruce, and Fraser 1988). All these forms of PrPSc and SAF have been 
identified from TSE-infected brain tissue where the prion hypothesis suggests 
PrPSc is the infectious agent of TSE disease (Kascsak et al. 1985; Merz et al. 
1981).  
 
In contrast studies carried out in our laboratory have questioned the correlation 
between PrPSc levels and titre of infectivity, showing that tissues containing 
minimal proteinase K-(PK) resistant PrP (PrP-res) can be infectious and harbour 
high titres of TSE infectivity (Barron et al. 2007), and that accumulation of prion 
protein in the brain may not be a reliable marker of these transmissible 
diseases (Piccardo et al. 2007). Additionally a separate study identified the 
presence of low levels of detergent insoluble aggregated PrP and PrP-res in 
uninfected human brains using sedimentation and size exclusion 
chromatography (Yuan et al. 2006) indicating abnormal PrP levels may be 
present in all brains but at very low levels. This highlights the requirement that 
further work must be carried out to enhance our overall understanding of these 
neurodegenerative diseases.  
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1.3 Altered forms of PrPC and amyloid fibril generation 
 
1.3.1 Altered isoforms of PrP 
 
PrPC and PrPSc have been shown to have the same primary structure (Stahl 
et al. 1993). Differences are found in the secondary, tertiary and quaternary 
structures where the abnormal PrPSc has an increase in β-sheet content (43%) 
and less α-helix content (30%) than the protein in its normal conformation 
described previously in Section 1.2.2 (Pan et al. 1993). This conformational 
change is thought to occur through a seeded-nucleation model where PrPSc 
acts as the template for the conversion of native PrPC to an abnormal form 
(Kocisko et al. 1994) which is protease-resistant, and insoluble in non-
denaturing detergents. After protease treatment, normal PrPC (33–38 kDa) is 
completely digested (Figure 1.3) however, PrPSc (27–30 kDa) is partially 
resistant to the enzyme with only 62 N-terminal amino acids being cleaved, 
leaving a core fragment of 141 amino acids (Jarrett and Lansbury 1993; Oesch 
et al. 1985). Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis 
(SDS-PAGE) followed by immunoblotting of PK-digested brain tissue detects 
PrPSc banding and can be used to diagnose TSE infected tissues (Towbin, 
Staehelin, and Gordon 1979). PrPSc profiles are generated based on the 
relative amounts and molecular weights of the diglycosylated, 
monoglycosylated and unglycosylated forms of the protein and can inform on 
disease type/agent (Figure 1.3). These specific profiles of glycoform ratios and 
molecular weights have supported the probability of a bovine origin for variant 
Creutzfeldt-Jakob disease (vCJD), a form of CJD disease first reported in the 
UK in 1996 (Will et al. 1996). Profiles from sporadic or iatrogenic forms of CJD 
are quite different from those of vCJD and BSE (Hill et al. 1997; Collinge et al. 
1996). These are examples of how differences in abnormal protein tertiary 
structure and post-translational modifications can be used to determine the 
nature and origin of prion diseases.  
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Figure 1.3: Glycosylation profiles obtained from mouse brain homogenates. 
(A-B) Uninfected mouse brain and (C-D) Scrapie ME7 infected mouse brain    
-/+ proteinase K treatment. Sodium Dodecyl Sulphate Polyacrylamide Gel 
Electrophoresis (SDS-PAGE), antibody7A12. 
 
 
1.3.2 Different types of protein conformations 
 
Many conformational states of native proteins may be present in a biological 
environment at any one time including amyloid (Figure 1.4). Amyloid is an 
extremely well structured aggregate of abnormal protein. The processes or 
pathways leading to amyloid formation are still poorly understood however, 
accumulation of these amyloid aggregates is a hallmark of many 
neurodegenerative disorders such as TSEs (prion protein), PD (α-Synuclein), 
ALS (superoxide dismutase) and AD (amyloid β peptide). From a 
morphological point of view protein aggregates or amyloid may be 
differentiated into two types; amorphous aggregates which consist mainly of 
disordered polypeptide chains or amyloid fibrils which are highly organised 
with repetitive structures where all polypeptides adopt a common fold 
(Invernizzi et al. 2012). Furthermore, amyloid fibrils, or plaques, are used to 
describe structures formed extracellularly, whereas the term intracellular 
inclusions refers to fibrils formed inside the cell (Westermark et al. 2005). 
Amyloid-associated disorders have a major impact on the elderly regarding 
degenerative pathologies and therefore are of huge concern in a rapidly aging 
world. Thus, understanding mechanisms associated with amyloid fibril 
formation, interactions in the brain or the failure of proteins to adopt or remain 
in their native functional conformational state is vital to progress our 
understandings of neurodegenerative diseases.   
36kDa 
20kDa 
    A             B                C             D 
    -            +             -            + 
Diglycosylated 
Monoglycosylated 
Unglycosylated 
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Figure 1.4: Schematic of the many complex conformational states that may be 
adopted from native protein. In a healthy biological environment, all of these 
different conformational states (refolding, ordered or disordered aggregate 
formation, and degradation) are constantly regulated using machinery such as 
molecular chaperones, degradatory systems, and quality control processes. 
Failure of these mechanisms triggers abnormal events, which in turn disturb 
factors such as axonal transport, and ion balance eventually leading to cell 
death. Adapted from (Chiti and Dobson 2006). 
 
The nucleation-polymerisation model shown in Figure 1.5 describes how the 
fibril amyloid assembly process occurs in vitro via nucleated polymerisation, 
where the initial nucleation step begins slowly. However after nucleation, 
polymerisation occurs more rapidly as the folding intermediate is capable of 
serving as a template (also known as a seed) for further conformational fibril 
growth (Jarrett and Lansbury 1993). This growth involves association of either 
monomers or oligomers with the nucleus (Chiti and Dobson 2006). The time 
required for the nuclei to form from soluble species (monomers) is referred to 
as the thermodynamically disfavoured lag phase and this time can be 
significantly shortened and ultimately abolished by the addition of a pre-formed 
nucleus or seed. Polymerisation and fibril growth is referred as the exponential 
phase, where eventually the exhaustion of monomers leads to a saturation 
phase where no more soluble species can associate to the ends of preformed 
fibrils resulting in fibril maturation (Invernizzi et al. 2012). Remarkably, it seems 
that all proteins which form amyloid may progress through the same 
intermediate steps (Kayed et al. 2003).  
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Figure 1.5: Nucleation-polymerisation model/ kinetics.  Thioflavin (ThT) assays 
are used to measure change in fluorescence intensity of ThT upon binding to 
amyloid fibrils. Congo red binding, X-ray crystallography and transmission 
electron microscopy are other alternative techniques utilised for the 
examination of amyloid. Adapted from (Nilsson 2004). 
 
 
Not all amyloid is pathological. Functional amyloid exists and is involved in 
many different biological processes, which can be physiologically useful for 
specific and specialised biological functions (Table 1.2). However, this is a 
highly regulated assembly process and if not tightly controlled could result in 
the occurrence of protein conformation associated diseases.  
 
 
Protein Organism Function 
Premelanosome 
protein (Pmel17)  
Homo 
sapiens 
Forms inside melanosomes, 
binds and orients reactive 
melanogenic precursors 
Curlin Escherichia 
coli 
Colonise inert surfaces and 
mediate binding to host proteins 
Neuron-specific 
isoform of Cytoplasmic 
Polyadenylation 
Element Binding 
protein (CPEB) 
Aplisia 
californica 
Promotes long-term 
maintenance of synaptic 
changes associated with 
memory storage 
 
Table 1.2: Naturally nonpathological amyloid-like fibrils with specific functional 
roles (Chiti and Dobson 2006; Kocisko et al. 1994).   
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1.4 PrP P101L Mutation and GSS 
 
1.4.1 Gerstmann-Sträussler-Scheinker (GSS) Disease 
 
Human prion diseases can be hereditary or acquired or can even arise 
sporadically. It is estimated that between 5-15% of human prion diseases are 
inherited and linked to disease-specific mutations in the prion protein gene 
(PRNP). Furthermore, the methionine/valine homozygosity at the polymorphic 
codon 129 of PRNP may cause a predisposition to diseases such as sporadic 
and iatrogenic CJD (Salvatore et al. 1994; Brown et al. 1994; Palmer et al. 
1991; Collinge, Palmer, and Dryden 1991). This association between codon 
129 polymorphism and accelerated pathogenesis is not evident in familial CJD 
patients (codon E200K mutation) or in GSS patients with the codon P102L 
mutation (Hainfellner et al. 1995; Gabizon et al. 1994; Barbanti et al. 1994). 
GSS is defined as a rare autosomal dominant disorder characterised clinically 
by progressive ataxia followed by a late onset of dementia (Liberski 2012). 
Patients diagnosed with GSS are normally between the ages of 20-60 years 
old where disease duration can range from a few months to a few years. GSS 
is characterised by the presence of multi-centric amyloid plaques derived from 
abnormal PrP and is also distinguished from other human TSEs using 
immunoblot analysis to show the presence of N- and C-terminal truncated 
PrPSc fragments ranging between 6 and 10 kDa and variable numbers of bands 
of higher molecular weight (Ferrer et al. 2011). The majority of cases of GSS 
found in Japan (Doh-ura et al. 1989), Britain (Hsiao et al. 1989), Italy 
(Kretzschmar et al. 1992), and France (Laplanche 1994) are linked to the 
P102L mutation in PRNP, and result in the substitution of proline (CCG) by 
leucine (CTG), creating an additional DdeI restriction endonuclease site within 
exon 3 of the PRNP gene. One study involving a large Italian family affected 
by this GSS P102L mutation, showed family members to have remarkable 
phenotypic variability of the disease with no correlation between clinical 
presentation and the codon 129 genotype (Barbanti et al. 1996).  
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Conversely, others have proposed a genotype-phenotype relationship with the 
genetic polymorphism at residue 129 between methionine and valine (Bianca 
et al. 2003), suggesting strain specific differences in clinical manifestation were 
evident.  Several further mutations in PRNP are also causative of GSS disease 
namely P102LM, P105LV, A117VV, G131MV, Q160X, H187RV, F198SV, 
D202NV, Q212PM, Q217RV, Y218N, Y226X, Q227X and M232T (ValineV, 
MethionineM on same allele) (Imran and Mahmood 2011; Liberski and Budka 
2004). Transmission experiments of P102L GSS disease to nonhuman 
primates have shown efficient transmission of infectivity to primates including 
squirrel monkeys, spider monkeys and marmosets (Baker et al. 1990; Tateishi 
et al. 1988). However to date no cases of GSS disease caused by human to 
human transmission have been reported (Liberski 2012).  
 
Genotype Age of 
onset 
Duration 
(Years) 
Clinical/Pathological signs 
P102L-
129M 
30-62 1-10 
Dementia, amyloid deposition in 
cerebellum, spongiosis, neuronal 
loss and astrogliosis, no 
neurofibrillary tangles (NFT’s) 
P102L-
129M- 219K 
31-34 4 
Fewer plaques and no spongiosis 
(comparison to above) 
P102L-129V 33 12 
Seizures, gait difficulties, 
widespread plaques, no 
dementia/spongiosis 
P105L-129V 40-50 6-12 
Late dementia, amyloid plaques, 
neuronal loss, gliosis, no 
spongiform changes/ NFT’s 
F198S-
129V* 
34-71 3-12 
More extensive amyloid deposits 
(than P102L-129M-219K). NFT’s in 
cerebral cortex, discreet spongiosis 
*Phenylalanine (TTC) to serine (TCC) substitution at codon 198 on a Val 129 
allele. 
 
Table 1.3: Genotype and corresponding phenotype of inherited GSS diseases. 
Adapted from (Mattson 2000).  
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1.4.2 101L Mutation 
 
A number of different transgenic murine models have been produced to model 
the P102L (proline to leucine, corresponding mutation in murine PrP is P101L) 
point mutation which is the most common point mutation present in human 
GSS disease (Table 1.4).  
 
Transgenic 
Identification 
PrPC 
Expression 
rate 
Spontaneous 
disease 
Reference 
MoPrP-P101L 
Tg174 (64 times 
gene copy) 
8-fold 
higher than 
wild-type 
Yes, ataxia, 
low levels of 
PrPSc, 
absence of 
plaques 
(166d) 
(Telling et al. 1996; 
Hsiao et al. 1991; 
Hsiao et al. 1990) 
101LL (Produced 
by gene 
targeting) 
WT levels 
of mutant 
protein 
No signs of 
neurological 
disease 
(900d) 
 
(Manson et al. 1999) 
Tg196/Prnp
-/-         
(9 copies of the 
transgene) 
2-fold 
higher than 
wild-type 
Yes in aged 
400-600d 
mice 
(Tremblay et al. 2004; 
Kaneko et al. 2000; 
Telling et al. 1996; 
Hsiao et al. 1994) 
Tg(GSS)2*,6*,12* 
22* 
0.5-1, 3, 6, 
and 12 fold 
respectively 
Yes, (except 
Tg(GSS)2 line 
which only 
expresses 2 
copies of the 
transgene 
(Nazor et al. 2005) 
 *Copies of transgene expressed 
 
Table 1.4: Examples of some of the transgenic murine mouse lines developed 
to further our understanding of GSS disease. 
 
 
 
20 
 
As shown in Table 1.4, disease was only noted in mice overexpressing PrPC 
and no signs of disease were reported in knock-in (gene replacement) 101LL 
transgenic mice. This may be due to the fact that 101LL mice were produced 
using gene targeting (not random insertion), where the 101L mutation was 
introduced into the endogenous murine Prnp gene in 129/Ola (WT) mice 
resulting in expression of PrPC at the same levels as WT mice (Manson et al. 
1999). This double replacement gene targeting method effectively generated 
101LL transgenic mice (Manson et al. 1999; Moore et al. 1995).  
 
All mammalian prion protein sequences (Figure 1.6) show a great deal of 
similarity and this homology could facilitate the transmission of prion disease 
between species.   
 
 
Figure 1.6: Alignment of PrP amino acids from elk, deer, sheep, bovine, rabbit, 
human and mouse species. Original source Pandeya et al. 2010; ISSN: 0976-
1683; alignment with ClustalW. 
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1.5 Synthetic protein, cellular interactions and processing pathways 
 
1.5.1 In vitro generated recombinant PrP and challenge experiments 
 
Recombinant PrP can be produced in Escherichia coli and consequently, can 
be used to investigate the structure of PrPC (Makarava and Baskakov 2008). 
In addition, various treatments using Guanidine-HCL (Gdn-HCl) and urea can 
change this predominantly α-helical structure into a structurally altered isoform 
that can be used to study the disease causing properties of refolded PrP in the 
brain in the absence of additional co-factors. Bacterially expressed 
recombinant PrP does however lack post-translational modifications found in 
eukaryotic PrPC as it is not glycosylated and lacks a GPI anchor (Kirby et al. 
2003). Previous work by our group examined whether in vitro generated 
misfolded fibril recombinant PrP was actually infectious in vivo and if it was 
capable of seeding further misfolded protein in the brain (Barron et al. 2016). 
To investigate this various forms of α-monomeric, β-oligomeric and fibril 
amyloid (both 101L and WT recombinant PrP) were inoculated by intracerebral 
(IC) injection into the brains of 101LL and WT mice and results indicated 
recombinant PrP (of any isoform) did not cause clinical TSE disease and both 
α-monomeric and β-oligomeric isoforms were not capable of initiating seeding 
of PrP aggregation in mice of both genotypes. In contrast, the recombinant PrP 
fibrils (both WT and 101L forms) did seed the formation of amyloid plaques in 
101LL mice but not in WT. This indicated that the 101L mutation in the host 
PrP was the important factor in this unique proteinopathy seeding model. 
Additionally, it was concluded the tertiary conformation of the inoculated 
material and not the primary amino acid sequence was important for the 
initiation of a seeding pathway, which targeted the hippocampal and corpus 
callosum areas of the brain. Subpassage of brain material from donor 101LL 
challenged mice (that contained seeded PrP amyloid plaques) into host 101LL 
recipients displayed an overall increase in deposition load of fibril amyloid 
deposits in the brain in comparison to primary brain tissues but the same areas 
of the brain were targeted.  
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It was postulated that a gain in GPI anchorage increased the efficiency and 
capability of the subpassaged inoculum to convert more native PrPC into its 
abnormal form upon subpassage. In summary misfolded PrP seeding was 
observed in 101LL and not WT mice. The amyloid fibrils formed did not cause 
an infectious prion disease, rather a proteinopathy. WT mice were capable of 
efficient clearance of recombinant fibrils and therefore curtailed seeding 
mechanisms from initiating.  
 
Studies by other laboratories have shown TSE disease initiation and 
transmission was possible following intracerebral inoculation of refolded 
recombinant PrP in hamsters/mice (Raymond et al. 2012; Makarava, Kovacs, 
Savtchenko, Alexeeva, Budka, et al. 2012; Makarava et al. 2010; Legname et 
al. 2004) however, these studies used different transgenic models and 
fibrilisation methods which seemed to generate infectious fibril aggregates 
(Colby et al. 2010). One study clearly demonstrated that inoculation with 
recombinant PrP fibrils formed in 2M Gdn-HCl does not cause infection and 
prion disease however, challenge with a more unstable 0.5M Gdn-HCl fibril 
form does cause disease in Syrian hamsters (Makarava, Kovacs, Savtchenko, 
Alexeeva, Ostapchenko, et al. 2012). Other factors such as dose and volume 
inoculated were also crucial to disease generation where many experiments 
claiming transmission of disease were dosing at volumes of up to 50µl at 
variable concentrations of up to 10µg of misfolded protein (mostly not noted in 
publications but through personal communication) which may overload 
systems important for protein clearance. In comparison, our group inoculated 
at much lower volumes and concentrations (1.4µg/20µl), which may be more 
physiologically relevant to disease. Additionally further studies have used 
magnetic beads to deliver fibril material to the brain which maximised the 
impact of the inoculum by enhancing the persistence of the fibrils (Raymond 
et al. 2012). Taking all these data into account further examination of seeding 
mechanisms and PrP fibril amyloid interactions in the brain in physiologically 
relevant conditions will need to be carried out to broaden our knowledge and 
understandings of misfolding protein diseases.  
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Despite this, the differences in the processing of recombinant PrP fibrils in WT 
and 101LL mice provide us with a useful tool to determine host-causative 
factors that either support or curtail the formation of abnormal protein fibrils.   
 
1.5.2 Neuronal and glial interactions with PrP 
 
One of the key features associated with PMDs is the ability of the abnormally 
folded proteins to seed and propagate in a “prion-like” manner and spread from 
neurons to neighbouring neurons and glia (Pearce et al. 2015; Brettschneider 
et al. 2015). However, the mechanisms involved are poorly understood and 
therefore this is an area of active investigation. Highest levels of PrPC 
expression are found in neurons and therefore much research has focused on 
the role of neuronal populations in defining mechanisms associated with 
protein misfolding in prion disease. Studies have shown that transgenic mice, 
which only express PrPC in their neurons, are susceptible to TSEs (Race et al. 
1995). Furthermore, it has been shown that manipulating PrPC expression in 
neurons during specific time points of a TSE disease resulted in the reversal 
of spongiosis and behavioural deficits in these models (Mirabile et al. 2015; 
Mallucci et al. 2007; Mallucci et al. 2003). Although pre-symptomatic 
incubation periods could be lengthened by reducing neuronal PrPC throughout 
the preclinical phase of disease, all animals ultimately developed a 
neurodegenerative disease (Manson 2011).  
 
Prnp mRNA expression is also present in non-neuronal cell types in the CNS 
such as astrocytes and microglia (Baker, Martin, and Manuelidis 2002; Moser 
et al. 1995; van Keulen et al. 1995). Studies have shown abnormal PrP 
accumulation in astrocytes was evident in TSE models suggestive of an 
involvement of this cell type in replication of abnormal PrP (Diedrich et al. 
1991). Additionally other reports have shown that transgenic mice expressing 
PrPC only in astrocytic cell populations were susceptible to TSE disease 
indicating that PrP expression in these specific cell types alone was sufficient 
to cause neurodegeneration (Raeber et al. 1997).  
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Astrocytes are extremely sensitive to any changes in the homeostasis of the 
brain and responses to misfolded proteins can be seen early in the course of 
disease by up-regulation of glial fibrillary acidic protein (GFAP) alongside 
hypertrophy of the cell bodies (Sofroniew 2009, 2005; Schenk et al. 1999). 
Studies have also shown astrocytes are capable of forming numerous 
intracellular connections including tunnelling nanotubes, often found 
colocalised with endolysosomal vesicles, which are capable of cell to cell 
transfer of misfolded PrP (Victoria et al. 2016). Microglia are another cell type 
sensitive to any environmental changes in the brain and are shown to change 
their morphology after activation at early stages of TSE disease (Perry and 
Teeling 2013). Inhibition of microglial proliferation can result in increased TSE 
incubation times suggesting microglial response is important in disease 
progression (Gómez-Nicola et al. 2013). Conversely, other studies have shown 
microglial-dependent neurotoxicity is induced after amyloidogenic polypeptide 
challenge in vitro and is associated with the progression of neurodegenerative 
disorders (Thellung et al. 2017). Microglial immune responses to TSE disease 
are accompanied by mixed cytokine responses including mediators of both 
inflammatory (IL-6) and anti-inflammatory responses (Tgfb1) (Boche et al. 
2006; Perry, Cunningham, and Boche 2002). Genetic knockout models of 
genes associated with these innate immune responses can influence 
incubation periods of TSE diseases (Bradford and Mabbott 2012) for example, 
knockout or knockdown of Tgfb1 shortens disease incubation times 
(Tamguney et al. 2008; Lacasse et al. 2008; Thackray et al. 2004). On the 
other hand, studies using AD models deficient in microglial response (APP 
transgenic mice crossed with chemically activated microglial suicide gene) 
have shown that there was no effect on plaque size or number when microglia 
were ablated suggesting they were not critically involved in Aβ plaque 
formation and clearance in the brain (Grathwohl et al. 2009). Interestingly, 
other studies have shown stimulating bone marrow-derived macrophages 
using macrophage colony stimulating factor (M-CSF) cleared amyloid plaques 
through lysosomal-dependent mechanisms (Boissonneault et al. 2009; 
Majumdar et al. 2007).  
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Microglia are capable of both engulfment and phagocytosis of Aβ fibril material, 
but whether this misfolded protein can be degraded intracellularly remains 
controversial (Lee and Landreth 2010). Research in our lab has shown both 
activated microglia and reactive astrocytes were present at the periphery of 
amyloid plaques seeded by fibril recombinant PrP inoculation indicating these 
cell populations do play are role in maintaining normal brain homeostasis after 
recombinant fibril insult (Barron et al. 2016). The predominantly 
neuroprotective role of microglia suggested in prion diseases may also be 
applicable to other neurodegenerative disorders and could broaden our 
understanding of the role of neuroinflammation (Aguzzi and Zhu 2017). In 
summary, non-neuronal cells are also involved in neurodegeneration and are 
associated with misfolded protein in the brain however, it is not clear whether 
their activation is in response to damaged neurons, abnormal proteins or other 
CNS danger signals.  
 
1.5.3 Misfolded PrP processing and degradation pathways 
 
Protein quality control is essential for cell viability and is essential for targeting 
rogue proteins towards degradation pathways. Any alterations in this 
homeostasis can be highly detrimental to the cell eventually leading to death 
(Wolfe and Cyr 2011). While most misfolded aggregates can be degraded and 
cleared by cellular protein control, some native and mutant proteins can be 
resistant to all known proteolytic pathways resulting in the formation of 
inclusion bodies or extracellular plaques (Ciechanover and Kwon 2015). 
Additionally the ability of cells to deal with misfolded protein seems to decline 
with age and response can vary between cell types (Cuervo et al. 2005). When 
PrP aggregate load increases beyond the tolerance limit of a cell, various 
intracellular quality control mechanisms can be affected. Lysosomal quality 
control machinery, which acts as a terminal degradative compartment of cells, 
emerges as one of the primary pathways overwhelmed during the 
pathogenesis of TSE diseases (Majumder and Chakrabarti 2017).  
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Endolysosomal pathway studies have shown that the majority of abnormal PrP 
is found in the endolysosomal system (Yao et al. 2013; Jeffrey et al. 2010) and 
in prion-infected brain tissue organelles such as late endosomes, lysosomes 
and autophagic vesicles are increased in size and numbers (Sikorska 2004; 
Boellaard et al. 1991). Aberrations in the endolysosomal system have also 
been observed in neurons from human sporadic CJD brains (Kovacs et al. 
2007) and disease was associated with blockages in lysosomal degradation 
where autophagosome-lysosome fusion was impaired (Majumder and 
Chakrabarti 2015). Interestingly, our studies have shown when the brains of 
101LL mice with plaques were analysed by electron microscopy (EM), large 
numbers of lysosomes were found in cells surrounding mature plaques 
however, no intra-lysosomal PrP accumulation was evident (Barron et al. 
2016). Inundation of these quality control mechanisms have also been 
reported in a number of other neurodegenerative diseases such as AD, PD 
and ALS (Majumder and Chakrabarti 2017). Studying these specific pathways 
after challenge with PrP fibrils may allow us to determine which conditions 
result in fibril amyloid generation/accumulation and which favour clearance. 
Routes involved in delivering misfolded proteins to lysosomes include 
endolysosomal, endoplasmic reticulum quality control (ERQC), Golgi QC and 
autophagic pathways (Saftig and Klumperman 2009). Interestingly, all of these 
independent pathways show signs of convergence which ensures efficient 
removal of unwanted cellular components (Nixon 2013). Proteins translocated 
directly to the endoplasmic reticulum (ER) during synthesis are monitored by 
specialised quality control systems within the ER lumen (ERQC), where any 
misfolded or defective proteins are translocated to the cytosol for degradation. 
This is known as the ER-associated degradation (ERAD) pathway where 
rogue proteins are targeted for lysosomal degradation by autophagy (Araki and 
Nagata 2011). Studies have shown misfolded PrP cannot be recognized and 
efficiently degraded by this system (Ashok and Hegde 2008). Other cellular 
compartments are also involved in misfolded protein clearance such as the 
Golgi quality control (Golgi QC) pathway which again directs abnormal proteins 
for lysosomal degradation (Anelli and Sitia 2008; Arvan et al. 2002).  
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More mature proteins associated with misfolding or aggregation are also 
subject to similar QC measures where degradation of soluble aggregates is 
aided by heat shock protein (Hsp) Hsp40, Hsp70 and Hsp100 chaperones 
(Kim et al. 2013). Neighbor of BRCA1 gene 1 (NBR1) and Nucleoporin p62 
(p62) are common adaptor proteins, which target insoluble aggregates for 
degradation (Kirkin et al. 2009; Bjorkoy et al. 2005). This process involves 
either two pathways namely, the ubiquitin-proteasome system (UPS) or the 
lysosomal proteolysis/ autophagic pathway. UPS is the principal route of 
abnormal protein degradation where mutations in different components of the 
system have been identified in patients with AD, PD and HD diseases (van 
Leeuwen et al. 2006; Kitada et al. 1998). Rogue proteins are targeted for 
proteasomal degradation by covalent conjugation of ubiquitin (Ub) in a 
sequential reaction involving three enzymes [(ubiquitin activating enzymes 
(E1), ubiquitin conjugating enzymes (E2) and ubiquitin ligases (E3)] that 
recognise and transfer Ub to an internal lysine residue on substrate proteins. 
These substrates are deubiquitinated, unfolded and cleaved into small 
peptides and delivered to and degraded by lysosomes via the chaperone 
mediated autophagy (CMA) pathway. However, this pathway may be restricted 
to soluble misfolded proteins only (Ciechanover and Kwon 2015; Bhat et al. 
2014; Goold et al. 2013). Insoluble aggregates, too large for entry into the 20S 
catalytic chamber, can avoid effective degradation through UPS impairment 
which results in an upregulation of autophagy highlighting the interplay 
between the two degradatory systems (Scotter et al. 2014; Hao et al. 2013; 
Deriziotis et al. 2011; Korolchuk, Menzies, and Rubinsztein 2010; Nedelsky, 
Todd, and Taylor 2008). Autophagy is a highly conserved degradation system 
that is capable of aggregate degradation after delivery to lysosomes and 
involves either macroautophagy, microautophagy or chaperone-mediated 
autophagy (Majumder and Chakrabarti 2017).  
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Macroautophagy is the most important pathway for neuronal proteostasis 
(Kochergin and Zakharova 2016; Yao et al. 2013) and is associated with 
cytosolic aggregates resistant to both UPS and the CMA that are sequestered 
either directly by importation into late endosomes/lysosomes or by formation 
of double membrane bound vesicles derived from ER membrane called a 
phagophore and upon closure of this isolation membrane autophagosomes 
are formed (Lamb, Yoshimori, and Tooze 2013; Yao et al. 2013). 
Autophagosomes can fuse with lysosomes to form autolysosomes and this is 
the site where degradation of aggregates occurs. Autophagy-related proteins 
include LC3 protein (microtubule-associated protein 1 light-chain 3, lapidated 
form LC3-II) and p62 and these proteins are used as markers for studying 
autophagy (Pankiv et al. 2007). Increased detection of autophagosomes of 
various sizes have been associated with numerous neurodegenerative 
diseases such as AD, PD ALS and prion. These were found located in 
neuronal perikarya, neurites and synapses indicating autophagy may be up-
regulated in these areas in these neurodegenerative diseases (Cai et al. 
2016). Increased p62 (a marker of autophagy) expression in prion-infected 
brains may also reflect attempts to promote clearance of aggregates by 
autophagy (Homma et al. 2014). Abnormalities in lysosomal systems was 
observed in patients with prion disease where the number and size of 
autophagic vessels was show to increase in affected brains (up-regulation of 
autophagy) possibly indicating enhanced clearance of aggregated proteins 
(Liberski et al. 2010; Sikorska et al. 2004; Boellaard et al. 1991). Dual-labelling 
of both abnormal PrP and lysosomal markers confirmed co-localisation of 
misfolded PrP within these organelles (Dearmond and Bajsarowicz 2010). 
Studies have shown that deletion of autophagy related 5 (atg5) protein in mice, 
which is a key autophagy intermediate in the CNS, leads to behavioural deficits 
and accumulation of abnormal ubiquitinated proteins which form aggregates 
in neurons, eventually causing neurodegeneration in these mice (Hara et al. 
2006). Abnormal levels of ubiquitinated protein are also found in the brains of 
prion infected animals, indicating these protein degradation pathways have 
failed to protect the host (Kristiansen et al. 2007).  
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In vitro studies have also shown autophagy to be the prominent pathway for 
abnormal PrP delivery to the lysosomes in infected cell cultures (Yao et al. 
2013; Heiseke, Aguib, and Schatzl 2010), where any interference of 
autophagic components results in increased abnormal PrP levels. Conversely, 
by increasing autophagic pathways in vitro there is a decrease in abnormal 
PrP load (Homma et al. 2014; Goold et al. 2013; Heiseke et al. 2009; Aguib et 
al. 2009). Overall, induction of the autophagic pathway in neurodegenerative 
models has shown beneficial effects through degradation of associated 
aggregated proteins (Ozcelik et al. 2013; Yao et al. 2013; Ravikumar et al. 
2004; Ertmer et al. 2004; Webb et al. 2003). Studies using neuroblastoma cells 
suggest the endolysosomal pathway is the main operative pathway for rapid 
misfolded protein clearance (Yamasaki et al. 2014). Similar results were 
reported in SN56 murine cell lines and primary hamster cell cultures where 
abnormal PrP was internalised by late endosomes and or lysosomes but not 
early endocytic, or raft-derived vesicles (Magalhaes et al. 2005). Indeed, 
studies have also shown that culture medium from infected cells can be 
infectious as infected cells release shedding vesicles (extracellular vesicles up 
to 1µm) and exosomes (50-100nm membranous vesicles) harbouring 
misfolded PrP (Mattei et al. 2009). These structures are generated by 
invagination of endosomal membranes to form intraluminal vesicles (ILVs) with 
MVBs. ILV sorting to lysosomes leads to degradation however, fusion of MVBs 
with plasma membrane followed by exocytosis leads of release of these 
extracellular infectious vesicles (Hartmann et al. 2017; Alais et al. 2008; Vella 
et al. 2007). It is possible that due to abnormal PrP overwhelming cellular 
internal protein QC mechanisms, an increase of ILV fusion with plasma 
membrane occurs resulting in increased exosomal release of abnormal PrP. 
Interestingly, exosomal PrPC can also display protective properties in other 
PMDs by binding and detoxifying Aβ oligomers in AD (Biasini et al. 2011), 
which indicates under normal homeostatic conditions this may be a beneficial 
process.  
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Although the UPS pathway has also been shown to be involved in abnormal 
PrP degradation in infected cultured cells (Goold et al. 2013) in vivo studies 
have shown that ubiquitination of abnormal PrP was restricted to larger 
aggregates present at late stages of disease (Kovacs et al. 2005; Kang et al. 
2004) and with low levels of colocalisation (Cammarata and Tabaton 1992), 
suggesting abnormal PrP is not ubiquitinated to a significant degree. These 
data highlight the intricacy of mechanisms of intracellular protein processing 
and clearance demonstrating the difficulty in underpinning specific defects 
induced by abnormal protein accumulation and also explain why to date, no 
therapeutic treatments are currently available for prion or other 
neurodegenerative diseases.  
 
One novel approach involving targeting the unfolded protein response (UPR) 
pathway, which is important in prion pathology (Hetz and Mollereau 2014; 
Moreno et al. 2012), using a protein kinase RNA-like endoplasmic reticulum 
kinase (PERK) inhibitor has shown clinical improvements in prion-infected 
overexpressing PrP mice (Moreno et al. 2013). Eukaryotic initiation factor 2 
alpha (elF2α) is a key regulator of protein translation (Walter and Ron 2011) 
and is targeted by a number of signal transduction pathways involved in 
controlling protein synthesis (Clemens 2004; Deng et al. 2002; Harding, 
Zhang, and Ron 1999). Activity of elF2α is inhibited by phosphorylation which 
then suppresses global protein synthesis (Walter and Ron 2011). The PERK 
inhibitor reduces chronic phosphorylation of elF2α and prion toxicity by 
allowing neurons to tolerate a greater accumulation of abnormal PrP and these 
findings were evident in animals treated both at the preclinical stage and also 
later in disease (Moreno et al. 2012). Although these findings are encouraging 
the pathogenesis of prion, and other neurodegenerative diseases is multi-
factorial, with many other factors contributing to toxicity which need to be 
examined (Aguzzi and Falsig 2012).  
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1.6 Thesis aims 
 
1.6.1 Overview 
 
Throughout this chapter, a number of unknown mechanisms and multi-factorial 
complexities have been associated with studying PMDs. Some studies have 
suggested abnormal proteins can be present at low levels in healthy brains 
(Yuan et al. 2006) indicating not all individuals are equally susceptible to 
neurodegeneration. However, the role of protein aggregates in 
neurodegeneration remains unclear, and early mechanisms involved in 
abnormal protein processing are poorly understood (Moreno-Gonzalez and 
Soto 2011). Due to this lack of understanding it is widely debated whether 
abnormal protein deposits are toxic to neurons or have a protective role (Wolfe 
and Cyr 2011; Treusch, Cyr, and Lindquist 2009; Haass and Selkoe 2007). 
Additionally, the role of alterations in protein quality control systems involved 
in maintaining homeostasis in the brain induced by abnormal protein challenge 
and age remains elusive (Gregersen and Bross 2010). It is crucial to better 
understand the mechanisms associated with initial processing of abnormal 
protein in PMDs to allow further investigation into how to promote their 
elimination without disturbing normal proteostasis of the cell. In addition, 
further understanding of the cellular interactions between neuronal and glial 
cells and their influence on the processing of misfolded protein are important 
factors that will contribute to the development of potential therapeutic 
treatments.  
 
1.6.2 Thesis hypothesis and objectives 
 
The main aim of this thesis is to gain more insight into these unknown 
mechanisms of cellular and molecular processing of abnormal protein using in 
vitro models composed of both neuronal and non-neuronal cell types 
challenged with misfolded recombinant PrP fibrils.  
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Cellular interactions and response, intra-cellular trafficking of abnormal 
protein, protein-protein interactions and molecular response will be analysed 
in genotypes which either support amyloid seeding and formation (101LL) or 
curtail its production (WT) to further understand factors that determine efficient 
clearance of abnormal protein. 
 
Hypothesis: WT and 101LL mice have different mechanisms of intracellular 
processing of abnormal protein that determine clearance versus the seeding 
of amyloid plaques.  
 
Objectives: The use of easily accessible cell cultures from transgenic mouse 
models that support the formation of amyloid plaques upon challenge with 
abnormal recombinant PrP (101LL) in comparison to cultures from mouse 
models that can clear abnormal recombinant PrP (WT) will allow the 
investigation of mechanisms involved in abnormal protein clearance that may 
be relevant to multiple PMDs. This project will focus on early cellular fibril 
interactions and the roles of multiple cell types involved in response to and 
processing of misfolded protein. Processing of misfolded protein will be further 
assessed at both the molecular and subcellular levels within these cultures. 
 
Objective 1: Generation of appropriate in vitro brain culture models using both 
WT and 101LL genotypes. 
 
Objective 2: Full characterisation of these cultures at a morphological, 
biochemical, and immunocytochemical level focusing on neuronal and glial cell 
populations. 
 
Objective 3: Production and characterisation of both WT and 101L monomeric 
recombinant PrP. 
 
Objective 4: Fibrillisation of monomeric recombinant PrP followed by labelling 
with a fluorescent tag. 
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Objective 5: Challenge in vitro models with fibrils and monitor early subcellular 
pathways associated with processing using various cell specific and organelle 
markers.  
 
Objective 6: Transcriptomic comparison of gene expression profiles 
associated with WT and 101LL in vitro cultures pre/post challenge to 
distinguish pathways involved in misfolded protein processing.
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2.1 Mouse Lines 
 
All experiments were conducted under home office project licence (2010-2015 
PPL 60-4125; 2015-2017 PPL 70-8523) within the regulations of the Animals 
(Scientific Procedures) Act 1986. Study numbers A820 and A821 were 
approved by Roslin’s Animal Welfare and Ethical Review Body. CD-1 albino 
mice were obtained from Charles River, 129/Ola (WT/101PP) mice from 
Jackson laboratories, PrP-/- and 101LL knock in transgenic mice were 
generated in-house. WT mice were homozygous for the wild type PrP gene 
(101PP) and 101LL were homozygous for the P101L mutation (Manson et al. 
1999; Manson, Clarke, Hooper, et al. 1994).  
 
2.1.1 Housing 
 
Mouse lines were maintained in a conventional animal facility with a 12 hour 
light and 12 hour dark cycle under specific pathogen free conditions at The 
Roslin Institute with access to food and water at all times. 
 
2.1.2 In-House mice 
 
101LL mice and PrP-/- were obtained from breeding colonies already 
established in-house. 101LL transgenics were generated as described in 
Chapter 1 (Section 1.4.2) using a double replacement gene targeting strategy 
(Manson et al. 1999; Moore et al. 1995), PrP-/- mice were generated as 
described previously (Manson, Clarke, Hooper, et al. 1994).  
 
2.1.3 DNA extraction 
 
Deoxyribonucleic acid (DNA) was extracted and purified from either mouse tail 
or ear punched tissues using the Qiagen DNeasy blood and tissue kit (Qiagen) 
according to manufacturer’s instructions. DNA was eluted in a final volume of 
100-200µl AE buffer then was stored at 4°C until further analysis.  
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2.1.4 Genotyping WT (101PP) and 101LL PrP transgenic mice 
 
Mouse genotype was confirmed through a process of genomic amplification 
by polymerase chain reaction (PCR) and restriction enzyme digestion, which 
produced a lower banding pattern for the mutated 101L PrP gene. Two 
methods were used for amplification of the mouse genomic DNA.  
 
Method One: PCR reaction buffer was prepared to the final concentrations: 1X 
PCR buffer (Invitrogen), 1.5mM magnesium chloride (MgCl2, Invitrogen), 
0.2mM dNTP’s (Promega solution containing ATP, CTP, GTP, TTP), 2pmol/µl 
oligonucleotides A044<>A045: 
A044:(5’-TCATCCCACGATCAGGAAGATGAG-3’)                                                        
A045:(5’-ATGGCGAACCTTGGCTACTGGCTG-3’); 2 units DNA Taq 
polymerase (Invitrogen, 500 U). Isolated mouse genomic DNA (1-2µl) was 
added to the PCR reaction buffer and the reaction tube was placed in a T3 or 
T3000 Thermo-cycler (Biometra). PCR conditions for amplification of the 
mouse DNA were: 94°C for 3 minutes, followed by 30 cycles of 94°C for 30 
seconds, 62°C for 30 seconds and 72°C for 1 minute. A 10 minute incubation 
at 72°C completed the reaction and DNA was stored at 4°C.  
 
Method Two: Type-IT Mutation Detect PCR Kit (Qiagen). PCR reaction buffer 
was prepared to the final concentrations: 1X Type-IT mastermix, 0.3pmol/µl 
oligonucleotides A044<>A045 [20µl mixed stock oligonucleotides (1:1) 
prepared in 500µl TE Buffer (10mM Tris/HCl, 1mM EDTA, pH 8.0)] to a total 
volume of 25µl distilled water (dH2O). Genomic DNA (1-2µl) was amplified 
using the following PCR conditions on the T3 or T3000 Thermo-cycler 
(Biometra): 95°C for 5 minutes followed by 35 cycles of 95°C for 30 seconds, 
60°C for 90 seconds, 72°C for 30 seconds, 68°C for 10 minutes then cooled 
to 4°C.  
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2.1.5 Restriction Enzyme Digest  
 
The amplified DNA product was digested with restriction enzyme DdeI 
(Promega, 1000 U) which identifies the leucine containing allele 101L due to 
the presence of an extra restriction site (101 mutation changes CCC-Proline 
to CTC-Leucine creating an additional DdeI site within exon 3) that is absent 
from proline allele 101P (Manson et al. 1999). The PCR product was digested 
with 0.1U DdeI (1000 U) in the presence of 1X Buffer D (final concentrations 
6mM Tris/HCl, 6mM MgCl2, 150mM NaCl and 1mM DTT) and 0.1mg/ml BSA 
(Promega) for 3 hours or overnight at 37°C. The digested PCR product was 
mixed with loading buffer (0.25% bromophenol blue (w/v), 0.25% xylene 
cyanol FF (w/v) in 20% ficoll solution, v/v) and gel electrophoreses was carried 
out using a 1.5% agarose gel (ThermoFisher Scientific) containing 1X 
concentration of SYPRO SAFE (Invitrogen) prepared with 1X TBE buffer 
(89mM Tris, 89mM boric acid and 3mM EDTA). A 1Kb ladder (Invitrogen) was 
used for sizing and quantification of DNA fragments and a positive and 
negative control were included for each reaction. DNA carrying the 101L allele 
produced a lower band of 464 base pair length whilst 101P produced a higher 
band of 614 base pair. The DNA banding pattern was visualised under UV light 
and photographed (Imager; Appligene Oncor). 
 
2.1.6 Genotyping PrP-/- mice 
 
PCR reaction buffer was prepared to the final concentrations: 1X PCR buffer 
(Invitrogen), 1.5mM MgCl2 (Invitrogen), 0.2mM Deoxyribonucleotide 
triphosphate (dNTP’s, Promega solution containing ATP, CTP, GTP, TTP), 
2pmol/µl oligonucleotides Null A1<> Null A2:                                                           
Null A1: (5’- GCCATCACGAGATTTCGATT -3’)                                                         
Null A2: (5’- ATCCCACGATCAGGAAGATG -3’), 2 units DNA Taq polymerase 
(Invitrogen, 500 U). Isolated mouse genomic DNA (1-2µl) was added to the 
PCR reaction buffer and the reaction tube was placed in a T3 or T3000 
Thermo-cycler (Biometra).  
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The PCR conditions for amplification were: 94°C for 3 minutes, followed by 30 
cycles of 94°C for 30 seconds, 62°C for 30 seconds and 72°C for 1 minute. A 
10 minute incubation at 72°C completed the reaction before the sample was 
cooled to 4°C. This reaction did not require restriction digest. The PCR sample 
was analysed by gel electrophoresis and the 1.2Kb PCR product was 
visualised under UV light and photographed (Imager; Appligene Oncor). 
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2.2 Production and characterisation of primary neuronal cultures 
 
Primary hippocampal neuronal cultures were prepared based on previously 
described methods (Seibenhener and Wooten 2012; Beaudoin et al. 2012; 
Chen et al. 2011; Kaech and Banker 2006; Bate, Reid, and Williams 2001; 
Gage, Ray, and Fisher 1995; Banker and Cowan 1977). Overnight breeding 
pairs of mice were set-up and pregnancies were monitored by animal staff. 
After 17 days from plug formation (plug formation = day 0) the pregnant mouse 
was culled (Schedule 1 termination by cervical dislocation). A non-Schedule 1 
termination of embryos proceeded which involved cooling of embryos on ice 
followed by immersion in chilled Basal Medium Eagle (BME, Gibco) buffer. 
 
2.2.1 Embryo brain removal and hippocampal dissection 
 
Each embryo was individually removed from BME buffer and decapitated. The 
embryo brain was removed from the skull according to previous protocols 
(Beaudoin et al. 2012; Fath et al. 2009). The tissue was placed fully submerged 
into a sterile petri dish containing Hanks/Hepes dissection buffer [Hank’s 
balanced salt solution (HBSS, Invitrogen), 10mM Hepes (Biochrom)]. Under a 
dissecting microscope, a sagittal cut along the brains midline allowed for 
separation of the two hemispheres. The cerebellum was discarded and the 
meninges were removed completely. The hippocampus was identified by its 
C-shaped structure and opacity, which differed from the surrounding cortical 
tissue. Hippocampi were dissected and placed immediately into a 15ml corning 
tube containing approximately 6mls of chilled Hanks/Hepes dissection buffer.  
 
2.2.2 Cell dissociation and plating 
 
In a laminar flow cell culture hood the hippocampi were transferred into 2ml 
dissection buffer containing 222µl Trypsin (2.5% 10X, Life Technologies) and 
20µl Deoxyribonuclease I (5mg/ml, Sigma). Samples were then incubated at 
37oC for 20 minutes.  
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The medium was aspirated off and the samples were washed twice in 10ml 
pre-heated growth media [500ml BME (Gibco), 50ml heat inactivated Horse 
Serum (Gibco), 8ml 32.5% Glucose solution (Sigma), 5ml Sodium Pyruvate 
100mM (Gibco), 5ml N2 Supplement (Gibco) and 5ml Penicillin-Streptomycin 
(10,000 U/ml, Gibco)]. Samples were then placed in 2ml pre-heated growth 
media containing 20µl Deoxyribonuclease I and cells were triturated using a 
fire-polished glass pipette (230mm, Volac). 8µl of the dissociated cells was 
taken to estimate cell density using a haemocytometer. Cell viability was 
checked using 0.4% Trypan Blue (Sigma, v/v). At this stage the desired 
number of cells were plated at standard plating densities on either in-house or 
commercially pre-labelled platforms where a number of substrates were 
investigated including Poly-L-Lysine (PLL, Sigma-Aldrich), Poly-D-Lysine 
(PDL, Sigma-Aldrich), and Fibronectin (Gibco). Approximately 400,000 cells 
were plated per well on Poly-L-Lysine 6 well plates (BD Biocoat), 150,000/ 
75,000 cells per coverslip on pre-labelled glass 14mm PDL coated coverslips 
(Neuvitro) and 30,000 cells per well on pre-labelled 96 well plates (Thermo 
Scientific). Plates were incubated at 37oC/ 5% CO2 for 4 hours. In-house 
coating of different platform types involved numerous steps. 14mm glass 
coverslips (Thermo Scientific) were placed into a heat-resistant glass container 
and rinsed in dH2O to remove any dust, submerged in 70% nitric acid (v/v) for 
18-36 hours then washed in sterile dH2O three times for 10 minutes followed 
by three 30 minute washes. The coverslips were allowed to soak for 2 hours 
in fresh dH2O, the remaining dH2O was aspirated off and the coverslips were 
allowed to air-dry. Finally the glass container holding the dried coverslips was 
placed into a dry heat oven at 220°C for 12-16 hours. Once baked the 
coverslips were stored at room temperature for one month ready for labelling. 
Glass coverslips and Corning/Nunc plates were coated in 2ml of PLL (50µg/ml) 
or PDL (100µg/ml) for a minimum of 2 hours then washed with numerous 
washes in PBS or dH2O. Fibronectin (100µg/ml) was added after this step 
(optional) for 1 hour or overnight followed by additional washes in PBS or 
dH2O.  
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Finally the remaining PBS/ dH2O was aspirated off, coverslips/plates were 
either allowed to air-dry then stored at 4oC until use or were stored in a fresh 
covering of distilled dH2O at 4oC until use.  
 
2.2.3 Culture Maintenance 
 
After cells were incubated for 4 hours, proficient cell settlement and attachment 
was confirmed by microscopy. Growth media was removed and replaced with 
an equal volume of serum free media [500ml neurobasal media (Gibco), 10ml 
B27 supplement 50X (Gibco), 5ml L-Glutamine (200mM, Gibco), 5ml 
Penicillin-Streptomycin (10,000 U/ml, Gibco)]. One-third of media was 
replaced with fresh pre-warmed serum free media twice a week to maintain a 
healthy culture. Supernatants were retained from each media change for 
analysis by SDS-PAGE and Lactate Dehydrogenase Assay (LDH). 
 
2.2.4 Cytotoxicity Assay (LDH Assay) 
 
The CytoTox 96 assay (Promega) quantitatively measures lactate 
dehydrogenase and was used according to manufacturer’s instructions. 
Supernatants were collected over a number of time points between 0-20 days 
in vitro (DIV0–DIV20) and stored at 4oC until subsequent analysis. Fluorescent 
values were normalized to Triton X-100 treated lysis cells that represent the 
maximum amount of LDH available for release. Samples were examined in 
duplicate or triplicate and data was analysed using GraphPad Prism package. 
 
2.2.5 Cell lysis and protein extraction 
 
For cell lysis preparations the cell culture dish was placed on ice and cells were 
washed twice in ice cold Dulbecco’s Phosphate Buffered Saline (DPBS, 
Gibco).  
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200µl of NP40 lysis buffer [1% NP40 (Abcam, v/v), 0.5% Sodium Deoxycholate 
(Sigma, w/v), 150mM NaCl (Fisher), 50mM Tris/HCL (Fisher) plus 1mM Phenyl 
Methyl Sulfonyl Fluoride (PMSF 200mM, Sigma)] was added to each well (6 
well plate) and cells were lysed using a cell scraper (Corning) along with gentle 
pipetting. The resulting cell suspension was transferred to a pre-cooled 
microfuge tube and incubated at 4oC under constant agitation for 30 minutes. 
The sample was then centrifuged at 4oC for 20 minutes at 12,000 rpm. The 
supernatant was aspirated off and stored for further analysis whilst the pellet 
was discarded. For the preparation of control brain homogenates, whole 
mouse brains were taken post mortem from either day 17 embryos, day 6 pups 
or adult mice and were snap frozen immediately then stored at -80°C until use. 
Brains were weighed and homogenized (100mg/ml) in glass dounce 
homogenisers using NP40 lysis buffer. The homogenate was centrifuged at 
4oC for 10 minutes at 10,000 rpm (Benchtop microcentrifuge) to aid cellular 
debris removal. The supernatant was aspirated off, aliquoted and stored at        
-80°C until further analysis whilst the pellet was discarded.  
 
2.2.6 Micro BCA kit and SDS-PAGE immunoblotting 
 
Protein concentrations were obtained using the micro BCA assay 
(Bicinchoninic acid assay, Thermo Scientific) according to manufacturer’s 
instructions. Optical density (562nm) was manually recorded, readings were 
plotted in excel and protein concentrations were calculated from XY scatter 
graph using standard control readings. To allow equal loading for SDS-PAGE, 
protein concentration adjustments were made using dH2O to produce final 
protein concentrations of 5μg. Tris-Glycine SDS sample buffer (10µl, 
Invitrogen) was added to each sample which was then denatured at 90°C for 
20 minutes. Samples were loaded onto either 10, 12 or 15 well pre-cast 
Novex® 12% Tris-Glycine Gels (Invitrogen) with the appropriate Seeblue plus 
2 pre-stained protein standard (Life Technologies). SDS-PAGE running buffer 
was made (0.02M Tris, 0.19M Glycine, 3.5mM SDS) and Tris-glycine gels were 
run at 130V for approximately 120 minutes.  
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Gels were removed from their cassettes and prepared for semi-dry protein 
transfer. Briefly, pre-cut polyvinylidene fluoride (PVDF) membranes (Millipore) 
were washed in methanol for 30 seconds, then dH2O for 2 minutes and finally 
immersed in transfer buffer (40mM Glycine, 48mM Tris, 1mM SDS and 20% 
methanol, v/v) for a minimum of 5 minutes. Each individual gel was placed in 
a sandwich of 6 pieces of filter paper (pre-soaked in transfer buffer), PVDF 
membrane, polyacrylamide gel and 6 pieces of filter paper then placed inside 
the semi-dry blotter (Bio-Rad) and a current of 125mA was applied (2mA/cm2) 
per gel for 90 minutes (limited to 25V) for efficient transfer of proteins to the 
PDVF membrane. The membrane was then placed in a 50ml conical tube and 
blocked for 30 minutes in 5ml of Odyssey® Blocking Buffer (LI-COR) where 
constant rotation was continually achieved by placing the tubes on a tube 
roller. The PVDF membrane was incubated overnight at room temperature 
with primary antibody 6H4 (Prionics) at 0.1µg/ml in 5ml Odyssey® Blocking 
Buffer (LI-COR) plus 5μl Tween 20. The following day the PVDF was washed 
six times in freshly prepared PBS then incubated with IRDye®680RD Goat anti-
mouse secondary antibody (LI-COR) at 0.2µg/ml in 5ml Odyssey® Blocking 
Buffer (LI-COR) plus 5μl Tween 20 for 1 hour 45 minutes (protected from the 
light). The PVDF was washed six times in PBS then finally the PVDF was 
scanned and analysed using Odyssey® imaging system and LI-COR software.  
 
2.2.7 Cell lysis and RNA extraction 
 
Ribonucleic acid (RNA) was extracted from both cell cultures and Day 6 mouse 
hippocampal tissues using the RNeasy Plus Micro Kit (Qiagen). Day 6 
hippocampal tissues were dissected similarly to embryonic mice however, 
after the brain was isolated it was placed immediately in RNAlater RNA 
stabilisation Reagent (Qiagen). The hippocampal areas were then dissected 
and placed in a pre-weighed tubes containing 1ml of RNA stabilisation reagent. 
The kit recommended using tissues < 30mg in weight so occasionally larger 
tissues were split between two separate tubes for processing.  
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RNA stabilisation buffer was removed and 600µl of Buffer RLT Plus (with ß-
mercaptoethanol) was added to each tube followed by an initial 
homogenisation step using disposable pestles (VWR) and a handheld pellet 
mixer (VWR). For cell cultures a starting volume of 350µl of Buffer RLT Plus 
(with ß-mercaptoethanol) was used for initial lysis. A QIAshredder was 
employed for both cell and tissue preparations which aided in a uniform 
homogenate preparation (samples spun at full speed for 2 minutes). The 
remaining steps were carried out according to the kit’s protocol and for the final 
elution 30µl of RNase free water was used to wash the RNeasy column 
membrane. After centrifugation this wash step was repeated again and          
RNA purity was measured using the Nanodrop (Thermo Scientific) 
spectrophotometer. Samples were stored at -80°C until further analysis. 
 
2.2.8 Immunostaining of primary cultures 
 
Cell media was removed and cells were incubated with 4% paraformaldehyde 
(PFA, v/v) serum free medium mix (1:1) for 2 minutes at room temperature. 
This media mix was removed and 1-2 ml of 4% PFA (v/v) was placed on cells 
for 15 minutes at room temperature followed by three 5 minute washes with 
DPBS containing Ca2+ and Mg2+ (Gibco). 1-2ml of ice-cold methanol was 
added to the cells for 10 minutes with incubation at -20oC followed by a 5 
minute incubation with 0.3% Triton-X (Sigma, v/v) at room temperature. Again 
wells were washed three times in DPBS at 5 minute intervals then blocked for 
1 hour at room temperature using Fc Block (purified recombinant Fc protein 
that blocks non-specific binding of Fc receptor expressing cells, CD16/32, 
BioLegend). Primary antibodies were incubated overnight in 5% Goat serum 
(Gibco, v/v) at 4oC (concentrations listed in Table 2.1). Cells were washed 
three times in DPBS (Gibco) and secondary antibodies diluted in 5% goat 
serum (v/v, Table 2.1) were added for 1 hour at room temperature in complete 
darkness followed by a further three washes as above. For the final wash a 4', 
6-Diamidino-2-Phenylindole, Dihydrochloride (DAPI, 300nM, Molecular 
Probes) counterstain was carried out.  
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Pre-labelled PLL 6 Well plates (Biocoat Cell Environments) were imaged using 
a live confocal microscope (Nikon). For glass coverslips preparations (14mm 
Neuvitro Corporation) 20µl of prolong diamond antifade mountant (Life 
Technologies) was placed on specialised cavity glass slides (Marienfeld). 
Using a forceps coverslips were removed from their specific well and placed 
inverted onto the antifade mountant (Life Technologies) and were allowed to 
dry for 4 hours at room temperature then overnight at 4oC. Coverslips were 
sealed using CoverGrip coverslip sealant (Cambridge BioScience) then 
imaged using the LSM710 inverted confocal microscope (Zeiss). Slides were 
stored at 4oC for several weeks without substantial loss of fluorescence.  
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Primary Ab Marker/ 
Concentration 
Secondary/ 
Concentration 
Supplier 
Anti-MAP2 
(Ab5392) 
Dendritic, 1/2000 Goat Anti-Chicken IgY 
(Alexa Fluor 488) 1/500 
Both Abcam 
Anti-GFAP 
(18-0063) 
Astrocyte, 1/100 Goat Anti-Rabbit IgG (Alexa 
Fluor 594) 1/200  
Both Thermo 
Scientific 
Anti-GFAP 
(Ab53554) 
Astrocyte, 1/500 Donkey Anti-Goat IgG 
(Alexa Fluor 555) 1/500 
Both Abcam 
Anti-GFAP 
(Ab4674) 
Astrocyte, 1/500 Goat Anti-Chicken IgY 
(Alexa Fluor 488) 1/500   
Both Abcam 
Anti-Sox9 
(Ab5535) 
Astrocyte, 1/500 Donkey Anti-Rabbit IgG 
(Alexa Fluor 488) 1/500 
Millipore  
Abcam 
Anti-ALDH1L1 
(Ab87117) 
Astrocyte, 1/500 Goat Anti-Rabbit IgG (Alexa 
Fluor 647) 1/200 
Both Abcam 
Anti-Tau 
(Ab64193) 
Axonal Marker, 
1/100 
Goat Anti-Rabbit IgG (Alexa 
Fluor 594) 1/200   
Abcam 
 
6H4 
(01-010) 
PrP amino acids 
143-151, 1/500 
Goat Anti-Mouse IgG 
(Alexa Fluor 647) 1/200 
Prionics 
Life Tech. 
7A12* PrP amino acids 
90-145, 1/500 
Goat Anti-Mouse IgG 
(Alexa Fluor 647) 1/200 
Gift* 
Life Tech. 
Synapsin 1 
(Ab64581) 
Pre-synaptic, 
1/200 
Goat Anti-Rabbit IgG (Alexa 
Fluor 594) 1/200   
Both Abcam 
PSD-95 
(Ab99009) 
Post-synaptic, 
1/200 
Goat Anti-Mouse IgG 
(Alexa Fluor 647) 1/200 
Both Abcam 
Anti-Iba1 
(019-19741) 
Microglia, 1/1000 Goat Anti-Rabbit IgG (Alexa 
Fluor 594)   
Wako 
Abcam 
Anti-Iba1 
(Ab139590) 
Microglia, 1/500 Goat Anti-Chicken IgY 
(Alexa Fluor 488) 1/500   
Both Abcam 
CD11b Alexa 
Fluor 647 
(Ab197702) 
Macrophages/ 
monocytes, 1/200 
 
n/a 
Abcam 
Myelin Basic 
Protein 
(Ab62631) 
Myelin, 1/500 Goat Anti-Mouse IgG 
(Alexa Fluor 647) 1/200 
Abcam 
Anti-LAMP1 
(Ab24170)/ 
LAMP2 
(108501) 
Lysosome, 
1/1000 
 
Goat Anti-Rabbit IgG (Alexa 
Fluor 594) 1/200   
Abcam 
BioLegend 
Anti-EEA1 
(Ab2900) 
Early Endosome, 
1/200 
Goat Anti-Rabbit IgG (Alexa 
Fluor 594) 1/200   
Both Abcam 
Anti-Rab9 
(Ab179815) 
Late Endosome, 
1/250 
Goat Anti-Rabbit IgG (Alexa 
Fluor 594) 1/200  
Both Abcam 
Transferrin 488 
(T13342) 
Endosome, 1/125 n/a ThermoFisher 
Cholera toxin  
Subunit B 488 
(C34775) 
Lipid-Raft, 1/200 n/a ThermoFisher 
Anti SQSTM1 
p62(ab109012) 
Autophagosome, 
1/1000 
Goat Anti-Rat IgG (Alexa 
Fluor 594) 1/200  
Both Abcam 
*Gift from Man-Sun Sy (Case Western Reserve University, Cleveland, USA) 
Table 2.1 Antibodies and markers used for immunolabelling experiments. 
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2.2.9 IMARIS software analysis of immunolabelled hippocampal cultures 
 
IMARIS software (Bitplane) allowed for data visualisation, analysis and 
interpretation of microscopy datasets. Various modules in IMARIS allowed for 
complex image processing to be carried out on “.czi” images obtained from 
confocal microscopy. For each image or channel within an image the 
intensities of all voxels are analysed using default standard IMARIS formulas 
that calculate mean, standard deviation and sum intensities (intensities do not 
have any units) and therefore these values can be used for relative comparison 
of targets of interest in different images. Slice View module allows for more 
robust image analysis and is a user integrative module that allows for accurate 
measurements of a particular structure, cell, or dendrite to be obtained based 
on the datasets scale bar parameters. FilamentTracer module allowed for the 
automatic detection of neurons and dendrites in 3D and supplied a vast range 
of morphological information including diameter, volume, area, length, width, 
and branching angle, all of which can be visualised in IMARIS Vantage. This 
analysis method was occasionally subjective to falsely identifying some 
structures and therefore semi-automatic detection or manual methods were 
predominantly used here. Briefly, for semi-automatic tracing the image was 
opened in IMARIS and a Filament object was created and the option Calculate 
Diameter of Filaments from Image was turned off. Region of interest was 
defined using the wizard and estimated diameters for the Starting points and 
Seed points were entered using measurements obtained in Slice View module. 
The next step involved setting the upper and lower threshold values to 0, 
starting points were added manually using shift-key + ctrl + left mouse button, 
and Seed points were added using shift-key + left mouse button. The image 
could be rotated to confirm correct placement of Seed points. At this stage All 
done could be selected or to Apply settings to the whole image Entire Image 
option was selected. For manual tracing a Filament object was created and 
skip automatic creation, edit manually was selected. Draw tab was displayed 
which provided tools for manually creating filaments.  
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Two options may be selected here AutoPath recommended for 2D data sets 
and AutoDepth (uses a FastMarching algorithm) recommended for 3D data 
sets which was predominantly used here. Using shift-key + left mouse button 
and drag, a new Filament was drawn. Pencil diameter could be changed using 
mouse wheel for accuracy. All algorithms employed by IMARIS software have 
been described previously (Meijering et al. 2004). To investigate localisation 
of PrPC to neurons and astrocytes an adaption of previous methods was 
carried out (Fogarty et al. 2013). In this analysis, Surface tool was used to build 
a computer-generated representation of the area of interest in the data set. In 
Surpass mode Create surface was selected for the channel of interest, 
Smoothing option was disabled and Background subtraction was enabled. 
Switching to Slice mode allowed for accurate measurements to be obtained 
for background correction. Voxel threshold graph was altered to map the signal 
with precision and finished surface creation was selected. The next stage 
involved filtering signals of interest. The newly created surface layer was 
selected followed by edit tab. The options Mask all and marker of interest were 
selected and the option Duplicate channel before applying mask was enabled 
and Constant inside/outside selected with Voxels OUTSIDE surface 0.0. 
These steps were repeated however “Set voxels INSIDE surface 0.0” was 
selected. Stage three involved creating spot layers from the previous filtering 
step. A new spot layer was created and the marker channel of interest 
(neuron/astrocyte) was selected whilst ensuring Background subtraction was 
enabled. Stage four entailed measuring total number of PrPC adjacent to the 
neuron or astrocyte. Neuron/astrocyte surface was selected followed by the 
Tools tab. Find spots close to surface was selected and MatLab in IMARISXT 
(multi-functional two-way interface) was automatically launched. Here a spot 
layer was chosen alongside a distance threshold for analysis. This resulted in 
the creation of two new spot layers, one with all the spots within the selected 
distance and the other containing all the more distant spots.  
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Figure 2.1: Flow chart summarising image analysis options available when using 
IMARIS software.  
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2.3 Production and purification of recombinant protein 
 
WT and 101L PrP protein was expressed from glycerol stocks (gift from Dr. 
Andy Gill) of Escherichia coli (E. coli) strain (Rosetta DE3) expressing a 
pTrcHis B vector containing PrP open reading frame from codons 23-230 
(Kirby et al. 2003). Briefly, full length murine PrP of Prnp genotype was 
amplified from genomic DNA using relevant primers (Locht et al. 1986). 
Alongside this the 6-histidine tag was removed from plasmid pTrcHis B 
(Invitrogen; http://www.lifetechnologies.com/order/catalog/product/V36020) 
by digestion with restriction enzymes Ncol/EcoRI.  PCR fragments were 
digested with these specific enzymes followed by ligation into the altered 
pTrcHis B vector. These specific vectors are designed for efficient recombinant 
protein expression and purification in E. coli where high levels of expression 
are achieved. The resultant recombinant vector encoded untagged PrP (23-
230). E. coli were then transformed with the recombinant vectors and the 
resulting strains (pTrcHis B vector in Rosetta DE3) were plated overnight at 
37oC on Luria-Bertani (LB, Sigma) culture plates to generate glycerol stocks.  
 
2.3.1 Bacterial expression and induction using the pTrc expression system 
 
Recombinant PrP expression protocols were adapted based on previous 
tested methods (Makarava and Baskakov 2008). Both WT and 101L PrP 
stocks (gift Dr. Andy Gill) were used here to produce fresh glycerol bacterial 
stock. Luria-Bertani (LB, Thermo-scientific) plates were prepared under sterile 
conditions containing ampicillin (0.1mg/ml, Sigma) and/or chloramphenicol 
(0.05mg/ml, Sigma). WT cultures required both antibiotics whilst 101L only 
required ampicillin. Plates were streaked with bacteria from WT or 101L 
glycerol stocks then incubated at 37oC overnight. The following day a bacterial 
colony was selected from each plate and was used to inoculate 10ml of LB 
broth (Thermo-scientific) containing either ampicillin (0.1mg/ml) and/or 
chloramphenicol (0.05mg/ml). The inoculated broths were incubated at 37oC 
overnight in an orbital shaker (200rpm).  
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For the production of fresh glycerol plasmid stocks 100l of overnight culture 
was added to 10ml LB broth containing ampicillin and/or chloramphenicol. This 
culture was incubated at 37oC for 4 hours in an orbital shaker (200rpm). 500l 
of this culture was added to 500l of 30% glycerol/LB (v/v) and was 
immediately snap frozen and stored at -80oC until further use. For further 
bacterial growth 4ml of overnight culture was added to 400ml of terrific broth 
(Sigma-Aldrich) containing the relevant antibiotics. Incubation was carried out 
in a conical flask at 37oC for 3 hours in an orbital shaker (200rpm). The cultures 
were grown to an OD600 of between 0.6-0.8 at which point PrP expression was 
induced by the addition isopropyl ß-D-1-thiogalactopyranoside (IPTG,       
Sigma-Aldrich) to a final concentration of 1mM. Induced cultures were 
incubated overnight at 37oC overnight in an orbital shaker (200rpm). Induction 
of recombinant protein was confirmed by SDS-PAGE. 20µl of either plus/minus 
IPTG sample was added to 10µl NuPage LDS sample loading buffer 
(Invitrogen) followed by protein denaturation at 90°C for 5 minutes. Samples 
were pulse centrifuged at 12,000rpm then loaded onto either a 10 or 15 well 
Nu-PAGE 12% Bis-Tris Gels (Life Technologies) along with the appropriate 
Seeblue plus 2 pre-stained protein standard (Life Technologies). Gel 
electrophoresis was carried out at 180V for 45 minutes in 1X NuPage running 
buffer (Invitrogen). The cassette was removed from gel tank, dismantled and 
the exposed gel was stained in instant blue buffer (Expedeen) for visualisation 
of the isolated protein. This confirmed PrP of the anticipated size was 
produced.  
 
2.3.2 Pellet harvesting and bacterial lysis 
 
Bacterial cells were harvested by centrifugation at 12,000rpm for 15 minutes 
using a Sorvall Lynx 4000 centrifuge and SLA1500 rotor. Cell pellets were 
stored at -80oC until lysis. Bacteria were lysed using 9ml of lysis buffer      
(50mM Tris pH8, 1mM EDTA, 100mM NaCl) per gram of cell pellet.  
 
54 
 
After this 20l lysozyme (10mg/ml, Sigma-Aldrich) per ml of lysis buffer was 
added to degrade the bacterial cell wall and this mix was incubated with 
constant stirring at 4oC for 40 minutes. Solid sodium deoxycholate was added 
to a final concentration of 1mg/ml to disrupt the cell membrane and release 
recombinant protein contained in inclusion bodies. To reduce the viscosity of 
the solution, after incubation of 1.5 hours, 5l of Deoxyribonuclease I from 
bovine pancreas (DNase) was added at 2mg/ml along with approximately 
500µl of 2M MgCl2. This mix was stirred for 1.5 hours then centrifuged in a 
Sorvall Lynx 4000 centrifuge (SLA1500 rotor) at 15,000 rpm for 15 minutes. 
The resulting pellets contained the inclusion bodies and were stored at -80oC 
until purification. 
 
2.3.3 Immobilized-Metal Affinity Chromatography (IMAC) PrP purification 
 
Stock buffers were prepared as follows:  
 9M Urea (Sigma-Aldrich) was prepared and then mixed with amberlite 
(Sigma-Aldrich) overnight at room temperature. This mix was then 
filtered through a 0.45μm filter (Millipore).  
 IMAC A: 8M Urea, 0.1M Sodium phosphate dibasic (Na2HPO4, Sigma-
Aldrich), 10mM Tris-HCL, 10mM reduced glutathione (Sigma-Aldrich), 
pH 8.0. 
 IMAC B: IMAC A buffer pH 4.5. 
 
Inclusion bodies were solubilised in IMAC A buffer using 10ml of buffer per 
gram of pellet. Once thoroughly resuspended (approximately 2 hours) the 
solution was spun in a Sorvall Lynx 4000 centrifuge (SLA1500 rotor) at    
15,000 rpm for 20 minutes. The resulting pellet was discarded and the 
supernatant was retained. Nickel-Nitrilotriacetic acid (Ni-NTA, 5ml) agarose 
(Qiagen) was poured into a 50ml tube, allowed to settle then was washed three 
times in dH2O followed by a final wash in IMAC A buffer. The supernatant was 
batch bound to this resin for approximately 1.5 hours by placing tube on a 360o 
spinner at room temperature.  
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The resin was poured into an empty gravity flow cartridge (Qiagen) and the 
flow through was collected. The column was washed with 15ml of IMAC A then 
recombinant PrP was eluted using 25ml of IMAC B. To minimise protein 
degradation 50µls of 0.5mM Ethylene Glycol Tetraacetic Acid (EGTA, Sigma-
Aldrich) was added to each fraction to give a final contraction of 5mM EGTA. 
The first two eluted fractions normally contained the target protein and this was 
validated by SDS-PAGE.  
 
2.3.4 PrP protein concentration  
 
Recombinant PrP fraction absorbance was measured using nanodrop 
spectrophotometry (Thermo Scientific) and the concentration of recombinant 
protein was calculated using the extinction co-efficient based on the PrP 
sequence (62,280), molecular weight of PrP (23,104) and the following 
equation:  
  Protein Concentration (mg/ml) = (
𝑂𝐷 280−𝑂𝐷 320
𝐸𝑥𝑡𝑖𝑛𝑐𝑡𝑖𝑜𝑛 𝑐𝑜−𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡
) x Molecular Weight 
 
2.3.5 Reduced glutathione removal using HiPrep 26/10 Desalting column 
 
The AKTA-Fast protein liquid chromatography (FPLC, GE Healthcare) system 
was utilised for filtration processing of IMAC fractions. Stock desalting buffer 
was prepared as follows: 6M Urea (Sigma-Aldrich) and  0.1M Tris-HCL pH 7.5. 
The HiPrep 26/10 desalting column (GE Healthcare) was equilibrated with 
desalting buffer, then the IMAC fractions containing diagnostic protein were 
combined and loaded on the column via a superloop. The column capacity was 
13mls so this was the maximum volume loaded at one time. Flow rate was set 
at 1ml/minute and maximum pressure at 0.15 MegaPascal (MPa). Samples 
were collected immediately as the protein normally eluted in the first two 
fractions, monitored by UV absorbance and validated by SDS-PAGE. 
Fractions containing PrP protein (range of 0.5–2.5mg/ml) were pooled and 
diluted immediately in desalting buffer to a final concentration of 0.3mg/ml.  
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This step was critical in minimising the formation of dimers during oxidative 
refolding of PrP. A final concentration of 5mM EGTA was also added to prevent 
protein degradation. A disulphide bond was then made by the addition of 
oxidised glutathione (0.075mM) and the protein was incubated overnight at 
room temperature with constant stirring.  
 
2.3.6 Reversed Phase HPLC for high purity prion protein purification 
 
After addition of a disulphide bond recombinant PrP was further purified using 
a reversed phase column (Vydac 214TP101522 RP) and a Dionex HPLC 
UltiMate 3000 system (Thermo Scientific). Stock buffer was prepared as 
follows:  
 HPLC Buffer A: 0.1% Trifluoroacetic Acid (Sigma-Aldrich, v/v) in 1L Milli 
Q dH2O. 
 HPLC Buffer B: 0.1% Trifluoroacetic Acid in Acetonitrile (Sigma-Aldrich, 
v/v).  
 
The reversed phase column was equilibrated with HPLC Buffer A, whilst 
equilibrating the oxidised PrP was filtered through a 0.22μm filter then diluted 
(1:3 v/v) in HPLC Buffer A to reduce urea concentration. The diluted sample 
was loaded on the column via a superloop where a maximum concentration of 
7mg protein was never exceeded. Flow rate (HPLC Buffer A) was increased 
to 1ml/minute and maximum pressure was limited to 4 MegaPascal (MPa). The 
sample was injected through the column and the flow through was collected 
immediately (approximately 40mls). Protein was eluted in HPLC Buffer B using 
a pre-determined multistep gradient flow program (Table 2.2). Fractions 
corresponding to UV peak readings were collected for SDS-PAGE analysis. 
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Minutes Flow (ml/min) %B 
0 1 0 
5 1 15 
35 1 35 
45 1 80 
50 1 80 
55 1 0 
 
Table 2.2: Multistep gradient flow program for efficient protein displacement 
using RP-HPLC.  
 
2.3.7 Protein lyophilisation 
 
Fractions containing the purest target protein (validated by SDS-PAGE) were 
selected for immediate lyophilisation using the Savant automatic 
environmental Speedvac system. Each individual fraction was aliquoted into 
100µl volumes. Speedvac was set to low drying rate and samples were 
incubated for 2 hours 15 minutes. After lyophilisation samples were stored at    
-80oC until further use. 
 
2.3.8 Mass spectrometry  
 
Mass spectrometry was performed in-house by Dr. Andy Gill, The Roslin 
Institute on lyophilised protein samples to confirm the presence and purity of 
the recombinant PrP protein and analysis reports were supplied accordingly.  
 
2.3.9 Fibrillisation of recombinant PrP 
 
Fibrillisation of recombinant PrP was carried out according to previous 
published methods (Graham et al. 2010; Breydo, Makarava, and Baskakov 
2008). Lyophilised recombinant PrP samples were reconstituted in 6M Gdn-
HCl      (pH 6.0) to a concentration of between 10-15mg/ml.  
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Reaction mixtures contained the following final concentrations: 2M Gdn-HCL, 
50mM MES, 10mM Thiourea and approximately 0.5-1mg/ml of reconstituted 
recombinant protein. To monitor fibrillisation kinetics, Thioflavin T (ThT) was 
added at a final concentration of 10µM. The reaction mix was dispensed into 
a FluoroNunc 96 well flat bottom plate (Thermo Fisher) along with 3 Teflon 
balls (2.381mm diameter, The Precision Plastic Ball Company). The plate was 
sealed with a plate sealer then placed in the Fluoroskan (Thermo Scientific). 
The fluorescent plate reader was set to shaking at 900rpm at 37°C and 
incubated for 24 hours. ThT fluorescence was measured every 5 minutes for 
24 hours (excitation at 444 nm, emission at 485 nm) to monitor fibril production. 
Data points generated were processed using a fibrillisation processor macro 
excel program which produced a sigmoidal kinetic curve based on ThT 
fluorescence readings output over-time. Fibrillisation reactions were also set 
up in the absence of PrP protein and were used to account for background 
fluorescence. Additionally, reactions were set-up without ThT to produce 
recombinant PrP fibrils for future challenge studies and these reactions were 
pooled and dialysed for storage. Dialysis was carried out against 2 litres of 
10mM sodium acetate pH 5.0 with two buffer changes. Final concentrations of 
fibrils was estimated using the nanodrop as previously described (Section 
2.3.4) then fibrils were stored at 4°C. 
 
2.3.10 Maturation and proteinase K digestion of fibrils 
Dialysed fibrils were processed according to standard protocols (Breydo, 
Makarava, and Baskakov 2008). Loading buffer was prepared as follows (all 
chemicals from Sigma-Aldrich): 125mM Trizma, 4.5M Urea, 20% (v/v) 
Glycerol, 1.25M β-mercaptoethanol, 4% (w/v) Sodium dodecyl sulfate, and 
0.02% (w/v) Bromophenol blue. Three samples were prepared for each batch 
of fibrils as per Table 2.3. 
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Ingredient  
Sample 1: 
Control no PK 
digestion (μl) 
Sample 2: 
PK digestion 
(μl) 
Sample 3: PK 
digestion with 
maturation (μl) 
PrP (0.5mg/ml) 2 2 2 
dH2O 4.8 4.8 4.8 
1M Tris pH 7.5 0.8 0.8 0.8 
1% Triton-X 100 0.4 0.4 0.4 
   Incubate at 80°C for 
15 minutes 
PK (20 μg/ml) n/a 0.5 0.5 
  PK Samples at 37°C for 1 hour 
Pefabloc 
100mM 
n/a 2.125 2.125 
 
Table 2.3: Reaction mix recipes for maturation analysis of fibrils.  
 
After preparing the samples as noted in Table 2.3, 8μl of loading buffer was 
added to each tube followed by a 10 minute incubation at 95°C. SDS-PAGE 
(12% NuPAGE Bis-Tris gel, Invitrogen) and silver staining was carried out next 
to aid protein visualisation (Chevallet, Luche, and Rabilloud 2006). 
 
2.3.11 Silver staining 
 
SDS-PAGE was carried out as described previously (Section 2.2.6) however, 
after electrophoresis the NuPAGE Bis-Tris gel (Invitrogen) was soaked in fixing 
solution (30% Ethanol, 10% Acetic acid, dH2O 40:10:50 v/v) overnight at room 
temperature. The gel was then incubated for 1 hour in sensitising solution [30% 
Ethanol (v/v), 5% Sodium thiosulphate (w/v), 0.84M Sodium acetate, 0.5mls 
Glutaraldehyde (25%)] followed by four 15 minute washes in dH2O. The gel 
was then stained with silver nitrate (0.25% w/v) in dH2O with formaldehyde 
(0.1% w/v) for 1 hour followed by two 1 minute washes in dH2O.  
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The gel was developed in 2.5% (w/v) sodium carbonate with formaldehyde 
(0.04% w/v) until bands were clear. After this step the gel was transferred 
immediately into stop solution (1.46% EDTA, w/v) and images were taken 
using a Typhoon scanner (GE Healthcare).  
 
2.3.12 Transmission Electron Microscopy (TEM) 
 
WT, 101L fibrils and WT α-helical monomeric protein samples were prepared 
for TEM by Stephen Mitchell, Kings Buildings, Edinburgh using formvar/carbon 
coated grids (Copper 200 mesh). Each grid was inserted into the single 
specimen holder of a JEM-1400 Plus Electron Microscope. Images of both 
fibrils and monomeric protein were taken at various magnifications and saved 
as .dm3 files. Fibril dimensions were determined using IMARIS Slice View 
module. 
 
2.3.13 Labelling fibrils with Alexa Fluor Succinimidyl Esters (NHS esters) 
 
To allow for efficient fibril labelling with Alexa fluor 555 succinimidyl ester 
fluorophores a buffer exchange was carried out to remove fibrils from sodium 
acetate pH 5.5 buffer and replace with sodium bicarbonate pH 9.0. Fibrils (1ml 
at 0.5mg/ml) were centrifuged at 13,200rpm for 15 minutes then the resulting 
pellets were washed in 0.1M sodium bicarbonate pH 9.0. This step was 
repeated three times, finally the pellets were reconstituted in 100μl of 0.1M 
sodium bicarbonate. 100μl of sterile Dimethylsulfoxide (DMSO) was added to 
one vial of Alexa Fluor 555 at 100μg (Molecular Probes). From this point all 
tubes were kept in tinfoil to protect from light. 5μl of Alexa Fluor was added to 
100μl of fibrils and this mix was incubated at room temperature for 1 hour on 
a 360o rotator followed by overnight incubation at 4oC with constant agitation. 
The following day 1.5M hydroxylamine hydrochloride pH 8.5 was added at 1:10 
(v/v) and the sample was incubated for 1 hour on a 360o rotator at room 
temperature.  
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Samples were centrifuged at 13,200rpm for 15 minutes, the supernatant was 
removed and 200μl of 0.1% sarkosyl/PBS was added to wash pellets. This 
centrifuge/ washing step was repeated five times. For the final centrifuge 
pellets were brought up in 100μl 0.1% Sarkosyl/PBS. Labelled fibrils were 
stored at 4oC protected from light. Sodium acetate alone (minus fibrils) was 
processed under exact same labelling conditions as a control for labelling. It 
was optional here to take 10μl for analysis by SDS-PAGE. Procedure as 
described previously (Section 2.2.6) however gel was protected from light and 
was developed in the following mix: 125ml methanol; 23ml acetic acid and 
102ml dH2O for 1 hour at room temperature. The gel was then placed in 
destain overnight (115ml Ethanol; 35ml acetic acid up to 500ml dH2O). The 
next day the gel was imaged using a Typhoon scanner (GE Healthcare) with 
excitation/emission Cy3 filter to confirm effective fibril labelling of the 
diagnostic PrP protein. 
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2.4 Primary culture challenge experiments 
 
A number of experiments were carried out using primary hippocampal cultures 
generated from WT or 101LL mice to access how both genotypes responded 
to external stimuli.  
 
2.4.1 Generic oxidative stress study 
 
Both WT and 101LL cultures were treated with hydrogen peroxide (30% v/v 
H2O2, Sigma) at DIV8 to induce oxidative stress. Samples were treated in 
duplicate at the following concentrations of H2O2: 0µM. 10µM, 100µM and 
300µM for 24 hours. LDH samples were taken at 0hr, 2hr, 4hr, 6hr and 24hr to 
monitor cellular toxicity over-time. After 24 hours incubation all culture 
coverslips were fixed and immunostained for neuronal and astrocytic 
response.  
 
2.4.2 Phagocytosis Assay 
 
The assay was carried out according to manufacturer’s instructions. Briefly all 
media was removed from cells and live cell media (ThermoFisher Scientific) 
was added to each well. Control wells contained live media alone whilst test 
cells contained live media with cells plus pHrodo beads added at 1mg/ml 
concentration. All wells were incubated for 2 hours at 37oC. Fluorescence 
readings were taken at 590nm using the Wallac 1420 plate reader. After this 
cells were fixed and imaged using LSM710 confocal microscope.    
 
2.4.3 WT and 101LL challenge with labelled/ unlabelled fibrils 
 
WT and 101LL cultures were challenged at specific time points with either 
labelled or unlabelled WT or 101L fibrils. Concentrations of fibrils used varied 
between the ranges 7.5μg/ml to 75μg/ml and cell densities between 30,000 
and 150,000 cells.  
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Fibrils were pulse sonicated (Ultrasonic Processor, HERT systems) for 10 
seconds (35% Pulsar) repeated three times before addition to cultures. Fibril 
challenge included both 6 and 24 hour incubations.  
 
2.4.4 101L unlabelled fibril challenge for RNA-seq analysis 
 
Both WT and 101LL cultures (400,000 cells) were challenged at DIV7 with 
7.5μg/ml of unlabelled 101L fibrils for 24 hours. Challenge experiments were 
replicated four times per genotype. Representative LDH media aliquots were 
taken from cultures pre/post challenge. Before addition to cultures, fibrils were 
pulse sonicated (HERT systems) for 10 seconds (35% Pulsar) repeated three 
times. After incubation period, wells were lysed and RNA was extracted as 
described earlier (Section 2.2.7) from fibril treated cultures at DIV8.  
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2.5 Transcriptomic analysis of 101LL and WT models 
 
RNA was isolated from: 
 WT and 101LL DIV8 primary cultures minus fibril challenge 
 WT and 101LL Day 6 hippocampal tissues 
 WT and 101LL DIV8 primary cultures plus fibril challenge 
 
Transcriptomic analysis comparison of WT and 101LL DIV8 primary 
hippocampal cultures minus fibril challenge along with WT and 101LL Day 6 
hippocampal tissues was carried out using the Affymetrix Mouse Gene 2.1 ST 
array plate (Edinburgh Genomics). Additionally, WT and 101LL DIV8 primary 
cultures minus fibril challenge were compared to WT and 101LL DIV8 primary 
cultures plus fibril challenge using Illumina RNA-sequencing (Edinburgh 
Genomics). Four replicate samples per group were analysed.  
 
2.5.1 RNA processing for transcriptomic analysis using microarray/RNA-seq 
 
RNA was isolated from 101LL and WT in vitro primary hippocampal cultures 
pre and post-fibril challenge and from Day 6 101LL and WT in situ 
unchallenged hippocampi tissues (Materials and Methods, 2.2.7). For in vitro 
RNA extractions typically a minimum of four hippocampi were dissociated and 
plated at 400,000 cells per well however, occasionally only two hippocampi 
were plated due to shortages in embryo availability. RNA extractions were 
always pooled in cases where more than one well was cultured from the same 
batch of embryos and this was counted as one sample. Fibril challenge 
experiments were always carried out in duplicate wells (Section 2.4.4). Four 
replicate samples were produced for each genotype group for downstream 
processing. Day 6 hippocampi tissues were isolated each time from three pups 
(six tissues) from the same batch and this produced one individual sample. 
Again, this was replicated four times per genotype. RNA extracted samples 
were processed by Edinburgh Genomics.  
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RNA integrity was determined using the Agilent TapeStation System and a 
RNA integrity number equivalent (RINe) was obtained for each sample. For all 
samples, RINe values of 9 or above were obtained indicating high quality intact 
RNA was isolated (data not shown). For microarray, cDNA was produced 
using the Ambion WT expression kit (Invitrogen) and accordingly labelled 
using the GeneChip WT terminal labelling kit (Affymetrix). Approximately 3µg 
of fragmented, biotin-labelled cDNA was hybridised to a Mouse Gene 2.1 ST 
array plate (Affymetrix) using the Gene Titan instrument (Affymetrix) and 
standard Affymetrix protocols. The microarray results generated probe cell 
intensity data CEL files which were analysed in-house using various software 
programs such as Affymetrix expression console (Section 2.5.2, Figure 2.2) 
and Partek Genomics Suite (Partek Inc., Section 2.5.3). IIumina                     
RNA-sequencing sample processing and preliminary analysis of RNA-seq 
data was carried out by Edinburgh Genomics. Both Ingenuity Pathway 
Analysis (Section 2.5.4) and Miru (Section 2.5.5) were used for                      
further analysis of both microarray and RNA-seq datasets                                                                            
(DOI: http://hdl.handle.net/10283/3168). 
 
2.5.2 Affymetrix Expression Console (Affymetrix) 
 
Expression console software was free to download and was used to analyse 
probe intensity levels pre/post normalisation to ascertain the presence of any 
outliers in the microarray dataset (Figure 2.2). It was also used to convert raw 
data CEL files to TXT files which could be analysed in Miru (Bio-layout) after a 
secondary conversion to Expression file format. Expression console was 
launched and a new study was created selecting CEL files under the add 
intensity files tab. CEL files were giving descriptive names and the run analysis 
option was selected along with Gene Level [Default: RMA-Sketch (Robust 
Multichip Average)].  
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While initiating analysis the file name suffix was left blank, results were 
accessed under the options QC (Signal distribution generated log probe cell 
intensity and log expression signal boxplots). Library annotation files were 
downloaded from Affymetrix site under Technical Documentation; Library 
Files; MouseGene2.1STArray (Zip, 21MB) for CEL file conversion and probe 
set annotation. Analysis of data was carried out as described above, under the 
Edit tab select create annotation merge file; create Affymetrix gene level merge 
file; select annotation file; select dataset; save; export results; results with 
annotations to TXT. Click   icon for options; select an annotation merge 
file; save as TXT file. For editing purposes the TXT file was then converted to 
a XLS file and the following editions were carried out in excel: Find and 
Replace option was used to replace cells containing “---“ with “N/A”. Two new 
columns were added on left side of sheet; Gene Symbol column was cut and 
pasted into new blank column beside Probe Set ID. Concatenate both columns 
using formula “=A1&”:”&B1”. All data at Log2 (RMA analysis) was delogged by 
copying all values to a new sheet then in a parallel new cell the formula “=2^A1” 
was entered and applied to all numbers. Delogged numbers were selected and 
copied and pasted as number only over original numbers and file was saved 
accordingly first as a XLS file then as Text (Tab delimited) and finally saved as 
a “filename.expression” file.  
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Figure 2.2: Affymetrix Expression console confirmed normal sample 
distribution. To examine if any outliers were present in microarray data pre and 
post normalisation, probe signal intensities profiles were compared across all 
16 samples (Section 2.5, 8 in vitro, 8 in vivo). (A) Log raw probe cell intensity 
box plot created in Affymetrix Expression console, x axis 16 samples, y axis 
log probe cell intensity values. (B) Log Expression signal based on normalised 
probe set signal intensities, x axis 16 samples, y axis log expression signal. 
Box plots were based on CEL file probe signal intensity values of 16 samples. 
Prior to normalisation (A) some differences in the distributions were present 
however, no samples were dramatically different from other replicates in the 
same group. After normalisation, all samples were comparable to each other 
and no outliers were present. RMA (Robust Multichip Average) algorithm 
performed a background correction, quantile normalisation and median polish 
summarisation of data.  
 
 
2.5.3 Partek Genomics Suite (Partek) 
 
Partek was launched using a remote desktop connection genepool-
vm.bio.ed.ac.uk and the relevant password required was entered. A new folder 
was created on this remote desktop and CEL files (microarray) were 
transferred to this folder. Partek Genomics tab was opened and Gene 
Expression workflow was selected and sample files were imported.  
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The option use RMA (Robust Multichip Average) was selected and then 
Import. Partek uses an robust multi-array average algorithm which performs a 
background correction, quantile normalisation and median polish 
summarisation of data. Box plots were accessed at this stage from the right 
panel of the Partek genomics suite. Sample attributes were selected followed 
by add a categorical attribute. Attribute name was Genotype and Group name 
was WT or 101LL. Samples were added followed by add another attribute 
option (selection based on group number for analysis) and option Yes was 
selected for save spreadsheet. From here data such as PCA (Principle 
Component Analysis) was accessed and saved as GIF files. Next select option 
detect differentially expressed genes; Genotype selected; Add factor; 
Contrast; Name; Add contrast level from candidate levels list; Add contrast. 
This provided a list of every gene that was up or down-regulated. To create a 
more constricted dataset a gene list was created. Select create gene list; select 
comparison groups (under contrast); Fold change default at > 1.5 or < - 1.5    
p-value with FDR < 0.1. Filters may be altered here; create; save as; .TXT in 
Partek; then files were transferred to users’ desktop and renamed to .xls files. 
 
2.5.4 Ingenuity Pathway Analysis (IPA, Qiagen) 
 
IPA was launched from the Qiagen website under the Ingenuity pathway 
analysis option using the appropriate password (link to website is: 
http://www.ingenuity.com/products/login. A new project was created and gene 
lists created from analysed RNA-seq data (Edinburgh Genomics) were added 
as per following instructions: New; New Core Analysis; Upload; File was .xls 
format; Select File format (Flexible); Contains column Headings (Yes); Select 
Identifier Type (Select All); Array platform used for experiments (Not Specified/ 
applicable). Column ID was selected for ID filter which recognises majority of 
genes in dataset. Fold change was used as Observation 1 followed by Save 
and Create Analysis; Choose relevant Project.  
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Parameters Selected as follows: General Settings: Relationships to consider 
(Direct and Indirect Relationships), Networks (Genes are always included: 
Molecules per network 35/ Networks per analysis 10), Data sources (All), 
Confidence (Select Experimentally observed), Species (Select all), Tissue & 
Cell lines (All), Mutation (All), Fold Change can be left as 0 or select a relevant 
value. Select run analysis; input descriptive name. A report was computed 
under Analyses and was headed by a Summary Tab followed by a number of 
tabs including Canonical Pathways, Upstream Analysis, Disease & Functions, 
Regulator Effects, Networks, Lists and My Pathways and Molecules. PDF 
summary sheets were generated and contained brief descriptions of all of the 
above data (Reference Table 6.5 for PDF summaries).  
 
2.5.5 Miru (BioLayout Express) 
 
Miru is a powerful tool specifically designed for the visualisation and analysis 
of large network graphs obtained from biological datasets (Theocharidis et al. 
2009). Before using this software excel datasheets obtained from microarray 
or RNA-seq analysis were altered to display all annotation data on the left of 
sheet and group headings were positioned in logical order. This altered file 
was saved as “filename.expression” (Section 2.5.2). Miru was launched from 
website: http://kajeka.com/. The normalised, non-log transformed gene 
expression files were inputted into the Miru platform. Miru displayed Load 
correlation data dialog box, ID columns red, meta-data green and raw data 
light blue and created visual graphs based on a Pearson correlation matrix. A 
sample to sample correlation matrix was calculated using the pre-processing 
option along with the transpose option. A Correlation Value of 0.95-0.99 was 
selected followed by ok. The resulting analysis displayed Nodes, representing 
individual data sets in the form of circular balls and Edges representing 
connections between each node (Red lines show close relation Pearson of 1, 
Blue lines represent lower end of threshold) and were saved accordingly. For 
gene analysis no pre-processing was required.  
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A pairwise transcript to transcript Pearson correlation matrix was calculated 
based on each transcripts profile across all samples in the experiment. For 
Expression Graph Settings various values were altered, generally a value of 
50 was entered for Filter Rows with all values less than 50 (background and 
or genes of little relevance) and 0.95-0.99 for Correlation Value (Nodes and 
Edges values are displayed accordingly). The network graph was further 
processed and clustered into groups of genes sharing similar profiles (unique 
clusters) using the Markov Clustering (MCL) algorithm, at an MCL inflation 
value set to 2.2 (controls granularity of clustering). Generally a value of 5-10 
was selected for the Smallest Cluster Allowed then click Run MCL. Under 
Class Viewer  icon the content of each cluster was viewed using the 
various options available. To identify clusters of interest Class viewer was 
selected and various clusters were explored. To remove Nodes without any 
assigned class a “no class” node was selected followed by Ctrl+Alt+S (select 
all nodes) then Ctrl H (Hide). Clusters of interest were selected using Ctrl+R 
(reverse selection) then Ctrl H or Ctrl U to unhide nodes. Tables of data were 
exported as TXT files. To separate gene name from I.D number in excel, select 
column, Data, Text to Columns, Delimited, Tick space, Finish. Gene lists 
associated with clusters were cross referenced with Analysis of variance 
(ANOVA) lists by the following method: Copy cluster list into new tab (gene 
name only), highlight and name column List1 (top left box, List1 enter), in 
another tab named reference (ANOVA) add all genes and P-Values,          
LogFC data (ANOVA), don’t include headings, enter code 
=VLOOKUP(A1,List1,1,FALSE), A1 can be changed to link to any column for 
comparison, highlight the correct number of cells, Select Home, Fill, Down.  
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2.5.6 PANTHER, GOrilla and DAVID gene expression analysis 
 
PANTHER (Protein Annotation Through Evolutionary Relationship), GOrilla 
(Gene Ontology enrichment analysis and visualisation tool) and DAVID 
(Database for Annotation, Visualisation and Integrated Discovery) are freely 
accessible bioinformatic databases (Mi et al. 2013; Eden et al. 2009; Huang, 
Sherman, and Lempicki 2008). PANTHER is a comprehensive system 
combining gene function, ontology, pathways and statistical analysis tools. 
GOrilla is another Gene Ontology (GO) analysis tool with fast running time and 
effective graphical representation. DAVID is also effective at extracting 
biological meaning for large gene lists. All programs were utilised here for 
analysing gene expression experimental data GO terms. Each tool was 
launched from the website link http://www.pantherdb.org/, http://cbl-
gorilla.cs.technion.ac.il/ and https://david.ncifcrf.gov/. From previously created 
gene datasets in excel a list of candidate gene symbols were copied and 
pasted into relevant box and Mus musculus was selected where applicable for 
organism identification. Selected Identifiers included either Affymetrix exon 
gene ID or official gene symbol. Various options were then selected based on 
each dataset and the relevant analysis was saved accordingly. 
 
2.5.7 BioGPS 
 
This gene annotation portal based on existing genetic and genomic resources 
is freely and publicly available at http://biogps.org/ and enables users to easily 
integrate data within the BioGPS platform and explore the landscape of gene 
annotation for one or more genes of interest (Wu et al. 2009). Genes of 
interested were inputted into this software and results were saved accordingly.  
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2.5.8 Real-Time quantitative Reverse Transcription PCR (RT qRT-PCR) 
 
Extracted RNA samples were used as a template for cDNA synthesis. RNA 
was diluted accordingly in RNase-free water based on nanodrop quantification 
values to get a final working volume of 1µg RNA. Samples were incubated with 
2μl (0.5μg/μl) of Oligo (dT)15 (Promega) plus 2μl 10mM dNTP’s (Invitrogen) 
and topped up to a final volume of 26μl using RNase-free water. Negative 
controls comprising RNase-free water alone were also included. The mixture 
was heated for 5 minutes at 65oC followed by immediate incubation on ice for 
1 minute. The following reaction for first strand synthesis was then carried out: 
8μl of 5X First strand buffer (Life Technologies), 4μl of 0.1M DTT (Life 
Technologies), 1μl Superscript III (Life Technologies) and 1μl RNasin Plus 
RNAse Inhibitor (Promega). The thermocycler was set-up to the following 
program: 60 minutes at 50oC followed by 15 minutes at 70oC then hold at 4oC. 
The synthesised cDNA had a concentration of 25ng/μl and was stored at -70oC 
until further use. A standard PCR as described in Section 2.1.4 was used to 
confirm the presence of cDNA. 15μl of mastermix (Table 2.4) was added to 
each well in a 96 well plate followed by the addition of 5ng/μl of cDNA (1/5 
dilution of stock). Controls included wells where cDNA was replaced with 
RNAse/DNAse free water. This controlled for cross contamination between 
wells or contamination of one or more reagents. Additionally, wells comprising 
the equivalent concentration of RNA (minus reverse transcription) were 
included as controls for genomic DNA contamination. 
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Components (All Primerdesign) Per Single Reaction (µl) 
Resuspended primer mix 1* 
2X PrecisionPLUS mastermix 10 
RNAse/DNAse free water 4 
Final Volume 15 
   *Working concentration of primers was 300nM in a 20μl reaction 
 
Components (Sigma Oligo’s) Per Single Reaction (µl) 
Brilliant III Ultra-Fast SYBR Green* 10 
Reference Dye (1/500 dilution) 0.3 
20µM Primer A 0.4 
20µM Primer B 0.4 
RNAse/DNAse free water 0.9 
Final Volume 12 
   *Agilent Technologies 
 
Table 2.4: Mastermix ingredients and quantities for RT-qPCR using 
Primerdesign or Sigma methods. All runs were carried out using the 
Stratagene Mx3005p system. In these studies SYBR green mastermix 
(Primerdesign/ Agilent technologies) was the fluorescent dye used. 96 well 
PCR plates (ABgene) and optical caps (Applied Biosystems) were used for all 
RT-qPCR runs. Each sample was loaded in triplicate.  
 
 
Primers were selected based on target genes of interest and included 
Transforming growth factor beta induced (Tgfbi), Laminin alpha 1 (Lama1), 
Transthyretin (Ttr), Myocyte Enhancer Factor 2C (Mef2c), Midline 1 (Mid1), 
Solute carrier family 9 member b2 (Slc9b2) and PrP (Prnp) all from 
Primerdesign. Tumor necrosis factor, alpha-induced protein 2 (Tnfaip2), Tumor 
necrosis factor (Tnf), Purinergic receptor P2Y, G-protein coupled, 14 (P2ry14), 
Lysosomal protein transmembrane 5 (Laptm5), and neurotrophic receptor 
tyrosine kinase 1 (Ntrk1) were obtained from Sigma.  
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To identify suitable reference/ housekeeping genes the GeNorm PCR kit 
(Primerdesign, Figure 2.3) was used as described in manufactures protocol 
(http://www.protocol-online.org/forums/uploads/monthly_07_2012/post-6378-
0-25922900-1342778301.ipb). The kit utilised a panel of 12 reference genes 
namely, B2m (Beta-2 microglobulin), Ubc (Ubiquitin C), Gapdh 
(Glyceraldehyde 3-phosphate dehydrogenase), Actb (Beta-actin), 18S 
(Ribosomal RNA), Ywhaz (Tyrosine 3-Monooxygenase/Tryptophan                    
5-Monooxygenase Activation Protein), Cyc1 (Cytochrome C-1), Canx 
(Calnexin), Rpl13a (Ribosomal protein LI3A), Atp5b (ATP synthase/ H+ 
transporting mitochondrial F1 complex), Eif4a2 (Eukaryotic Translation 
Initiation Factor 4A2) and Sdha (Succinate Dehydrogenase Complex). 
Mastermix for reactions described previously in Table 2.4 and sample cDNA 
was added to 96 well plate in triplicate at 5ng/μl (1/5 dilution of stock). As 
shown in Table 2.5, amplification conditions varied slightly between 
Primerdesign and Sigma and were selected according to primers used.  
 
 
Cycling Step Time 
(seconds) 
Temperature 
oC 
  Enzyme activation 120 95 
 
Cycling x40 
Denaturation 10 (15) 95 
DATA Collection* 60 (30) 60 
    *Fluorogenic data collected through SYBR green channel. 
 
Table 2.5: Amplification conditions for 2X PrecisionPLUS qPCR mastermix 
used in conjunction with the Mx3005p system (Primerdesign). Conditions in 
brackets were used for brilliant III Ultra-Fast SYBR Green mastermix (Sigma). 
The result of each run was saved as both MXP and TXT format.  
 
To analyse results, MxPro software was launched and SYBR Green (with 
dissociation curve) option was selected followed by relevant saved mxp file. 
The plate was labelled according to sample identification and the all tab was 
selected followed by the analysis and the results tab.  
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Under the Amplification plots option all Ct (Cycle threshold) values were 
viewed to confirm reproducibility and variability between replicates (< 0.5 
difference in Ct values acceptable). Consolidated reports were generated and 
saved as bmp files. Text report option was selected and the following 
parameters were chosen: Well, Well name, Dye, Well type, Ct (dR), and 
Quantity (copies) and this information was exported as a Text file. Text files 
were saved as xlsx for standard analysis. Results from the GeNorm PCR kit 
were analysed using the Biogazelle qbase+ analysis software. This software 
included a module for GeNorm analysis. The software was launched and a 
new project was created followed by next tab. The relevant TXT files were 
imported under manual import option. Manual import configuration had the 
following parameters – Mx3000xP, Open Runs (Never), Extract well Info 
(Selected) and Sample (Selected). The next options were variable depending 
on sample analysis type where maximum replicate variability (Difference in Cq) 
was set to 0.5 and default settings were selected for the rest of the available 
parameters. Quality control outputs demonstrated 100% pass rates. Analysis 
results produced a graph showing average expression stability of 12 reference 
targets ranking according to expression stability (left of graph least stable, right 
most stable). 
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Figure 2.3: Identification of the most stable reference/housekeeping genes. 
The GeNorm kit was used to identify genes that would be stably expressed 
across all samples, to provide suitable reference/ housekeeping genes for 
normalisation to be carried out of all RT-qPCR runs. The top graph shows 
expression stability of 12 individual reference targets (Section 2.5.8) generated 
using Biogazelle qbase (geNorm technologies) software based on MxPro 
(Stratagene) obtained data. Least stable genes are to the left of the graph 
(bottom) and increase in stability to the right. Enlarged image (dotted line box) 
clearly demonstrates that Succinate dehydrogenase complex (Sdha), Tyrosine 
3-monooxygenas/tryptophan 5-monooxygenase (Ywhaz) and ATP synthase/ 
H+ transporting mitochondrial F1 complex (Atp5b) were stably expressed 
across all 16 microarray untreated samples and therefore were selected as 
reference/housekeeping genes for all RT-qPCR runs. Y axis geNorm M-value, 
calculated by GeNorm is a measure of stability of gene expression, lower M-
values show increased stability. X axis, genes were ranked starting with least 
stable genes on left. 
 
Relative changes in gene expression were calculated using the Delta Delta                     
Ct (C
T
 ) method using the formula shown in Table 2.6 (Livak and Schmittgen 
2001). 
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Sample Gene 
     Target (Gene of interest) Reference 
Calibrator 
(WT) 
      CT(target, calibrator) CT(reference, calibrator) 
Test (101LL)      CT(target, test) CT(reference, test) 
 
Table 2.6: Relative Quantification using the Livak, or C
T 
method. 
Normalisation was carried out against the most stable reference gene. Three 
stages were carried out in excel based on the average of C
T 
readings:                 
1. Normalise C
T 
(target gene) to C
T 
(reference gene); 2. Normalise C
T 
of test 
sample to C
T 
of calibrator [C
T
 = C
T 
(test) - C
T 
(calibrator)]; and 3. Calculate 
expression ratio, or fold difference [2- CT]. 
 
2.6 Organotypic brain slice culturing 
 
Brain organotypic brain slice cultures (BOSC) were developed based on a 
modified version of the original protocol described by Stoppini (Stoppini, 
Buchs, and Muller 1991). Organotypic brain slices were obtained from brains 
of mice at postnatal Days 6-7 (Cho, Wood, and Bowlby 2007). A non-Schedule 
1 termination of each individual postnatal pup involved decapitation followed 
by immediate brain removal and immersion into oxygenated artificial 
cerebrospinal fluid (aCSF). The aCSF was prepared as follows and mixture 
was cooled until slush like appearance: 125mM NaCl, 26mM NaHCO3, 25mM 
Glucose, 2.5mM KCl, 1.25mM NaH2PO4H2O, 1mM CaCl2 and 4mM MgCl2 pH 
7.4. The aCSF slush was then oxygenate using 95% O2 / 5% CO2 gas (BOC). 
After a 3 minute incubation in oxygenated aCSF the brain sample was placed 
on the Mcilwain tissue chopper and 400μm thick coronal brain sections were 
cut. The sectioned brain was carefully placed in aCSF buffer and slices were 
dissected under a dissection microscope which aided efficient separation. Both 
full brain slices and hippocampal only slices were taken for culturing. The 
freshly prepared slices were placed on pre-warmed 6 well culture plates 
containing sterile 0.4µm pore 30mm membrane inserts (Millipore) and 1ml of 
culture medium.  
78 
 
Organotypic slice culture medium ingredients were obtained from Invitrogen 
and the formula was as follows: 49.6ml Minimum Essential Medium (1X) liquid 
(with Earle's Salts, 25mM HEPES, without L-Glutamine), 24.8ml Hank’s 
balanced salt solution, 24.8ml Horse serum (heat-inactivated), 1ml Penicillin-
Streptomycin (10,000 U/ml, Gibco) and 0.25% L-Glutamine 100X (200mM). 
Plates were incubated at 37oC in 5% CO2. Organotypic slice culture medium 
was replaced twice a week with fresh pre-warmed medium to maintain a 
healthy culture. Fixation of organotypic slices for immunolabelling was carried 
out as follows: organotypic slices were incubated with 4% PFA (w/v) for 45 
minutes at room temperature. The PFA was removed and slices were washed 
three times with DPBS containing Ca2+ and Mg2+ (Gibco). 1-2ml of ice-cold 
methanol was added to the cells for 10 minutes at -20oC followed by a 5 minute 
incubation with 0.3% Triton-X (v/v, Sigma-Aldrich) at room temperature. Cells 
were blocked for 2 hours at room temperature using Fc Block (Anti-mouse 
CD16/32 BioLegend). Primary antibodies (Table 2.1) were incubated overnight 
in 5% Goat serum (v/v, Gibco) at 4oC, then were washed three times in DPBS 
containing Ca2+ and Mg2+ (Gibco). Incubation in secondary antibodies listed in 
Table 2.1 followed for 1.5 hours at room temperature in complete darkness. 
Slices were  washed three times again in DPBS, for the final wash and a DAPI 
(Molecular Probes) counterstain was carried out (300nM). Using a scalpel the 
membrane supporting the tissue slice was dissected from the insert and was 
placed in 40µl of Prolong Diamond Antifade Mountant (Life Technologies) 
which was previously loaded onto a specialised cavity glass slide (Marienfeld). 
Coverslips were placed over membranes and were allowed to dry for 4 hours 
at room temperature then overnight at 4oC. Coverslips were sealed using 
CoverGrip Coverslip Sealant (Cambridge BioScience) and imaged using the 
LSM710 inverted confocal microscope (Zeiss). Slides were stored at 4oC for 
several weeks without substantial loss of fluorescence. 
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CHAPTER 3 
 
Development and characterisation of primary hippocampal 
neuronal culture model 
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3.1 Abstract 
 
An in vitro system was established at the Roslin Institute with which to study 
the cellular and molecular mechanisms of prion-induced neurodegeneration. 
The hippocampal area of the brain is vulnerable in a range of protein misfolding 
diseases, therefore primary mixed neuronal cultures were prepared from 
murine hippocampi and characterised for cell representation and synapse 
formation. This model system contained readily accessible neurons and 
important supportive cells such as astrocytes and microglia. Cultures were 
established from wild type animals and a number of different transgenic 
animals with altered PrPC production. This study mainly focused on two 
genotypes, PrP 101LL mice (101LL) that support PrP fibril formation and 
129/Ola mice (WT) that do not. The cultures developed highly branched 
neuronal networks supported by glia. In-depth analysis of immunolabelled cell 
populations was carried out using IMARIS modelling software and no obvious 
morphological differences were noted between WT and 101LL genotypes. 
Neuronal maturity was confirmed by the presence of both pre and                  
post-synaptic protein markers and cultures were maintained for up to twenty 
days. PrPC was detectable in cultures from DIV3 (Days in vitro) and 
biochemical analysis confirmed a similar glycosylation profile to murine brain 
suggesting PrPC in this model was processed similarly to the in vivo 
environment. In conclusion, this system provided an excellent in vitro model 
for investigating early misfolded protein processing. 
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3.2 Introduction 
 
The brain is the most complex organ of the body therefore the development of 
more simplified easily accessible but still appropriately representative in vitro 
models is paramount for studying neurodegeneration. Currently there are no 
effective treatments for neurological disorders such as Alzheimer’s disease 
(AD), Parkinson’s disease (PD) and Prion disease all of which are associated 
with misfolding proteins. A well characterised in vitro model system may 
provide mechanistic insights of misfolded protein metabolism relevant to the 
development of new therapeutic strategies for these diseases. Currently there 
are numerous cell lines used in the neurodegenerative field to study 
neurodegeneration including PC12 (rat adrenal medulla pheochromocytoma 
cells), SH-SY5Y (human neuroblastoma cells), N2a (mouse neuroblastoma 
cells) and GT1 (mouse hypothalamic cells), however each of these cell lines 
have their limitations in their overall representation of the brains cellular     
make-up (Schlachetzki, Saliba, and Oliveira 2013; Bosque and Prusiner 2000). 
Primary neuronal cells are more biologically relevant and can be used to 
culture neurons and other supporting cells from numerous mouse lines 
relevant to the study of neurodegenerative disease. In this chapter, a primary 
hippocampal neuronal system was developed based on previous published 
work (Kaech and Banker 2006; Banker and Cowan 1977). The hippocampus 
is associated with cognition, learning and memory and is one of the first 
regions to suffer damage in AD (Mu and Gage 2011), is implicated in cognitive 
dysfunction observed in PD’s (Calabresi et al. 2013) and also is a target area 
associated with early synaptic loss in some Prion diseases (Hilton et al. 2013; 
Cunningham et al. 2003). Furthermore, our previous studies have indicated 
that this specific area of the brain is a target for abnormal protein seeding in 
101LL mice and therefore may play a major role in protein misfolding diseases 
(Barron et al. 2016). Studying subcellular distribution and misfolded protein 
interactions in the hippocampus in vivo is extremely difficult due to its position 
within the brain. Thus, this area is the focus for in vitro modelling in this study.  
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The development of a primary culturing system from the hippocampus can 
help to address this to a certain extent whilst providing an easily accessible 
and manipulatable system for studying misfolded protein trafficking and 
degradation pathways. Hippocampal cultures were prepared from late-stage 
mouse embryos (Day 17). There were a number of considerations that 
influenced this choice of time point including but not limited to, the presence of 
pyramidal neurons, ease of tissue dissociation, and comparatively low 
presence of glial cells. However, the trade-off for these positive factors is that 
the generation of dentate granule neurons has not yet begun (Banker and 
Cowan 1977). Traditionally an astrocyte feeder layer system was used to 
provide trophic support to the neurons. Here an alternative strategy was 
employed where neurons were maintained in growth medium containing N2 
and B27 supplements that enhanced and promoted neuronal growth and 
maintenance (Kaech and Banker 2006; Brewer et al. 1993). To summarise, 
previous studies by our group have shown that WT mice were able to curtail 
protein misfolding seeding mechanisms whilst 101LL mice supported it. Both 
WT and 101LL mouse lines therefore provided excellent tools for investigating 
misfolded protein interactions. Thus, primary hippocampal neuronal models 
were generated from these genotypes providing an excellent in vitro platform 
to enable the investigation of neuronal and neuroglia interactions when 
challenged with misfolded protein. Any processing pathways found here might 
also be relevant to other neurodegenerative diseases.   
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3.3 Results 
 
3.3.1 Optimising conditions for hippocampal dissection and cell 
dissociation 
 
CD-1 mice were initially used to develop the workflow and establish a 
reproducible hippocampal dissection and processing methodology as these 
mice are reliable breeders and provided large numbers of embryos. After this 
optimisation WT, 101LL and PrP knockout line (PrP-/-) were used for 
generating primary hippocampal cultures. In accordance with Home Office 
non-schedule 1 procedures, the embryos were chilled on ice until a complete 
lack of responsiveness was observed and then immersed into ice-cold BME 
buffer (Materials and Methods, 2.2). As shown in Figure 3.1 each embryo head 
was removed and the brain isolated. A tail snip was also retained from each 
embryo (applicable to all genotypes) and PCR was subsequently used to 
confirm genotype. 
 
 
Figure 3.1: Illustration of the technique to remove brains from Day 17 embryos. 
Each embryo was approximately 2cm in length. The head was decapitated and 
using a fine scissors, a midline incision at the skin surface was made and the 
skull was separated into two halves. The brain was carefully removed and was 
placed into a 35mm culture dish containing ice-cold Hanks/Hepes buffer. 
Hippocampi were then isolated with the aid of a dissection microscope.  
 
To facilitate efficient dissociation of hippocampal cells, trypsin from two 
manufactures Worthington Biochemical Corporation and Life Technologies 
were initially investigated.  
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Cells needed less trituration using Life Technologies Trypsin minimising 
damage during cell dissociation and therefore this brand was used for all 
subsequent hippocampal dissociation procedures. Cell density was calculated 
using a hemocytometer and cell viability was determined using 0.4% Trypan 
Blue solution. In all cases where Trypan blue was used to test cellular viability 
the majority of cells tested were colourless indicating minimal presence of 
damaged cells in relation to cell dissociation methods. Approximately 400,000 
cells were isolated per embryo and cells were plated at concentrations relevant 
to the culture platform used (Materials and Methods, 2.2.2). Cells were initially 
plated overnight in growth medium however, this generated surplus debris in 
the cultures, which contributed to cell stress and neuronal deterioration within 
a couple of days in culture. To overcome this problem initial incubation time in 
growth medium was decreased from 24 hours to 4 hours allowing adequate 
time for cellular adherence to the relevant attachment factor. This also allowed 
for rapid removal of unwanted cellular debris from the cultures. After this step, 
cells were maintained in serum-free medium. Two different recipes of media 
were investigated to determine which would provide maximum neuronal 
support and growth in vitro (Table 3.1). These recipes were made with either 
GS21 (Sigma) or B27 (Gibco) supplements and culture growth and 
sustainability was monitored accordingly. GS21 claimed to be superior to B27 
regarding long-term neuronal viability however, when cellular viability was 
measured using a Lactate dehydrogenase (LDH) cytotoxicity assay (Section 
3.3.2), B27 cultures showed better neuronal viability (Appendix Figure 3a). 
Light phase contrast microscopy of cultures confirmed the development and 
morphological characteristics of neuronal-like cells. This was useful in 
determining if cells were present but was limited in its overall contributions to 
understanding the development and viability of these cultures over-time. Other 
characterisation methods were therefore employed to help with these 
investigations. 
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Original Serum-Free Medium  Improved Serum-Free Medium  
Basal Medium Eagle 500ml  (Gibco) Neurobasal Medium 500ml (Gibco) 
B27 50X 10ml (Gibco) B27 50X 10ml (Gibco) 
32.5% Glucose 8ml  (Sigma) L-Glutamine 200mM 5ml (Gibco) 
Penicillin-Streptomycin 5ml (Gibco) Penicillin-Streptomycin 5ml (Gibco) 
Sodium Pyruvate 100mM 5ml (Gibco)  
N2 supplement 5ml (Gibco)  
 
Table 3.1: Different formulas for supporting primary cultures were investigated. 
Initially cultures were incubated with original serum-free medium recipe 
however, due to various problems incurred during culturing this formula was 
changed to the improved serum-free medium, which supported long-term 
viable neuronal growth.  
 
3.3.2 Monitoring neuronal viability in normal and stressed environments 
 
To assess the suitability of different culturing protocols it was necessary to 
determine the viability of cellular preparations to identify to most sustainable 
and optimal methods for maintaining primary neuronal cultures in vitro. Thus, 
cellular viability of WT and 101LL cultures was evaluated using a commercially 
available CytoTox 96 Non-Radioactive cytotoxicity LDH Assay (Materials and 
Methods, 2.2.4). This assay quantitatively measures a stable cytosolic enzyme 
LDH that is released from damaged cells into the medium and is therefore 
used to determine cellular health (Smith et al. 2011). Supernatants removed 
during routine culture maintenance were retained for LDH analysis (Materials 
and Methods, 2.2.3). Initial experiments indicated retained supernatants could 
not be frozen for long term storage as recommended by the supplier, instead 
they were stored at 4oC (LDH consists of five isoenzymes which have varied 
responses to different storage conditions, LDH 4 and LDH 5 are sensitive to 
freezing). LDH readings in WT cultures were minimal indicating neuronal cells 
were viable in their new in vitro environment (Figure 3.2). Low concentrations 
of LDH measured over-time suggested that WT cell cultures were viable up to 
eight days in vitro.  
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101LL neuronal cultures displayed a similar LDH response trend but were 
more susceptible to cellular stress after initial plating (Appendix Figure 3.a). To 
determine how long viable primary hippocampal cultures could be maintained 
for, longer time point experiments were carried out and results confirmed cells 
were stable up to DIV20 (Appendix Figure 3.b). Similar studies were also 
carried out using a PrP knockout line (PrP-/-). PrP-/- mice lack the presence of 
PrPC protein, which has been proposed to have neuro-protective properties 
suggesting these cells may be more susceptible to stresses from in vitro 
culturing. LDH studies showed minimal stress levels were evident in PrP-/- 
cultures even after initial plating indicating PrPC may not play an important role 
in neuroprotection (data not shown).  
 
W
T
 1
W
T
 2
W
T
 3
 
W
T
 1
W
T
 2
W
T
 3
 
W
T
 1
W
T
 2
W
T
 3
 
W
T
 1
W
T
 2
W
T
 3
 
0
5
1 0
1 5
5 0
1 0 0
%
 L
D
H
 R
e
le
a
s
e
D IV  0
D IV  3
D IV  7
D IV  8
 
Figure 3.2: Minimal levels of Lactate Dehydrogenase (LDH) were found in 
primary hippocampal cultures. LDH was measured in the supernatant of 
primary cultures prepared from WT mice at 0, 3, 7 and 8 days in vitro (DIV) 
and was used to monitor cellular viability over-time and cell viability was 
maintained up to DIV8. Individual sample readings also confirmed viability was 
reproducible in cultures. Fluorescent values were normalized to Triton X-100 
treated lysis cells that represent the maximum amount of LDH available for 
release. WT cells plated at 400,000 cells per well on pre-coated PLL 6 well 
plates, Graph mean plus standard deviation, n=3 triplicate technical replicates. 
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3.3.3 Characterisation of neuronal development                                                
 
Cell growth was initially characterised based solely on the morphological 
appearance of cells under phase contrast microscopy, in conjunction with LDH 
analysis (Figure 3.2, 3.3). Further insight on cell development was gained from 
live cell imaging where neurons developed as expected and were seen to be 
constantly monitoring their environment by either contracting or extending their 
processes. Snapshots obtained from live imaging (Figure 3.3), show early 
neuronal developmental as previously described by other groups (Beaudoin et 
al. 2012). These stages were determined by morphological alternations and 
included; DIV0-1 cell attachment to the chosen substrate followed by extension 
of lamellopodia; DIV1-2 emergence of several minor/short neuronal processes 
known as neurites; DIV2-3 individual neurite growth forming long axons and 
DIV3 axon development where dendrites started to grow and branch. Further 
development involved synapse formation and neuronal maturation, which will 
be discussed later in this chapter (Section 3.3.5). Based on phase contrast 
image analysis from both WT and 101LL cultures it was concluded that both 
neuronal cultures develop in a similar manner, reflective of that reported in the 
literature (Beaudoin et al. 2012; Kaech and Banker 2006). Some individual 
cellular variation in cell maturity was seen within cultures but by DIV6, all cells 
were at equivalent stages of growth. Phase contrast microscopy showed the 
development of neuronal-like cells from primary hippocampal cultures 
however, this was not an absolute identification of these cell types. To address 
this, immunofluorescent labelling of neuronal specific proteins was used to 
confirm neurons were present and allowed for in-depth morphological analysis 
to be carried out. Immunolabelling for both MAP2 and Tau confirmed the 
presence of neurons in culture (Figure 3.4). MAP2 is commonly used as a 
marker for neuronal cells and their dendritic processes. Tau is expressed 
abundantly in neurons and to a lesser extent in astrocyte and oligodendrocyte 
cell populations. Both markers highlighted the complexity of these neuronal 
communication networks however, the intensity of Tau immunolabelling was 
too complex for any additional computational analysis to be carried out. 
88 
 
Therefore, MAP2 was predominantly used for future morphological analysis 
studies using IMARIS image analysis software (Materials and Methods, 2.2.9). 
IMARIS software was developed to explore and analyse complex datasets and 
was used throughout the characterisation of primary hippocampal cultures. 
Initial analysis employed IMARIS filament tracer, which reconstructed MAP2 
immunolabelled confocal images and showed some 3D characteristics were 
maintained after fixation of cultures using specialised concave microscope 
slides (Figure 3.5). Additional analysis allowed for the detailed examination of 
neuronal population morphologies from both WT and 101LL genotypes, that 
were shown previously to have contrasting responses to abnormal protein 
insult in vivo (Barron et al. 2016). No differences were seen in dendrite area 
(sum of the generated surfaces of a frustum or truncated cone) and dendrite 
branching angle (angle directly at a branch point) parameters in both 
genotypes (Figure 3.6; mean dendrite area WT 34.56; 101LL 35.40; mean 
dendrite branching angle WT 16.12; 101LL 15.95). However, differences in 
dendrite length (the sum of the length of all edges, which compose a dendrite) 
were detected (Figure 3.6; mean dendrite length WT 6.02; 101LL 4.98). 
Further investigations determined variation in this parameter occurred 
between cultures even of the same genotype and therefore, any significant 
morphological differences between genotypes should be viewed cautiously as 
these results may not be of biological significance. Additionally, the intricacy of 
the neuronal networks were challenging to the algorithms employed in the 
IMARIS software, which may have introduced some misconstructions. Overall, 
it was concluded no obvious differences were evident in the intrinsic properties 
of 101LL cultures that might support abnormal protein production after          
fibril challenge. Monitoring the development of primary neurons over-time by 
immunocytochemistry was important in determining growth, development and 
survival in vitro. MAP2 staining was used to investigate this at a number of 
time points. Neuronal growth was evident and constantly developing over-time 
(Figure 3.7). At DIV20, a noticeable decrease in neuronal staining was evident 
which complemented previously obtained LDH results (Appendix Figure 3.b) 
suggesting a loss of neuronal viability from this time point.  
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Figure 3.3: Morphological development of dissociated cells into neuronal-like 
cells. In vitro development of dissociated neuronal cultures was visualised 
using the live cell observer and snapshots from live imaging videos were taken 
from 0-3 days in vitro (DIV) to confirm neuron-like cells were developing 
normally. Neuronal-like processes were evident from DIV2-3, confirming 
normal growth of cells. Scale bar WT DIV 0-1; 1-2; 2-3 50µm, WT DIV 3 30µm 
Zeiss live cell axiobserver. 
 
 
 
 
 
Figure 3.4: Immunolabelling of neuronal specific proteins confirmed neurons 
were present in cultures. Primary cultures labelled with (A) Dendritic marker 
Microtubule Associated Protein 2 (MAP2/Green) and (A1) Neuronal marker 
Tau (Red). Tau immunolabelled images displayed less definition in comparison 
to MAP2. (B-B1) Plating at low cell density was advantageous for studying 
neuronal morphology. Hippocampal cultures (A) 150,000 (B) 75,000 cells, 
plated on PDL/Fibronectin glass coverslips, Scale bar 50µm, Zeiss LSM 710.  
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Figure 3.5: Concave mounting of cultures conserved neuronal architecture. 
IMARIS reconstructions of MAP2 (neuronal) immunolabelled images were 
generated for concave and flat mounting methods. (A-A1) Concave coverslip 
mounting and (B-B1) Flat coverslip slip mounting. Concave images displayed 
abundant 3D processes throughout sections, highlighted in blue. Flat mounting 
showed limited 3D processes present in the sections therefore, concave 
mounting was always used for imaging which helped maintain neuronal 
structures. 101LL DIV8 cultures 75,000 cells, plated on PDL/Fibronectin glass 
coverslips, Scale bar (A, B) 10μm, and (A1, B1) 5μm, Zeiss LSM 710.  
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Figure 3.6: Morphological comparison of neuronal networks from both 
genotypes. Neuronal structure of WT and 101LL cultures were compared using 
IMARIS software to identify if any differences were apparent which might 
explain how one genotype curtails abnormal PrP production (WT) whilst the 
other supports it (101LL). Additionally, morphological analysis provided 
baseline data of neuronal cells pre-fibril challenge. IMARIS Vantage (Materials 
and Methods, 2.2.9) produced visual representative graphs based on IMARIS 
filament tracer datasets obtained from MAP2 immunolabelled images of WT 
and 101LL DIV8 cultures. (A) Dendrite area (μm^2, sum of the generated 
surfaces of a frustum), (B) Dendrite branching angle (Âo, angle directly at a 
branch point) and (C) Dendrite length (μm, the sum of the length of all edges 
which compose a dendrite) were compared. (D) Schematic diagram of different 
areas of the neuron. No differences were evident between genotypes when 
comparing dendrite area and dendrite branching angle however, significant 
differences were obtained for dendrite length (P-Value <0.0001), suggesting 
both similarities and differences were evident between WT and 101LL 
comparisons. GraphPad Prism was used to analyse IMARIS Vantage 
readings, unpaired t test.  
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Figure 3.7: Neuronal growth was constantly developing over-time in vitro. 
Immunolabelling with neuronal marker MAP2 (Green) was used to monitor 
neuronal growth and neurons were still present in cultures at DIV20. 101LL 
cultures 150,000 cells, plated on PDL/Fibronectin glass coverslips, Scale bar 
30µm, Zeiss LSM 710. 
 
 
3.3.4 Characterisation of non-neuronal cells 
 
As primary cultures are derived from hippocampal mixed brain cell origins, 
neurons may not be the only cell populations present in these cultures. Thus, 
the presence of other non-neuronal supporting cells and their abundance, form 
and degree of interaction at the morphological level was explored. 
Immunolabelling using the marker Anti-Glial Fibrillary Acidic Protein (GFAP) 
for astrocytic cells was positive suggesting these supporting glial cells were 
present in vitro and were shown here to be interlinked with neurons           
(Figure 3.8). GFAP is however expressed in numerous cell types in the CNS 
including astrocytes and ependymal cells. Therefore, to determine if GFAP 
specifically labelled astrocytes within these cultures two additional markers 
were used namely; Aldehyde dehydrogenase 1 family, member L1 (ALDH1L1) 
and Sry-related HMG-box (Sox9). ALDH1L1 is a marker that selectively labels 
astrocytes in the presence of neurons and microglia (Yang et al. 2011).  
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ALDH1L1 positive immunolabelling suggested cells identified in primary 
cultures were astrocytes (data not shown). Anti-Sox9 antibody is a member of 
the Sry-related HMG-box gene family of transcription factors and is a more 
definitive astrocytic marker as it is almost selectively expressed by astrocytes 
in the brain except for ependymal cells and in the neurogenic regions where it 
is also expressed by neural progenitor cells (Sun et al. 2017). As shown in 
Figure 3.9, GFAP positive cells also expressed Sox9 confirming accurate 
identification of astrocytes. Gene expression studies described in Chapter 6 
(Section 6.3.2) provided transcriptomic data that was mined here to investigate 
gene expression levels of astrocytic associated cells in cultures to distinguish 
if genotypic differences were present. No differences in gene expression 
values for both Gfap and Sox9 as assessed by microarray were evident 
between genotypes suggesting similar numbers of astrocytes were present in 
both WT and 101LL cultures (Figure 3.9). Morphologically, astrocytes 
appeared in the form of star shaped glial cells (Figure 3.10). The presence of 
highly ramified processes enable cellular interactions and extracellular 
homeostasis (Agarwal and Bergles 2014). Importantly, no morphological 
differences were identified between genotypes and astrocytes appeared to be 
in surveillance mode pre-fibril challenge.  
 
 
Figure 3.8: Dual-immunolabelling of neurons and astrocytic cells in culture. To 
investigate if non-neuronal cells were present in primary cultures, dual-
immunolabelling for neurons and supporting astrocytic cells were carried out. 
Anti-Glial Fibrillary Acidic Protein (GFAP/Red) positive immunolabelling 
suggested astrocytes were present in vitro and were interlinking with neuronal 
(MAP2/Green) populations. WT DIV6 cultures 75,000 cells, Scale bar 20μm. 
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Figure 3.9: Astrocytic populations were present in cultures. To confirm GFAP 
positive cells were actually astrocytes, dual-immunolabelling with additional 
astrocyte specific antibodies was carried out. Transcriptomic data obtained 
from analysis presented in Chapter 6 (Section 6.3.2) was also used to compare 
astrocytic expression levels in both WT and 101LL cultures to ascertain if these 
glial cell populations were present in similar numbers in both genotypes.          
(A) Anti-Sox9 antibody (Sox9/Green) and (GFAP/Red) immunolabelling 
confirmed GFAP positive populations were astrocytes. (B) Transcriptomic data 
was mined to examine gene expression profiles of both Gfap and Sox9 in WT 
and 101LL DIV8 cultures and confirmed no significant differences were evident 
between genotypes suggesting similar numbers of astrocytes were present in 
both genotypes. An increase in GFAP signal would represent increased 
number of astrocytes or activation of gliosis. WT cultures 30,000 cells, plated 
on PDL plastic plates, Scale bar 100, 30 and 20µm, Zeiss LSM 710. Graph 
mean plus standard deviation, n=4, n=individual cultures, Gfap P-Value 0.11 
and Sox9 P-Value 0.53, unpaired t test. 
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Figure 3.10: Morphological similarities in astrocytic structure were evident 
between WT and 101LL cultures. Astrocyte morphologies in WT and 101LL 
cultures were compared using IMARIS software to provide a baseline 
characterisation of these supportive cells in both genotypes. IMARIS Vantage 
(Materials and Methods, 2.2.9) was used to reconstruct astrocytic populations 
based on GFAP immunolabelled images. (A) WT and (B) 101LL primary 
cultures immunolabelled with astrocytic marker (GFAP/Red) and DAPI 
(Nuclear/Blue). (A1) WT and (B1) 101LL IMARIS astrocyte reconstructions. 
(C-F) Comparison between WT and 101LL astrocytic morphologies based on 
IMARIS generated data-set analysis, which included the following parameters; 
dendrite area (μm^2, sum of the generated surfaces of a frustum), length (μm, 
the sum of the length of all edges which compose a dendrite), mean diameter 
(μm) and branching angle (Âo, angle directly at a branch point). 
Immunolabelled cells and reconstructions displayed a multiple process 
phenotype in both genotypes indicating astrocytes were in surveillance mode. 
No significant differences of any parameters were evident between WT and 
101LL genotypes suggesting astrocytic morphologies were comparable 
between genotypes pre-fibril challenge. GraphPad Prism was used to plot and 
analyse IMARIS data-set values, P-Values C-F; 0.05, 0.09, 0.20, 0.18, 
unpaired t test. Scale bar 100µm, Zeiss LSM 710. 
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Microglia are another type of glial cell involved in maintaining the homeostasis 
of the brain. Immunocytochemistry studies using two microglial markers 
namely Cluster of differentiation molecule 11b (CD11b) and Ionized calcium-
binding adapter molecule 1 (Iba1) confirmed the presence of these resident 
macrophages in primary hippocampal cultures (Figure 3.11). Microglial 
populations appeared ramified with long processes, suggestive they were in 
surveillance mode. Increased immunolabelling of CD11b and Iba1 was 
detected in PrP-/- cultures suggesting higher numbers of microglia were 
present in these cultures in comparison to those in WT or 101LL (data not 
shown). This indicated microglial levels might vary dependent on PrP 
genotype. This could not be effectively assessed by immunocytochemistry 
therefore, transcriptomic data presented in Chapter 6 (Section 6.3.2), was 
mined to investigate gene expression levels of microglial associated cells in 
both WT and 101LL cultures. As indicated in Figure 3.11, no differences in 
gene expression of microglial-associated genes, Growth arrest specific 6 
(Gas6) and MER proto-oncogene tyrosine kinase (Mertk) were apparent 
suggesting WT and 101LL cultures had similar levels of microglial present in 
culture. 
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Figure 3.11: Microglial populations were present and in surveillance mode. 
Immunolabelling for microglial specific markers was carried out to identify if 
microglial cells were present in primary cultures. Transcriptomic data obtained 
from analysis presented in Chapter 6 (Section 6.3.2) was used to compare 
microglial specific gene expression levels in both WT and 101LL cultures to 
ascertain if these glial cell populations were present in similar numbers in both 
genotypes. (A-A1) Microglial markers included Cluster of differentiation 
molecule 11b (CD11b/White) and (C) Ionized calcium-binding adapter 
molecule 1 (Iba1/Red). (A1) Higher magnification of CD11b positive cells.      
(B) IMARIS reconstruction of CD11b positive cell displaying integration with 
neurons (MAP2/Green). (D) Transcriptomic data was mined to examine gene 
expression profiles of genes uniquely expressed in microglial populations, 
namely Growth arrest specific 6 (Gas6) and MER proto-oncogene tyrosine 
kinase (Mertk) (Butovsky et al. 2014). Immunolabelling for microglial 
populations confirmed these resident macrophages were present in cultures 
and IMARIS reconstructions indicated a multiple process phenotype 
suggesting microglia were in surveillance mode. Gas6 and Mertk expression 
was present in WT and 101LL DIV8 cultures and no significant differences 
were evident between genotypes suggesting similar numbers of microglia 
were present in WT and 101LL cultures. WT cultures 30,000 cells, plated on 
PDL plastic plates, Scale bar (A) 200µm, (A1 and C) 50 µm, (B) 5µm, Zeiss 
LSM 710. Graph mean plus standard deviation, n=4, n=individual cultures, 
Gas6 P-Value 0.20 and Mertk P-Value 0.34, unpaired t test. 
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3.3.5 Investigating neuronal maturation 
 
To determine the functional maturity of neurons in culture the presence of both 
pre and post-synaptic markers were determined using immunocytochemistry. 
Anti-synapsin I antibody was used as a pre-synaptic marker and Anti-
Postsynaptic Density protein 95 (PSD-95) as a post-synaptic marker. Synapsin 
1 is first expressed in Day 17 embryos in growing axonal and dendritic 
processes and PSD-95 is associated with the formation and maturation of 
excitatory synapses (Sheng and Kim 2011; Mason 1986). Both pre and       
post-synaptic markers were detectable in primary cultures and IMARIS 
analysis confirmed similar levels of staining were present in both genotypes as 
shown in Figure 3.12. These findings were important as they highlighted no 
differences in synaptic populations were evident between genotypes pre      
fibril challenge. These data also confirmed the primary hippocampal neuronal 
cultures developed into an intricate network of structurally mature synapses 
relatively comparable to that found in the brain.  
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Figure 3.12: Primary cultures developed into structurally mature neuronal 
synaptic networks. To confirm cultures were developing synaptic networks in 
culture, labelling with pre and post-synaptic markers was carried out. (A) Pre-
synaptic marker, Synapsin 1 (Syn1/Red) and (B) Post-synaptic marker,                          
Anti-Postsynaptic Density protein 95 (PSD-95/White). (C) Data intensity sums 
generated in IMARIS (Materials and Methods, 2.2.9) based on neuronal 
(MAP2), pre-synaptic (Syn1) and post-synaptic (PSD-95) labelling were 
plotted from both genotypes. Labelling of pre and post-synaptic markers 
confirmed the presence of mature neuronal synaptic networks, and IMARIS 
analysis showed levels of synapses present in WT and 101LL cultures were 
comparable. These data provided baseline synaptic profiles of both genotypes 
pre-fibril challenge. WT and 101LL cultures 30,000 cells, plated on PDL plastic 
plates, Scale bar 50µm, Zeiss LSM 710. Graph mean plus standard deviation, 
n=4, n=individual WT culture images, P-Values MAP2 0.60; Syn 0.53 and 
PSD-95 0.12, unpaired t test. 
 
Collectively, data from these characterisation experiments suggest that WT 
and 101LL hippocampal cultures were differentiated into highly branched 
neuronal networks supported predominately by astrocyte populations with a 
smaller contribution from microglial cells. Additionally synaptic markers were 
present from DIV8 indicating neuronal maturity from this time point. LDH 
assays in combination with immunocytochemical analysis concluded these 
neuronal cultures were viable up to twenty days in vitro. At this point, no 
obvious differences between genotypes were apparent that might explain how 
one model is capable of supporting fibril formation whilst the other is not.  
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3.3.6 Cellular associations with PrPC 
 
Normal cellular PrPC can be converted into an abnormal isoform resulting in 
the formation of amyloid fibrils, and addition of abnormal PrP fibril seeds can 
enhance this process as reported in previous studies (Barron et al. 2016). The 
presence of normal PrPC is essential for this seeding mechanism to occur. The 
presence of PrPC in primary cultures was therefore analysed by 
immunocytochemistry using anti-PrP antibodies 6H4 (recognises amino acids 
143-151) and 7A12 (recognises amino acids 90-145) to determine PrP protein 
levels and cellular associations in culture. PrPC was associated with both 
neuron and astrocyte cell populations, and where confocal images were 
analysed using IMARIS tool function (Materials and Methods, 2.2.9), PrPC 
detection was predominantly associated with neurons (Figure 3.13). Genotype 
specific profiles were also created by IMARIS based on neuronal, astrocytic 
and PrPC signals (Figure 3.14). Based on these profiles it can be concluded 
no obvious differences regarding cell or PrPC expression were apparent when 
comparing WT and 101LL cultures.  
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Figure 3.13: PrPC was detectable on both neuronal and astrocytic cells. To 
investigate if PrPC protein was present and detectable in cultures and to 
identify cellular associations with this protein, immunocytochemistry using an 
anti-PrP antibody was carried out. (A) Anti-PrP antibody 7A12 (PrPC/White), 
neurons (MAP2/Green) and DAPI (Nuclear/Blue). (B) 7A12 (PrPC/White), 
astrocytes (GFAP/Red) and DAPI (Nuclear/Blue). (C) IMARIS tool function 
analysis (Materials and Methods, 2.2.9), of PrPC cellular localisation. Close to 
parameters were within 1µm distance of cell and far from parameters were 
greater than 1µm distance from cell. PrPC was associated with both neuron 
and astrocyte cell populations however, IMARIS localisation analysis showed 
PrPC detection was predominantly associated with neurons (within 1µm) whilst 
astrocytic PrPC localisation was further away (> 1 µm). 101LL cultures 30,000 
cells, plated on PDL plastic plates, Scale bar 15µm, Zeiss LSM 710. Graph 
mean plus standard deviation, n=2, n=individual culture images. 
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Figure 3.14: WT and 101LL cultures have similar cellular profiles. To 
investigate if WT and 101LL cultures were comparable based on predominant 
neuronal and astrocytic cell populations, including PrPC expression, genotype 
specific profiles were generated in IMARIS for genotype comparisons to be 
carried out. These investigations provided baseline profiles of WT and 101LL 
cultures pre-fibril challenge. (A) WT and (B) 101LL immunolabelling for 
neurons (MAP2/Green), astrocytes (GFAP/Red) and PrPC (6H4/White).         
(C) WT and (D) 101LL IMARIS data intensity sums based on immunolabelled 
images. Note DAPI images not included. Based on immunolabelling and 
IMARIS generated profiles no obvious differences regarding cell or PrPC 
expression were apparent when comparing WT and 101LL culture. WT and 
101LL cultures DIV8, Scale bar 50µm, Zeiss LSM 710. Graph mean plus 
standard deviation, n=2, n=individual culture images. 
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Immunocytochemistry was invaluable for confirming the presence of PrPC 
protein in culture however, this technique was limited in providing information 
about post-translational modifications of PrPC. To address this point and to 
gain more information with regards to PrP glycoform profiles, immunoblotting 
experiments were carried out (Materials and Methods, 2.2.6). Immunoblotting 
validated immunolabelling results whilst providing additional information on the 
glycoform patterns associated with the protein. PrPC can either be un-, mono- 
or di-glycosylated during post-translational modification (Xanthopoulos et al. 
2009) and as shown in Figure 3.15, WT and 101LL cultures showed all three 
glycosylated states of PrPC were present and were at comparable levels 
suggesting normal PrPC processing was occurring in primary cultures. 
Additionally, di-glycosylated higher molecular bands appeared more 
prominent in in vitro lysates which was comparable to adult brain profiles 
obtained suggesting again similar translational modifications of PrPC were 
been carried out in both systems. In comparison, lower levels of detectable 
PrPC were shown in embryonic brain lysates where unglycosylated banding 
appeared extremely faint. Immunocytochemical results have previously show 
an increase in neuronal growth over-time in culture (Figure 3.7), and as PrPC 
is predominantly expressed by neurons, an increase in protein production 
would be expected, as shown by immunoblot (Figure 3.15). These results 
suggested levels of PrPC were increasing with neuronal development in 
culture, which was confirmed by immunocytochemical labelling of PrPC        
over-time in culture (Appendix Figure 3.c). These observations were also 
similar to previous studies monitoring PrPC mRNA expression during 
embryogenesis that showed as the embryo develops the levels of PrPC mRNA 
also increase (Manson et al. 1992). In conclusion, both immunocytochemical 
and biochemical analysis confirmed the presence of PrPC in primary cultures 
and both WT and 101LL cultures had similar expression levels of the protein. 
Furthermore, expression levels of the Prnp gene based on transcriptomic data 
presented in Chapter 6 (Section 6.3.2), confirmed no significant differences in 
Prnp expression were evident between genotypes pre-fibril challenge. 
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Figure 3.15: Typical glycosylated forms of PrPC were present in primary culture 
lysates. Biochemical analysis of primary culture lysates was carried out to 
investigate if PrPC glycoform patterns found in cultures were similar to that 
found in an in vivo brain. (A-B) Immunolabelling of PrPC cell culture lysates, 
(C-D) Whole embryo (Day17) murine brain lysates and (E-F) Adult murine 
brain homogenates. All three glycoform bands were present at anticipated 
sizes in WT and 101LL primary culture lysates and both genotypes showed 
similar banding intensities, suggesting normal PrPC processing was occurring 
in primary cultures in both genotypes. Furthermore, di-glycosylated molecular 
bands appeared more prominent in culture lysates which was comparable to 
adult brain profiles used here to show diagnostic PrPC banding, suggesting 
again similar translational modifications of PrPC were been carried out in both 
in vitro and in vivo systems. Equal protein loading at 5µg based on micro BCA 
assay (Thermo Scientific), 12 well Tris/ Glycine gel, 6H4 antibody. 
 
In order to evaluate intracellular processing of PrPC it was important to be able 
to detect intracellular organelles crucial to this process. A number of organelle 
markers were used to label cultures such Early Endosome Antigen 1 (EEA1/ 
early endosomes), Ras-related protein Rab9 (late endosomes) and 
Lysosomal-Associated Membrane Protein 1 (LAMP1/ lysosomes). 
Additionally, cholera toxin Ganglioside GM1 ligand Subunit B was used to label 
lipid-rafts (Nichols et al. 2001) which are involved in membrane protein 
trafficking (Taylor and Hooper 2006). Co-localisation of PrPC and cholera toxin 
Subunit B was detected indicating some PrPC protein was present on lipid-rafts 
(Figure 3.16). These domains are known to be involved in the membrane 
localisation and recycling of PrPC and trafficking of misfolded PrP.  
105 
 
Thus, identifying and studying these membrane microenvironments will be 
important to determine their involvement in conformational conversion 
processing of abnormal protein after fibril challenge. PrPC immunolabelling 
also co-localised with EEA1, Rab9 and LAMP1 showing PrPC protein was 
present in early/ late endosomes and in lysosomes (Figure 3.16). Cellular PrPC 
is known to be recycled from the cell membrane via an endocytic pathway, 
where the protein is transported back into the cell by endosomes (Peters et al. 
2003) or it is routed to the lysosomes for degradation via late endosomes 
(Campana, Sarnataro, and Zurzolo 2005). The presence of PrPC within these 
structures confirmed normal PrPC processing was occurring within these 
cultures, which was evident in both genotypes and these data supported 
biochemical analysis (Figure 3.15), showing normal glycoform profiles. 
Immunocytochemical analysis (Appendix Figure 3.d), suggested predominant 
organelle association with neuronal cell populations. Analysing these 
organelles will be key in identifying pathways involved in misfolded PrP 
processing after cultures are challenged with misfolded PrP fibrils. 
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Figure 3.16: PrPC localisation with lipid-rafts and endolysosomal organelle 
domains. To ascertain if PrPC was undergoing normal processing in primary 
cultures, a number of endolysosomal associated organelles were labelled 
using various markers. (A) Lipid-rafts were labelled with Cholera Toxin B 
(Cholera B/Red), (B) Early endosomes with Early Endosomal Marker 1 
(EEA1/Red), (C) Late endosomes with Ras-related protein 9 (Rab9/Red) and 
lysosomes with Lysosomal-Associated Membrane Protein 1 (LAMP1/Red). 
PrPC was immunolabelled with 6H4 (Green). Merged images displayed           
co-localisation (Yellow) was evident between lipid-rafts, early and late 
endosomes, lysosomes and PrPC indicative that PrPC was undergoing normal 
recycling via an endolysosomal pathway. Scale bar 2µm, Zeiss LSM 710. 
 
 
107 
 
3.3.7 Genotype specific response to chemically induced stress 
 
Both WT and 101LL cultures displayed similar characteristics after a range of 
immunocytochemical and biochemical tests were carried out. The next stage 
of characterisation involved investigating if any differences were present 
between genotypes regarding their response to chemically induced stress. 
Thus, both WT and 101LL cultures were exposed to increasing concentrations 
of hydrogen peroxide (30% w/w H2O2, Materials and Methods, 2.4.1) and 
cellular response stress levels were monitored over a 24 hour time frame using 
the LDH assay. Immunocytochemistry was carried out at end point to ascertain 
cytotoxic effects on neuronal and astrocytic populations. PrP-/- cultures were 
also tested to distinguish if PrPC actually does have neuroprotective properties 
as claimed in the literature (Roucou, Gains, and LeBlanc 2004). LDH analysis 
included cell supernatants harvested at 0hr, 2hr, 4hr, 6hr, and 24hr time points 
(Figure 3.17, Appendix Figure 3.e). Results of the LDH assay indicated 101LL 
cultures were more susceptible to stress than WT. Interestingly PrP-/- cultures 
maintained a high percentage of cell viability after 24hrs at 100μM H2O2 
(Appendix Figure 3.e), indicating that PrPC may not be actively involved in 
neuroprotection. End point immunocytochemistry results reflected LDH data 
showing neuronal and astrocytic populations were reduced in cultures in a 
dose dependent manner in response to H2O2 (Figure 3.18). A noticeable 
reduction of 101LL neuronal cells in comparison to WT was evident at 100μM 
and 300μM H2O2 concentrations, again complementing LDH results. Positive 
immunolabelling for 101LL astrocytic populations was evident at 300μM H2O2 
however, these cells did not appear healthy. In conclusion, 101LL cultures 
appeared more susceptible to hydrogen peroxide induced oxidative stress 
than WT cultures.  
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Figure 3.17: 101LL cultures were highly susceptible to chemically induced 
stress. Although WT and 101LL cultures shared similarities based on 
morphological and immunocytochemical profiling, it was unknown if both 
genotypes would respond in a similar manner to chemically induced stress. To 
investigate this further, WT and 101LL cultures were exposed to increasing 
concentrations of H2O2 (0, 10, 100, 300µM) and cellular response was 
measured using the LDH cytotoxicity assay. (A) WT stressed cultures and       
(B) 101LL stressed cultures. Culture supernatants were sampled at 0, 2, 4, 6 
and 24hrs and LDH activity measurements were plotted accordingly. 101LL 
cells appeared more susceptible to oxidative stress than WT cultures and 
displayed earliest cytotoxic effects. Fluorescent values were normalized to 
Triton X-100 treated lysis cells that represent the maximum amount of LDH 
available for release, then the percentage of viable cells were calculated by 
percentage LDH release value minus 100. WT and 101LL cells plated at 
150,000 cells per well on PDL/Fibronectin glass coverslips, Graph mean plus 
standard deviation, n= 2 duplicate technical replicates. 
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Figure 3.18: Induced oxidative stress leads to neuronal and astrocytic decline 
in both WT and 101LL cultures. To monitor the effect of oxidative stress on 
cellular populations in primary cultures, immunolabelling of neurons and 
astrocytes was carried out after 24-hour exposure to various concentrations of 
H2O2 (0, 10, 100, 300µM). Immunolabelling of neurons (MAP2/Green) and 
astrocytes (GFAP/Red) in both WT and 101LL primary cultures showed a clear 
reduction of MAP2 (neurons) and GFAP (astrocytes) immunolabelling at both 
100μM and 300μM concentrations in both genotypes confirming both cellular 
populations and genotypes were susceptible to oxidative stress. Neuronal 
populations appeared more susceptible in 101LL cultures. Astrocytic 
immunolabelling was evident in 101LL cultures at 300µM concentration 
however, these cells did not look healthy. Scale bar 50μm, LSM710. 
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3.4 Discussion 
 
The overall aim of this study was to develop a representative model of the 
brain to study neuron-glia interactions after challenge with misfolded PrP 
fibrils. Murine primary neuronal cultures were therefore established and 
characterised at the morphological, biochemical and immunocytochemical 
level. Previous studies by other groups have focused more on the initial 
practical preparation procedures involving isolating neuronal cells from the 
brain but have failed to further characterise the resulting cultures in more detail 
(Seibenhener and Wooten 2012; Beaudoin et al. 2012; Kaech and Banker 
2006). Other studies have characterised their cultures to a better extent 
however, this was from neuronal cultures isolated from adult rat brains and 
again was limited regarding validation experiments (Ray et al. 2009). The work 
described in this chapter provided a well characterised and optimised model 
system to study abnormal protein interactions in a controlled easily accessible 
system. 
 
The hippocampal area of the brain is a prime target for misfolded protein 
accumulation and was therefore selected to provide cells for primary culture. 
The initial procedures for dissecting hippocampal areas from Day 17 embryo 
brains were developed in accordance with both Home office and Roslin 
veterinary staff. Initially embryos from each individual mother were removed 
and immediately decapitated however, when embryo numbers were high 
(above four) this method proved inefficient and resulted in rapid tissue 
degradation in embryos that were culled last. The method established in this 
chapter provided a more effective, efficient and ethically sound way of using 
all the embryos from a single pregnancy. Once tissues were isolated and 
dissociated, a number of options for further processing were available. 
Previous methods have shown that hippocampal cultures need to be co-
cultured with an astrocyte feeder layer (Gardner, Jukkola, and Gu 2012; Kaech 
and Banker 2006).  
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This method was not employed here, instead trophic support of neurons was 
provided using various co-factor supplements which proved to be a quicker 
less complicated method of establishing viable primary neurons (Brewer and 
Price 1996; Brewer et al. 1993).  
 
Morphologically the primary hippocampal neurons differentiated into highly 
branched synaptically connected neuronal networks characterised using Tau, 
MAP2, PSD-95 and Synapsin 1 immunolabelling. These neurons were 
supported by astrocytic and microglial populations. These glial cells play an 
important role in maintaining neuronal networks and protect neurons from 
toxicity reflected here by the fact that cells were viable in culture for over twenty 
days in vitro (Boehler, Wheeler, and Brewer 2007; Ye and Sontheimer 1998). 
The hippocampus also contains other subsets of neuroglial cells such as 
oligodendrocytes which are involved in axon myelination which enhances the 
speed and efficiency of axon conduction. Myelin basic protein (MBP) is 
expressed exclusively in these myelinating glia. Limited MBP immunoreactivity 
was evident in both WT and 101LL cultures (data not shown) which confirmed 
previous reports which showed co-culture with seeded oligodendrocytes 
dissociated from the cerebellum and brain stem was needed to achieve 
efficient myelination in vitro (Gardner, Jukkola, and Gu 2012). It should be 
noted however that these co-culturing methods resulted in some but not all 
neurons undergoing myelination and therefore were limited regarding 
myelination studies. Studying myelination of axons and related mechanisms 
was not essential to this study therefore, no further investigations were carried 
out.  
 
Biochemical studies showed PrPC glycosylation profiles obtained from primary 
cell lysates were comparable to adult brain lysates. This confirmed the 
presence of PrPC in these cultures and showed the same biosynthetic pathway 
found in vivo must also be occurring in the primary neuronal models.  
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PrPC expression was validated using immunolabelling and organelle 
localisation of PrPC confirmed normal trafficking and recycling of the protein 
via an endolysosomal pathway. Endolysosomal pathways are also involved in 
delivering misfolded proteins to lysosomes (Yamasaki et al. 2014; Saftig and 
Klumperman 2009) therefore, identifying these pathways in primary cultures 
was important as it will allow for the monitoring of fibril processing after 
challenge in cultures. 
 
Genotypes used in this study were selected based on previous studies which 
showed 101LL mice supported misfolded PrP seeding in vivo whilst WT mice 
were capable of curtailing this process after challenge with recombinant PrP 
fibrils (Barron et al. 2016). Generating in vitro cultures from these mice allowed 
for a novel, more accessible system to study early misfolded PrP cell 
interactions in detail. Additionally, a PrP-/- primary line was used in some 
studies as a control for PrP antibodies and to gain insight into neuronal activity 
in the absence of PrPC which is thought to have neuroprotective properties. 
Generic stress studies indicated PrP-/- cultures were less susceptible to 
oxidative stress than WT and 101LL genotypes indicating that expression of 
the PrPC protein did not guarantee neuroprotection. This study also highlighted 
the fact that after induction of oxidative stress, 101LL cultures appeared more 
susceptible to changes in culture homeostasis than WT (Figure 3.17, 3.18). 
This preliminary data was the first indication that differences may exist 
between WT and 101LL cultures regarding response to external stimuli.   
 
IMARIS software was used to perform novel in-depth analysis of 
immunostained cells in both WT and 101LL genotypes and no obvious 
differences were apparent between cultures pre-fibril challenge that could 
explain how one curtails and the other supports protein misfolding. 3D 
neuronal matrixes were maintained even after coverslip mounting (Figure 3.5) 
protecting the intricacy of neuronal networks formed. These techniques 
resulted in generating neurons comparable to that found in vivo (Figure 3.4).  
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IMARIS analysis showed PrPC was expressed predominantly by neurons 
(Figure 3.13) however, PrPC expression was also associated with astrocytes 
and microglia to a lower degree (data not shown). Both WT and 101LL cultures 
had similar composition profiles regarding the proportions of neurons, 
astrocytes and PrPC based on data intensity sum plots generated in IMARIS 
(Figure 3.14). Importantly, astrocyte morphological profiles and expression of 
astrocyte-associated genes were similar between WT and 101LL cultures and 
astrocytic populations appeared to be in surveillance mode in both genotypes 
in these unchallenged cultures. Microglial phenotypes analysed using IMARIS 
reconstruction were shown to be integrated with neuronal populations and 
morphological appearances showed they were ramified in appearance 
exhibiting long processes (Figure 3.11). This suggested microglia were in 
surveillance mode as opposed to an amoeboid state where cell bodies are 
large and processes are short and thick, a phenotype correlated with microglial 
activation in response to neuronal injury (Arcuri et al. 2017; Ling and Wong 
1993). Collectively, these analyses provided a baseline neuronal and non-
neuronal profile pre-fibril challenge where any changes overserved after fibril 
insult would be attributed to the addition of recombinant PrP fibrils. 
 
Another means of characterisation of in vitro cultures is by electrophysiological 
studies. Cellular electrophysiological activity is critical for neurons and action 
potentials can be monitored in vitro using patch clamp technologies (Bourke et 
al. 2014). Although patch clamp analyses could not be performed on these 
cultures due to logistical issues, the presence of both pre and post-synaptic 
markers in these cultures was shown (Figure 3.12) indicating a complex 
neuronal communication network was present and structurally mature. 
Importantly, baseline profiles pre-fibril challenge indicated similar synaptic 
populations were present in both genotypes.  
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To summarise, the data presented in this chapter confirm a well-established 
primary hippocampal neuronal culture model has been developed. After a 
number of characterisation steps no obvious differences were noted between 
genotypes pre-fibril challenge that would support different processing 
capabilities of misfolded PrP. Additionally, transcriptomic analysis confirmed 
similar Prnp expression levels between genotypes indicating the point 
mutation in the 101LL’s was not effecting the levels of PrPC present. 101LL 
cultures were however more susceptible to oxidative stress than WT cultures, 
which was also observed in LDH response after initial plating of 101LL cells. 
In conclusion, this model provides an essential tool to investigate the intricacy 
of early misfolded PrP interactions with neuronal, astrocytic, microglial and 
synaptic populations in cultures from both WT and 101LL genotypes. 
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4.1 Abstract 
 
Abnormal PrP protein processing and accumulation can be studied either in 
vivo or in vitro using recombinant PrP fibrils as a seed to initiate further protein 
misfolding however, tracking fibrillar protein cellular interactions and 
processing proves difficult. One way to circumvent this is to label recombinant 
fibrils with a fluorescent dye. In this study both WT and 101L PrP protein was 
expressed in Escherichia coli (Rosetta DE3) from a pTrcHis B derived vector 
containing codons 23-230 of the PrP open reading frame. PrP expression from 
bacterial cells was carried out using the Isopropyl ß-D-1-thiogalactopyranoside 
(IPTG) induction pTrc expression system. Further purification involved a 
multistep process including Immobilised Metal Affinity Chromatography 
(IMAC) using Nickel-Nitrilotriacetic acid (Ni-NTA); size exclusion 
chromatography and Reverse Phase High Performance Liquid 
Chromatography (RP-HPLC). Recombinant PrP displaying the highest purity 
validated by Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis 
(SDS-PAGE) and Mass Spectrometry (MS) was selected to produce fibrils 
using the prion fibrillisation assay. Silver staining and electron microscopy 
confirmed the presence of these refolded forms of PrP which were then 
labelled with Alexa Fluor Succinimidyl Esters (NHS esters) to aid visualisation 
of fibril trafficking in vitro. Fibrils generated in this chapter displayed similar 
characteristics to fibrils isolated from infected brains and therefore provided a 
useful surrogate of in vivo generated misfolded PrP, which was amenable to 
fibril based challenge experiments in primary hippocampal neuronal cultures. 
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4.2 Introduction  
 
PMD’s such as AD, PD, HD and TSEs or prions are associated with the 
accumulation of abnormally folded proteins in specific regions of the brain 
(Knowles, Vendruscolo, and Dobson 2014; Braak et al. 2003; Caughey and 
Lansbury 2003; Forloni et al. 2002; Bucciantini et al. 2002). The generation 
and spread of these misfolded protein aggregates or fibrils is common to all 
PMD’s, and it is widely debated whether these abnormal fibrillar deposits are 
toxic to surrounding neurons or if they are generated as a protective 
mechanism to sequester smaller soluble forms of misfolded protein (Treusch, 
Cyr, and Lindquist 2009; Haass and Selkoe 2007). Additionally, early 
mechanisms involved in fibril processing are poorly understood (Moreno-
Gonzalez and Soto 2011). Pervious work by our group has shown both WT 
and 101L recombinant PrP fibrils are capable of seeding misfolded PrP 
amyloid in the brains of 101LL mice but not in WT. Therefore, both of these 
genotypes were employed in order to study the different processing pathways 
associated with misfolded fibril interactions. Furthermore, Prnp fibril genotype 
was irrelevant to seeding occurrence however, genotype of the challenged 
host was important. To confirm no differences existed between fibrils due to 
genotype, fibrils were produced and characterised from both WT and 101L 
Prnp plasmid vectors. These fibrils will be used to challenge primary 
hippocampal neuronal cultures generated from both WT and 101LL 
genotypes, and the results of this challenge will be discussed in Chapters 5 
and 6.  
 
Recombinant PrP protein generated from E. coli has been used extensively in 
prion research however; producing protein of high purity is difficult. This may 
be due to traditional methods of recombinant PrP production utilising a fusion 
of PrP to histidine tags, or other methods which resulted in PrP that was 
partially degraded or of insufficient purity (Rezaei et al. 2000; Jackson et al. 
1999; Hornemann et al. 1997; Zahn, von Schroetter, and Wüthrich 1997).  
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The methods used here were based on published protocols generated from 
various groups and allowed for the expression of tag-free recombinant PrP of 
the highest purity (Makarava and Baskakov 2008; Kirby et al. 2003). Fibrils 
generated from recombinant PrP using the prion fibrillisation assay were then 
labelled with a fluorescent dye which was advantageous for tracking fibril 
interactions with neuronal, astrocytic and microglial cell populations along with 
monitoring general trafficking and organelle processing. Some fibrils were left 
unlabelled to act as controls for challenged experiments.   
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4.3 Results 
 
4.3.1 Bacterial growth and induction using the pTrc system 
 
Recombinant PrP was produced from E. coli bacteria carrying the plasmid 
containing the mouse Prnp gene. Bacterial glycerol plasmid stocks were kindly 
gifted by Dr. Andy Gill and were used here to produce both WT and 101L 
recombinant PrP based on the pTrc expression system (Materials and 
Methods, 2.3.1). As shown in Figure 4.1, protein expression was effectively 
induced by the addition of isopropyl ß-D-1-thiogalactopyranoside (IPTG), 
resulting in the production of recombinant PrP of anticipated size (23,104kDa).  
 
 
 
Figure 4.1: Bacterial cultures were induced using the pTrc expression system. 
SDS-PAGE was used to confirm recombinant PrP expression. Pre IPTG 
induction (-) and post IPTG induction (+). Red boxes show diagnostic PrP 
bands were present in IPTG treated samples confirming efficient induction of 
recombinant PrP. Novex 12% Bis-Tris Protein Gels, 1.0 mm, 15-well; SeeBlue 
Plus 2 Pre-Stained Standard, gel stained with Instant blue. 
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4.3.2 Bacterial lysis and IMAC PrP protein purification 
 
The next processing step involved crudely purifying inclusion bodies 
containing the recombinant protein from induced bacterial culture cell pellets 
by bacterial lysis. Immobilized-Metal Affinity Chromatography (IMAC) 
purification followed and eluted recombinant PrP fractions were collected 
accordingly (Figure 4.2).  
 
 
 
Figure 4.2: Immobilized-Metal Affinity Chromatography (IMAC) purified 
fractions were visualised using SDS-PAGE stained gel. IMAC purification 
allowed for elution of non-specifically bound proteins whilst recombinant PrP 
was retained bound to Nickel-Nitrilotriacetic acid agarose. SDS-PAGE was 
used to confirm what fraction recombinant PrP eluted in. FT= Flow through, 
W= Wash, F= Fraction. Majority of recombinant PrP was eluted in fractions F1 
and F2 (Red Box). NuPAGE Novex 12% Bis-Tris Protein Gels; SeeBlue Plus 
2 Pre-Stained Standard, gel stained with Instant blue. 
 
4.3.3 AKTA-Fast Protein Liquid Chromatography  
 
IMAC buffer processing resulted in binding of recombinant PrP with reduced 
glutathione which aided protein solubilisation and prevented the formation of 
disulphide bonds in the denatured protein during IMAC purification (Zahn, von 
Schroetter, and Wuthrich 1997).  
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For further downstream purification of IMAC fractions shown in Figure 4.2, 
reduced glutathione was removed using a size exclusion column (HiPrep 
26/10) which allowed large proteins to elute first before smaller substances 
such as salts and other small molecules. As shown in Figure 4.3 the majority 
of PrP of expected size eluted in a single fraction. 
 
 
     
 
 
 
 
 
 
 
Figure 4.3: Recombinant PrP was further purified using a desalting method. 
AKTA-Fast protein liquid chromatography (FPLC) separation method was 
employed for protein filtration. (A) Ultraviolet (UV) measurements (mAU units) 
were recorded in conjunction with fraction collection and an isolated peak was 
identified and obtained for Fraction 2, (\ /) symbols denote where fraction 
began/ended. (B) SDS-PAGE confirmed majority of protein eluted in F2. 
NuPAGE Novex 12% Bis-Tris Protein Gels; SeeBlue Plus 2 Pre-Stained 
Standard, gel stained with Instant blue. 
 
4.3.4 Reversed Phase HPLC for high purity prion protein purification 
 
After FPLC filtration, solubilised recombinant PrP fractions were refolded using 
oxidised glutathione. This resulted in the formation of a disulphide bond 
analogous to the in vivo PrPC protein, where α-helixes 2 and 3 are stabilised 
by the presence of this disulphide bond (Riesner 2003). Further purification 
was carried out using Reversed Phase High Performance Liquid 
Chromatography (RP-HPLC).  
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Recombinant PrP protein is hydrophobic and therefore attaches to the reverse 
phase column tightly. An organic solvent can then subsequently elute the 
hydrophobic PrP bound to the column. PrP was eluted and collected in 
individual fractions, each displaying highly pure PrP protein (Figure 4.4).  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4: Reversed Phase HPLC produced highly pure PrP fractions. 
Recombinant PrP purity was analysed using Ultraviolet (UV) and SDS-PAGE. 
(A) UV measurements (mAU units) were recorded in conjunction with fraction 
collection, (\ /) symbols denote where fractions began/ended. (B) SDS-PAGE 
confirmed protein presence and purity in F2 and F3. NuPAGE Novex 12% Bis-
Tris Protein Gels; SeeBlue Plus 2 Pre-Stained Standard gel stained with 
Instant blue. 
 
Protein concentrations varied from fraction to fraction and were calculated 
accordingly (Materials and Methods, 2.3.4). Highly pure fractions were 
lyophilised immediately using the Savant SPD2010 SpeedVac (Section 2.3.7) 
and stored at -80oC until further use. Mass Spectrometry (Section 2.3.8) 
validated PrP purity (Appendix Figure 4.a) and any recombinant PrP samples 
displaying protein modifications were discarded.  
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4.3.5 PrP fibrillisation assay 
 
The principle of this step was to take soluble, monomeric recombinant PrP and 
convert it into a fibril form by shaking the protein vigorously in the presence of 
Gdn-HCL and Thiourea reaction mixtures. This fibril conversion was monitored 
in real time using both an amyloid binding dye, Thioflavin T (ThT), and a 
fluorescence plate reader. The presence of fibrils was confirmed by increased 
fluorescence from ThT, monitored in real time by the fluorescence reader 
(Figure 4.5). Increased ThT fluorescence indicated the fibrillisation assay was 
efficiently converting monomeric forms of recombinant PrP into fibril 
conformations. 
 
 
 
Figure 4.5: Recombinant PrP conversion to fibril form. Fibrillisation of 
recombinant PrP was monitored in real time by fluorescence and data 
generated was plotted accordingly. (A) Real-time fluorescent monitoring of 
ThT increase was visualised over-time using the Fluoroskan. Samples were 
loaded in triplicate, first three contained protein plus ThT, the next protein alone 
and finally ThT alone. (B) An excel macro analysed all readings collected over 
24 hour period and produced a plot of Fluoroskan reading (485 nm) against 
time (minutes). Both readings displayed typical sigmoidal kinetic curves as 
expected confirming fibril production.   
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4.3.6 Maturation and proteinase K (PK) digestion of fibrils  
Fibrils produced from recombinant PrP present proteinase K (PK) resistant 
bands at 10 and 12 kilodaltons (kDa) when examined using SDS-PAGE, 
however so do non-specific aggregates of recombinant PrP (Breydo, 
Makarava, and Baskakov 2008). To distinguish between both types, samples 
obtained from the PrP fibrillisation assay were heated at 80oC a method known 
as maturation. Upon this maturation the pK resistant core of amyloid fibrils 
expand to 16 kDa, a characteristic which is not evident in non-fibrillar 
aggregates. The presence of this diagnostic band was validated by              
SDS-PAGE which confirmed efficient and specific amyloid fibril generation            
(Figure 4.6). 
 
                                    
 
Figure 4.6: Silver stain of proteinase K (PK) treated fibrils confirmed specific 
amyloid fibril generation. Maturation and PK digestion of fibrils was carried out 
and analysed using SDS-PAGE and silver staining. Sample 1: Control no PK 
digestion, Sample 2: PK digested sample, Sample 3: PK digestion with 
maturation. As shown in lane 3, the characteristic 16kDa diagnostic band 
associated with amyloid fibrils was present confirming fibril generation. 
NuPAGE Novex 12% Bis-Tris Protein Gels. 
 
 
 
 
 
16kDa
28kDa
1   2    3 
125 
 
4.3.7 Transmission electron microscopy  
 
To determine if recombinant fibrils from different Prnp genotypes had similar 
morphological characteristics, transmission electron microscopy (TEM) was 
carried out. Samples were prepared for TEM by Steve Mitchell (Materials and 
Methods, 2.3.12). A JEM-1400 Plus electron microscope was used to image 
fibrils to investigate their structures. TEM images confirmed fibrils were 
successfully produced and were morphologically similar between genotypes 
(Figure 4.7). Diluted fibril preparations allowed for measurements of fibril 
length and width to be obtained using the Slice View module in IMARIS 
software (Materials and Methods, 2.2.9) which allowed accurate 
measurements of fibrils based on scale bar parameters to be obtained. 
IMARIS results confirmed fibrils were morphologically similar between 
genotypes and no significant differences were noted between length and width 
parameters measured. In conclusion, no differences in fibril structure were 
apparent by TEM/IMARIS analysis of fibrils produced from WT or 101L Prnp. 
These data support previous literature suggesting that fibril genotype does not 
influence how PrP fibrils are processed and instead host Prnp genotype is the 
more important determining factor. 
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Figure 4.7: Transmission Electron Microscopy (TEM) used for visualisation of 
fibril structures. To confirm fibril presence and gain insights into fibril structures, 
TEM imaging of both WT and 101L fibrils was carried out. (A)-(B) WT, (C)-(D) 
101L diluted fibril preparations and (E)-(F) Measurements of fibril length and 
width calculated using IMARIS software based on WT and 101L (1/20 dilution) 
EM images. Fibril presence was confirmed and no significant differences were 
noted between genotype dimensions: WT versus 101L fibril length P-Value 
0.0502, WT versus 101L fibril width P-Value 0.5485. Scale Bar (A) and (C) 
0.3μm, (B) and (D) 0.2 μm. Graph mean plus standard deviation, n=12,            
n= individual fibrils, unpaired t test. 
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4.3.8 Labelling fibrils with Alexa fluor succinimidyl esters (NHS esters) 
 
To allow tracking and visualisation of fibrils in in vitro experiments, fibrils were 
labelled with a fluorescent dye. Alexa Fluor 555 NHS (N-HydroxySuccinimid) 
Ester (Succinimidyl Ester) was selected to label fibrils due to the dyes superior 
fluorescence emissions and greater photostability in comparison to other 
spectrally similar fluorophores. Additionally, the Succinimidyl esters (NHS 
esters) of Alexa Fluor dyes are easily conjugated to primary amines (R-NH2) 
located on proteins. Fibrils produced from both WT and 101L Prnp genotypes 
were labelled with Alexa Fluor 555 NHS esters. Fluorescent labelling was 
confirmed using a Typhoon scanner in conjunction with SDS-PAGE (Figure 
4.8). To check labelled fibrils would be detectable by confocal microscopy 
aliquots of labelled fibrils were placed on a 96 well culture plate and were 
imaged using a Zeiss LSM710 confocal microscope. As shown in Figure 4.8, 
fibrils were detectable by confocal microscopy. Confocal images were 
measured using IMARIS software which provided a baseline measurement of 
the size of labelled fibrils before any challenge experiments were carried out. 
In summary, recombinant PrP fibrils were successfully produced from both WT 
and 101L Prnp genotypes and no differences in fibril structure were apparent 
between genotype. Fibrils were effectively conjugated to Alexa Fluor 555 
which will allow in vitro tracking of fibril processing upon primary hippocampal 
culture challenge.  
 
 
 
 
 
 
128 
 
 
 
Figure 4.8: Fibrils were efficiently labelled with detectable fluorescent tags. 
Fluorescent labelling of fibrils was confirmed using two visualisation methods, 
the typhoon scanner and confocal microscopy. (A) Typhoon image using Cy3 
filter of labelled fibrils at 5 and 0.5 mg/ml concentrations. (B) Confocal image 
of 3μl of labelled fibrils (7.5μg/ml). (C) Images of labelled fibrils obtained using 
the confocal microscope were analysed in IMARIS Slice view module to give 
an approximation of overall size. Typhoon scanner identified fluorescent bands 
of expected size for recombinant PrP and fibrils were detectable by confocal 
microscopy. IMARIS analysis of labelled fibrils generated baseline 
measurements before challenge experiments (mean size of 3.61 µm).              
(A) Typhoon image: NuPAGE Novex 12% Bis-Tris Protein Gel, 1.0 mm,           
15-well; SeeBlue Plus 2 Pre-Stained Standard. Images obtained from Typhoon 
FLA9500 scanner, Cy3. (B) Scale Bar 10μm. (C) Graph mean plus standard 
deviation 1.92, n=30, n= individual labelled fibrils. 
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4.4 Discussion 
 
In this chapter the production and characterisation of recombinant PrP fibrils 
was optimised, and the misfolded recombinant PrP generated will be used to 
challenge primary neuronal cultures in vitro. WT and 101L recombinant PrP 
was produced, refolded into fibril form and labelled with a fluorescent tag. 
Previous studies from our group have shown both WT and 101L recombinant 
PrP fibrils seeded plaque formation in 101LL mice but not in WT mice 
indicating that the primary sequence of recombinant PrP fibrils does not 
influence seeding mechanisms (Barron et al. 2016). Data in this chapter 
showed both WT and 101L generated fibrils share similar physical dimensions 
by EM (Figure 4.7) irrespective to PrP sequence complimenting previous 
results by our group. Both WT and 101L fibrils were generated however, from 
characterisation data and previous in vivo studies, the Prnp genotype used to 
generate fibrils should have no influence on challenge outcome.  
 
Improvements to traditional methods were introduced throughout recombinant 
PrP production. Immobilized-Metal Affinity Chromatography (IMAC) was one 
of the first alternative steps involved in producing highly pure recombinant PrP 
from crude lysates. The principle of this purification step is that proteins that 
bind to metal ions will adhere to an IMAC column which is composed of nickel 
ions chelated by beads. For recombinant PrP there was no need to append a 
His-tag to the protein as the N-terminal copper binding domain of PrP can be 
used in the absence of a His-tag for efficient binding to the immobilised nickel 
ions (PrP contains 10 endogenous histidines). As shown in Figure 4.2, this was 
an effective method of binding recombinant PrP which was then easily eluted 
off the column using specific buffers. Another important step for recombinant 
PrP purification involved reduced glutathione removal which was present in 
protein-containing fractions isolated from the IMAC step. Efficient removal and 
purification of PrP using a desalting method was shown in Figure 4.3. 
Recombinant PrP was then further purified using Reversed Phase High 
Performance Liquid Chromatography (RP-HPLC).  
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Here substances were separated by hydrophobicity and as recombinant PrP 
protein is relatively hydrophobic it attached to the column tightly and efficiently. 
An organic solvent was then used to progressively elute the hydrophobic PrP 
which was collected in numerous fractions and SDS-PAGE confirmed highly 
pure PrP was obtained (Figure 4.4). All processing steps were fully 
characterised using SDS-PAGE, MS and EM all of which confirmed highly pure 
recombinant PrP fibrils were generated free of PrP adducts normally 
generated from spontaneous oxidation or degradation (Makarava and 
Baskakov 2012). Studies by other groups have shown fibrils isolated from 
infected tissue are resistant to PK digestion (Parchi et al. 2000; Collinge et al. 
1996), appear fibrillar and “rod-like” in structure when imaged by EM (Prusiner 
et al. 1983) and have a width measurement of between 0.003-0.0035μm 
(Caughey et al. 2009). The artificially “in vitro” created fibrils described in this 
chapter share similar characteristics (Figure 4.6, 4.7, 4.8) and therefore 
provide a suitable synthetic surrogate of in vivo generated misfolded PrP for 
fibril challenge experiments.  
 
Fibrillisation of recombinant PrP was carried out according to previously 
published methods (Graham et al. 2010; Breydo, Makarava, and Baskakov 
2008). Initially lyophilised recombinant PrP samples were reconstituted in 6M 
Gdn-HCl pH 6.0 to a concentration of 3mg/ml however this was later increased 
to between 10-15mg/ml which aided in the production of highly concentrated 
fibrils whilst reducing the volume needed for fibril challenge studies in primary 
neuronal cultures. The conditions associated with the refolding of monomeric 
recombinant PrP to produce fibril material vary between laboratories and 
involve using different concentrations of denaturant and buffering along with 
variations in speed of agitation (Raymond et al. 2012; Makarava et al. 2010; 
Novitskaya et al. 2006; Legname et al. 2004). Our group have previously 
shown that fibrils produced as described in this chapter can seed further fibril 
aggregation in the brain in the absence of disease.  
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These results also agreed with other published data irrespective of how the 
fibrils were generated (Makarava, Kovacs, Savtchenko, Alexeeva, 
Ostapchenko, et al. 2012; Makarava et al. 2011; Makarava et al. 2010).  
 
Fluorescent analysis using SDS-PAGE and a typhoon scanner in conjunction 
with confocal microscopy confirmed efficient labelling of fibrils with Alexa Fluor 
dye. The dye is water soluble and pH insensitive from pH 4-10 which was 
advantageous for working in biological environments. Additionally, 
succinimidyl esters attach to amine-containing molecules forming amide bonds 
which are as stable as peptide bonds (Banks and Paquette 1995). Studies 
have demonstrated using TEM that these small extrinsic fluorescent tags do 
not interfere with the formation of amyloid fibrils and can therefore be used as 
a marker for studying protein aggregation (Anderson and Webb 2011). 
Additionally, other groups have shown cell lines and primary cultures were 
capable of cellular internalisation and processing of Alexa fluor labelled 
misfolded proteins again confirming fluorescent labelling of fibrils will be a 
suitable method for  the visualisation of misfolded protein uptake and 
processing in primary cultures (Hollister et al. 2015; Magalhaes et al. 2005).  
 
In summary, highly pure recombinant WT and 101L PrP fibrils were produced 
from bacterial cultures and then fluorescently labelled allowing for easy 
detectability of fibrils when added to primary neuronal cultures in vitro. This 
was important as it will allowed direct visualisation of abnormal protein 
trafficking and interactions in mixed cellular populations, crucial to 
understanding the mechanisms of misfolded protein processing in neuronal 
cultures.  
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CHAPTER 5 
 
Monitoring fluorescently labelled fibril trafficking and cellular 
processing in primary hippocampal cultures 
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5.1 Abstract 
 
Accumulation and spread of misfolded protein is common to all protein 
misfolding diseases (PMDs) however, mechanisms involved in abnormal 
protein trafficking and spreading remain unclear and non-neuronal cellular 
responses are poorly understood. To characterise pathways involved with the 
uptake and trafficking of misfolded protein, fluorescently labelled PrP fibrils 
were used to challenge primary neuronal hippocampal cultures and cellular 
response associated with both neuronal and non-neuronal cells was 
examined. Primary cultures generated from the 101LL genotype, which 
supports abnormal fibril seeding, and the WT genotype, which curtails 
abnormal protein formation, provided ideal candidates for these investigations 
to be carried out based on the hypothesis that both have different mechanisms 
of intracellular processing of abnormal protein that determine clearance versus 
the seeding of amyloid plaques. Fibril interactions with neurons and PrPC 
protein in both 101LL and WT cultures were apparent however, no significant 
neuronal loss was evident over a 24-hour exposure period indicating fibril 
concentrations investigated were not initially neurotoxic. Fibril internalisation 
by cells trafficked fibrils into early and late endosomes in both genotypes 
indicating early sorting and recycling of fibrils was occurring and was been 
mediated via an operative endocytic pathway. Intracellular labelling of 
lysosomal vesicles in WT cultures indicated cells were capable of internalising 
fibrils proficiently for degradation however, 101LL cells did not. This impeded 
lysosomal processing of fibrils in 101LL cultures may explain how this 
genotype is capable of supporting the aggregation of abnormal protein in the 
brain. Non-neuronal cellular processing of fibrils was evident in both cultures. 
WT astrocytic populations appeared hypertrophic in comparison to 101LL 
astrocytes indicating glial cells were responding to fibril challenge whilst 
playing an active role in fibril uptake and processing in WT challenged cultures. 
Microglial response was evident in both 101LL and WT cultures and microglia 
appeared to be actively phagocytosing fibrils.  
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Synaptic fibril associations were evident in both genotypes and 101LL cultures 
had significant reduction in post-synaptic marker PSD-95 after fibril challenge 
suggesting 101LL neurons were more susceptible than WT to fibril challenge. 
These experiments visualise and characterise the initial steps associated with 
misfolded protein uptake and processing, and show evidence of associations 
with both neuronal and non-neuronal cells in two divergent genotypes. The 
results presented here highlight misfolded proteins in this case fibrils can 
interact with numerous cells types not just neurons. Additionally, abnormalities 
in endolysosomal degradation pathways identified in the 101LL cultures that 
impede fibril degradation provides insights into abnormal protein processing 
and provides test targets for further investigations for intervention in PMDs.  
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5.2 Introduction 
 
One of the key features associated with PMDs is the ability of the abnormally 
folded proteins to propagate in a “prion-like” manner (Section 1.5.2) and 
spread from neurons to neighbouring neurons and glia however, the cellular 
mechanisms involved are poorly understood (Pearce et al. 2015; 
Brettschneider et al. 2015). Studies in prion infected neuroblastoma cells 
indicated that once abnormal PrP is formed on the cell surface or in 
endosomes, it can be sequestered in lysosomes (Magalhaes et al. 2005; 
Caughey et al. 1991). In prion infected brains, abnormal PrP usually 
accumulates in extracellular deposits but can also be located in late 
endolysosomal vesicles in neurons (Laszlo et al. 1992). Additionally, glial 
response to environmental changes in the brain can include astrocytic and  
microglial cell activation characterised by a notable change in cell morphology 
at early stages of neurodegeneration (Perry and Teeling 2013). Abnormal 
proteins can induce these glial responses, characterised by the presence of 
hypertrophic cell bodies (Sofroniew 2009, 2005; Schenk et al. 1999), and 
studies have shown both astrocytes and microglia cell types are capable of 
phagocytosis of Aβ fibril material (Jones et al. 2013; Lee and Landreth 2010). 
More recently, astrocytic endolysosomal vesicles were found to be capable of 
cell-to-cell transfer of misfolded PrP (Victoria et al. 2016). These observations 
suggest both neuronal and non-neuronal cells play important roles in PMDs 
and endolysosomal vesicles may be a major route for abnormal protein 
degradation. To gain further insights into these associations, initial responses 
to misfolded PrP fibril challenge were investigated using primary hippocampal 
cell cultures. Fluorescently labelling PrP fibrils allowed for the visualisation of 
trafficking and processing associated with abnormal fibrils. Additionally, 
hippocampal cultures were generated from mice with PrP genotypes that were 
capable of supporting PrP misfolding or that curtailed it and thus, provided a 
means for gaining further insights into possible different mechanisms 
associated with efficient or deficient misfolded protein processing.  
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Genotype specific responses were characterised using immunocytochemistry 
in conjunction with IMARIS software which provided a novel platform for 
performing detailed analysis of cellular interactions with fluorescently-labelled 
fibrils in vitro.  
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5.3 Results 
 
5.3.1 Neuronal response to fibril challenge in primary hippocampal cultures 
 
Recombinant PrP fibrils were produced and fluorescently labelled (Chapter 4, 
Figure 4.8) for use in fibril challenge experiments. Primary neuronal cultures 
are capable of cellular internalisation and processing of Alexa fluor labelled 
misfolded proteins (Hollister et al. 2015; Magalhaes et al. 2005) therefore, 
primary hippocampal cultures generated from WT and 101LL embryos 
(Chapter 3, Section 3.3.3) were used in these fibril challenge experiments to 
allow visualisation of abnormal protein uptake and processing in vitro. Initial 
challenge studies indicated fibrils were not neurotoxic at 7.5μg/ml 
concentrations over a 24-hour time period as measured by LDH release 
(Figure 5.1). IMARIS analysis of immunolabelled images supported these 
findings and showed no significant differences between unchallenged and 
fibril-challenged cultures were evident based on neuronal marker MAP2 
(Appendix Figure 5.a) confirming a lack of neurotoxicity within these 
parameters (6 and 24-hours, 7.5μg/ml). This was an important finding as it 
provided baseline parameters for future investigations. To examine if fibril 
insult could induce cytotoxicity at higher concentrations, a range of fibril 
concentrations (0-45μg/ml) were applied to cultures over a 24-hour period and 
cellular cytotoxicity was monitored. A correlation with increased fibril 
concentration and cellular cytotoxicity measured by LDH release was evident 
(Figure 5.1). At 30μg/ml approximately 40% cells were showing signs of 
cellular stress confirming fibrils were capable of inducing cellular toxicity in 
primary cultures in a dose dependant manner. Similar cytotoxic effects were 
evident using unlabelled fibrils (Figure 5.1) suggesting labelling with a 
fluorescent tag was not effecting cellular response to fibrils. and also confirmed 
studies by other groups that have shown labelling with extrinsic fluorescent 
tags can be used to study protein aggregation (Anderson and Webb 2011).  
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Throughout the investigations presented in this chapter, cultures were 
challenged for either 6 or 24-hours at fibril concentrations of 7.5 or 30μg/ml, 
parameters that were deemed sufficient for eliciting limited cellular degradation 
(7.5μg/ml) whilst possibly stimulating a strain on organelle clearance pathways 
(30μg/ml). WT and 101L fibrils were used as previous results showed both 
shared similar physical dimensions (Chapter 4, Figure 4.7) and previous data 
from our group demonstrated that both fibril types were capable of seeded 
plaque formation in 101LL mice but not in WT mice, indicating the primary 
sequence of recombinant PrP fibrils does not influence seeding mechanisms 
(Barron et al. 2016). Super-resolution studies using the Zeiss AiryScan 880 
confocal microscope were performed to examine the precise location of fibrils 
after addition to cultures, and to investigate if fibrils were localising with PrPC. 
The AiryScan 880 has a 32-channel gallium arsenide phosphide 
photomultiplier tube area detector that collects a pinhole-plane image at every 
scan position which improves resolution and signal-to-noise ratio, and can 
resolve structures of 120 nm in x,y and 350 nm in z dimensions (Huff 2015). 
As shown in Figure 5.2, fibrils were directly localising with neuronal dendritic 
processes and around neuronal cell bodies and IMARIS reconstructions 
(Figure 5.2), highlighted these associations. Furthermore, fibrils localised with 
PrPC and this may be an indication of initial mechanisms associated with fibril 
conversion of normal cellular PrPC to the abnormal form, a process known as 
seeding-nucleation conversion (Prusiner 1996; Kocisko et al. 1994). These 
data also show fibril detection can be distinguished from normal PrPC 
immunolabelling when using anti-PrP antibody 6H4. Unfortunately, only limited 
super-resolution studies were carried out due to lack of AiryScan confocal 
resources.   
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Figure 5.1: Cellular response to fibrils was dose dependant in primary cultures. 
To investigate if fibrils were capable of inducing neurotoxicity in cultures, a 
range of fibril concentrations (0-45µg/ml) were applied to cells over a 24-hour 
timeframe. The effect of fluorescently labelling fibrils was also examined to 
ascertain if this fluorescent tag was influencing toxicity in cultures. (A) LDH 
readings from WT cells challenged with Alexa Fluor 555 WT fibrils and (B) WT 
cells challenged with unlabelled WT fibrils. A correlation between cytotoxicity 
and increased fibril concentration was evident in labelled and unlabelled 
challenged groups confirming fibrils were capable to inducing cellular toxicity 
at higher concentrations. Additionally, LDH profiles were comparable between 
groups, for example at 30µg/ml, approximately 40% cells were showing signs 
of cellular stress in both labelled and unlabelled challenged cultures. These 
data suggest labelling fibrils with a fluorescent tag does not affect cytotoxicity.  
(C) Fibrils did not induce neurotoxicity in either WT or 101LL primary cultures. 
LDH assay was used to monitor cytotoxicity associated with fibril challenge in 
both WT and 101LL cultures. LDH readings showed no significant increase 
after challenge (WT F, 101LL F) in comparison to control readings (WT, 101LL) 
indicating fibrils were not neurotoxic at this concentration and incubation 
timeframe. (A-B) WT cells plated at 30,000 cells per well on pre-coated PDL 
plates, Graph mean plus standard deviation, n=2 duplicate technical 
replicates. Note only one value available for both 30 and 45µg/ml readings in 
(B) due to pipetting error. (C) 400,000 cells challenged with 7.5μg/ml of 101L 
fibrils for 24-hours at DIV7, Graph mean plus standard deviation, WT n=10, 
WT F n=12, 101LL n=8, 101LL F n=8, n= duplicate technical replicates of 
individual wells, unpaired t test. Fluorescent values were normalized to Triton 
X-100 treated lysis cells that represent the maximum amount of LDH available 
for release. 
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Figure 5.2: Fluorescence image analysis of fibril-challenged cultures.       
Super-resolution imaging using the Zeiss AiryScan 880 allowed for detailed 
image reconstructions to be carried out using IMARIS which allowed for 
efficient fibril interaction analysis. These analysis were used to investigate 
whether fibrils were localising with neuronal cells and PrPC and whether anti-
PrP antibody labelling could be distinguished from fibril labelling. (A) and (B) 
Fibrils (Red) appeared to be interacting with neuronal processes 
(MAP2/Green), neuronal cellular bodies (MAP2/Green; Nuclear/DAPI/Blue) 
and PrPC (6H4/White). (C) and (D) IMARIS reconstructions confirmed these 
observations and clearly show fibrils were interacting with PrPC along dendritic 
processes and around neuronal nuclear bodies. These data confirmed fibril 
detection can also be distinguished from normal PrPC immunolabelling when 
using anti-PrP antibody 6H4. 101LL cultures 75,000 cells, challenged with 
7.5µg/ml WT fibrils, glass coverslip. Scale bar (A) 5µm, (B) 3µm, (C), (D) 2µm, 
Confocal AiryScan 880. 
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5.3.2 Non-Neuronal response to fibril challenge in primary hippocampal 
cultures 
 
To ascertain if neuronal and or non-neuronal cells were capable of fibril 
endocytosis, a phagocytosis assay was initially carried out using pHrodo red 
S.aureus bioparticle conjugates (Materials and Methods, 2.4.2). When beads 
are internalised by cells acidification of the pHrodo dye conjugated to the 
particles increases fluorescence as the pH of its surroundings becomes more 
acidic and this signal can be detected using a plate reader or can be visualised 
by confocal microscopy. Neurons, astrocytes and microglia were capable of 
phagocytosing pHrodo bioparticles (data not shown) implying these cellular 
populations should be able to actively process fibrils in a similar manner. Thus, 
fibril aggregate diameter (FAD) measurements were obtained using IMARIS 
(Section 2.2.9) before and after addition to WT and 101LL cultures to ascertain 
if changes in fibril size were evident after challenge indicative of active cellular 
fibril processing. A significant decrease in fibril size was noted in both WT and 
101LL cultures after 6 hours (Figure 5.3). Longer incubation timeframes did 
not result in significantly more degradation of fibrils indicating both genotypes 
were rapidly responding to fibril insult within a few hours suggesting cells were 
actively trying to reduce fibril burden in primary cultures. Results obtained from 
the pHrodo phagocytosis assay, confirmed both neuronal and non-neuronal 
cells were capable of phagocytosis of unwanted materials and as fibril 
challenge was not causing any obvious morphological changes in neuronal 
populations (Appendix Figure 5.a), the possibility that other non-neuronal cells 
could be actively interacting with and possibly degrading fibrils to protect 
neuronal populations was investigated. Thus, both astrocytic and microglial 
response was monitored after fibril challenge in primary cultures as studies 
have shown these glial cells maintain neuronal networks and protect neurons 
from toxicity (Boehler, Wheeler, and Brewer 2007; Ye and Sontheimer 1998).  
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Previous immunolabelling characterisation results (Chapter 3, Figure 3.10), 
confirmed astrocytic populations were present in WT and 101LL cultures and 
were morphologically comparable displaying multiple process phenotypes pre-
fibril challenge. Astrocytes in both genotypes were interacting with fibrils 
however, only WT challenged cultures exhibited a change in astrocytic 
morphology (Figure 5.4). This hypertrophic astrocytic response to misfolded 
protein has been previously described in other studies that showed reactive 
astrocytes played a role in restricting inflammation and protecting neurons, 
therefore reducing CNS degeneration (Sofroniew 2009, 2005; Schenk et al. 
1999) suggesting WT astrocytic response was neuroprotective. Conversely, 
other studies have shown reactive astrogliosis response may contribute to 
neurodegeneration via loss of normal astrocyte function or gain of abnormal 
effects (Sofroniew and Vinters 2010). Neuronal populations present in WT 
fibril-challenged primary cultures did not show any signs of degradation 
suggesting reactive astrocytes were neuroprotective in this case and were 
possibly actively phagocytosing fibrils. No evidence of astrocytic activation in 
101LL cultures indicated either a delayed response, a lack of response or an 
inactivated response due to the 101LL point mutation however, this did not 
cause any obvious neuronal toxicity over the timeframes investigated. 
Increasing fibril load or challenge time may result in a reactive astrocytic 
response or may even induce cellular toxicity however, this was not explored 
further due to time constraints. As described in Chapter 3 (Figure 3.13) PrPC 
was also associated with astrocyte cell populations, although to a lower degree 
than neurons and fibril localisation with PrPC on astrocytic bodies was evident 
in both WT and 101LL cultures (Figure 5.4). Studies have shown astrocytic 
involvement in replication of abnormal PrP protein (Diedrich et al. 1991). 
Further reports indicated TSE infection was evident in transgenic mice 
expressing PrPC only in astrocytes indicating that PrPC expression in these 
specific cell types alone was sufficient to cause neurodegeneration (Raeber et 
al. 1997). Due to the short timeframe associated with fibril challenge 
experiments in this study, it could not be concluded if abnormal PrP replication 
was happening in this cell type.  
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However, initial investigations of PrPC immunolabelling after challenge 
(Appendix Figure 5.f) showed no significant differences pre and post-challenge 
in both genotypes, indicating that within a 24-hour timeframe no PrPC 
conversion was occurring nevertheless, this would have to be confirmed 
biochemically in future investigations as discussed in Section 7.3.1. Fibril 
localisation with astrocytic PrPC protein does however indicate normal cellular 
function may be altered in these cell types which could lead to abnormal PrP 
replication. Microglia were also present in unchallenged primary cultures 
(Chapter 3, Figure 3.11), however, their presence was less abundant than 
astrocytic cell populations. Microglial cells in unchallenged cultures appeared 
ramified exhibiting long processes indicating they were in surveillance mode 
as opposed to an amoeboid state where cell bodies are large and processes 
are short and thick, a phenotype correlated with microglial activation in 
response to neuronal injury (Arcuri et al. 2017; Ling and Wong 1993). After 
fibril challenge, microglial cells appeared short and thick indicating microglia 
were activated after fibril insult (Appendix Figure 5.b). High magnification 
imaging confirmed localisation between fibrils, microglia and PrPC and 
enlarged images showed many smaller fibril structures were present in these 
activated phagocytic cells suggesting phagocytosis was occurring possibly to 
aid fibril degradation and this was evident in both WT and 101LL cultures. 
Localisation of fibrils with PrPC suggest the possibility of fibrils acting as seeds 
for the conversion and misfolding of normal host PrP protein however, this was 
not investigated here. More so, previous studies have shown by EM that 
activated microglial are normally absent where abnormal PrP is confined solely 
to membranes indicating microglia were not essential for conversion of normal 
PrP to the abnormal disease form (Jeffrey et al. 2012). Overall, activation of 
microglia in both genotypes indicated this was a generic response to fibril 
challenge that was limiting neuronal damage in primary cultures. 
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Figure 5.3: Fibril size was reduced after addition to cultures. To investigate if 
fibrils were been degraded in cultures, fibril aggregate diameter measurements 
before and after addition to cells were taken at two time points. (A-C) 
Representative images of (A) Fibrils only, (B) Fibrils plus cells (WT culture, 6-
hour fibril challenge) and (C) Fibrils plus cells (WT culture, 24-hour                  
fibril challenge). (D) and (E) Measurements of fibril diameter were calculated 
using IMARIS software for both WT (Mean diameter fibrils only 4.63; fibrils plus 
cells 6-hour 0.76, 24-hour 0.36 µm) and 101LL (Mean diameter fibrils only 
4.63; plus cells 6-hour 0.40; 24-hour 0.61 µm) cultures. Significant differences 
in diameter readings were noted in both WT (P-Value 0.001) and 101LL (P-
Value 0.0004) cultures indicating fibril size was been reduced after addition to 
primary cultures. Timeframes show this happened rapidly within a 6-hour 
period. No significant differences in readings were evident between WT and 
101LL 6-hour culture fibril values (P-Value 0.40). Longer incubation timeframe 
(24-hour) did not result in significantly more degradation of fibrils (P-Value 
0.40, 0.40), indicating both genotypes were rapidly responding to fibril insult 
and were actively trying to reduce fibril burden. WT and 101LL cultures 30,000 
cells, challenged with 7.5µg/ml WT fibrils for 6 or 24-hours, Scale Bar 20µm, 
Confocal LSM710. Graph mean plus standard deviation, n=20, n= individual 
fibril diameter, unpaired t test. 
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Figure 5.4: Astrocytic response differed between fibril-challenged genotypes. 
Immunolabelling of astrocytes after fibril challenge was carried out to 
investigate if glial cells were interacting and responding to fibrils. (A) and (B) 
Unchallenged WT and 101LL controls; (A1-A3; B1-B3) WT and 101LL 
challenged cultures with fibrils (Yellow), astrocytic marker (GFAP/Red), PrPC 
(6H4/White), and DAPI (Nuclear/Blue). Localisation of fibrils with astrocytes 
was evident (Arrows) in both genotypes however, only WT challenged 
astrocytes displayed a change in morphology (A1,A2,A3) in comparison to 
unchallenged controls. This hypertrophic change characterised by a 
shortening and thickening of processes indicated a reactive astrogliosis 
response was occurring in WT cultures which was absent in 101LL cultures. 
Localisation of fibrils with PrPC on astrocytic bodies was also evident in both 
WT and 101LL cultures. WT and 101LL cultures 75,000 cells, challenged with 
7.5µg/ml WT fibrils, Scale bar (A-B) 15µm, (A1-A3; B1-B3) 10µm, Confocal 
LSM710. 
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5.3.3 Synaptic response to fibril challenge in primary hippocampal cultures 
 
Previous studies have shown the hippocampus is a target area associated with 
early synaptic loss in prion diseases which precedes neuronal death (Hilton et 
al. 2013; Cunningham et al. 2003). Synapsin 1 (Syn) is a pre-synaptic vesicle-
associated protein, involved in the regulation of axonogenesis and 
synaptogenesis (Qin et al. 2004; Chin et al. 1995). PSD-95 is the most 
abundant scaffold protein localised in post-synaptic terminals of excitatory 
neurons and has a critical role in post-synaptic function and plasticity (Yuki et 
al. 2014). The presence of both pre and post-synapses were evident in both 
WT and 101LL cultures (Chapter 3, Figure 3.12) and IMARIS data intensity 
value comparisons confirmed similar levels of synaptic populations were 
evident between genotype comparisons based on Synapsin 1 and PSD-95 
labelling pre-fibril challenge. Fibril localisation with synapses was evident in 
both genotypes however, only 101LL cultures showed a significant reduction 
in PSD-95 labelling after fibril challenge and this reduction was occurring 
before any detectable neuronal loss (Figure 5.5). WT cultures did not show 
any changes in synaptic markers after fibril challenge indicating they were less 
susceptible to fibril synaptic interactions over a 24-hour period. Studies have 
shown early synaptic loss precedes neuronal death (Hilton et al. 2013) and 
this would explain the lack of correlation between neuronal loss and PSD-95 
reduction observed here. AD hippocampal studies have also shown neuronal 
loss was disproportionate to initial decrease in synaptic number and density 
(Davies et al. 1987). Collectively, the initial fibril effects reported in this chapter 
support the hypothesis that synaptic loss is an early event and precedes 
neuronal loss. It also indicates results obtained using primary hippocampal 
cultures compliment in vivo data obtained from investigations into 
neurodegenerative diseases such as AD (Scheff et al. 2006; Masliah et al. 
2001) indicating this in vitro system was providing a suitable model for studying 
neurodegeneration.  
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Figure 5.5: Fibril challenge reduced PSD-95 in 101LL cultures. After               
fibril challenge, pre and post-synaptic protein and fibril interactions were 
investigated to ascertain if fibrils were localising and possibly disrupting 
neuronal synapses. (A-A1) WT and (B-B1) 101LL images showed interactions 
between fibrils (Yellow); neurons (MAP2/Green); Synapsin 1 pre-synaptic 
marker (Syn/Red) and post-synaptic marker (PSD-95/White) were evident in 
both cultures. (C) WT and (D) 101LL IMARIS analysis of data signal intensities 
obtained from MAP2, Syn and PSD-95 immunolabelling. No significant 
differences were noted in neuronal immunolabelling after challenge and 
between synaptic markers in WT cultures however, as shown in (D) a 
significant reduction in PSD-95 was evident in 101LL cultures (P-Value 0.02). 
These data confirm fibrils were interacting with synapses in both genotypes 
however, no changes in MAP2 signalling suggested neurons were not affected 
over the 24-hour challenge period. In 101LL cultures, a significant reduction in 
PSD-95 confirmed fibrils were actively reducing this scaffold protein. WT and 
101LL cultures 30,000 cells, challenged with 7.5µg/ml 101L fibrils for 24-hours, 
Scale Bar (A,A1-B,B1) 1µm, Confocal LSM710. Graph mean plus standard 
deviation, n=4, n= data intensity sum of individual wells, unpaired t test. 
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5.3.4 Fibril trafficking and organelle associations 
 
To identify the subcellular compartments involved in uptake and trafficking of 
fibrils in primary hippocampal cultures, co-staining with a variety of organelle 
markers (Chapter 3, Figure 3.16) was carried out. Previous studies have 
indicated abnormal PrP localisation with raft membranes and these 
associations may provide a means of cellular internalisation of fibrils via 
clathrin-coated pits (Taylor and Hooper 2006; Vey et al. 1996). Cholera toxin 
Ganglioside GM1 ligand Subunit B was used to label lipid-rafts to explore if 
fibril interactions were associated with these glycolipoprotein microdomains. 
Image analysis (Appendix Figure 5.c), indicated some fibrils were localising to 
these areas in both genotypes however these observations were rare. Lipid-
rafts have been shown to be more abundant in mature hippocampal neurons 
than other cell types such as astrocytes (Malchiodi-Albedi et al. 2010) 
indicating fibrils were mainly internalised by neurons via this route however, 
specific cells types were not immunolabelled in these studies. As fibril lipid-raft 
domain localisation was only evident in some cases, internalisation via this 
route may also be limited. These findings support studies that have shown if 
abnormal PrP formation occurred outside of raft domains they may lack raft 
associations (Magalhaes et al. 2005). Misfolded proteins and exogenous 
abnormal PrP can also be taking up by cells in a relatively nonselective 
process such as macropinocytosis, which delivers internalised substances to 
endosomal or lysosomal organelles (Silverman et al. 2016; Swanson and 
Watts 1995). This uptake may also be occurring in primary cultures as 
vesicular structures associated with macropinocytosis called macropinosomes 
range in size from 0.2 to 5µm therefore, would be capable of internalising fibrils 
which were within this size range (Figure 5.3) (Lim and Gleeson 2011). It is 
also known recycling of normal PrPc occurs via an endocytic pathway, where 
the protein is transported back into the cell by endosomes (Peters et al. 2003) 
or it is routed to the lysosomes for degradation via late 
endosome/multivesicular bodies (MVB) (Campana, Sarnataro, and Zurzolo 
2005) and therefore, this pathway was important for trafficking investigations.  
150 
 
To establish if cells were actively involved in the uptake and further organelle 
processing of fibrils, similar endolysosomal routes as described above were 
investigated by co-staining with Early Endosome Antigen 1 (EEA1/ early 
endosomes), Ras-related protein Rab9 (Rab9/late endosomes) and 
Lysosomal-Associated Membrane Protein 1 (LAMP1/ lysosomes) (Chapter 3, 
Figure 3.16). Both WT and 101L fibrils were localising in neuronal early 
endosomal domains in both WT and 101LL cultures (Figure 5.6). This 
indicated early sorting and recycling via an endocytic pathway was operative 
in neurons. These results also confirmed no differences were apparent in initial 
fibril processing routes associated with either WT and 101L fibrils, 
complementing previous results that showed both shared similar physical 
dimensions (Chapter 4, Figure 4.7). Further visualisation of fibril trafficking 
(Figure 5.7) using late endosomal marker Rab9, confirmed fibrils (both WT and 
101L) were associating with neuronal late endosomal organelles (astrocytic 
associations were also noted in both genotypes, data not shown) confirming 
maturation of early endosomes into late endosomes was occurring. Ras-
related protein Rab5 localises to early endosomes and is involved in recruiting 
Rab7 and Rab9 associated with maturation of these compartments to late 
endosomes (Kaur and Lakkaraju 2018; Pollard 2017). These data confirmed 
fibrils were on route for lysosomal degradation in both genotypes and studies 
by others have shown fibril material can be cleared through acidification of 
lysosomes (Boissonneault et al. 2009; Majumdar et al. 2007). The 
internalisation of fibrils into lysosomal vesicles was investigated using 
lysosomal marker LAMP1 (Figure 5.8). IMARIS reconstruction clearly showed 
fibrils (WT and 101L) were internalised by WT neuronal lysosomal organelles. 
This processing of fibrils in WT cultures suggested cultures were actively trying 
to degrade fibrils in these acidic lysosomal organelles. Interestingly, and as 
mentioned in the introduction, studies have shown astrocytes are capable of 
cell-to-cell transfer of misfolded PrP often found colocalised with 
endolysosomal vesicles (Victoria et al. 2016). WT astrocytic cells were 
hypertrophic and co-staining with LAMP1 showed fibrils were also internalised 
into lysosomal vesicles in this cell type (Appendix Figure 5.d).  
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Additionally, as this process was occurring beside what appears to be a 
neuron, it could be conclude that astrocytes were playing a neuroprotective 
role however, because of this close proximity, cell-to-cell transfer of fibril 
materials may also be possible as studies have shown insufficient acidification 
of astrocytic lysosomes can result in inadequate digestion of material (Loov et 
al. 2012). When lysosomal-fibril associations were investigated in 101LL 
cultures, no evidence of fibril internalisation was found in neuronal lysosomal 
organelles (Figure 5.9) or astrocytic lysosomal organelles (data not shown). 
This failure to traffic fibrils through lysosomal compartments in 101LL neuron 
and glia was the first indication of a major difference in fibril processing 
between genotypes and avoidance of lysosomal degradation may explain how 
the 101LL genotype is capable of supporting misfolded protein seeding in the 
brain. An alternative hypothesis would be that rapid lysosomal processing was 
occurring in 101LL cultures and the 24-hour time-point used for analysis was 
too late for detection however, this was doubtful as fibrils were clearly localising 
and were detectable in early and late endosomes after the 24-hour                  
fibril challenge. To validate lysosomal results further additional co-staining 
using LAMP2 was carried out. Both LAMP1 and LAMP2 are estimated to 
contribute to half of all proteins of the lysosome membrane (Eskelinen 2006). 
LAMP2 staining confirmed fibrils were associating with lysosomes in WT 
cultures but not in 101LL cultures (Appendix Figure 5.e). Pervious work in our 
laboratory has also indicated no intra-lysosomal abnormal PrP accumulations 
were noted in the brains (end-point) of 101LL mice inoculated with recombinant 
fibrils suggesting in vitro observations presented here were accurate (Barron 
et al. 2016). Defects in endocytic sorting have been associated with enlarged 
endosomes in AD (Kaur and Lakkaraju 2018) and accumulation of amyloid-β 
by astrocytes can also result in enlarged endosomes (Söllvander et al. 2016). 
To address if size or structure of early/late endosome and lysosome organelles 
was changing after fibril challenge in primary cultures which may account for 
differences noted between genotypes, a number of control versus fibril treated 
organelle confocal image comparisons were carried out alongside IMARIS 
organelle signal analysis (Section 2.2.9).  
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As shown in Figure 5.10 no obvious differences based on visual inspection 
were evident in all organelle size comparisons between control and fibril 
treated groups and between genotypes. This indicated no obvious changes in 
organelle structures were apparent after 24-hour challenge that might account 
for different fibril processing between genotypes. However, IMARIS data 
intensity analysis based on organelle staining did show a significant reduction 
in LAMP1 staining in 101LL cultures was evident after fibril challenge (Figure 
5.10), suggesting less lysosomal activity was occurring in this genotype. 
Recent studies have confirmed that promoting LAMP1 or lysosomal organelle 
degradation of Aβ using a small molecular URMC-099 (lineage kinase type 3 
inhibitor), was crucial in restoring synaptic integrity and hippocampal 
neurogenesis in AD mice. Hence, endolysosomal clearance via lysosomes 
provided a neuroprotective role and this degradation route was evident in WT 
cultures following fibril challenge (Kiyota et al. 2018). The reduction in LAMP1 
activity and the lack of localisation of fibrils within lysosome structures evident 
in 101LL fibril-challenged cultures indicated fibril degradation was impeded in 
this genotype. These results highlighted the 101LL point mutation was 
influencing the endolysosomal pathway potentially resulting in the seeding of 
fibril aggregates in this genotype. 
 
Throughout these investigations PrPC associations with fibrils, lipid-rafts and 
organelles was evident. These associations could be involved in the 
conformational conversion of PrPC to the abnormal form for example, studies 
have shown lipid-rafts appear to be involved abnormal protein conversion as 
these structures provide favourable environments for the process to occur 
(Taylor and Hooper 2006). Additionally, experimetal evidence also suggests 
the involvement of recycling endosomes as potential intracellular sites for this 
conversion (Marijanovic et al. 2009). As discussed previously in Section 5.3.2, 
confomational coversion of PrPC was not investigated in this chapter however, 
initial investigations for changes in PrPC immunolabelling levels after challenge 
(Appendix Figure 5.f) indicated that within a 24-hour timeframe no PrPC 
conversion was occurring in both genotypes.  
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Additional preliminary studies investigated if fibrils were associating with other 
processing pathways such as autophagy. Studies have shown p62 binds to 
ubiquitin and targets abnormal proteins for degradation through the 
autophagolysosomal pathway (Homma et al. 2014), therefore increased levels 
of p62 is used as an  indicator of autophagy (Bartolome et al. 2018). Using p62 
as an autophagosome marker (Materials and Methods, Table 2.1) fibril 
autophagosome localisation was explored in primary cultures. Preliminary 
results indicated fibrils were localising with these autophagic vacuoles in WT 
cultures which would possibly result in fibril degradation over longer periods of 
time however, no evidence of fibril localisation was noted in 101LL cultures 
(Appendix Figure 5.g). Due to limited time full investigation of this pathway 
could not be carried out however, these data do indicate that an autophagy 
pathway was also evident in WT cultures which would further contribute to fibril 
degradation. A summary of the significant findings in this chapter can be found 
in Figure 5.11 and Figure 5.12. These figures detail the differences in fibril 
processing pathways in WT and 101LL primary neuronal hippocampal cultures 
and highlight the possible changes/failures in these pathways that ultimately 
lead to the seeding of PrP amyloid plaques in fibril-challenged 101LL mice. 
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Figure 5.6: Intracellular trafficking of fluorescent-tagged fibrils. Organelle 
markers were used to investigate if fibrils were been internalised into cells via 
an endosomal mechanism and to ascertain if WT and 101L fibrils were 
trafficked in a similar manner in cultures. (A-A1) WT cultures challenged with 
101L fibrils (Yellow/Arrows), Early endosomal marker (EEA1/Red), PrPC 
(6H4/White) and DAPI (Nuclear/Blue). (B-B1) 101LL cultures challenged with 
WT fibrils (Yellow/Arrows) and (C-C1) 101LL cultures challenged with 101L 
fibrils. Arrows indicate both large are small fibril interactions with early 
endosomes were evident. WT and 101L fibrils were possibly internalised into 
neurons in both WT and 101LL cultures and were localising with early 
endosomal organelle domains indicating an endocytic processing pathway 
was operative. No differences in uptake were evident between the two fibril 
types or between genotypes. WT and 101LL cultures 30,000 cells, challenged 
with 30µg/ml of WT or 101L fibrils for 24-hours, Scale Bar (A-A1; C-C1) 5µm, 
(B-B1) 10µm, Confocal LSM710. 
155 
 
 
 
Figure 5.7: Targeting of fibrils to late endosomal organelles. To investigate if 
fibrils were been trafficked to late endosomes which would be indicative of a 
functional and operative endosomal pathway, cultures were labelled with a late 
endosomal marker. (A-A1) WT cultures challenged with 101L fibrils 
(Yellow/Arrows), Late endosomal marker Rab9 (Red), PrPC (6H4/White) and 
DAPI (Nuclear/Blue). (B-B1) 101LL cultures challenged with WT fibrils 
(Yellow/Arrows) and (C-C1) 101LL cultures challenged with 101L fibrils. Arrows 
indicate both large are small fibril interactions with late endosomes were 
evident. Localisation of both WT and 101L fibrils with late endosomal 
organelles was evident in both WT and 101LL neuronal cultures confirming 
maturation of early endosomes into late endosomes was occurring. No 
differences were evident between processing routes of the two fibril types or 
between genotypes. WT and 101LL cultures 30,000 cells, challenged with 
30µg/ml of WT or 101L fibrils for 24-hours, Scale Bar (A-A1; C-C1) 5µm, (B-
B1) 10µm, Confocal LSM710. 
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Figure 5.8: Fibrils were localising in lysosomes in WT cultures. To examine if 
fibrils were been trafficked to lysosomal domains, WT cultures were labelled 
with a lysosomal marker to examine if lysosomal degradation pathways were 
operative in this genotype. (A-A1) WT cultures challenged with WT fibrils 
(Yellow/Arrows), labelled with Lysosomal marker LAMP1 (Red), PrPC 
(6H4/White) and DAPI (Nuclear/Blue). Panel below shows IMARIS 
reconstructions of fibril and organelle interactions. (B-B1) WT cultures 
challenged with 101L fibrils (Yellow/Arrows). Arrows indicate both large are 
small fibrils were present however, only smaller fibrils appeared to localise with 
lysosomes. Lysosomal labelling in WT cultures showed both WT and 101L 
fibrils were present in these acidic organelle domains. IMARIS reconstructions 
confirmed WT fibrils were clearly embedded in organelle structures. PrPC 
localisation with fibrils was also evident. WT cultures 30,000 cells, challenged 
with 30µg/ml WT or 101L fibrils for 24-hours, Scale bar 10µm, Confocal 
LSM710. 
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Figure 5.9: Lack of localisation of fibrils in 101LL cultures. To investigate if fibrils 
were been targeted to lysosomal domains for degradation in 101LL cultures, 
dual-labelling with a lysosomal marker was carried out. (A-A1) 101LL cultures 
challenged with WT fibrils (Yellow/Arrows), Lysosomal marker LAMP1 (Red), 
PrPC (6H4/White) and DAPI (Nuclear/Blue). (B-B1) 101LL cultures challenged 
with 101L fibrils (Yellow/Arrows). Arrows indicate lack of interactions was 
evident with both large and small fibrils. Lysosomal labelling showed both WT 
and 101L fibrils were not localising in lysosomal organelle domains in 101LL 
cultures and therefore, fibrils were avoiding lysosomal degradation, possibly 
supporting protein misfolding and seeding. 101LL cultures 30,000 cells, 
challenged with 30µg/ml WT or 101L fibrils for 24-hours, Scale bar 5µm, 
Confocal LSM710. 
 
 
 
 
 
 
 
 
 
 
158 
 
 
 
Figure 5.10: Reduced lysosomal activity was evident in 101LL challenged 
cultures. Defects caused by accumulation of abnormal proteins can enlarge 
organelles therefore, organelle size before and after fibril challenge were 
compared to investigate if any changes were occurring in primary cultures 
which might account for the irregularities noted in 101LL fibril lysosomal 
processing pathways. (A) Panel of organelle images from WT and 101LL 
challenged cultures (Plus F) including controls minus fibrils (Minus F) labelled 
with Early endosomal marker (EEA1), Ras-related protein Rab9 (Rab9) and 
Lysosomal-Associated Membrane Protein 1 (LAMP1) all in red. (B) and (C) 
IMARIS analysis of data signal intensities obtained from organelle markers 
EEA1, Rab9 and LAMP1 minus or plus fibrils in WT and 101LL cultures. No 
noticeable differences were noted in organelle size and structure after           
fibril challenge. IMARIS analysis in WT cultures showed no significant changes 
from organelle comparisons however analysis of 101LL cultures indicated a 
significant reduction in LAMP1 staining after fibril challenge (P-Value 0.02) 
suggesting less lysosomal activity was occurring in the genotype. WT and 
101LL cultures 30,000 cells, challenged with 30µg/ml 101L fibrils for 24-hours, 
Scale Bar 5µm, Confocal LSM710. Graph mean plus standard deviation, (B) 
Controls minus fibrils n=2, plus fibrils n=5 for all markers, (C) Controls minus 
fibrils n=3, plus fibrils EEA1 n=5, Rab9 n=7 and LAMP1 n=9. n=data intensity 
sum of individual wells, unpaired t test. 
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Figure 5.11: Summary of cellular response to fibril challenge observed in 
primary hippocampal neuronal cultures. Fibrils were localising along the entire 
neuronal cell including synapses in both genotypes. Although fibrils were not 
inducing a neurotoxic effect over a 24-hour period at 7.5µg/ml concentrations, 
a significant reduction in PSD-95 was evident in 101LL cultures showing 
synaptic loss preceded neuronal loss and this result highlighted 101LL neurons 
were more susceptible than WT to fibril insult. WT astrocytes became activated 
and hypertrophic after fibril challenge and fibrils were localising within 
lysosomal organelles suggesting cells were actively degrading these abnormal 
conformations. Fibril localisation with 101LL astrocytes was also evident 
however, glial cells did not appear activated and no lysosomal interactions 
were apparent. Fibrils were internalised by activated microglia in both 
genotypes and reduced fibril sizes detected indicated degradation was 
occurring in these cells. PrP
C
 was detected in all cell types and localisation 
with fibrils indicated normal monomeric PrP
C
 could be targeted for conversion 
to fibril aggregates however, after 24-hour challenge no significant reduction 
in PrP
C
 was evident indicating this conversion was not occurring within this 
timeframe. 
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Figure 5.12: Summary of organelle processing results obtained after              
fibril challenge. Minimal lipid-raft localisation of fibrils was evident suggesting 
limited fibrils were been internalised into cells via clathrin-coated pits. 
Macropinocytosis provided a possible alternative route of internalisation which 
delivers internalised substances to endosomal or lysosomal organelles. Fibrils 
were detected in both early and late endosomal organelles in both genotypes 
indicating an operative endocytic pathway and early sorting and recycling of 
fibrils was occurring after cellular uptake. Neuronal and astrocytic processing 
of fibrils in late endosomes in both genotypes confirmed fibrils were on route 
for lysosomal degradation through acidification. In WT cultures, fibrils were 
internalised by neuronal and astrocytic lysosomal organelles indicative that 
active degradation was occurring. No fibril lysosomal localisation was evident 
in 101LL cultures and a significant reduction in lysosomal organelle activity 
after challenge suggested fibrils would survive and possibly propagate further 
in this genotype. A second lysosomal marker was used to confirm these 
observations and validated the results presented here. Autophagy was also 
evident in WT cultures only and provided another degradation pathway by 
fusion of autophagic vacuoles with lysosomes however, due to time constraints 
of this project these associations were not fully explored in this chapter.   
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5.4 Discussion 
 
The initial interactions of misfolded protein with neuronal and non-neuronal 
cells is poorly understood however, the presence of misfolded protein is 
common to all PMDs. The data presented in this chapter provide insights into 
initial neuronal interactions with misfolded PrP fibrils and also highlight the 
involvement of supporting glial cells such as astrocytes and microglia which 
appeared to play neuroprotective roles (Figure 5.11, 5.12). Additionally, 
fluorescently labelling fibrils proved advantageous for the visualisation of 
uptake and trafficking of misfolded protein within primary cultures. Fibrils were 
shown to localise along entire neuronal dendrites within the 24-hour fibril 
exposure timeframe and no significant neuronal loss was evident at lower fibril 
concentrations indicating fibrils were not neurotoxic within this timeframe at 
lower concentrations. Interestingly, as initial mechanisms involved in misfolded 
protein processing are poorly understood (Moreno-Gonzalez and Soto 2011), 
it is widely debated whether abnormal protein deposits are toxic to neurons or 
if they are generated as a protective mechanism to sequester smaller soluble 
forms of misfolded protein (Wolfe and Cyr 2011; Treusch, Cyr, and Lindquist 
2009; Haass and Selkoe 2007). Although the data presented here 
demonstrate lack of toxicity (Figure 5.1c), increasing fibril dose did escalate 
toxicity of fibrils (Figure 5.1a,b) either by gain of toxic function of fibrils or loss 
of native function of surrounding cells. Additionally, increasing timeframes of 
fibril challenge may also induce neurotoxicity however, due to time constraints 
of this project these thresholds were not investigated further here. Fibril insult 
did however, significantly reduce PSD-95 in 101LL cultures, confirming reports 
that synaptic loss precedes neuronal loss (Hilton et al. 2013) and these results 
show 101LL neurons were more susceptible than WT. Interestingly, similar loss 
of PSD-95 was reported in AD patients before any neuronal loss was evident 
(Yuki et al. 2014), and in mouse models of HD (Smith et al. 2014), suggestive 
that this protein may be a vulnerable target associated with many PMDs.  
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Indeed, a recent study in AD has shown Aβ oligomer-induced loss of PSD-95 
could be recovered in mouse hippocampal slices using compounds isolated 
from medicinal plants (Zolezzi et al. 2018). These data highlight synapse loss 
can be recovered and identification of PSD-95 vulnerability in the 101LL      
fibril-challenged primary culture model provides potential future targets for 
studying effects of novel compounds that could impede or recover synaptic 
decline. Although understandings of misfolded protein induced synaptic 
reduction and dysfunction are incomplete, data presented in the chapter 
indicate primary hippocampal cultures would provide a suitable model for 
further investigations of initial synaptic response to fibrils. Future studies 
examining these interactions and consequences thereafter would improve our 
understandings of the mechanisms contributing to synapse dysfunction 
leading to possible therapeutic targets to halt neurodegeneration associated 
with PMDs.  
 
Early responses to misfolded proteins include activated morphological 
response by astrocytic and microglial cell populations and these changes can 
be detected at early stages of TSE disease (Perry and Teeling 2013; Sofroniew 
and Vinters 2010). Research in our lab has also shown activated microglia and 
reactive astrocytes were present at the periphery of amyloid plaques in 101LL 
mice challenged with recombinant PrP fibrils (Barron et al. 2016), indicating 
glial cell populations play a role in maintaining brain homeostasis in response 
to misfolded protein insult. However, these results were based on analysis of 
animals approximately 500 days after inoculation with fibrils and therefore do 
not represent initial responses to abnormal protein insult. In this study, 
astrocytic cell populations in WT primary cultures appeared hypertrophic in 
comparison to 101LL astrocytes and controls. These data indicate that WT 
astrocytes were rapidly responding to fibril insult and possibly inducing early 
fibril degradation. As activated astrocytes were observed prior to any neuronal 
or synaptic defects in WT cultures, it was suggestive of a neuroprotective role.  
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This response may also be applicable to other neurodegenerative disorders 
and can be further studied using primary neuronal cultures derived from other 
mouse models to broaden our understandings of fibril induced neuroprotective 
astrogliosis. As mentioned already, previous in vivo work in our lab has shown 
reactive astrocytes were associated with amyloid plaques in 101LL                 
fibril-challenged mice. Contrasting results shown here where 101LL cultures 
were showing no astrocytic activation although fibrils were in their proximity 
suggest this response must either be dose dependant or time dependant, and 
this could be explored in future experiments however, the focus of this study 
was investigating initial cellular response to fibril challenge. Studies have 
shown microglia are capable of both engulfment and phagocytosis of Aβ fibril 
material (Lee and Landreth 2010) and when investigated here, microglia were 
responding rapidly to fibril insult and appeared both activated and phagocytic 
in both genotypes. Conversely, Alzheimer models using APP transgenic mice 
crossed with a chemically activated microglial suicide gene have shown that 
when microglial cells were ablated there was no effect on plaque size or 
number suggesting microglia were not critically involved in plaque formation 
and clearance in the brain. Microglial fibril engulfment and possible 
phagocytosis were shown here (Appendix Figure 5.b) in both genotypes and 
as no changes in neuronal populations were evident after fibril challenge 
(Figure 5.a), this response was deemed neuroprotective. This activated 
microglial response could change with increased fibril insult or challenge 
timeframe leading to over activated microglial states resulting in the release of 
reactive oxygen species (ROS) that could cause neurotoxicity (Block, Zecca, 
and Hong 2007). Although time constraints did not allow such analysis to be 
performed during this project, this could be a focus of future study. Microglial 
responses observed here suggest modulating microglial cellular and or 
inflammatory responses could provide possible therapeutic targets for removal 
of misfolded proteins in PMDs however, further characterisation of microglial 
activation states and the mechanisms by which these states may be 
modulated to decelerate neurodegeneration would have to be carried out first.  
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Recent studies have however highlighted, there is a lack of relevant microglial 
cell model systems available which has precluded progress in this area 
(Ginhoux 2016). The fibril-challenged primary neuronal culture model 
described in this chapter could bridge this gap and could be used for future 
investigative experiments for the identification of possible therapeutic targets 
for the modulation of microglial response in PMDs.   
 
Localisation of fibrils with neuronal, astrocytic and microglial PrP
C
 was evident 
in fibril-challenged cultures and could represent pathways for generating 
further misfolded protein (Kocisko et al. 1994) however, within the 24-hour 
exposure timeframe no significant reduction in PrP
C
 was evident (Appendix 
Figure 5.f) indicating conversion was not occurring within this timeframe. 
Abnormal forms of PrP are known to utilise and manipulate various intracellular 
quality control mechanisms during neurodegeneration (Chapter 1, Section 
1.5.3) and the lysosomal quality control machinery emerges as one of the 
primary targets (Majumder and Chakrabarti 2017). The lysosomal pathway 
acts as a terminal degradative compartment of cells and routes involved in 
delivering misfolded proteins to lysosomes include; endolysosomal, ERQC, 
Golgi QC and autophagic pathways (Saftig and Klumperman 2009). In this 
study, endolysosomal and autophagic pathways were investigated as 
alterations in both, due to blocked vesicular fusion or lack of cargo loading in 
the vesicles have been associated with a number of neurodegenerative 
diseases (Chapter 1, Section 1.5.3). Multiple organelle markers were used 
(Figures 5.6, 5.7, 5.8 and 5.9) in the assessment of neuronal lysosome 
distribution and trafficking as current research has indicated lysosomal 
labelling used alongside various endolysosomal markers is more accurate 
than relying on lysosomal staining alone (Cheng et al. 2018). As summarised 
in Figure 5.12, intracellular labelling of lysosomal vesicles in WT cultures 
indicated both neuronal and astrocytic cells were capable of internalising fibrils 
proficiently for degradation via a endolysosomal pathway and this was evident 
using either WT and 101L fibril preparations.  
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Additionally, fibril associations with p62 in WT cultures showed autophagy was 
also an activated pathway in WT cultures. Studies have shown the autophagy-
related protein p62 can be used for monitoring autophagy activity (Pankiv et 
al. 2007) and increased levels of p62 in prion-infected brains is linked to the 
promotion of aggregate clearance by autophagy (Homma et al. 2014). 
Conversely, fibrils were only associating with early and late endosomal 
organelles in 101LL cells indicating lysosomal pathways were been impeded 
and this inefficient processing of fibrils for degradation may explain how this 
genotype is capable of supporting abnormal protein seeding in the brain. 
Studies have shown deficient fusion between endosomes and lysosomes may 
be due to impaired ability of endosomes to recruit Ras-related protein Rab7, a 
GTPase required for endosome-lysosome fusion and this impairment may also 
be occurring in 101LL cultures (Urwin et al. 2010; Rink et al. 2005). Indeed, 
recent studies confirmed Rab7 is a main regulator of membrane trafficking at 
late endosomes and membrane fusion of late endosomes to lysosomes and 
autophagosomes to lysosomes (Modica and Lefrancois 2017) however, how 
cells regulate these interactions is not well understood. The model presented 
in this chapter provides a system to allow further investigations into Rab7 
function. Gathering more insights into these proteins and how they regulate 
fusion to acidic organelles is crucial for the modulation of effective and efficient 
abnormal protein degradation. Collectively these data suggest possible 
pharmacological enhancement of lysosomal activity may encourage abnormal 
PrP clearance and that proteins such as p62 and Rab7 could be potential 
targets for therapeutic control of misfolded proteins associated with PMDs. 
Treatment with autophagy-inducing compounds such as lithium and rapamycin 
can reduce abnormal PrP in cultured neuroblastoma cells (Heiseke et al. 
2009), and studies have shown rapamycin activation in vivo delayed disease 
onset, reduced plaque burden in the brain and improved survival of GSS     
prion-infected A116V mice (Cortes et al. 2012). However, activation of the 
autophagic pathway alone may not be enough to eliminate intracellular 
abnormal PrP aggregates from within cells (Browman and Zurzolo 2013).  
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Therefore, further extensive research into autophagy and related pathways will 
be required before establishing a possible pharmacological approach for 
treatment of PMDs and the fibril-challenged model presented in the chapter 
provides a means of preforming these investigations.  
 
In conclusion, the data described in this chapter provide visual evidence of 
important pathways associated with misfolded protein trafficking, processing 
and possible degradation involving both neuronal and non-neuronal cells in 
two divergent genotypes. Currently studies involving manipulating quality 
control lysosomal degradation pathways in neurodegenerative diseases are 
been carried out and the data presented in this chapter support targeting these 
pathways for efficient removal of unwanted cellular components (Majumder 
and Chakrabarti 2017; Nixon 2013; Saftig and Klumperman 2009).  
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6.1 Abstract 
 
Accumulation and spread of misfolded protein is common to all PMDs 
however, the mechanisms initiating these processes are poorly understood. 
The aim of this study was to use transcriptomic profiling to gain mechanistic 
insights into cellular responses to misfolded PrP protein. The 101LL genotype 
supports seeding of misfolding by fibrils in the brain whilst the WT genotype 
curtails abnormal protein formation after fibril challenge therefore; both 
provided ideal models for studying misfolded protein interactions. 
Transcriptome analysis comparing hippocampal brain tissue with primary 
hippocampal neurons established both systems were broadly similar. Gene 
expression profiles were also similar in primary hippocampal cultures form 
both genotypes indicating the 101LL point mutation was not influencing gene 
expression levels pre-fibril challenge. Post-fibril challenge transcriptomic 
analysis indicated both 101LL and WT cultures exhibited changes in gene 
expression. In WT fibril-challenged cultures, an increase in gene expression of 
genes associated with endocytosis, macrophage engulfment and ER-
associated misfolded protein catabolic processes, all of which would 
encourage fibril degradation was observed. These pathways were not induced 
in 101LL cultures. This suggests the induction of these processes is required 
to curtail abnormal protein folding after fibril challenge and highlights possible 
targets to investigate further for intervention in PMDs.  
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6.2 Introduction  
 
PMDs such as AD, PD, HD and TSE are associated with the accumulation of 
abnormally folded proteins in specific regions of the brain such as the 
hippocampus. However, the mechanisms involving seeding, processing and 
degradation of these rouge proteins are poorly understood (Holmes and 
Diamond 2012; Moreno-Gonzalez and Soto 2011). In this chapter, the 
response of primary hippocampal cultures to fibril challenge was investigated 
on a transcriptome level. This provided insights into molecular mechanisms 
associated with misfolded protein handling using cultures that either support 
misfolded protein generation (101LL) or that curtail its production (WT). 
Primary hippocampal cultures were used for this analysis as they provided a 
readily accessible defined system for fibril challenge and rapid extraction of 
RNA for transcriptome analysis. Differentially expressed genes (DEGs) 
identified after fibril challenge were investigated using several software 
platforms to provide insights into the phenotypic variations in fibril response of 
101LL and WT animals (Barron et al. 2016). As primary cultures were 
generated from hippocampal tissue, the transcriptomic data presented in this 
chapter is specific to a brain area vulnerable to disease. Initial baseline 
transcriptome profiles were generated by microarray analysis however, over 
the course of the project, a more comprehensive analysis using RNA-
sequencing (RNA-seq) for pre and post-fibril challenge transcriptome analysis 
was carried out.  
 
101LL versus WT in vitro (hippocampal culture) and 101LL versus WT in vivo 
(hippocampal tissue) comparisons were made by microarray analysis to 
ascertain if the P101L mutation was causing any gene expression changes in 
the 101LL genotype. Using standard analysis parameters no DEGs were 
identified in these genotype comparisons indicating that the point mutation had 
no effect on basal gene expression in comparison to the WT genotype.  
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These data also provided baseline gene expression profiles where any 
changes after challenge would be fibril-specific responses. Microarray analysis 
was also carried out to compare in vitro hippocampal cultures and in vivo 
hippocampal tissues to establish if in vitro cultures would provide a genetically 
comparable model to the brain. Transcriptome results indicated gene 
expression profiles in primary cultures were comparable and grossly similar to 
acutely dissected hippocampal tissue. Thus, primary hippocampal cultures 
would provide an appropriate in vitro representation of the hippocampal area 
of the brain for studying misfolded protein interactions. To establish the 
genotype-specific response to fibril challenge, cultures from WT and 101LL 
animals were challenged at DIV7 with 7.5μg/ml of unlabelled 101L fibrils for 24 
hours, after which point total RNA was isolated (Materials and Methods, 2.4.4). 
DEG lists specific to each genotype were then identified by RNA-seq analysis. 
WT cultures had double the amount of DEG changes than 101LL cultures after 
fibril challenge (WT versus WT plus fibrils 1,080 DEGs, 101LL versus 101LL 
plus fibrils 545 DEGs). DEG lists identified were analysed further using 
Ingenuity Pathway Analysis (IPA) and Miru software along with PANTHER and 
DAVID platforms to gain insights into processes associated with these specific 
gene expression changes. In WT cultures, fibril challenge induced initiating 
mechanisms associated with misfolded protein degradation such as 
endocytosis and macrophage engulfment. These mechanisms were not 
induced in 101LL cultures suggesting fibrils may be processed inefficiently in 
this genotype which could explain how 101LL mice are unable to curtail and 
degrade abnormal misfolded protein in vivo (Barron et al. 2016). Furthermore, 
genes associated with amyloid beta clearance, microglial and glial cell 
activation were down-regulated in 101LL fibril-challenged cultures suggesting 
mechanisms involved in fibril processing and clearance were dampened in this 
genotype. In conclusion, the emphasis of this study was to investigate early 
cellular responses in primary cultures after fibril challenge. Biological 
processes associated with protein degradation whilst reducing inflammatory 
responses were associated with WT response after fibril challenge, but not in 
101LL cultures.  
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Processes identified here provide a number of possible test targets that can 
be further explored in future experiments and developed for potential 
therapeutics against PMDs. These findings may also be applicable to other 
neurodegenerative diseases involving abnormally formed proteins such as Aß, 
tau and α-synuclein.  
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6.3 Results 
 
6.3.1 Methodology for sample transcriptomic analysis 
 
RNA isolation, processing and quality control from 101LL and WT cultures and 
tissues (Figure 6.1) was described previously in Materials and Methods (2.2.7, 
2.4.4 and 2.5.1). Microarray analysis was carried out on unchallenged 101LL 
and WT primary hippocampal cultures (derived from Day17 embryos), and 
101LL and WT Day 6 hippocampal tissues (Figure 6.1). The same 
unchallenged 101LL and WT primary hippocampal culture samples (used for 
microarray) and fibril-challenged 101LL and WT primary cultures (Materials 
and Methods 2.4.4) were analysed using Illumina RNA-sequencing. Additional 
workflows based on producing good quality data (Fuller et al. 2016) included 
data filtering and validation of results (Figure 6.1). 
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Figure 6.1: Experimental design and workflow. Overview of methodology from 
origin at Tissue and Cell Sampling through to Validation of data produced from 
microarray and RNA-seq. Stringent data filtering and unbiased transcriptomic 
analysis allowed for the generation of good quality data. 
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6.3.2 WT versus 101LL gene expression in primary cultures and acutely 
dissected tissue 
 
Does the 101LL point mutation influence gene expression levels pre                
fibril challenge? To address this question, microarray analysis of unchallenged 
WT versus 101LL primary hippocampal cultures and WT versus 101LL Day 6 
hippocampal tissues which both contain a mixed population of cells was 
carried out. These comparisons generated probe cell intensity data (CEL) files 
which were evaluated using Partek Genomics Suite software (Materials and 
Methods, 2.5.2, 2.53) and Principal Component Analysis (PCA) plots were 
generated to emphasise variation and bring out strong patterns in the datasets. 
As shown in Figure 6.2, there was a clear separation in sample distribution 
between in vivo and in vitro systems suggesting all samples were correlating 
correctly and both hippocampal dissection and RNA extraction methods were 
reproducible for both systems. Further processing of CEL files using Partek 
Genomics Suite and one-way analysis of variance (ANOVA) based on various 
contrasts (comparisons) selected (Materials and Methods, 2.5.3) was used to 
generate DEG lists from both WT versus 101LL primary hippocampal cultures 
and WT versus 101LL Day 6 hippocampal tissues comparisons. False 
Discovery Rate (FDR) parameters were applied for generating more 
constricted datasets. FDR reduces the number of false positives and increases 
the chances of identifying all the differentially expressed genes in a dataset. 
The principles of FDR are that P-Values are first sorted and ranked, the 
smallest value gets rank 1, the second rank 2, and the largest gets rank N,  
each P-Value is multiplied by N and divided by its assigned rank to give the 
adjusted P-Values (Benjamini and Hochberg 1995). Using standard 
parameters (FDR P-Value < 0.05 or 0.1) no DEGs were identified when 
comparing genotypes in unchallenged 101LL versus WT in vitro cultures and 
101LL versus WT in vivo tissues, indicating the 101LL point mutation was not 
influencing gene expression levels pre-fibril challenge in either system (Table 
6.1).  
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Using less stringent parameters (Unadjusted P-Value of < 0.01) including Fold 
Change (FC, < 1.5 or > 1.5) a limited number of DEGs (Tables 6.2, 6.3) were 
detected when comparing 101LL versus WT genotypes in both in vitro (19 
DEGs) and in vivo systems (16 DEGs). For validation of DEG lists (Tables 6.2, 
6.3), a number of genes were processed by RT-qPCR and expression trends 
obtained confirmed (Figure 6.3, 6.4, 6.5, 6.6) microarray data was accurate. 
Transforming growth factor, beta induced (Tgfbi) which plays an important role 
in cell proliferation (Zhang et al. 2009) and Laminin, alpha 1 (Lama1) which is 
involved in neuronal differentiation, migration and survival (Graner, 
Mercadante, et al. 2000b) and can inhibit fibril formation (Monji et al. 1998) 
were confirmed to be up-regulated in 101LL cultures (Figure 6.3) suggesting 
cells may be primed to inhibit fibril formation whilst encouraging 
neuritogenesis. Conversely, Myocyte Enhancer Factor 2C (Mef2c) which is a 
central regulator of neuronal differentiation and survival (Cho et al. 2011) was 
shown to be down-regulated in 101LL cultures indicating variability in gene 
expression relating to neuronal survival was evident in this genotype. In tissue, 
Transthyretin (Ttr) which inhibits Aβ aggregation and detoxifies cell-damaging 
conformers (Wang et al. 2014) was shown to have Increased expression in 
WT tissue (Figure 6.5) suggesting this genotype may be capable of inhibiting 
abnormal PrP aggregation processes. Increased expression in both tissue and 
cells, of Midline1 (Mid1) which is associated with microtubule stabilisation 
(Aranda-Orgillés et al. 2008) and has been associated with the pathogenesis 
of Alzheimer’s disease (AD) where it binds to and regulates translation of 
BACE1 mRNA implicated in generation of amyloid plaques (Hettich et al. 2014) 
was evident in the 101LL genotype (Figure 6.2). This suggested neurons may 
be less stable in the 101LL genotype and therefore, require higher expression 
levels of Mid1 to stabilise neuronal microtubule structures. Prnp which is 
involved in cell signalling, formation and maintenance of synapses and 
promotion of neuronal growth and survival (Harris 2003; Walz et al. 1999) was 
confirmed to be consistently expressed across all genotypes and systems 
(Figure 6.2).  
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These data confirmed the 101LL mutation was not influencing PrP expression 
and supported the use of the primary culture system to provide a suitable in 
vitro model for investigating abnormal PrP protein interactions. For 
completeness, validation of genes was also assessed in both in vivo and in 
vitro systems to investigate if gene expression profiles were similar between 
systems and some discrepancies were evident (Figure 6.3, 6.4, 6.5). For 
example, although Tgfbi was confirmed to be significantly up-regulated in 
101LL cultures (Figure 6.3a), this was not evident in 101LL tissues. These 
findings showed gene expression may vary between systems and this will be 
addressed further in Section 6.3.3. RNA-seq of unchallenged 101LL versus 
WT in vitro cultures using standard parameters (FDR P-Value < 0.05, FC 2) 
identified only 3 DEGs to have increased expression in the 101LL genotype 
namely, Tnfaip2, Tgfbi and Gm21742. Tgfbi was previously identified and 
validated to have increased expression in 101LL cultures (Figure 6.3) and 
Gm21742 is an unprocessed pseudogene that had no count readings for WT 
groups. Tumor necrosis factor, alpha-induced protein 2 (Tnfaip2) is involved 
with cell differentiation and is also associated with amyotrophic lateral sclerosis 
(ALS) disease where overexpression increased cell death, inflammatory 
processes and TNF signalling (Brohawn, O’Brien, and Bennett 2016; Kurji et 
al. 2010) making cells more susceptible to neurodegeneration. The increased 
expression of Tnfaip2 identified by RNA-seq in 101LL cultures suggests these 
cells maybe more susceptible to stressors in comparison to WT cultures 
however, RT-qPCR analysis did not validated these differences (Figure 6.6). 
In summary, microarray analysis using standard parameters (P-Value            
FDR < 0.05 or 0.1) showed no differences in gene expression was evident 
when comparing WT versus 101LL genotypes in either in vitro or in vivo 
systems, indicating both genotypes had similar baseline gene expression 
profiles pre-fibril challenge. Additionally, Prnp expression levels were shown 
not to be influenced by the 101LL point mutation. RNA-seq analysis of WT 
versus 101LL cultures did identify three DEGs however, only one was validated 
to be accurate.  
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Thus, both microarray and RNA-seq results complimented each other and any 
changes in baseline gene expression profiles described after fibril challenge 
would be a genotypic specific response.  
 
 
Figure 6.2: Principal Component Analysis (PCA) showed a clear separation 
between culture and tissue samples. A PCA plot generated from microarray 
analysis of all 16 in vivo and in vitro samples was used to visualise patterns 
associated with in vivo and in vitro datasets. This visualisation plot generated 
using Partek genomics suite confirmed a clear separation and pattern was 
evident between cell (square symbol) and tissue (triangle) groups of arrays 
analysed by principal component suggesting all samples were correlating 
correctly and sample-to-sample processing was reproducible for both systems.  
(B) Genes showing similar expression across both systems were validated 
using RT-qPCR. Relative expression values and RT-qPCR results are shown 
from in vivo (tissue) and in vitro (cell) systems. Expression values obtained 
from microarray generally matched with RT-qPCR results validating 
transcriptomic results. Prnp expression in both tissue (P-Value 0.37; 0.31) and 
culture (P-Value 0.20; 0.56) showed no significant differences in expression 
values validating microarray results. Reference gene Ywhaz, Graph mean plus 
standard deviation, n=4, n=individual samples, unpaired t test. Fold changes 
from RT-qPCR were calculated using 2-ΔΔCt method (Materials and Methods, 
2.5.8) and relative expression values were obtained from microarray data. 
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Partek Analysis 101LL vs WT Culture 101LL vs WT 
Tissue 
P-Value FDR < 0.05 Negative* Negative* 
P-Value FDR < 0.1 Negative* Negative* 
Unadjusted P-Value < 0.01, FC 
1.5 
19 DEGs 16 DEGs 
*Nothing passed. 
Table 6.1: Standard filtering of microarray datasets showed no differences in 
gene expression were evident between WT and 101LL groups. Partek analysis 
of microarray datasets from 101LL and WT genotypes in culture (in vitro) and 
tissue (in vivo) systems using standard FDR parameters showed no DEGs 
were identified in genotype comparisons. However, unadjusted analysis 
showed a limited degree of variation was present regarding gene 
representation between genotype comparisons in both systems.  
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Gene (Protein Coding) Function Fold Change  
Nescient Helix-Loop-
Helix 1 (Nhlh1) 
DNA binding protein/ controlling cell 
type determination 
 
-1.99 
 
Cortistatin (Cort) 
Inhibits cAMP (Cyclic adenosine 
monophosphate) production 
 
-1.73 
Myocyte Enhancer 
Factor 2C (Mef2C) 
Crucial for normal neuronal 
development, distribution and electrical 
activity 
 
-1.63 
 
Reelin (Reln) 
Regulates microtubule function in 
neurons and neuronal migration 
 
-1.57 
Collagen Type III Alpha 
1 Chain (Col3a1) 
Encodes pro-alpha1 chains of type III 
collagen  
 
2.90 
Biglycan (Bgn) Collagen fibril assembly/ regulation 
inflammation and innate immunity 
 
3.27 
Ectonucleotide 
Pyrophosphatase/Phos
phodiesterase 1 
(Enpp1) 
Broad specificity and cleaves a variety 
of substrates 
 
3.86 
Nidogen 1 (Nid1) Distributed in basement membranes 
and tightly associated with laminin 
 
4.03 
Collagen Type I Alpha 
1 Chain (Col1a1) 
Fibril-forming collagen found in most 
connective tissues  
 
4.08 
Laminin, alpha 1 
(Lama1) 
PrPC is a specific receptor for laminin   
4.20 
Collagen Type I Alpha 
2 Chain (Col1a2) 
Fibril-forming collagen  
4.49 
T-Box 18 (Tbx18) Embryonic development 5.00 
Cytochrome P450 
Family 1 Subfamily B 
Member 1 (Cyp1b1) 
Involved in synthesis of cholesterol and 
other lipids 
 
5.27 
Transforming growth 
factor, beta induced 
(Tgfbi) 
Cell proliferation  
5.50 
Apolipoprotein D 
(Apod) 
Protein binding/ lipid transporter activity  
5.93 
Lumican (Lum) Protein/ Collagen fibril organisation 6.32 
Alanyl Aminopeptidase, 
Membrane (Anpep) 
Degrade neurotransmitters at synaptic 
junctions 
 
6.64 
LOC101055644  
Midline1 (Mid1) 
Metal ion/ protein/ zinc ion binding/ 
Microtubule-associated ubiquitin ligase 
 
7.53 
Solute Carrier Family 6 
Member 13 (Slc6a13) 
In presynaptic terminals regulates 
GABA signalling termination through 
GABA uptake 
 
7.69 
 
*Ensembl genome ID 
 
Table 6.2: Limited gene expression differences were evident between 101LL 
and WT cultures. Partek comparisons of 101LL and WT cultures using 
unadjusted P-Value of < 0.01 and FC < -1.5 or > 1.5, identified a limited number 
(19) of DEGs. Negative FC values indicate down-regulated genes in 101LL 
whilst remaining numbers were all up-regulated in 101LL cultures. 
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Gene (Protein Coding) Function Fold Change  
 Transthyretin (Ttr) Transports thyroid hormone thyroxine 
and retinol, can inhibit Aβ aggregation 
 
-2.30 
Cytochrome P450 
Family 2 Subfamily C 
(Cyp2c69) 
Synthesis of cholesterol and other 
lipids, iron ion binding and 
epoxygenase P450 pathway 
 
-1.90 
Lysyl Oxidase (Lox) Cross-linking of extracellular matrix 
proteins 
 
-1.81 
Olfactory receptor 420 
(Olfr420) 
G-protein coupled receptor activity, 
olfactory receptor activity 
 
-1.76 
Collectin Subfamily 
Member 12 (Colec12) 
Scavenger receptor, may play role in 
clearance of amyloid beta in Alzheimer 
disease 
 
-1.61 
 
Olfactory receptor 420 
(Olfr390) 
Olfactory receptor activity  
-1.55 
Complement Factor HH 
(Cfh) 
Regulation of complement activation  
-1.53 
Olfactory receptor 420 
(Olfr960) 
Olfactory receptor activity  
-1.52 
Ribonucleoprotein 
(Nop56) 
Part of a large pre-ribosomal 
ribonucleoprotein (RNP) complex 
 
1.52 
Mitochondrial Encoded 
TRNA Proline            
(Mt-tp)* 
RNA gene affiliated with the non-coding 
RNA class 
 
1.56 
 
Heat Shock Protein 
Family A (Hsp70) 
Member 8 (Hspa8) 
Functions as a chaperone and binds to 
nascent polypeptides to facilitate 
correct folding 
 
1.59 
 
RAB6B, Member RAS 
Oncogene Family 
(Rab6b) 
Retrograde transport in neuronal cells  
1.63 
 
Calcineurin Like EF-
Hand Protein 1 (Chp1) 
 
Mediates the association between 
microtubules and membrane-bound 
organelles of the endoplasmic reticulum 
and Golgi apparatus 
 
1.70 
 
 
Ribosomal Protein L13 
(Rpl13) 
RNA binding, protein binding  
1.70 
Mitochondrial Encoded 
TRNA Glutamine       
(Mt-tq)* 
RNA Gene affiliated with the non-
coding RNA class 
 
2.50 
 
LOC101055644   
Midline1 (Mid1)** 
Metal ion/ protein/ zinc ion binding/ 
Microtubule-associated ubiquitin ligase 
 
3.84 
*RNA gene **Ensembl genome ID 
 
Table 6.3: Limited differences in gene expression were evident between 101LL 
and WT tissues. Partek comparisons of 101LL and WT tissues using 
unadjusted P-Value of < 0.01 and FC < -1.5 or > 1.5, identified a limited number 
(16) of DEGs. Negative FC values indicate down-regulated genes in 101LL 
whilst remaining numbers were all up-regulated in 101LL cultures. 
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Figure 6.3: Microarray data from cell culture was validated using RT-qPCR. 
Relative expression values and RT-qPCR results are shown from both in vivo 
(tissue) and in vitro (cell) systems for general comparisons. (A) Transforming 
growth factor, beta induced (Tgfbi) and (B) Laminin, alpha 1 (Lama1). 
Expression values obtained from microarray matched with RT-qPCR results 
validating transcriptomic results. (A) Tgfbi showed no expression differences 
in tissue (P-Value 0.11) however, RT-qPCR did show significant differences 
were evident (P-Value 0.04). Significant differences were noted and 
comparable in cell comparisons (P-Value 0.006; 0.01). (B) Lama1 microarray 
expression showed significant differences between tissue groups (P-Value 
0.004) however, corresponding RT-qPCR did not show significance (P-Value 
0.06). Significant differences were noted in cell comparisons (P-Value 0.009; 
0.04). Differences in gene expression were also evident between systems. RT-
qPCR normalisation reference gene Ywhaz, Graph mean plus standard 
deviation, n=4, n=individual samples, unpaired t test. Fold changes from        
RT-qPCR were calculated using 2-ΔΔCt method (Materials and Methods, 
2.5.8) and relative expression values were obtained from microarray data. 
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Figure 6.4: Validation of microarray data from cell culture using RT-qPCR. 
Relative expression values and RT-qPCR results are shown from in vivo 
(tissue) and in vitro (cell) systems for general comparisons of Myocyte 
Enhancer Factor 2C (Mef2c) expression. Expression values obtained from 
microarray matched with RT-qPCR results validating transcriptomic results. 
Mef2c gene expression showed no differences in tissue (P-value 0.46; 0.07) 
but was significantly down-regulated in 101LL cell cultures (P-Value 0.0007; 
0.003). Reference gene Ywhaz, Graph mean plus standard deviation, n=4, 
n=individual samples, unpaired t test. Fold changes from RT-qPCR were 
calculated using 2-ΔΔCt method (Materials and Methods, 2.5.8) and relative 
expression values were obtained from microarray data. 
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Figure 6.5: Validation of Transthyretin (Ttr) and Midline 1 (Mid1) expression 
from tissue using RT-qPCR. Relative expression values and RT-qPCR results 
are shown from in vivo (tissue) and in vitro (cell) systems for comparisons. Ttr 
and Mid1 expression values obtained from microarray generally matched with 
RT-qPCR. (A) In tissue, Ttr microarray expression was shown to be 
significantly down-regulated (P-Value 0.02). RT-qPCR confirmed down-
regulation was evident however; the P-Value obtained although borderline was 
not significant (P-Value 0.05). No expression differences were noted in cell 
comparisons (P-Value 0.28; 0.33). (B) Mid1 was up-regulated in 101LL tissue 
(P-Value 0.01; 0.08) and cultures (P-Value 0.0002; 0.005). Additionally this 
data confirm that Mid1 as identified by Ensembl genome was correct. 
Reference gene Ywhaz for Ttr and Sdha for Mid1, Graph mean plus standard 
deviation, n=4, n=individual samples, unpaired t test. Fold changes from RT-
qPCR were calculated using 2-ΔΔCt method (Materials and Methods, 2.5.8) 
and relative expression values were obtained from microarray data. 
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Figure 6.6: Tumor necrosis factor, alpha-induced protein 2 (Tnfaip2) 
expression was not validated by RT-qPCR. RNA-seq comparisons of WT and 
101LL cultures identified Tnfaip2 to be significantly up-regulated in 101LL 
cultures (P-Value 0.0004) however; RT-qPCR could not validate this 
observation. Reference gene Sdha, Graph mean plus standard deviation, n=4, 
n=individual samples, unpaired t test. Fold changes from RT-qPCR were 
calculated using 2-ΔΔCt method (Materials and Methods, 2.5.8) and 
Fragments Per Kilobase of transcript per Million (FPKM) values were obtained 
from RNA-seq data. 
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6.3.3 Is gene expression analogous between primary cultures and acutely 
dissected tissues?  
 
To investigate the comparability between both in vitro and in vivo systems in 
more detail (Figure 6.1), direct comparisons of microarray datasets from both 
was carried out using Partek. As primary hippocampal cells were been cultured 
in vitro, some changes in gene expression between both systems were to be 
expected. Using standard parameters (P-Value FDR <0.01, FC 1.5) 
differences were apparent and genes were predominantly down-regulated in 
cultures (Figure 6.7). Similar numbers of DEGs identified between WT (330 
DEGs) and 101LL (380 DEGs) comparisons (Figure 6.7) was expected as 
previous results confirmed both genotypes had comparable gene expression 
profiles (Table 6.1). Relevant functions of DEG lists identified in Figure 6.7, 
were investigated using various bioinformatic databases (Materials and 
Methods, 2.5.6) including, PANTHER, GOrilla and DAVID (Mi et al. 2013; Eden 
et al. 2009; Huang, Sherman, and Lempicki 2008). PANTHER analysis of up 
and down-regulated gene lists from 101LL DEGs (121 up-regulated and 259 
genes down-regulated in culture in comparison to tissue), WT DEGs (95 up, 
235 down, graph not included) and overlap or common DEGs (54 up, 280 
down, graph not included) was carried out (Figure 6.8). Majority of genes were 
associated with cellular and metabolic processes in all gene lists and similar 
GO profiles from both up and down-regulated gene lists were obtained 
indicating although majority of genes were down-regulated in culture they 
shared similar GO enrichment profiles to up-regulated genes. Additionally, all 
groups were associated to a lesser extent with other functions such as 
response to stimulus, immune system, biological and developmental 
processes (graphs not shown). Cellular and metabolic processing may be the 
dominant functions identified as they relate to a number of processes, for 
example, cellular processing includes cell communication, cell-cell signalling, 
synaptic signalling, trans-synaptic signalling, cellular component organisation, 
membrane organisation and regulation of membrane lipid distribution.  
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Metabolic processing includes positive regulation of cellular metabolic 
processes, regulation of dephosphorylation, regulation of phosphorus 
metabolic processes and regulation of phosphorylation. To gain more clarity 
on gene enrichment associations with DEGs identified both GOrilla and DAVID 
platforms were used. GOrilla results were limited and no GO enrichment 
results were obtained for up-regulated genes in 101LL and WT groups and for 
the down-regulated overlap group (data not shown). DAVID GO enrichment 
for biological processes provided more informative results (Figure 6.9). Genes 
up-regulated in both WT and 101LL system comparisons were associated with 
lipid metabolic processes indicating cultures were involved in synthesis and 
degradation of lipids for energy. Lipids can be broadly classified into five 
categories including fatty acids, triacylglycerols (TAGs), phospholipids, sterol 
lipids and sphingolipids (Tracey et al. 2018). The data presented in Figure 6.9, 
indicate sterol lipid involvement. Cholesterol is a sterol lipid, is vital to cell 
membrane structure and functions as a precursor to fat-soluble vitamins and 
steroid hormones. Cholesterol is also a major  constituent of the brain, and is 
tightly regulated between the major brain cells (neurons, astrocytes, microglia) 
and is essential for normal brain development (Orth and Bellosta 2012). These 
findings along with other associations identified such as cell differentiation and 
positive regulation of neuron differentiation indicate cells were actively 
encouraging neuronal growth in culture and energy required for this 
development was acquired from lipid processing. This data supports neuronal 
development characterisation studies described in Chapter 3 (Figure 3.3, 3.7) 
showing active neuronal growth was occurring in cultures. Down-regulated 
genes had associations with signal transduction, which is described as the 
movements of electrical potentials from neuron to neuron. As cells were 
cultured in vitro, it was possible that a reduction in neuronal stimulation and 
electrical impulses would be observed in comparison to in vivo tissue. 
Additionally, this principle would apply to other processes identified such as 
feeding behaviour.  
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In conclusion, DEGs were identified when comparing in vitro versus in vivo 
systems. PANTHER analysis showed both up and down-regulated genes from 
all in vitro and in vivo system comparisons (Figure 6.8) shared similar GO 
enrichment profiles indicating none of the processes identified were dominant 
regarding gene expression. In contrast, DAVID GO enrichment showed up and 
down-regulated gene lists were associating with different processes indicating 
PANTHER and DAVID platforms can produce variance in GO analysis and 
therefore, more than one system for investigating gene expression should 
always be used to avoid bias. Importantly, biological processes identified in 
DAVID suggest an environmental adaptation of cells was occurring in vitro, 
which was a normal observation as cells were removed from in vivo and were 
adapting accordingly by promoting neuronal growth. Thus, although DEGs 
were identified between both system comparisons, biologically no major 
differences were identified suggesting both systems were comparable. 
 
An alternative approach to compare both in vitro and in vivo systems involved 
using Miru (Materials and Methods, 2.5.5). Miru is a complex pattern 
recognition software, designed specifically for the integration, visualisation and 
analysis of network graphs derived from whole biological datasets in a non-
bias manner (Theocharidis et al. 2009) and therefore, was used to compare 
both systems without any filtering of datasets. Miru generated a visual network 
graph consisting of clusters of co-expressed genes (Figure 6.10). These 
cluster profiles were visualised in Miru to compare both in vitro and in vivo 
systems and as shown in Figure 6.11, Cluster 001 was comprised of 539 
genes which were all up-regulated in vivo in both 101LL and WT genotypes 
(99% of genes identified had a P-Value of < 0.05). GO enrichment of these 
genes confirmed associations with cellular and metabolic processes similar to 
comparison results previously obtained using PANTHER (data not shown). 
DAVID enrichment (Cluster001) for biological processes ranked gene 
associations to angiogenesis, signal transduction, chemical synaptic 
transmission, ion transport and feeding behaviour (data not shown).  
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Interestingly, all these processes were identified previously using Partek 
analysis and DAVID enrichment (Figure 6.9) and were associated with down-
regulated genes in vitro supporting Miru observations. Angiogenesis is a 
physiological process through which new blood vessels form and therefore, 
associations identified here were expected, as cells grown in vitro would have 
no need for a blood supply. Signal transduction and feeding behaviour have 
been discussed already and synaptic transmission may be related to higher 
numbers of neurons present in the tissues. Importantly, results shown here 
support DAVID enrichment results obtained from Partek generated DEG lists 
(Figure 6.9). Cluster 005 was comprised of 34 genes, which were all up-
regulated in both 101LL, and WT cultures (Figure 6.11). Go enrichment of this 
cluster showed genes association with post-embryonic development, 
multicellular organism growth and axon guidance. All these processes were 
important in enhancing and maintaining the growth of isolated embryonic 
neuronal cells in vitro, which was also reflected in PANTHER analysis, 
presented earlier (Figure 6.8). The remaining clusters identified did not show 
any major differences between both systems and collectively showed many 
similarities were evident (Appendix Figure 6.a). These clusters were 
associated with a range of processes identified in DAVID including, protein 
transport, proteolysis, response to metal ion and lipid metabolic processes, 
protein targeting to mitochondria, intracellular protein transport, tumor necrosis 
factor-mediated signalling pathway, G-protein coupled receptor signalling 
pathway, myeloid cell differentiation, cell surface receptor signalling pathway, 
actin cytoskeleton organisation and regulation of canonical Wnt signalling 
pathway. Collectively these data show numerous clusters of genes were 
identified with similar expression profiles in both in vitro and in vivo systems 
associated with a range of functions, suggesting both systems were grossly 
comparable. To summarise, when entire datasets were processed in Miru, only 
a small subset of genes (Cluster 001) were identified to be collectively             
up-regulated in vivo in comparison to in vitro systems and gene enrichment 
showed processes identified were rational to each systems requirements.  
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Remaining clusters showed both systems were comparable across a broad 
range of functions. This analysis approach supported Partek results and 
although gene expression was not analogous between cultures and tissues, 
the differences identified were limited. In conclusion, primary hippocampal 
culture models were grossly comparable to in vivo tissue and therefore, 
provided a realistic neuronal cell model for studying misfolded protein 
interactions in vitro.  
 
                  
 
Figure 6.7: Limited differences in gene expression were evident between 
systems. Partek analysis of microarray data was used to compare in vitro 
(culture) with in vivo (tissue) systems in both genotypes. Partek filtering using 
P-Value FDR <0.01, FC 1.5; identified 330 DEGs from WT culture versus 
tissue (235 down-regulated and 95 up-regulated); 380 DEGs from 101LL 
culture versus tissue (259 down-regulated and 121 up-regulated) and an 
overlap of 334 DEGs (280 down-regulated and 54 up-regulated) common to 
both with similar up or down-regulated patterns in both genotypes (two genes 
were borderline for FC common comparisons so were removed from list). Red 
arrows up-regulated genes and green arrows down-regulated genes in culture.  
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Comparisons in 
vitro vs in vivo 
systems  (DEGs) 
% genes associated with 
cellular processing 
% genes associated 
with metabolic 
processing 
WT 235 Down 27% 18% 
WT 95 Up 25% 25% 
101LL 259 Down 31% 16% 
101LL 121 Up 24% 25% 
Overlap 280 Down 29% 18% 
Overlap 54 Up 29% 22% 
 
 
Figure 6.8: Similar GO enrichment profiles from system comparisons were 
evident between up and down-regulated gene lists. DEG lists from system 
comparisons were enriched for gene ontology using PANTHER. Down-
regulated (259 DEGs, 101LL culture versus tissue) gene associations are 
shown in top graph, of which 31% were associated with cellular processing 
and 16% with metabolic processing. Bottom graph represents up-regulated 
genes (121 DEGs, 101LL culture versus tissue) and shows a similar profile to 
down-regulated genes (rhythmic process not identified). Y-axis equals 
numbers of genes. PANTHER analysis of all WT, 101LL, and overlap DEG 
groups is highlighted in table underneath showing DEG lists were 
predominantly associated with cellular and metabolic processing. 
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Figure 6.9: Summary of DAVID enrichment of biological processes. Data 
obtained from comparisons of in vitro (culture) with in vivo (tissue) systems in 
both genotypes using microarray identified DEG lists from Figure 6.7. Top six 
hits arranged according to significance (P-Values not included). Biological 
processes identified in each genotype showed comparability between groups 
and processes identified in generic response were also comparable to each 
genotype indicating biological processes identified in DAVID were not 
genotype specific. GO enrichment for up-regulated genes shown in red text, 
down-regulated gene associations in green text. 
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Figure 6.10: Miru generated visual graphs showing spatial representation of 
genes orientated accordingly to their correlation to one another. Network 
analysis was carried out on WT and 101LL microarray transcriptomic data from 
both in vivo and in vitro systems. (A) Miru created a complete graph based on 
entire gene lists and correlation values inputted. (B) Markov clustering 
algorithm divided main graph into clusters of co-expressed transcripts, 
represented as different colors in the graph. (C) A representative single cluster 
of genes identified in Miru. Correlation Value (R) 0.95, Filter 50, MCL 2.2, 10 
smallest cluster allowed.  
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Figure 6.11: Cluster profiles were visualised in Miru to compare both in vitro 
and in vivo systems. (A) Cluster 001 comprised 539 related genes, 99% of 
these genes identified had a P-Value of < 0.05 when compared to ANOVA 
lists. These genes were all up-regulated in both 101LL and WT tissue samples 
(yellow bar) in comparison to culture (red bar). DAVID GO enrichment of this 
dataset showed cellular and metabolic processes to be major biological 
processes identified. (B) Cluster 005 comprised 34 genes all up-regulated in 
both 101LL and WT cell culture samples. GO enrichment of this dataset 
showed associations with post-embryonic development, multicellular organism 
growth and axon guidance. Y-axis equals normalised expression intensity 
values. 
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6.3.4 Do fibril-induced molecular responses vary between genotypes? 
 
To address this question, RNA-seq analysis was carried out on RNA extracted 
from unchallenged and fibril-challenged WT and 101LL primary cultures 
(7.5μg/ml of unlabelled 101L fibrils for 24 hours, 2.4.4) at Edinburgh Genomics. 
A principal components analysis was undertaken on normalised filtered 
expression data to explore observed patterns with respect to experimental 
factors analysed (Appendix Figure 6.b). Unchallenged 101LL samples 
displayed more variable global expression profiles than WT samples however, 
both genotypes exhibited strong responses to fibril challenge in such a way as 
to make their expression patterns consistent with one another and their 
clusters to converge (Figure 6.12). As discussed in Section 6.3.2, increased 
expression of Tnfaip2 and Tgfbi was identified in unchallenged 101LL cultures 
(RT-qPCR did not validate Tnfaip2 observation Figure 6.6). As shown in 
Appendix Table 6.a, after fibril challenge, Tnfaip2 was significantly down-
regulated in 101LL cultures, no significant changes were noted in WT cultures, 
and this was validated by RT-qPCR (Figure 6.13). As discussed previously 
(Section 6.3.2), Tnfaip2 overexpression can make cells more susceptible to 
neurodegeneration (Brohawn, O’Brien, and Bennett 2016; Kurji et al. 2010), 
therefore reduced expression of this gene after fibril challenge in 101LL 
cultures may be a survival response to lower susceptibility of cells to fibril 
insult. Tgfbi which is involved in cell proliferation (Zhang et al. 2009), showed 
a significant increase in expression in WT fibril-challenged cultures and no 
changes were noted in 101LL fibril-challenged cultures (Appendix Table 6.a) 
suggesting cell proliferation was increasing in the WT genotype in response to 
fibril challenge. This cell proliferation may be associated with microglial 
activation (Monif, Burnstock, and Williams 2010) which was shown by 
immunocytochemical analysis in Chapter 5 to be occurring in WT fibril-
challenged cultures (Appendix Figure 5.b), and involved possibly in fibril 
degradation. Collectively, initial results confirmed fibril insult was causing 
strong responses in cultures and preliminary investigations suggest fibril 
response may vary between genotypes. 
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To investigate the possibilities of variance in fibril responses between 
genotypes, a heatmap of the top 50 most differential genes between WT and 
101LL fibril-challenged groups identified by FDR was generated (Figure 6.14), 
and confirmed genotype specific responses were evident. The gene 
Lipoprotein receptor-related protein 1b (Lrp1b) was identified as the top most 
differential gene up-regulated in 101LL genotype. Lrp1b has been associated 
with neuroprotective roles in AD, where it interacts with APP and reduces the 
processing of Aβ by regulating endocytic trafficking (Cam and Bu 2006). Lrp1b 
is also a central mediator of complement protein C1q-induced neuroprotection 
against Aβ in AD mice (3xTg) and this neuroprotective response was triggered 
early on in the progression to AD before the accumulation of plaques and 
ensuing complement activation and inflammation (Benoit et al. 2013). This 
early neuroprotective response may also be occurring in 101LL cultures 
exposed to PrP fibrils and may have important applications for future PMD 
therapies. Cathepsin Z (Ctsz) was identified as the top most differential gene 
down regulated in 101LL fibril-challenged cultures or conversely, up-regulated 
in WT fibril-challenged cultures. This gene belongs to the C1 family of 
lysosomal cysteine proteases, is restricted to immune system cells including 
macrophages and dendritic cells and is involved in normal intracellular protein 
degradation (Santamaria et al. 1998). Variations in lysosomal pathways in 
101LL cultures have already been highlighted in Chapter 5 by 
immunocytochemistry (Figure 5.9). The reduction in lysosomal associated 
gene expression identified here in 101LL fibril-challenged cultures support 
these findings and highlight a means by which fibrils may be maintained due 
to irregularities in lysosomal degradation pathways. GO enrichment of all 50 
DEGs using DAVID showed processes identified such as oligodendrocyte 
development and astrocyte differentiation were associated with down-
regulated genes in 101LL fibril-challenged cultures and therefore were            
up-regulated in WT fibril-challenged cultures.  
 
As shown in Chapter 5 (Figure 5.4) fibrils induced a hypertrophic astrocyte 
response in WT fibril-challenged cultures only, suggesting increased astrocyte 
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differentiation processes identified here could be actively increasing the 
presence of normal functional astrocyte populations to compensate for 
abnormal fibril-induced astrogliosis. 
 
 
 
Figure 6.12: Both genotypes show similar response to fibril challenge. PCA 
plots of first, second and third components from PCA analysis using all 16 WT 
and 101LL samples pre and post-fibril challenge. 101LL displayed more global 
expression profiles than WT samples however, both 101LL and WT responded 
similarly to fibril challenge. PC 1 was associated with 2 factors: Group (P Value 
1.92e-05) and Treatment (P-Value 1.38e-06), PC 2 was not associated with 
any experimental factors, PC 3 was associated with 2 factors: Group (P Value 
0.0354) and Type (P Value 0.03). P-Values were generated in Edinburgh 
Genomics ANOVA report, Reference Appendix Figure 6.b.  
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Figure 6.13: Tumor necrosis factor, alpha-induced protein 2 (Tnfaip2) 
expression changes after fibril challenge were validated by RT-qPCR. Relative 
expression values and RT-qPCR results are shown from in vitro unchallenged 
and fibril-challenged cultures. Expression values obtained from RNA-seq 
generally matched with RT-qPCR results validating transcriptomic results. 
Tnfaip2 was confirmed to be significantly down-regulated in 101LL                  
fibril-challenged cultures (101LL F, P-Value 0.008) and no changes were 
evident in WT cultures although this was borderline (P-Value 0.05). Reference 
gene Sdha, Graph mean plus standard deviation, n=4, n=individual samples, 
unpaired t test. Fold changes from RT-qPCR were calculated using 2-ΔΔCt 
method (Materials and Methods, 2.5.8) and Fragments Per Kilobase of 
transcript per Million (FPKM) values were obtained from RNA-seq data. 
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DAVID GO enrichment  
(DEGs up-regulated in 101LL Plus Fibrils) 
Gene Count P-Value 
Nervous system development  5 1.6E-4 
Neuron migration 3 4.0E-3 
Axon guidance  3 5.8E-3 
DAVID GO enrichment  
(DEGs down-regulated in 101LL Plus Fibrils) 
Gene Count P-Value 
Oligodendrocyte development 3 6.8E-4 
Astrocyte differentiation 2 1.6E-2 
Membrane protein ectodomain proteolysis  2 2.8E-2 
 
Figure 6.14: Top 50 most differential genes identified by FDR between WT 
challenged (WTPlusF) and 101LL fibril-challenged groups (101LLPlusF). 
Heatmap generated with the pheatmap package (Edinburgh Genomics) 
showed genotype differences to fibril response were evident. GO enrichment 
of these DEGs using DAVID provided some insights into these responses and 
identified processes such as proteolysis which is involved in misfolded protein 
degradation to be down-regulated in 101LL Plus fibrils or conversely                
up-regulated in WT Plus fibrils cultures therefore, was either impeding (101LL) 
or supporting (WT) fibril degradation in fibril-challenged cultures. 
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6.3.5 Fibril influence on Prnp expression in WT and 101LL cultures 
 
RNA-seq data highlighted Prnp expression was highly variable in 
unchallenged 101LL cultures and highly consistent in WT cultures (Appendix 
Figure 6.c), which might explain variable global expression noted by PCA 
(Figure 6.12). However, as previously shown (Figure 6.2) no significant 
expression differences were noted between WT and 101LL unchallenged 
groups. After fibril challenge, Prnp expression was shown to be significantly 
up-regulated in WT fibril-challenged cultures although this was a subtle 
increase (LogFC 0.20, FC 1.15, FDR 0.02) and no significant changes were 
noted in 101LL fibril-challenged cultures (LogFC -0.33, FC 0.79, FDR 0.59). 
RT-qPCR validated expression profiles however, did not show any significant 
differences between groups (Figure 6.15). As the FC increase for WT            
fibril-challenged cultures was minimal, it was concluded no relevant biological 
differences in Prnp expression were apparent in fibril-challenged WT and 
101LL cultures. Interestingly, these data compliment previous immunolabelling 
studies shown in Chapter 5 (Appendix Figure 5.f), that showed fibrils were not 
changing levels of PrPC protein in WT and 101LL cultures after 24-hour          
fibril challenge. Collectively these data also suggest abnormal PrP fibrils may 
not be inducing immediate conformational changes of normal PrPC to the 
abnormal form, as this would have resulted in noticeable changes in either 
Prnp expression or detectable PrPC.  
 
 
 
 
 
 
 
 
 
200 
 
 
Figure 6.15: Prnp expression changes after fibril challenge were validated by 
RT-qPCR. Relative expression values and RT-qPCR results are shown from 
in vitro unchallenged and fibril-challenged cultures. Expression values 
obtained from RNA-seq generally matched with RT-qPCR results validating 
transcriptomic expression however, no significant differences were evident 
between groups (P-Value WT 0.50; 101LL 0.26). Reference gene Ywhaz, 
Graph mean plus standard deviation, n=4, n=individual samples, unpaired t 
test. Fold changes from RT-qPCR were calculated using 2-ΔΔCt method 
(Materials and Methods, 2.5.8) and Fragments Per Kilobase of transcript per 
Million (FPKM) values were obtained from RNA-seq data. 
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6.3.6 Fibril insult activated stronger DEG responses in WT cultures 
 
As indicated in Section 6.3.4, initial investigations suggested both WT and 
101LL cultures may respond differently to fibril insult. To investigate this in 
more detail and to gain further insights into specific genotype fibril response, 
DEG lists from RNA-seq data were generated based on unchallenged WT 
versus WT Plus Fibrils and unchallenged 101LL versus 101LL Plus Fibrils 
using standard filtering parameters (P-Value FDR of 0.05, FC 2). As shown in 
Table 6.4, a number of DEGs were identified in both unchallenged WT versus 
WT Plus Fibrils (1,080 DEGs) and unchallenged 101LL versus 101LL Plus 
Fibrils (545 DEGs). Based on gene numbers identified, fibril challenge elicited 
a greater DEG response in WT fibril-challenged cultures. Of the total 1,080 WT 
DEGs, 761 or 70% of DEGs were up-regulated and 319 or 30% DEGs were 
down-regulated in WT fibril-challenged cultures. In comparison, 101LL           
fibril-challenged cultures had 299 (55%) DEGs up-regulated and 246 (45%) 
DEGs down-regulated. These results confirmed differences were apparent 
between genotype fibril responses and the majority of DEGs identified in WT 
fibril-challenged cultures were associated with increased gene expression. To 
identify what responses were specifically associated to each genotype and to 
examine if any generic responses to fibril challenge were evident, DEG 
datasets were compared between unchallenged WT versus WT Plus Fibrils 
(1,080 DEGs) and unchallenged 101LL versus 101LL Plus Fibrils (545 DEGs). 
737 DEGs were specific to WT genotype, 202 were specific to 101LL genotype 
and 343 DEGs were common to both genotypes (Figure 6.16). Overall, fibrils 
were activating stronger changes in gene expression in WT fibril-challenged 
cultures in comparison to 101LL fibril-challenged cultures. These gene sets 
were investigated further (Sections 6.3.7, 6.3.8, 6.3.9) using various platforms 
referred to in Figure 6.1, to identify molecular processes related to these 
specific genotype responses. 
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Contrast name Up Down 
Unchallenged WT vs WT Plus Fibrils (1,080 DEGs) 761 319 
Unchallenged 101LL vs 101LL Plus Fibrils (545 DEGs) 299 246 
 
Table 6.4: Fibril insult caused DEG responses to double in WT cultures. DEG 
lists from RNA-seq data were generated based on unchallenged WT versus 
WT Plus Fibrils and unchallenged 101LL versus 101LL Plus Fibrils using 
standard filtering parameters (P-Value FDR of 0.05, FC 2). Fibril challenge 
generated a larger gene expression response in WT fibril-challenged cultures 
(1,080 DEGs) in comparison to 101LL fibril-challenged cultures (545 DEGs).  
 
 
 
           
 
Figure 6.16: Specific genotype responses identified for WT and 101LL           
fibril-challenged cultures. DEG lists were compared between unchallenged WT 
versus WT Plus Fibrils and unchallenged 101LL versus 101LL Plus Fibrils to 
identify gene sets specific to each genotype response and to ascertain if any 
common genes were present between both WT and 101LL DEGs identified. 
Of the total 1,080 WT and 545 101LL DEGs identified, 737 were specific to 
WT genotype, 202 were specific to 101LL genotype and 343 were common to 
both genotypes. Of the 343* common genes identified 342 shared common up 
or down-regulation profiles in both genotypes. One gene however, namely 
purinergic receptor P2Y, G-protein coupled, 14 (P2ry14) showed an increase 
in gene expression in WT versus WT Plus Fibrils (LogFC 1.65, FC 3.14, FDR 
0.04) and a decrease in gene expression in 101LL versus 101LL Plus Fibrils 
(LogFC -1.71, FC 0.30, FDR 0.01, reference Section 6.3.9).   
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6.3.7 WT cells are primed to curtail abnormal protein formation by increasing 
expression of genes associated with fibril degradation processes                                                                   
 
To understand WT molecular responses to fibril challenge and possibly gain 
insights into how WT mice curtail abnormal PrP formation, data analysis of WT 
specific DEG lists (Figure 6.16) was carried out, using IPA and PANTHER. IPA 
searches through gene lists and determines genes that are involved in well 
documented canonical signal transduction pathways (Krämer et al. 2014). IPA 
generated information on top networks and diseases and disorders associated 
with specific gene lists identified in Figure 6.16. A summary of IPA reports is 
shown in Table 6.5. Both WT (737 DEGs) and 101LL (202 DEGs) specific DEG 
lists were associated with different top networks, WT were associated with 
cellular function and maintenance whilst 101LL response was associated with 
auditory disease. Cellular function and maintenance included engulfment by 
macrophages, and gene expressions associated with this process were 
predominantly increased (Table 6.6) in WT fibril-challenged cultures 
suggesting WT cells were positively responding to fibril insult by increasing 
macrophage degradation of misfolded fibrils. In comparison, the 202 DEG list 
specific to 101LL culture fibril response had seven genes (Cd14, Dock2, Fas, 
Itgam, Itgb2, Si1 and Tlr9) identified by IPA to be associated with engulfment 
by macrophages however, these were all down-regulated. Further enrichment 
of top genes lists generated in IPA was carried out using PANTHER, to gain 
more insight into biological process associations specific to genotype. 
Separating genes into up and down-regulated groups allowed applicable 
PANTHER GO enrichment analysis to be carried out. Genes shown in Table 
6.6 were associated with top networks identified in IPA in WT fibril-challenged 
cultures (cellular function and maintenance, engulfment by macrophages).  
Up-regulated genes had associations with positive regulation of the adaptive 
immune system (Cd44, Fcgr3 and P2rx7); defence response (Hck, Capg, 
Fcgr3, Gsn, P2rx7 and Cd44); endocytosis (Hck, Fcgr3, Gsn, Tgm2, Scarb1 
and P2rx7) and finally response to stimulus (Hck, Capg, Hgf, Pros1, Fcgr3, 
Nodal, Ch25h, Gsn, Tgm2, Scarb1, P2rx7 and Cd44).  
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Down-regulated genes C3 and Btk were associated with positive regulation of 
hypersensitivity and acute inflammatory response. From this data, WT cultures 
seemed to be positively responding to stimulus (fibrils) by activating a defence 
and adaptive immune response whilst damping acute inflammatory responses. 
Additionally, up-regulation of endocytosis suggested WT cultures were 
escalating the engulfment of molecules such as fibrils into the cell for further 
processing. IPA identified inflammatory response to be top in diseases and 
disorders associations in WT fibril-challenged cultures (Table 6.5) and 
infectious disease was identified for 101LL fibril-challenged cultures. 
PANTHER enrichment of up-regulated genes from Table 6.7, identified innate 
immune response (Cfh, Hck, Capg, Rap27a, Il12rb1, Gsn, Il34 and SerpinG1) 
and negative regulation of apoptotic processing and programmed cell death 
(Hck, Vip, Agtr1, Prkcd, Cdknia, Cx3cr1, Cd44, Hgf, Vegfa, Itga5, Angptl4, Fn1, 
Spp1 and Adoraa2a) to be associated with the WT specific response. 
Conversely, gene associations with positive regulation of apoptotic processing 
and programmed cell death (Agtr2, Tnfsf12, P2rx7, Cd40, Prkcd, Nupr1, 
Bmp2, Cd44, Nodal, Gsn, Tgm2, Casp8, Ripk3, Nfatc4 and Adoraa2a) were 
also identified suggesting these processes were both positively and negatively 
regulated in WT cultures. Down-regulated genes were associated with 
inflammatory response (Gper1, Cxcl5, Chil3, C3 and Hc) and innate immune 
response (Gper1, C3 and Hc). From this analysis we can conclude, WT fibril-
challenged cultures were capable of both positively and negatively regulating 
innate immune response and apoptotic processes. Down-regulation of genes 
associated with major components of the innate immune response (C3 and 
Hc) was an interesting finding. The activation of the Complement (C) system 
can occur through three pathways including classical, lectin and alternative, 
each triggered by different agents. Complement C3 which is part of both 
classical and alternative complement pathways, has been shown to 
exacerbate prion disease (Kane et al. 2017; Michel et al. 2013) suggesting 
down-regulation noted in WT fibril-challenged cultures (Table 6.6,               
LogFC -1.75, FC 0.29, FDR 0.02), may be inhibiting and curtailing misfolded 
protein replication and accumulation.  
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Complement factor H (Cfh) was up-regulated after challenge (LogFC 2.50, FC 
5.66, FDR 0.001) and is a negative regulator of the alternative pathway of the 
complement system (suppresses conversion of C3b to C3a) therefore, this 
response may be promoting the downregulation of the complement cascade 
in WT fibril-challenged cultures (Table 6.7). In comparison, no significant 
changes in complement components were identified in 101LL fibril-challenged 
cultures however, complement C3d receptor 2 (Cr2) was up-regulated (LogFC 
2.12, FC 4.36, FDR 0.007) after fibril challenge. Studies have shown Cr2 is 
expressed in neuronal progenitor cells (NPCs) of the dentate gyrus and two of 
its ligands, C3d and interferon inhibit proliferation of NPCs (Moriyama et al. 
2011). Cr2 was up-regulated in 101LL fibril-challenged cultures suggesting 
fibril insult was possibly inhibiting the generation of neurons and glia after 
challenge. Inflammatory response was also identified in IPA for top network 
associations using 101LL specific DEG list (Table 6.5). For comparison, genes 
associated with this response (Table 6.8) of which were all down-regulated 
were enriched using PANTHER.  Associations with innate immune response 
(Lcn2, Cybb, Tgfb1, Tlr9, Cd14 and Cc12); positive regulation of immune 
response (Fos, Icam1, NcKap1, Itgam, Itgb2, Tgfb1, Aif1, Tlr9, Cd14 and 
Ccl2); positive regulation of response to stimulus (Icam1, Nckap1, Itgam, 
Tgfb1, Ctss, Aif1, Tlr9, Dock2, Cd14 and Ccl2); positive regulation of 
endocytosis (Nckap1, Dock2, Cd14 and Ccl2); amyloid beta clearance (Itgam 
and Itgb2) and finally microglial and glial cell activation (Itgam, Aif1 and Tlr9) 
were identified. As all genes were down-regulated it suggested immune 
response, response to stimulus, endocytosis, amyloid clearance and microglial 
and glial activation were all reduced in 101LL cultures. In conclusion, the data 
shown here based on both IPA and PANTHER analysis suggested WT cultures 
were positively responding to fibril challenge by activating defence and 
adaptive immune responses. Additionally, WT cultures appeared primed to 
respond to fibril insult as after challenge, endocytosis and macrophage 
degradation processes were up-regulated.  
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These molecular changes would actively reduce fibril burden in cultures whilst 
curtailing further abnormal formation. Interestingly, WT cultures appeared to 
be capable of both positively and negatively regulating responses such as 
innate immune response and apoptotic processes and this balancing influence 
may be advantageous in maintaining normal cellular homeostasis.  
 
DEG Group Top Networks Diseases and 
Disorders  
WT Fibril-
challenged 
cultures 
(specific 737 
DEGs) 
 
Cellular function and maintenance, 
Cellular growth and proliferation, 
Cellular development, Cellular 
movement, Organismal injury and 
abnormalities, Cell-To-Cell 
signalling and interaction 
Inflammatory response, 
Cancer, Organismal 
injury and abnormalities, 
Metabolic disease, 
Dermatological diseases 
and conditions 
101LL Fibril-
challenged 
cultures (202 
specific DEGs) 
Auditory disease, Organismal injury 
and abnormalities, Cell 
morphology; Inflammatory 
response 
 
Infectious diseases, 
Endocrine system 
disorders, 
Gastrointestinal disease, 
Immunological disease 
 
Table 6.5: Summary of IPA reports comparing genotype specific responses to 
fibril challenge. Top networks ranked by overall network score (data not shown) 
and diseases and disorders were ranked by P-Value (data not shown).  
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Gene 
Symbol 
Gene Name LogFC 
Btk 
C3 
Capg 
Cd44 
Ch25h 
Fcgr3 
Gsn 
Hck 
Hgf 
Mirlet7c 
Lum 
Nodal 
P2rx7 
Pla2g5 
Pros1 
Scarb1 
Tgm2 
 
Bruton tyrosine kinase 
Complement C3 
Capping actin protein, gelsolin like 
CD44 molecule (Indian blood group) 
Cholesterol 25-hydroxylase 
Fc fragment of IgG receptor IIa 
Gelsolin 
HCK proto-oncogene, Src family tyrosine kinase 
Hepatocyte growth factor 
MicroRNA let-7a-1 
Lumican 
Nodal growth differentiation factor 
Purinergic receptor P2X 7 
Phospholipase A2 group V 
Protein S 
Scavenger receptor class B member 1 
Transglutaminase 2 
 
-1.65 
-1.76 
1.09 
1.53 
1.97 
1.01 
1.29 
1.20 
1.40 
-1.66 
2.12 
2.26 
1.76 
-1.53 
1.00 
1.21 
2.94 
 
Table 6.6: WT specific fibril response included engulfment by macrophages 
response. IPA identified top networks for WT specific genes associated with 
fibril response. Gene lists shown here are associated with cellular function and 
maintenance and this specific gene list was associated with engulfment by 
macrophages and was predominantly associated with up-regulated genes 
suggesting WT cells were increasing processes associated with foreign 
material (fibril) degradation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
208 
 
Gene Symbol Gene Name LogFC 
Ache 
Adgre5 
Adoraa 
Agtr1a 
Agtr2 
Agtr1b 
Angpt2 
Angpt4 
Blnk 
Bmp2 
C3 
Hc 
C1qtn3 
Calca 
Capg 
Casp8 
Cd40 
Cd44 
Cdkna 
Cfh 
Chil3 
Creb33 
Crh 
Ctsg 
Cx3cr1 
Cxcl1 
Cxcl2 
Cxcl5 
Dpp4 
E2f2 
Edn3 
Efs 
Eng 
Ets1 
Fcgr3 
Flt1 
Fn1 
Ggt5 
Gli1 
Gper1 
Gsn 
Hck 
Hgf 
Gm899 
Ier3 
Il34 
Il12rb1 
Itga5 
Kdr 
Mirlet2 
Acetylcholinesterase (Cartwright blood group) 
Adhesion G protein-coupled receptor E5 
Adenosine A2a receptor 
Angiotensin II receptor type 1 
Angiotensin II receptor type 2 
Angiotensin II receptor, type 1b 
Angiopoietin 2 
Angiopoietin like 4 
B-cell linker 
Bone morphogenetic protein 2 
Complement C3 
Complement C5 
C1q and TNF related 3 
Calcitonin related polypeptide beta 
Capping actin protein, gelsolin like 
Caspase 8 
CD40 molecule 
CD44 molecule (Indian blood group) 
Cyclin dependent kinase inhibitor 1A 
Complement factor H 
Chitinase-like 3 
CAMP responsive element binding protein 3 like 3 
Corticotropin releasing hormone 
Cathepsin G 
C-X3-C motif chemokine receptor 1 
C-X-C motif chemokine ligand 2 
C-X-C motif chemokine ligand 3 
C-X-C motif chemokine ligand 6 
Dipeptidyl peptidase 4 
E2F transcription factor 2 
Endothelin 3 
Embryonal Fyn-associated substrate 
Endoglin 
ETS proto-oncogene 1, transcription factor 
Fc fragment of IgG receptor IIa 
Fms related tyrosine kinase 1 
Fibronectin 1 
Gamma-glutamyltransferase 5 
GLI family zinc finger 1 
G protein-coupled estrogen receptor 1 
Gelsolin 
HCK proto-oncogene, Src family tyrosine kinase 
Hepatocyte growth factor 
Major histocompatibility complex, class I, A 
Immediate early response 3 
Interleukin 34 
Interleukin 12 receptor subunit beta 1 
Integrin subunit alpha 5 
Kinase insert domain receptor 
MicroRNA let-7a-1 
1.32 
1.08 
1.42 
2.31 
2.50 
1.58 
1.86 
3.15 
-1.35 
1.71 
-1.76 
-2.31 
-2.78 
2.47 
1.09 
1.03 
2.07 
1.53 
1.21 
2.50 
-2.26 
1.53 
1.44 
-1.45 
1.31 
1.60 
2.71 
-2.63 
1.68 
1.06 
1.94 
1.18 
1.15 
1.79 
1.01 
1.09 
1.09 
2.07 
-2.67 
-1.39 
1.29 
1.20 
1.40 
2.88 
2.36 
1.02 
1.60 
1.26 
-1.75 
-1.66 
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Loxl2 
Lum 
Mmp28 
Nfatc4 
Nodal 
Nt5e 
Nupr1 
P2rx7 
Pla2g5 
Prkcd 
Pros1 
Ptgdr 
Ptger2 
Ptges 
Ptgs1 
Rab2a 
Ripk3 
Scarb1 
Serpia 
Serpi1 
Serpi1 
Slc1a5 
Sod3 
Spp1 
Stat6 
Tgm2 
Thbd 
Thbs4 
Tnfaip6 
Tnfsf12 
Trpm2 
 
Tuba8 
Vegfa 
Vip 
 
Lysyl oxidase like 2 
Lumican 
Matrix metallopeptidase 28 
Nuclear factor of activated T-cells 4 
Nodal growth differentiation factor 
5'-nucleotidase ecto 
Nuclear protein 1, transcriptional regulator 
Purinergic receptor P2X 7 
Phospholipase A2 group V 
Protein kinase C delta 
Protein S 
Prostaglandin D2 receptor 
Prostaglandin E receptor 2 
Prostaglandin E synthase 
Prostaglandin-endoperoxide synthase 1 
RAB27A, member RAS oncogene family 
Receptor interacting serine/threonine kinase 3 
Scavenger receptor class B member 1 
Serpin family B member 1 
Serpin family F member 1 
Serpin family G member 1 
Solute carrier family 1 member 5 
Superoxide dismutase 3 
Secreted phosphoprotein 1 
Signal transducer and activator of transcription 6 
Transglutaminase 2 
Thrombomodulin 
Thrombospondin 4 
TNF alpha induced protein 6 
TNF superfamily member 12 
Transient receptor potential cation channel        
subfamily M member 2                                           
Tubulin alpha 8 
Vascular endothelial growth factor A 
Vasoactive intestinal peptide 
 
1.75 
2.12 
1.24 
1.90 
2.26 
1.59 
3.27 
1.76 
-1.53 
1.17 
1.00 
3.79 
2.47 
1.50 
2.31 
1.45 
1.27 
1.21 
-1.88 
1.12 
1.03 
1.96 
1.28 
1.57 
1.09 
2.94 
1.57 
1.38 
1.49 
1.01 
 
1.12 
1.91 
1.59 
1.80 
 
 
Table 6.7: IPA identified inflammatory response was top in diseases and 
disorders in genes specific to WT response. Genes were predominantly           
up-regulated in this dataset. 
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Gene 
Symbol 
Gene Name LogFC 
Aif1 
Aoah 
Ccl2 
Cd14 
Col18a1 
Ctss 
Dock2 
Dock5 
Fas 
Fos 
Hpgds 
Icam1 
Itgam 
Itgb2 
Lcn2 
Lcp1 
Myo1f 
Ncka1l 
Plp1 
Spi1 
Tgfb1 
Tlr9 
Usp18 
Vsir 
 
  Allograft inflammatory factor 1 
  Acyloxyacyl hydrolase 
  Chemokine (C-C motif) ligand 2 
  CD14 molecule 
  Collagen type alpha 1 chain cathepsin S 
Cytochrome b-245 beta chain 
Dedicator of cytokinesis 2 
Dedicator of cytokinesis 5 
Fas cell surface death receptor 
Fos proto-oncogene, AP-1 transcription factor  
Hematopoietic prostaglandin D synthase 
Intercellular adhesion molecule 1 
Integrin subunit alpha M 
Integrin subunit beta 2 
Lipocalin 2 
Lymphocyte cytosolic protein 1 
Myosin IF 
NCK associated protein 1 like 
Proteolipid protein 1 
Spi-1 proto-oncogene 
Transforming growth factor beta 1 
Toll like receptor 9 
Ubiquitin specific peptidase 18 
V-set immunoregulatory receptor 
  
-1.07 
-3.12 
-2.63 
-1.58 
-1.92 
-2.04 
-2.67 
-1.96 
-1.46 
-1.11 
-2.45 
-2.63 
-2.95 
-2.21 
-3.37 
-1.30 
-1.73 
-1.00 
-1.22 
-3.75 
-1.24 
-2.48 
-2.24 
-1.49 
 
Table 6.8: IPA inflammatory response associated genes specific to 101LL fibril 
response were all down-regulated.  
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6.3.8 101LL molecular response to fibrils provides insights into processes that 
imped efficient abnormal protein degradation 
 
To gain insights into how the 101LL genotype supports abnormal PrP 
processing, data analysis of 101LL specific DEG lists (Figure 6.16) was carried 
out, using IPA and PANTHER. As previously shown in Table 6.5, IPA analysis 
of the 202 DEGs identified top network associations with auditory disease and 
organismal injury and abnormalities. As auditory disease was deemed 
unrelated to fibril response in vitro, further investigation into genes associated 
with organismal injury and abnormalities was carried out (organ degeneration, 
Table 6.9) using PANTHER. No GO enrichment was evident from the four       
up-regulated genes (Esrrg, Mak, Ntf3 and Pdzd7). Down-regulated genes 
were associated with inflammatory response (Cybb, Ngfr, Tgfb1 and Ccl2); 
defence response (Cybb, Ngfr, Ddx58, Tgfb1 and Ccl2) and response to 
stresses (Cybb, Ngfr, Msrb3, Ddx58, Slc2a4, Tgfb1 and Ccl2). As organ 
degeneration was not identified in IPA analysis of the WT specific DEG list no 
direct comparisons could be made. In conclusion, inflammatory responses 
were reduced in 101LL fibril-challenged cultures and defence response was 
impeded which was opposite to what was seen in WT fibril-challenged 
cultures. Additionally, genes associated with response to stress were identified 
suggesting fibril challenge was disturbing cellular homeostasis in 101LL 
cultures and as this GO term was associated with down-regulated genes it was 
concluded this stimulus may be restricting cellular response in 101LL cultures 
to fibrils. Infectious diseases (Table 6.5) was identified as top diseases and 
disorders. Briefly, no PANTHER GO terms were identified for up-regulated 
genes associated with this term and down-regulated gene associations 
identified included microglial and glial cell activation, amyloid beta clearance, 
regulation of endocytosis, defence response, inflammatory response, positive 
regulation of immune system and positive regulation of response to stimulus 
(data not shown). These processes were already shown to be down-regulated 
in 101LL fibril-challenged cultures (Section 6.3.7) indicating these were 
dominant responses in 101LL cultures after fibril challenge.  
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Previous results shown in Chapter 5 (Figure 5.9) have indicated a lack of fibril 
localisation with lysosomes in 101LL fibril-challenged cultures and therefore 
an impairment of the fibril degradation pathway. Although IPA did not identify 
any lysosomal related disorders, reduced expression of the gene Lysosomal 
protein transmembrane 5 (Laptm5) which is associated with lysosome 
organelles was found in the 101LL specific 202 DEG list (LogFC -2.03, FC 
0.24, FDR 0.009). These molecular findings support immunocytochemical 
observations (Figure 6.8) and suggest endolysosomal processing was 
reduced in the 101LL genotype after fibril challenge. As this was an important 
finding, RT-qPCR was used to validate RNA-seq gene expression data and as 
shown in Figure 6.17, these observations were accurate. In conclusion, 
impedance of microglial and glial cell activation, endocytosis, defence 
response and lysosomal degradation pathways suggests fibrils would be 
maintained in 101LL fibril-challenged cultures and would not be actively 
degraded, possibly resulting in further abnormal protein generation over-time. 
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Gene 
Symbol 
Gene Name LogFC 
Abca4 
Ccl2 
Col181 
Cybb 
Ddx58 
Esrrg 
Folh1 
Lrit3 
Mak 
Msrb3 
Ngfr 
Ntf3 
Pdzd7 
Slc2a4 
Tgfb1 
 
ATP binding cassette subfamily A member 4 
Chemokine (C-C motif) ligand 2 
Collagen type XVIII alpha 1 chain 
Cytochrome b-245 beta chain 
DExD/H-box helicase 58 
Estrogen related receptor gamma 
Folate hydrolase 1 
Leucine rich repeat, Ig-like and transmembrane  
Male germ cell associated kinase 
Methionine sulfoxide reductase B3 
Nerve growth factor receptor 
Neurotrophin 3 
PDZ domain containing 7 
Solute carrier family 2 member 4 
Transforming growth factor beta 1 
 
-1.51 
-2.63 
-1.92 
-2.08 
-1.05 
1.29 
-1.23 
-1.98 
1.25 
-1.75 
-1.26 
1.15 
1.20 
-1.15 
-1.24 
 
 
Table 6.9: IPA identified organismal injury and abnormalities (organ 
degeneration) as one of the top networks associated in genes specific to 101LL 
fibril response. Genes were predominantly down-regulated suggesting this 
was possibly a protective response associated with 101LL cultures. 
 
 
Figure 6.17: Lysosomal protein transmembrane 5 (Laptm5) expression 
changes after fibril challenge were validated by RT-qPCR. Relative expression 
values and RT-qPCR results are shown from in vitro unchallenged and         
fibril-challenged cultures. Expression values obtained from RNA-seq matched 
with RT-qPCR results validating transcriptomic expression showing Laptm5 to 
be significantly down-regulated in 101LL fibril-challenged cultures (P-Value 
0.004), and no change was reported in WT groups (P-Value 0.17). Reference 
gene Ywhaz, Graph mean plus standard deviation, n=4, n=individual samples, 
unpaired t test. Fold changes from RT-qPCR were calculated using 2-ΔΔCt 
method (Materials and Methods, 2.5.8) and Fragments Per Kilobase of 
transcript per Million (FPKM) values were obtained from RNA-seq data. 
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6.3.9 Generic gene responses to fibril insult provide therapeutic targets for 
impeding neurodegeneration  
 
Generic fibril responses were evident between WT and 101LL cultures and 
were expected as baseline transcriptomic data indicated WT and 101LL 
genotypes were comparable (Table 6.1). Identifying specific genes associated 
with these generic responses would be advantageous for identify potential 
therapeutic targets for modulating neurodegenerative processes. Thus, 343 
DEGs shown in Figure 6.16, were investigated and initial analysis showed 342 
genes shared similar up and down-regulated profiles between genotypes 
although variations were noted in FC. Purinergic receptor P2Y, G-protein 
coupled, 14 (P2ry14) was the individual gene which was up-regulated in the 
WT fibril-challenged group (LogFC 1.65, FC 3.14, FDR 0.04) but                  
down-regulated in the 101LL group (LogFC -1.71, FC 0.30, FDR 0.01) 
validated by RT-qPCR (Figure 6.18). P2ry14 is expressed in immune, 
cardiovascular, digestive, endocrine and respiratory systems and is involved 
in immune system processes and response to stimulus and signalling. This 
gene may also play a role in neuroimmune function and may therefore, be 
stimulating a positive immune response in WT cultures whilst damping this 
response in 101LL cultures. Other genes of interest identified after fibril 
challenge and common to both genotypes included; Triggering receptor 
expressed on myeloid cells 2 (Trem2), SRY-box 7 and 10 (Sox7, Sox10), 
Solute carrier family 9 member b2 (Slc9b2) and Neurotrophic receptor tyrosine 
kinase 1 (Ntrk1) which were all up-regulated. Briefly Trem2 (WT LogFC 2.56, 
FC 5.88, FDR 0.008 and 101LL LogFC 2.28, FC 4.86, FDR 0.02) is involved 
in phagocytic and anti-inflammatory pathways (Zhong et al. 2017), Sox7 (WT 
LogFC 2.23, FC 4.69, FDR 0.001, 101LL LogFC 1.44, FC 2.71, FDR 0.01) is 
involved in promoting neuronal apoptosis (Wang et al. 2015), Sox10 (WT 
LogFC 4.97, FC 31.44, FDR 1.46E-05 and 101LL LogFC 2.40, FC 5.30, FDR 
0.03), is involved in development of glia (Kuhlbrodt et al. 1998) and as shown 
here was substantially up-regulated in WT cultures.  
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Slc9b2 (WT LogFC 2.68, FC 6.40, FDR 3.79E-05 and 101LL LogFC 2.07, FC 
4.22, FDR 0.004), plays a role in clathrin-mediated endocytosis and Ntrk1 (WT 
LogFC 3.59, FC 12.06, FDR 2.34E-05 and 101LL LogFC 2.32, FC 5.01, FDR 
0.01) is essential for development and survival of neurons (Kaplan and Miller 
2000) and was noticeably more up-regulated in WT cultures (both genes 
Slc9b2 and Ntrk1 validated RT-qPCR Figure 6.19). For down-regulated genes, 
Tumor necrosis factor (Tnf) (WT LogFC -3.21, FC 0.10, FDR 0.02 and 101LL 
LogFC -6.48, FC 0.01, FDR 0.009) which is involved in cell death apoptosis 
was substantially down-regulated in 101LL cultures (See Discussion 6.4, 
validated by RT-qPCR, Figure 6.20). Complement C3a receptor 1 (C3aR) (WT 
LogFC -1.14, FC 0.45, FDR 0.03 and 101LL LogFC -2.35, FC 0.19, FDR 
0.001) is expressed in the central nervous system by neurons, reactive 
astrocytes and microglia (Rynkowski et al. 2008) and is involved in 
neuroprotection (van Beek et al. 2001). C3a-C3aR interactions are also a 
positive regulator of neurogenesis (Rahpeymai Bogestål et al. 2007). C3aR 
was down-regulated after fibril challenge in both 101LL and WT cultures 
suggesting neuroprotection response in both genotypes was reduced. 
Although generic DEGs were identified in both genotypes after fibril challenge, 
expression values did vary between genotypes for example, Sox10 had a FC 
of 31.44 in WT fibril-challenged cultures as opposed to FC 5.30 in 101LL      
fibril-challenged cultures. Studies have shown Sox10 involvement with the 
development of glial cells (Weider and Wegner 2017; Kuhlbrodt et al. 1998) 
and astrocyte differentiation (Kordes and Hagel 2006). Thus, WT                     
fibril-challenged cultures were inflicting a greater glial response in comparison 
to 101LL cultures. Interestingly, immunolabelling studies shown in Chapter 5 
(Figure 5.4), have also confirmed a dramatic change in astrocytic morphology 
in WT fibril-challenged cultures suggesting Sox10 may also be playing a role 
in regulating astrocytic cellular response to fibrils. In conclusion, up-regulation 
of genes associated with endocytosis, phagocytosis, neuron development and 
survival was occurring in both genotypes respectively and therefore, may 
provide possible therapeutic targets for impeding neurodegeneration.  
 
216 
 
 
Figure 6.18: Purinergic receptor P2Y, G-protein coupled, 14 (P2ry14) 
expression changes after fibril challenge were validated by RT-qPCR. Relative 
expression values and RT-qPCR results are shown from in vitro unchallenged 
and fibril-challenged cultures. Expression values obtained from RNA-seq 
generally matched with RT-qPCR results validating transcriptomic expression 
however, significant differences were not evident between groups (P-Value 
0.06; 0.20). Reference gene Ywhaz, Graph mean plus standard deviation, n=4, 
n=individual samples, unpaired t test. Fold changes from RT-qPCR were 
calculated using 2-ΔΔCt method (Materials and Methods, 2.5.8) and 
Fragments Per Kilobase of transcript per Million (FPKM) values were obtained 
from RNA-seq data. 
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Figure 6.19: Validation of generic genotype responses by RT-qPCR. Relative 
expression values and RT-qPCR results are shown from in vitro unchallenged 
and fibril-challenged cultures. (A) Solute carrier family 9 member b2 (Slc9b2) 
and (B) Neurotrophic receptor tyrosine kinase 1 (Ntrk1). Expression values 
obtained from RNA-seq generally matched with RT-qPCR results validating 
transcriptomic results. (A) Slc9b2 expression was confirmed to be significantly 
up-regulated in both genotypes (P-Values 0.009; 0.04). (B) Ntrk1 expression 
was significantly up-regulated in WT fibril-challenged cultures (WT F) (P-Value 
0.02) however, in 101LL fibril-challenged cultures it was up-regulated but not 
significantly (P-Value 0.13). Reference gene Ywhaz, Graph mean plus 
standard deviation, n=4, n=individual samples, unpaired t test. Fold changes 
from RT-qPCR were calculated using 2-ΔΔCt method (Materials and Methods, 
2.5.8) and Fragments Per Kilobase of transcript per Million (FPKM) values 
were obtained from RNA-seq data. 
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Figure 6.20: Tumor necrosis factor (Tnf) expression changes after                   
fibril challenge were validated by RT-qPCR. Relative expression values and 
RT-qPCR results are shown from in vitro unchallenged and fibril-challenged 
cultures. Expression values obtained from RNA-seq matched with RT-qPCR 
results validating transcriptomic expression (P-Values 0.003; 0.004). 
Reference gene Ywhaz, Graph mean plus standard deviation, n=4, 
n=individual samples, unpaired t test. Fold changes from RT-qPCR were 
calculated using 2-ΔΔCt method (Materials and Methods, 2.5.8) and 
Fragments Per Kilobase of transcript per Million (FPKM) values were obtained 
from RNA-seq data. 
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6.3.10 Alternative platforms for investigating fibril response in WT and 101LL 
cultures 
 
Miru software was used as an alternative platform to understand and visualise 
the different gene expression trends across all datasets in a non-bias manner 
and was used here as an alternative platform to gain insights into fibril 
response in WT and 101LL fibril-challenged cultures. As shown in Figure 6.21, 
genes up-regulated in WT fibril-challenged cultures only (53 genes, Cluster 
0064) were enriched for GO terms using DAVID, as this platform works well 
with larger DEG lists. GO enrichment for biological processes confirmed 
associations with regulation of protein localisation to cell surface and              
ER-associated misfolded protein catabolic processes, which, are involved in 
breaking down misfolded proteins by targeting them to cytoplasmic 
proteasomes for degradation. These data provide insights into how WT mice 
may be more efficient at curtailing abnormal protein misfolding than 101LL. No 
clusters were identified in WT fibril-challenged cultures involving                   
down-regulated genes. Genes predominantly up-regulated in 101LL              
fibril-challenged cultures (Appendix Figure 6.d), were associated with 
phosphorylation GO enrichment processes. Interestingly, studies have shown 
post-translational modifications such as phosphorylation are known to induce 
protein conformational changes (Giannopoulos et al. 2009) and therefore this 
response may be an indicator of more protein conformational changes 
occurring in 101LL fibril-challenged cultures. Genes down-regulated in 101LL 
fibril-challenged cultures were enriched for response to stimulus 
complementing previous reported data generated from PANTHER enrichment 
(Section 6.3.7). Miru identified Cluster 0001 (791 genes) and Cluster 0002 
(262 genes) which were associated with up-regulated genes in both WT and 
101LL fibril-challenged cultures (Appendix Figure 6.e). DAVID enrichment for 
Cluster 0001, confirmed associations with glycolytic processes, metabolic 
processes, synaptic transmission, apoptosis and response to stimulus. Cluster 
0002 associations included response to mechanical stimulus, response to 
drug, apoptosis and nervous system development.  
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Genes associated with similar functions such as apoptosis and neuron and 
glia development were identified previously in Section 6.3.9, supporting 
observations here. Down-regulated clusters of genes identified in both WT and 
101LL fibril-challenged cultures were associated with inflammatory response, 
immune response, endosomal transport and endocytosis (data not shown). It 
should be highlighted Miru software incorporates a complex pattern 
recognition algorithm which groups genes based only on expression profile 
and therefore does not take parameters such a P-Value into account however, 
similarities in results gained from Miru and DAVID analysis were evident when 
comparing to previously described results obtained from IPA and PANTHER 
platform analysis suggesting all observations reported here were genuine and 
provide additional non-bias insights in fibril responses in both genotypes. As a 
vast amount of data was generated from IPA, Miru, PANTHER and DAVID 
analysis a summary of results was constructed as shown in Figure 6.22.  
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DAVID GO enrichment (Biological 
Process) 
Gene 
count 
P-Value 
Regulation of protein localisation to cell 
surface 
2 1.8E-2 
ER-associated misfolded protein 
catabolic process 
2 2.0E-2 
Dopamine receptor signalling pathway 2 2.6E-2 
Arachidonic acid secretion 2 3.5E-2 
Antigen processing and presentation of 
peptide antigen via MHC class 1 
2 5.6E-2 
Positive regulation of cell-substrate 
adhesion 
2 7.7E-2 
 
Figure 6.21: Miru and DAVID analysis of RNA-seq data. Cluster 0064 was 
identified in Miru and genes associated with this cluster were up-regulated in 
WT fibril-challenged cultures only in comparison to other groups. Readings 
based on mean counts per million (normalised expressed intensity values). 
Class viewer scaling was raw, class plot was mean line. GO enrichment for 
Cluster 0064 (53 genes) using DAVID showed WT fibril-challenged cultures 
were associated with protein localisation and ER-associated misfolded protein 
catabolic processes. This biological process is associated with chemical 
reactions and pathways resulting in the breakdown of misfolded proteins, 
which are then transported from the endoplasmic reticulum and targeted to 
cytoplasmic proteasomes for degradation. Genes involved in this process were 
protein-O-mannosyltransferase 2 (Pomt2) and torsin family 1, member A 
(Tor1a).  
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Figure 6.22: Summary of IPA, Miru, PANTHER and DAVID molecular analysis 
of DEGs lists associated with specific and generic genotype responses to     
fibril challenge. Gene associations and GO enrichment for up-regulated genes 
are shown in red text, down-regulated genes in green. Additionally, as shown 
in Figure 6.14, top 50 DEGs, astrocyte differentiation and proteolysis was 
associated with up-regulated genes in WT fibril-challenged cultures and 
nervous system development, neuron migration and axon guidance with         
up-regulated genes in 101LL fibril-challenged cultures. 
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6.4 Discussion 
 
The overall aim of this study was to investigate gene expression responses to 
fibril challenge in both WT and 101LL genotypes to ascertain insights into how 
one model supports protein misfolding whilst the other curtails it. Initial 
transcriptome investigations pre-fibril challenge confirmed gene expression 
was comparable between genotypes in both in vitro and in vivo systems 
indicating the 101LL point mutation was not influencing gene expression 
levels. Comparison between both in vitro and in vivo systems suggested gene 
expression was broadly comparable between systems. Similar observations 
were shown by other groups (Dabrowski et al. 2003; Diaz et al. 2002) 
supporting the use of primary hippocampal cultures for studying protein 
misfolding interactions in vitro. In general, post-fibril challenge, WT cultures 
exhibited a stronger molecular response in comparison to 101LL. As 
summarised in Figure 6.22, analysis of gene expression data indicated 
biological processes such as endocytosis, macrophage engulfment, response 
to stimulus, defence response and ER-associated misfolded protein catabolic 
processes were enriched in WT cultures. Immunolabelling studies presented 
in Chapter 5 confirmed microglial engulfment of fibrils was occurring (Appendix 
Figure 5.b). As these processes appeared to support misfolded protein 
degradation and clearance it was concluded WT fibril-challenged cultures were 
responding positively and effectively to fibril challenge. These responses were 
not evident in 101LL fibril-challenged cultures. Reduced expression of genes 
associated with endocytosis, response to stimulus, amyloid clearance and 
microglial and glial activation were identified suggesting 101LL cultures were 
not responding proficiently to fibril challenge for efficient misfolded protein 
degradation and clearance. Again, immunological findings presented in 
Chapter 5 (Figure 5.4) supported some of these findings whereby no evidence 
of astrocytic activation in 101LL cultures was shown indicating, either a 
delayed response or an reduced astrocytic response as described here was 
occurring in 101LL fibril-challenged cultures.  
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The innate immune system has been mentioned throughout this chapter and 
is involved in the detection and clearance of invading microorganisms, 
senescent cells and aged proteins in the brain therefore, maintaining a healthy 
environment for both neuronal and glial cells. This immune response was 
predominantly associated with an increased expression of genes in WT       
fibril-challenged cultures suggesting this was a positively activated defence 
system in WT cultures, however a minority of genes associated with the innate 
immune response were also showing reduced gene expression, namely C3 
and C5 (Table 6.6, 6.7). Complement factors are involved in neurogenesis, cell 
survival, cell death, synapse remodeling (Shinjyo et al. 2009; Ren et al. 2008; 
Stevens et al. 2007) and can be locally produced in the brain. Indeed, studies 
have shown that neuronal and glia cells can produce complement and express 
complement receptors (Veerhuis, Nielsen, and Tenner 2011). In Alzheimer’s 
disease β-amyloid can induce complement activation by binding to C1q which 
promotes either neuroprotection or neurotoxicity (Guan et al. 1994). When C1q 
binds to and coats pathogens, a protease cascade involving complement 
protein C3 is activated. Unwanted material can then be eliminated by 
deposited C3 activating C3 receptors on microglia, triggering elimination by 
phagocytosis, or activated C3 can trigger terminal activation of the 
complement cascade, which involves formation of lytic membrane attack 
complex resulting in cell lysis (Stevens et al. 2007). Interestingly, the role of 
complement factors in prion neurodegeneration within the CNS remain unclear 
(Hasebe et al. 2012) however, studies have proposed complement proteins 
such as C3 can intensify neurodegeneration in prion disease by promoting 
trafficking of misfolded proteins to cells expressing normal PrPC which act as 
substrates for prion replication (Kane et al. 2017; Michel et al. 2013). In this 
chapter, WT cultures were shown to be responding to fibril challenge by 
dampening the C3 complement cascade.  
 
 
 
225 
 
In comparison, no significant changes in these complement components were 
identified in 101LL fibril-challenged cultures however, activated microglia in 
both genotypes indicated that phagocytosis of fibrils was still possibly 
occurring (Appendix Figure 5.b), suggesting complement factors may not be 
influencing microglial phagocytosis (Figure 6.22). Collectively, these studies 
suggest complement processes were reduced in WT fibril-challenged cultures, 
possibly to limit trafficking of fibrils for prion replication and thus may be 
neuroprotective. These responses also identify specific targets for future 
therapeutic intervention studies.  
 
Transcriptome analysis (validated by RT-qPCR, Figure 6.17) identified 
reduced expression of the gene Laptm5 in 101LL fibril-challenged cultures. 
This gene is associated with lysosome organelles suggesting endolysosomal 
processing may be reduced in 101LL cultures. Additionally, studies have 
shown high Laptm5 expression levels are associated with an increase in 
lysosomal activity of microglial cells (Williams et al. 1994). As gene expression 
was confirmed to be reduced in 101LL fibril-challenged cultures, it can be 
concluded a dampening of lysosomal processing and therefore fibril 
degradation was evident in 101LL cultures which was also supported by 
immunological findings presented in Chapter 5 (Figure 5.9). Miru analysis 
identified ER-associated misfolded protein catabolic processes to be 
associated with up-regulated genes in WT fibril-challenged cultures only 
(Figure 6.22). This was an important finding as this response was specific to 
WT fibril-challenged cultures and involves targeting misfolded proteins to 
cytoplasmic proteasomes for ER-associated degradation (Smith, Ploegh, and 
Weissman 2011). Conversely, phosphorylation processes were identified to be 
up-regulated in 101LL cultures (Appendix Figure 6.d) in response to fibril 
challenge and are known to induce protein conformational changes 
(Giannopoulos et al. 2009). Interestingly, recent studies have also shown 
synaptic activity is highly regulated by phosphorylation of PSD-95 (Pedersen 
et al. 2017) and as described in Chapter 5 (Figure 5.5) PSD-95 was 
significantly reduced in 101LL fibril-challenged cultures.  
226 
 
An increase in phosphorylation suggested 101LL neurons might be actively 
trying to maintain synaptic activity after fibril insult and PSD-95 maybe a 
vulnerable target for fibril proteins in 101LL neurons. From this data, it can be 
concluded fibrils elicited different responses in both genotypes; WT cultures 
appeared to be actively processing fibrils for degradation whereas the 101LL 
cultures seemed to be damping degradative processes possibly supporting 
fibril survival.  
 
Genes common to both genotypes were identified after fibril challenge 
however, differences in FC values were noted for example, increased 
expression of Ntrk1 was evident in both genotypes however, WT cultures had 
a FC of 12.06 in comparison to 101LL cultures that had a FC value of 5.01. 
RT-qPCR validated these observations (Figure 6.19) and indicated increases 
were only significant in WT fibril-challenged cultures. Ntrk1 is essential for the 
regulation, growth, development, survival and repair of neurons mediated 
through binding to its primary ligand, nerve growth factor which regulates a 
number of signalling cascades such as GRB2-Ras-MAPK and Ras-PI3 kinase-
AKT1 (Kaplan and Miller 2000). Post-mortem studies in brains from patients 
diagnosed with early stage Alzheimer’s disease (AD) have also shown Ntrk1 
expression is reduced in basal forebrain cholinergic neurons, indicating 
downregulation of this gene contributes to the loss of neurons and early onset 
of AD (Counts and Mufson 2005). As Ntrk1 expression was increased in both 
WT and 101LL fibril-challenged cultures (more so in WT) it can be concluded 
this generic response was supporting neuronal survival after fibril challenge. 
Tnf was down-regulated in both genotypes and more so in 101LL cultures (FC 
WT 0.10, 101LL 0.01), validated by RT-qPCR (Figure 6.20). Tnf gene encodes 
a multifunctional proinflammatory cytokine expressed predominantly by 
immune cells and is involved in immune response and inflammation, 
proliferation, differentiation and apoptosis (Malagoli 2016) however, the 
function of Tnf signalling in the hippocampus and cortex has not been fully 
elucidated (McCoy and Tansey 2008).  
227 
 
Some studies have shown Tnf regulates hippocampal neuronal development 
(Golan et al. 2004) and others have shown Tnf potentiates excitotoxicity 
directly through activation of glutamate-NMDA receptors (Zou and Crews 
2005) and indirectly by inhibiting glial glutamate transporters on astrocytes 
(Choi 1988). Tnf signalling has also been shown to enhance AD-associated 
pathology and is detrimental to neuronal viability (Janelsins et al. 2008). 
Conversely, other studies have shown mice that overexpress Tnf were 
protected from glutamate toxicity (Marchetti et al. 2004). As Tnf expression 
was suppressed in both genotypes it may be possibly this generic response 
was to reduce inflammatory response and excitotoxicity in both cultures (more 
so in 101LL cultures) as a result of fibril insult. However, more studies will have 
to be carried out to address the overall effect of Tnf suppression on neurons 
and other brain-resident populations, including microglia and astrocytes and 
may provide a possible therapeutic target for the modulation of glial response 
in PMDs.   
 
The data presented in this chapter confirm primary hippocampal neuronal 
cultures provide a genetically comparable representative model to 
hippocampal tissue for the investigation of protein misfolding interactions in 
vitro. Findings based on microarray and RNA–seq analysis complimented 
each other and further analysis using IPA and Miru confirmed specific gene 
associations with each genotype. PANTHER, GOrilla and DAVID platforms 
provided further insights into these DEG associations. From these analyses, it 
can be concluded both genotypes showed specific responses to fibril 
challenge and GO terms obtained suggested the WT cultures were processing 
fibrils for possible degradation and the 101LL cultures were damping this 
response. These data provide insights into how WT mice are more efficient at 
curtailing abnormal protein misfolding and seeding than 101LL genotypes that 
support it. Genes associated with processes or biological pathways identified 
in this chapter (Figure 6.22), provide possible test targets to investigate in 
future experiments for intervention in PMDs. 
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7.1 Summary of findings 
 
The generation and spread of misfolded protein aggregates is common to all 
PMDs however, the early mechanisms underpinning the apparent 
perturbations in protein handling and processing in such conditions remain 
poorly understood. The main aim of this thesis was to investigate the initial 
mechanisms associated with cellular processing and response to abnormal 
PrP fibrils using an in vitro model composed of neuronal and non-neuronal cell 
types derived from transgenic mouse lines that either support amyloid seeding 
and formation (101LL) or prevent its production (WT). Both histological and 
molecular techniques were used to monitor cellular responses to fibril 
challenge including visualisation of cellular interactions with fibrils, intracellular 
fibril trafficking and gene expression changes induced by fibril challenge. To 
address the hypothesis that WT and 101LL mice have different mechanisms 
of intracellular processing of abnormal protein that determine clearance versus 
the seeding of amyloid plaques, a range of objectives listed in Chapter 1 
(Section 1.6.1), were carried out and completed. 
 
7.1.1 Primary cultures are viable models to track early cellular processing of 
misfolded protein  
 
Primary hippocampal neuronal cultures were developed and characterised at 
a morphological (Figure 3.3, 3.6, 3.10), biochemical (Figure 3.15), and 
immunocytochemical level (Figure 3.4, 3.8, 3.14). These analyses showed 
cultures contained readily accessible neurons (Figure 3.4, 3.5) that developed 
into highly branched mature networks connected by synapses as indicated by  
the presence of both pre and post-synaptic proteins (Figure 3.12). Cultures 
also supported the growth and development of non-neuronal cells such as 
astrocytes (Figure 3.9) and microglia (Figure 3.11) and were stable for up to 
twenty days in vitro (Appendix Figure 3.b). Characterisation of cultures 
provided baseline profiles of neuronal and glial cell population interactions pre-
fibril challenge.  
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Understanding cellular composition and baseline characteristics of primary 
cultures was crucial to determine changes induced by fibril challenge. In order 
to study cellular responses to misfolded fibril protein, highly pure recombinant 
PrP fibrils were produced (Figure 4.4), characterised (Figure 4.7) then 
fluorescently labelled (Figure 4.8) which allowed direct visualisation of fibril 
protein trafficking and interactions in mixed cellular populations which was 
crucial to understanding the mechanisms involved in cellular responses to 
misfolded protein insult. In conclusion, primary cultures along with 
fluorescently labelled fibrils provided essential tools for investigating the 
intricacy of early misfolded PrP interactions with neuronal, astrocytic, 
microglial and synaptic populations in cultures from both WT and 101LL 
genotypes. 
 
7.1.2 Cultures challenged with labelled fibrils mimicked neurodegenerative 
pathogenic events 
 
Typical neurodegenerative features associated with abnormal protein 
misfolding in the brain include neuro-inflammation in the form of reactive 
astrocytes, activated microglial and synaptic alternations (B. Martin 1999). 
Exogenous fibrils added to culture interacted with neurons and PrPC protein 
(Figure 5.2) in both 101LL and WT cultures without inducing neuronal loss 
(Figure 5.1) over a 24-hour exposure period indicating fibril concentrations 
used were not neurotoxic at this concentration and exposure time. Fibrils were 
internalised by cells and were processed via the endolysosomal pathway 
(Figure 5.6, 5.7). These processing mechanisms appeared to be functional in 
WT cultures (Figure 5.8) but were impaired in 101LL cultures (Figure 5.9). 
Microglial activation and possible phagocytosis of fibrils was evident in both 
genotypes (Appendix Figure 5.b). Hypertrophic astrocytes were evident only 
in WT fibril-challenged cultures (Figure 5.4) indicating differential glial 
responses were occurring between genotypes.  
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Fibrils localised to synapses in both genotypes however, a significant reduction 
in post-synaptic marker PSD-95 occurred only in 101LL cultures suggesting 
101LL neurons were more susceptible to synaptic loss than WT. In agreement 
with these data, PSD-95 was reduced in the brains of AD patients (Yuki et al. 
2014) and in mouse models of HD (Smith et al. 2014) suggesting PSD-95 may 
be a vulnerable target associated with many PMDs which will be discussed 
further in Section 7.2.3. Collectively, these results confirm that exogenously 
challenged fibrils interacted with all hippocampal derived cell populations 
resulting in genotype-specific differences in intracellular processing and 
cellular response to fibrils that may be related to susceptibility to disease 
pathology in PMDs. 
 
7.1.3 Differential gene expression in response to fibril challenge  
 
Comparison of baseline transcriptomic profiles obtained pre and post-fibril 
challenge showed an increase in expression of genes in WT cultures 
associated with endocytosis, macrophage engulfment, immune and defence 
response and ER-associated misfolded protein catabolic processes none of 
which were induced in 101LL fibril-challenged cultures (Figure 6.22). This 
suggests the dysfunction of multiple mechanisms may be associated with an 
inability to clear misfolded protein in the disease context and highlight targets 
to investigate further for intervention in PMDs. A decrease in expression of 
genes in 101LL cultures associated with endocytosis, amyloid clearance, an 
inability to respond to exogenous stimulus and activation of glial support cells 
suggested all these processes were reduced in 101LL fibril-challenged 
cultures (Figure 6.22). These data suggested 101LL cultures were not 
efficiently detecting and responding to fibril challenge for efficient misfolded 
protein degradation and clearance. Collectively these changes in gene 
expression in both genotypes support the hypothesis that differences in the 
initial processing of abnormal protein between WT and 101LL mice determine 
whether abnormal protein is cleared or is seeded as fibril amyloid.  
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7.2 Highlights of the research and future investigations 
 
7.2.1 Primary hippocampal neuronal model and alternative systems 
 
Primary neuronal cultures are one of the most important models used for 
performing advanced research in different PMDs (Schonfeld-Dado and Segal 
2009), and complete characterisation of these models at baseline is essential 
to gain accurate information on neurodegenerative-associated processes. 
Unfortunately, numerous studies using these models to investigate 
neurodegeneration focus on the initial neuronal culture preparation procedures 
and fail to fully characterise the resulting cultures (Seibenhener and Wooten 
2012; Beaudoin et al. 2012; Kaech and Banker 2006) or perform limited culture 
characterisation studies (Ray et al. 2009). In contrast, in this study, cultures 
were characterised at a morphological and histological level using antibodies 
to detect neurons (MAP2), astrocytes (GFAP), PrPC (6H4, 7A12), microglia 
(Iba1, CD11b) and pre and post-synaptic markers (PSD-95, Synapsin 1) to 
profile factors crucial in analysing cellular response to challenge with misfolded 
protein including cellular composition, synaptic maturity and host PrPC 
interactions. The primary hippocampal neurons developed here were highly 
branched neuronal networks connected via synapses and supported by both 
astrocytic and microglial populations. IMARIS reconstructions of these mixed 
cell cultures (Figure 3.5, 3.6, 3.10, 3.11) provided unique insights into the 
cellular morphologies of these cell types whilst providing baseline cellular 
profiles on proportions of neuronal, astrocytic, PrPC and synaptic proteins 
(Figure 3.12, 3.14) present in WT and 101LL cultures pre-fibril challenge. 
 
Advances in primary neuronal cultures include using agarose hydrogels 
(Bellamkonda et al. 1995) or most recently other matrices such as elastomeric 
scaffolds that are able to instruct 3D growth of primary neurons (Bosi et al. 
2015) or starPEG-heparin-based hydrogels that promote proliferation of 
primary neuronal stem cells (Papadimitriou et al. 2018).  
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The recreation of 3D neuronal circuits in vitro is advantageous as it represents 
a more physiologically normal preparation of cultures including supporting glial 
cells that can be used for neurodegenerative related studies (Smith et al. 
2015). As described in Chapter 3, IMARIS reconstructions of primary cultures 
(Figure 3.5) highlighted some 3D properties were maintained however; 
cultures were still primarily 2D or monolayer. GSS disease has already been 
modelled using adult murine stem cells infected with prion brain homogenate 
in 3D cultures and biochemical changes related to prion pathology were 
induced within 2-3 weeks in culture suggesting 3D cultures would provide a 
suitable physiological competent model of prion related neurodegeneration 
(Collins and Haigh 2017). However, these cultures were free-floating 
neurospheres (clusters of neural stem cells) and are associated with some 
major drawbacks, such as sensitivity to culturing methods used where 
variations in cell density can affect proliferation capacity (Tropepe et al. 1999). 
Media constituents or concentrations of factors in the media (Irvin et al. 2003; 
Arsenijevic et al. 2001), frequency and number of passages after isolation 
(Caldwell et al. 2001) also lead to differences in cellular composition and 
properties between individual neurospheres. Due to these sensitivities and 
variations, it can often be difficult to consolidate data from different groups 
(Parmar et al. 2002) or even interpret results within the same study (Eriksson, 
Bjorklund, and Wictorin 2003) to make comprehensive conclusions. The 
primary cell culture model presented in this thesis did not require any cell 
passage, is well established and contains distinct neuronal, astrocyte and 
microglial cellular populations and therefore provided a more robust model for 
studying neuronal and non-neuronal interactions in vitro.  
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3D cultures have previously been used to study mechanisms of AD 
pathogenesis due to the lack of relevant models that recapitulate all AD related 
features (Park et al. 2018). Researchers used a microfluidic device containing 
a 3D culture of human neurons (overexpressing APP with familial AD 
mutations) and glial cells was developed which displayed AD like pathology 
including beta-amyloid aggregation, phosphorylated tau accumulation and 
neuroinflammatory activity. This provided a model that can systematically 
recapitulate multistage intracellular interactions in human AD brains whilst 
providing insights into mechanistic neuronal-glial interactions related to AD 
pathogenesis. One limitation of this study was that it used immortalised 
neuronal precursor cells and microglial cells and therefore these cells did not 
accurately replicate the primary cells found in vivo. Overall, although 3D 
cultures appear more physiological relevant than 2D cultures, these models 
can be cumbersome, time-consuming and require specialised equipment 
unlike 2D models which are well established, require basic equipment and are 
easier to set-up.  
 
Induced pluripotent stem cell (iPS) cell technology pioneered by Yamanaka’s 
lab in 2006 is an another method for generating in vitro models of 
neurodegenerative diseases. This method involves the introduction of four 
specific genes encoding transcription factors that convert adult cells into 
pluripotent stem cells (Shi et al. 2017; Takahashi and Yamanaka 2006). 
Therefore, iPS cell technology can be used to generate in vitro models of 
disease-relevant cells reprogrammed directly from accessible tissues from 
living patients whereas neuronal stem cells have to be obtained post-mortem. 
This technology was applied to prion studies where iPS cells derived from 
somatic cells (dermal fibroblasts) from a human GSS case were differentiated 
into neuronal and non-neuronal cells (Matamoros-Angles et al. 2018). 
Although iPS cells were unable to spontaneously generate a human prion 
disease, cultures did show relevant prion disease associations such as 
astrogliosis, p-Tau and cell death, mostly recapitulating some of the 
neuropathological features reported in the donor patient.  
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These results show iPS cell technologies will be useful for future human 
associated neurodegenerative disease studies. Indeed, iPS cells have been 
generated from patients with AD (Muratore et al. 2014), PD (Schondorf et al. 
2014), HD (Jeon et al. 2012) and ALS (Zhang et al. 2015). Although iPS cell 
technologies are widely used and can model human genetic diseases they are 
associated with low reprogramming rates and formation of genetic mutations 
and or tumours which are some of the disadvantages related to this cell 
reprogramming technology. Overall iPS cells are useful for investigating 
pathology associated with specific human disease gene alterations but not so 
useful for studying generic mechanisms common between diseases.   
 
An alternative in vitro model that offers a three-dimensional system for 
studying cellular functions in a controlled environment is brain organotypic 
slice cultures (BOSCs). These models are easily accessible and retain tissue 
architecture along with functional synaptic circuitry and therefore are used to 
study many neurodegenerative diseases (Harwell and Coleman 2016; 
Novotny et al. 2016; Wolf et al. 2015; Falsig et al. 2012; Falsig et al. 2008; Duff 
et al. 2002; Bruce, Malfroy, and Baudry 1996). BOSCs were developed during 
this thesis (Supplementary Chapter 8) and characterisation results highlighted 
organotypic slices were susceptible to stretching and degradation             
(Figure 8.2-8.4), microglial activation (Figure 8.5) and astrocytic scarring 
(Figure 8.9) pre-fibril challenge and therefore were deemed unsuitable models 
for studying cellular interactions of abnormal fibril protein in vitro.  
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7.2.2 Analysis of transcriptional differences between in vivo tissue and in vitro 
cultures 
 
A major finding in this thesis showed that primary hippocampal cultures and 
acutely dissected hippocampal tissues were broadly comparable based on 
gene expression profiles obtained from transcriptomic analysis                    
(Figure 6.7, 6.10). These comparisons of both in vitro and in vivo systems were 
novel and confirmed primary cultures would provide a suitable in vitro model 
for studying abnormal protein interactions at a transcriptional level. Previous 
groups have attempted similar investigations however, direct comparisons 
between identical genotypes from both systems was not carried out and 
microarray data for system comparisons were obtained from separate studies, 
which were later combined. For example, one study focused on murine gene 
expression in developing hippocampus in vivo (Mody et al. 2001), and the 
second on expression profiling of primary hippocampal neurons undergoing 
differentiation in vitro (Dabrowski et al. 2003; Diaz et al. 2002). Both were then 
combined for comparisons to be carried out. Although results showed in vitro 
and in vivo expression profiles were similar complementing findings presented 
in this thesis, the study was comparing primary cultures obtained from CD1 
outbred mice which have more genetic diversity (Dabrowski 2003) with 
hippocampal tissue from C57BL/6 inbred mice which are almost genetically 
identical (Mody 2001). Therefore, these studies did not represent an accurate 
comparison of in vitro and in vivo systems. A more recent study using a similar 
approach (combining two separate studies) described both similarities and 
differences of biological processes between neural cells grown in vitro and in 
vivo (LoVerso, Wachter, and Cui 2015). However, these results were based 
on rat neural cells obtained from commercial sources (in vitro) compared to 
mouse acutely purified neural cells (in vivo), so involved studying cross-
species transcriptomic comparisons. Therefore, although in vitro and in vivo 
system comparisons have been carried out previously, the studies were 
limited.  
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In this thesis, novel direct comparisons between both genotypes and systems 
were carried out and although some DEGs were identified between both 
system comparisons (Figure 6.7, 6.10) biologically, no major differences were 
identified suggesting both systems were broadly comparable. These data 
highlighted primary hippocampal cultures would provide a realistic neuronal 
cell model for studying misfolded protein interactions in vitro at a transcriptional 
level.  
 
7.2.3 Specific targeting of synapses in 10LL derived neuronal cultures  
 
A major obstruction in studying prion neurotoxicity has been the lack of 
amenable model systems in which changes associated with degeneration can 
be studied in cell culture and the mechanisms by which prions cause toxicity 
are still poorly understood. Increasing evidence points to synapses as the site 
where AD, PD and HD pathology begins. In these studies, primary 
hippocampal cultures presented relatively early pathogenic events (24 hours, 
Figure 5.5) in response to fibril challenge. PSD-95 was significantly reduced in 
101LL fibril-challenged cultures however, this decrease did not induce 
neurotoxicity at this time point. These data support previous findings in in vivo 
models showing the hippocampus is a target area associated with early 
synaptic loss in prion diseases which also precedes neuronal decline (Hilton 
et al. 2013). It is interesting to note that fibrils were interacting with neurons in 
both WT and 101LL cultures (Figure 5.2), but only causing a decline in post-
synaptic proteins in those derived from the 101LL genotype suggesting the 
101LL mutation induced specific vulnerability to the post-synapse after fibril 
challenge. Indeed, although the precise function of PrPC is unknown one of the 
proposed roles is maintenance of synapses (Brown 2003), and it may be 
possible the 101LL mutation reduces this function resulting in increased 
vulnerability to misfolded protein pathological effects. Future studies using 
additional synaptic markers could examine if synapses were actually 
degenerating or were just losing PSD-95 proteins.  
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Additionally, during synaptic pruning microglia actively engulf synaptic material 
(Paolicelli et al. 2011), however, this was shown in developmental brain 
studies and it is currently unknown if synaptic material found within microglia 
is due to active pruning or due to debris clearance from degenerated synapses, 
and these interactions could also be a focus for future investigations. Fibril-
induced loss of PSD-95 may be associated with the binding of fibrils to PrPC 
on target neurons, as cell-surface PrPC was expressed along dendrites and 
can act as a receptor for abnormal PrP (Figure 5.2), which then may elicit a 
toxic signal or result in dendritic damage. Transcriptomic analysis of WT and 
101LL fibril-challenged cultures identified an increase in gene expression 
associated with phosphorylation in 101LL fibril-challenged cultures (Figure 
6.22). Phosphorylation processes are known to be involved in protein 
conformational changes (Giannopoulos et al. 2009) and therefore this 
response in 101LL fibril-challenged cultures may be an indicator that more 
protein conformational changes were occurring in 101LL cultures possibly 
resulting in a toxic decline in PSD-95. Interestingly, it has also been shown that 
synaptic activity is highly regulated by phosphorylation of PSD-95 (Pedersen 
et al. 2017). Therefore promoting phosphorylation processes in 101LL         
fibril-challenged cultures could be a cellular response to loss of PSD-95 by 
actively trying to maintain synaptic activity after fibril insult. Alternatively, 
phosphorylation could be inducing PSD-95 loss. Further studies are required 
to definitively determine the association between increased phosphorylation 
and synaptic loss in 101LL fibril-challenged cells. Similar PSD-95 
vulnerabilities and loss have also been reported in neurodegenerative 
diseases such as AD (Yuki et al. 2014) and HD (Smith et al. 2014), suggesting 
this protein is a vulnerable target associated with many PMDs and current 
studies have highlighted that activity and distribution of post-synaptic 
components may provide promising targets for the detection of subtle but 
measurable changes related to synaptopathy (Ghiglieri, Calabrese, and 
Calabresi 2018).  
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Remarkably, Aβ oligomer-induced loss of PSD-95 in hippocampal brain slices 
can be recovered using compounds such Ferruginol, Jatrophone, and 
Junicedric Acid isolated from medicinal plants (Zolezzi et al. 2018), again 
confirming a role of PSD-95 in neurodegeneration whilst highlighting potential 
therapeutic avenues for future research to recover or reduce synaptic decline.  
One limitation of this study was that synaptic images obtained using the 
confocal microscope were of relatively low resolution in comparison to high 
resolution microscopy and therefore, interactions between fibrils and pre and 
post-synaptic markers could not be reconstructed using specialised software 
for further analysis. For future studies, super-resolution microscopy as 
described in Chapter 5 (Figure 5.2), could be used to obtain higher resolution 
images that could then be reconstructed providing more accurate information 
on interactions between neurons, PrPC, fibrils and synapses in primary         
fibril-challenged cultures. Further investigations into the mechanisms that 
determine why synapses are specifically targeted in 101LL neurons or why WT 
neurons are not vulnerable are essential for the development of new strategies 
for therapeutic intervention. The primary culture model used in this thesis 
provides an ideal system for these investigations to be carried out in a 
controlled, readily accessible model system. 
 
7.2.4 Differential responses of glia in WT and 101LL fibril-challenged cultures 
 
Glial cells are essential for maintenance of neuronal networks and protection 
of neurons from toxicity (Boehler, Wheeler, and Brewer 2007; Ye and 
Sontheimer 1998) and studies characterising cellular composition of cultures 
confirmed both microglia and astrocytes were present and in surveillance 
mode in primary cultures pre-fibril challenge (Figure 3.10, 3.11). Although 
fibrils did not induce neurotoxicity after 24-hour challenge (Figure 5.1), a rapid 
and activated microglial response was evident in both genotypes based on 
phenotypical changes observed (Arcuri et al. 2017; Ling and Wong 1993).  
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Microglia morphology converted from extended processes indicative of 
surveillance mode (Figure 3.11) to a more rounded, ramified cell body 
(Appendix Figure 5.b) indicating a switch to activation mode which was evident 
in cultures from both genotypes after fibril challenge. These data are in 
agreement with studies showing microglia activation was detected at early 
stages of murine prion disease in vivo (Perry and Teeling 2013; Sofroniew and 
Vinters 2010). The localisation of fibrils with activated microglia (Appendix 
Figure 5.b), alongside a reduction in fibril size after addition to both WT and 
101LL cultures (Figure 5.3) suggested this was a generic response to fibril 
insult, possibly to limit neuronal damage and promote fibril degradation 
through phagocytosis. Transcriptome analyses also identified an increase in 
expression of genes associated with phagocytosis in both genotypes        
(Figure 6.22) supporting immunocytochemical observations. These results 
were not surprising as microglia are capable of both engulfment and 
phagocytosis of Aβ fibril material (Lee and Landreth 2010). Research in our 
lab has previously shown activated microglia were present at the periphery of 
amyloid plaques in 101LL mice challenged with recombinant PrP fibrils (Barron 
et al. 2016), indicating microglial response to fibril insult may play a role in 
maintaining neuronal homeostasis as challenged animals did not reproduce a 
pathological phenotype of prion disease. As highlighted by Ginhoux, there is 
lack of relevant microglial cell model systems available for studying the 
mechanistic responses by which microglial activation states reduce 
neurodegeneration (Ginhoux 2016). The model system presented in this thesis 
helps bridge this gap and provides insights into how non-neuronal cell types 
may also play a role in maintaining neuronal homeostasis after fibril insult. 
Modulating these responses could provide possible therapeutic treatments to 
encourage the removal of abnormal proteins in all PMDs. Fibril challenge also 
induced differential responses in astrocyte populations. WT fibril-challenged 
cultures were associated with astrocyte morphology conversion from a multiple 
process phenotype indicative of surveillance mode (Figure 3.10) to a shorter 
and thicker cell phenotype (Figure 5.4) indicating a switch from surveillance to 
astrocytic activation was occurring in WT fibril-challenged cultures.  
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101LL fibril-challenged cultures displayed no astrocyte activation possibly due 
to a delayed or an inactivated response due to the 101LL mutation (Figure 
5.4). In accordance with previous data, a delayed response may be more 
realistic as reactive astrocytes were previously shown to be present at the 
periphery of amyloid plaques in 101LL mice challenged with fibril recombinant 
PrP (Barron et al. 2016). However, these observations were only made 
approximately 500 days post-inoculation with fibrils, a time point where 
terminal disease would be reached in other prion models. This suggests 
astrocytes would eventually react to fibril challenge but response may be 
delayed in 101LL cells. Activation of reactive astrocytes is reported to reduce 
CNS degeneration (Sofroniew 2009, 2005; Schenk et al. 1999) suggesting 
reactive astrocytic cell responses in WT fibril-challenged cultures may also be 
neuroprotective. Other studies have indicated reactive astrocytes may 
contribute to neurodegeneration via a loss of normal astrocyte function 
resulting in reduced maintenance of neurons (Sofroniew and Vinters 2010). 
Studies have also shown activation of astrocytes is important in removing 
fibrillar amyloid from neurons and reducing plaque degradation (Wegiel et al. 
2000). As astrocytes were only activated in WT fibril-challenged cultures and 
no reduced PSD-95 was observed in these cultures (Figure 5.5), there may be 
an association between protective responses of astrocytes to fibril challenge 
and reduced synaptic loss. However, further investigation would be required to 
determine any such role. In agreement with these findings transcriptomic 
analysis of fibril-challenged cultures showed increased expression of genes 
associated with astrocyte differentiation in WT fibril-challenged cultures 
(Figure 6.14) and an increased expression of the Sox10 gene (Section 6.3.9). 
Sox10 is reported to play a role in the development of glial cells (Weider and 
Wegner 2017; Kuhlbrodt et al. 1998) and astrocyte differentiation (Kordes and 
Hagel 2006). Increased Sox10 expression may be an indicator of the rapid 
astrocytic response in WT fibril-challenged cultures. Fibrils were found to be 
associated with lysosomal domains in WT hypertrophic astrocytic cells 
(Appendix Figure 5.d), suggesting they were been processed for degradation.  
243 
 
In support of this, similar lysosomal associations were evident in studies 
investigating prion uptake in cultures derived from adult hamster brains 
(Hollister et al. 2015; Magalhaes et al. 2005). Astrocytic internalisation and 
trafficking of fibrils to lysosome organelles in WT fibril-challenged cultures 
preceded any neuropathological changes associated with fibril insult (Figure 
5.1, 5.5, Appendix Figure 5.a). This suggested astrocytic associated activation 
may be an important contributor to degradation of fibrils during early stages of 
PMDs. Broadening our understandings of astroglial responses to abnormal 
protein may therefore be useful to determine future therapeutic strategies for 
internalisation. 
 
7.2.5 A failure of endolysosomal control systems in 101LL fibril-challenged 
cultures 
 
The lysosomal quality control pathway acts as a terminal degradative 
compartment of cells and is one one of the primary targets for abnormal forms 
of PrP to manipulate to promote abnormal protein propagation (Majumder and 
Chakrabarti 2017). The endolysosomal and autophagic pathways are the two 
main routes involved in delivering misfolded protein to lysosomes (Saftig and 
Klumperman 2009). Preliminary results indicated fibrils were localising with 
autophagic vacuoles in WT fibril-challenged cultures and no evidence of fibril 
localisation was noted in 101LL fibril-challenged cultures (Appendix Figure 
5.g), indicating fibril degradation via autophagic pathways was only occurring 
in WT fibril-challenged cultures. However, due to time constraints, further 
investigations of this pathway could not be completed therefore, processing in 
the endolysosomal control system will be the focus of this discussion. 
Endolysosomal pathways have been associated with processing abnormal 
PrP in prion-infected human and mammalian brain tissue (Yao et al. 2013; 
Jeffrey et al. 2010) and aberrations in this system have also been detected in 
neurons from human sporadic CJD brains (Kovacs et al. 2007). 
 
244 
 
Intracellular labelling showed localisation of fibrils with both endosomes and 
lysosomes in WT cells (Figure 5.6, 5.7, 5.8) indicating a normal functional 
endolysosomal pathway was operative. However, localisation in 101LL cells 
was primarily endosomal and no localisation with lysosomes was evident 
(Figure 5.9). These data suggest malfunctions in the endolysosomal quality 
control system in 101LL cultures. Complementary to these results, no          
intra-lysosomal abnormal PrP accumulations were found in the brains of 101LL 
mice inoculated with recombinant fibrils as observed by electron microscopy 
suggesting in vitro observations presented here were an accurate 
representation of abnormal PrP processing in 101LL mice in vivo (Barron et al. 
2016). Transcriptomic analysis further supported these results by identifying 
reduced expression of genes Laptm5, which is directly associated with 
lysosomal activity (Williams et al. 1994), and the gene Ctsz, which belongs to 
lysosomal cysteine proteases family involved in intercellular protein 
degradation (Santamaria et al. 1998), in 101LL fibril-challenged cultures 
(Figure 6.17, 6.15). These findings indicate endolysosomal processing was 
reduced in the 101LL genotype after fibril challenge. Previous attempts to 
follow abnormal PrP processing and trafficking have been carried out using 
primary cortical cultures from adult hamster brains (Hollister et al. 2015; 
Magalhaes et al. 2005), and abnormal PrP obtained from prion infected 
animals or recombinant PrP fibrils. These studies also showed abnormal PrP 
was processed via endolysosomal pathways complementing results presented 
in this thesis. However, these studies showed limited baseline characterisation 
of primary cultures and in the case of Magalhaes et al., results were primarily 
based on murine SN56 cell lines which are immortalised neuronal cells and 
therefore lack biological relevance.  
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Analysis of early localisation of fibrils after challenge in WT and 101LL primary 
cultures indicates the 101LL genotype confers a failure of lysosomal 
processing of abnormal protein that may be associated with reduced 
degradation and a propensity to accumulate misfolded protein. This 
impairment in the endolysosomal pathway in 101LL cultures should induce 
cytotoxicity over-time however, due to limited time further analysis of this 
pathway could not be carried out. Nevertheless, these data do indicate the 
endolysosomal control system was impaired in 101LL fibril-challenged 
cultures, and this could be a focus for future studies. Such investigations could 
involve examining longer fibril challenge incubation times and a more detailed 
analysis of endolysosomal mechanisms. For example, blocked vesicular 
fusion (Majumder and Chakrabarti 2015), improper loading of abnormal protein 
into vesicles and lysosomal associated enzymes such as cathepsins (Kovacs 
et al. 2007), are all of major concern in PMDs and would be useful to 
investigate in the 101LL model. Additionally, proteins such as Rab7 which 
have been identified as main regulators of membrane trafficking at late 
endosomes and membrane fusion of late endosomes to lysosomes could also 
be investigated (Modica and Lefrancois 2017). Thus, the primary                    
fibril-challenged culture model presented in this thesis could provide a means 
for carrying out these investigations to gain further insights into abnormal 
protein degradation via regulation of endolysosomal fusion to acidic 
organelles.  
 
Treatment with various compounds can be used to manipulate endolysosomal 
or autophagy pathways. For example, tamoxifen has been shown to modulate 
prion disease in infected neuronal cells, where it was reported to divert and 
traffic abnormal PrP to lysosomes for degradation (Marzo et al. 2013). 
Recently, pharmacological activation of autophagy has also been shown to 
favour clearance of intracellular aggregates of abnormal prion protein in an 
immortalised murine neuronal cell line (Thellung et al. 2018).  
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These pharmaceutical intervention methods could be applied to primary                     
fibril-challenged cultures in future studies to provide insights into the 
effectiveness of these therapeutic treatments in a more biologically relevant 
model, where any beneficial findings may be applicable to other 
neurodegenerative conditions. Interestingly, a recent review has highlighted 
the endolysosomal quality control system may be one of the primary targets 
for disease-causing iso-forms of PrP, and may also be involved in many other 
neurodegenerative diseases such as AD, PD, HD and ALS and therefore these 
disorders are collectively referred to as “lysosomal diseases” (Majumder and 
Chakrabarti 2017). The data presented in this thesis support these 
observations that endolysosomal pathways may be important modulators of 
neurodegeneration whilst proving tools that can be used for future 
investigations into fibril trafficking pathways and lysosomal processing 
essential for degradation of abnormal proteins in models that support protein 
misfolding (101LL) or that curtail it (WT).  
 
One aspect that could not be investigated using primary cultures which might 
be involved in fibril clearance in vivo was the glymphatic system. This system 
involves the flow of interstitial fluid (ISF) in the brain along basement 
membranes of capillaries and arteries which finally drains into the 
leptomeningeal arteries and cervical lymph nodes (Weller et al. 2008). This 
flow of ISF is essential for clearance of solutes from extracellular spaces 
(Abbott 2004), and studies have indicated partial ISF blockage appeared to be 
a possible contributer to pathology in amyloid prion disease (Rangel et al. 
2013). The possibility that this blockage of fibril material or inefficient drainage 
of fibrils may also be occurring in 101LL mouse brains could not be addressed 
using primary cultures. However, for future work a number of studies could be 
carried out to investigate these mechanisms in vivo using inoculated 
fluorescently-labelled fibrils to provide further insights into lymphatic drainage 
systems associated with abnormal protein in a living brain.  
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7.2.6 Transcriptome insights into molecular responses of primary cultures to 
fibril insult  
 
Transcriptomic comparisons between in vivo tissue and in vitro cultures has 
been already discussed (Section 6.2.2) and supported the use of primary 
cultures for studying abnormal fibril interactions in vitro (Figure 6.7). 
Transcriptomic analysis was also advantageous to confirm levels of astrocyte 
and microglial related genes were expressed at similar levels to verify cellular 
composition of cultures at baseline (Figure 3.9, 3.11). These analyses 
suggested a similar frequency of these cells were present in cultures from both 
genotypes in agreement with immunocytochemical observations (Figure 3.14).  
After fibril challenge, as discussed in Section 6.1.3, WT cultures appeared 
primed to respond efficiently to fibril insult, whilst 101LL cultures appeared to 
have an impaired or delayed response (Figure 6.22) supporting the 
hypotheses that WT and 101LL mice have different mechanisms of 
intracellular processing of abnormal protein that determine clearance versus 
the seeding of amyloid plaques. Gene expression profile changes relating to 
glial and endolysosomal control system responses were also discussed in 
Section 6.2.4 and 6.2.5 and differences between genotypes were evident and 
supported immunocytochemical results. Collectively, these results along with 
immunocytochemical analyses provided a complete multi-cellular response 
profile to fibril insult, which was lacking in similar investigations carried out by 
other groups using only neuronal cultures (Hollister et al. 2015; Magalhaes et 
al. 2005). These data support the original hypothesis and provide key 
information on pathways and cellular mechanisms involved in either clearance 
of misfolded protein or initiation of amyloid formation. Identifying these 
pathways provides a number of possible test targets with the potential of 
impacting diagnosis and/or intervention in PMD’s such as AD, PD and prions. 
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Due to limited time, transcriptomic datasets obtained in these studies were not 
compared to previously obtained datasets obtained from genomic studies 
investigating differential gene expression in prion disease. For example, 
studies using murine models of scrapie, a prion disease in sheep (Chapter 1, 
Section 1.2.1, 1.2.3, 1.2.4) compared gene expression between scrapie-
infected mice and mock-infected mice at both pre-symptomatic and 
symptomatic time points (Skinner et al. 2006). This study identified          
disease-associated alterations in gene expression related to 
endosome/lysosome functions, immunity and synapse function. Another, more 
comprehensive, study described by Hwang et al. (Hwang et al. 2009) 
compared a number of mouse and scrapie stains at different time points of 
TSE disease and identified changes in gene expression associated with 
microglial activation, reactive astrocytic gliosis and synapse loss lending 
support to the data gathered in in vitro cultures in this study. Although no direct 
comparisons of these scrapie datasets and fibril-challenged datasets were 
carried out, similar pathways identified between these studies indicated 
processes identified are important in neurodegeneration. Gene expression 
changes in a human prion-infected brain have also been determined (Tian et 
al. 2013) and although limited samples were included in this study, it could 
provide additional datasets for comparisons which would identify if gene 
alterations were species specific or non-specific. Cross-referencing with other 
transcriptome profiling studies investigating AD, PD and HD (Matarin et al. 
2015; Courtney et al. 2010; Reddy et al. 2004) could additionally provide 
information if gene expression changes identified in prion challenged cultures 
were common to multiple PMDs. All studies cited were carried out using 
microarray analysis and therefore were subject to limiting factors such as 
reference information available during production and/or high signal-to-noise 
ratios, all of which are eliminated in the RNA-seq analysis carried out in this 
thesis.  
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7.3 Further research questions identified from this thesis 
 
Analysis of data within this thesis provided a number of differences in cellular 
processing of fibrils that could explain why WT mice can clear misfolded 
protein whereas 101LL mice instead accumulate plaques. However, a number 
of research questions that warrant further investigation have also been 
identified during analysis of this data that due to time constraints were unable 
to be carried out. Some of these questions will be briefly discussed here 
including potential experimental methods that could be useful for future 
investigations. 
 
7.3.1 Biochemical analysis of fibril-challenged cultures 
 
It was determined that fibrils did not localise with lysosomes in 101LL             
fibril-challenged cultures suggesting aberrant activation of endolysosomal 
processing of fibrils. It may be possible that 101LL cultures were capable of 
biochemically modifying fibrils resulting in a lack of co-localisation in 
lysosomes, whilst fibrils remained intact in WT lysosomes. The investigation of 
the biochemical characterisation of fibrils after challenge using fluorescence 
gel scanning would be useful to determine if cultures were modifying fibril 
forms within the 24-hour challenge period. Furthermore, biochemical analysis 
of lysosomal crude fractions obtained from fibril-challenged cultures could be 
used to validate immunocytochemistry results that showed fibril localisation in 
WT lysosomes and no associations in 101LL lysosome organelles. 
Biochemical studies could also be used to investigate if abnormal PrP 
replication was occurring in fibril-challenged cultures. Conformational changes 
are thought to occur through a seeded-nucleation model where abnormal PrP 
acts as the template for the conversion of normal PrPC to an abnormal form 
(Kocisko et al. 1994). Biochemical analysis could confirm if these 
conformational changes were occurring in fibril-challenged cultures and thus, 
provide further insights into seeded-nucleation and prion related 
neurodegeneration.  
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7.3.2 Optimisation of microscopy platforms  
 
Immunocytochemical analysis of cells and protein trafficking in cultures was 
mainly carried out using standard 96-well plates. Although 96 well platforms 
were ideal to carry out multiple experiments using minimal volumes of cells 
and fibrils, imaging of these platforms was limited by resolution. Therefore, 
many images shown in Chapter 5 were obtained using unconventional 
methods. For example, as an oil lens could not be used with plastic plates, it 
was substituted with an air lens, which did produce informative images 
however, resolution was not optimal. Optically enhanced confocal 96 well 
plates were introduced at a later stage but were still not completely compatible 
with high magnification microscope lenses. As shown in Figure 5.2, when glass 
coverslips were used in combination with the confocal AiryScan 880, high 
resolution images were obtained however, these methods required higher 
volumes and concentrations of both cells and fibrils which were only available 
in limited quantities. Furthermore, the AiryScan 880 high resolution 
microscope was not available for the majority of these studies. For future 
studies, the consistent use of glass coverslips for challenge experiments along 
with the confocal 710 or 880 would improve image quality and resolution 
dramatically, allowing for more detailed analysis and co-localising experiments 
to be carried out regarding future fibril trafficking experiments. Live cell 
confocal microscopy would also be beneficial for monitoring exactly when 
fibrils were internalised in both WT and 101LL models in real-time. 
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7.3.3 Cross-seeding investigations  
 
Studies have proposed that AD and other neurodegenerative diseases may 
spread through a cross-seeding mechanism which proposes seeds composed 
of one protein can accelerate a second misfolding process in an unrelated 
protein (Morales et al. 2010). Future investigations could involve challenging 
primary cultures with a different source of abnormal protein such as Aβ to 
examine these mechanisms and clarify if cellular PrPC does act as a high-
affinity neuronal receptor for Aβ (Rushworth et al. 2013). As discussed in 
Chapter 1 (Section 1.2.3), Prnp-/- mice are more resistant to the neurotoxic 
effect of Aβ oligomers than WT mice in both in vivo and in vitro models (Kudo 
et al. 2012), implying Aβ/PrPC binding mediates neurotoxicity. Alternative 
reports showed PrPC was capable of binding and detoxifying Aβ oligomers 
(Biasini et al. 2011). The primary culture model described in this thesis could 
be used as a tool to investigate precise mechanisms associated with PrPC in 
Aβ oligomer-induced neurotoxicity. 
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7.4 Conclusion 
 
Selective synaptic alternations and neuro-inflammation in the form of reactive 
astrocytes and activated microglia are typical features of neurodegeneration 
associated with abnormal protein misfolding, aggregation and accumulation in 
the brain (B. Martin 1999). Similar traits were evident in fibril-challenged 
primary cultures presented in this thesis supporting the use of these models 
for studying neurodegeneration and for investigating the impact of abnormal 
proteins which are hypothesised to be implicated in a range of 
neurodegenerative related disorders (Soto and Estrada 2008). During fibril 
challenge experiments, there was no evidence of neuronal loss suggesting 
that homeostatic alterations identified were all related to initial or early events 
that would later possibly trigger neurodegeneration.  
 
In conclusion, the data presented in this thesis support the hypothesis that WT 
and 101LL mice have different mechanisms of intracellular processing of 
abnormal protein that determine clearance versus the seeding of amyloid 
plaques, whilst providing key information on cellular mechanisms and 
molecular pathways involved in either clearance of misfolded protein (WT) or 
initiation of amyloid formation (101LL). Identifying these pathways and 
understanding their neurodegenerative-related mechanisms provides a 
number of possible test targets and candidate genes with the potential of 
impacting diagnosis and/or intervention in PMD’s such as AD, PD and prions 
for future investigations.  
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8.1 Abstract 
 
In vitro cell cultures provide an essential tool for gaining insights into cellular 
processes associated with the brain. Brain organotypic slice cultures (BOSCs) 
are an example of such an in vitro model that offers a three-dimensional 
system for studying cellular functions in a controlled environment. As BOSCs 
maintain brain cell composition and architecture these models are commonly 
used to study neurodegeneration in vitro. To investigate if this system would 
provide a suitable model for studying misfolded PrP protein interactions in 
vitro, brain organotypic slice cultures were established from WT, 101LL and 
PrP-/- Day 6 postnatal mouse brains. Characterisation of cell representation in 
these models confirmed the presence of neurons and other glial cells such as 
astrocytes and microglia. Astroglial cells were however shown to form atypical 
scarring, which enclosed the entire brain slice tissue in culture and microglial 
cells appeared hypertrophic indicating these glial populations were in an 
activated state, normally associated with neurodegeneration. Long-term 
culturing of BOSCs (DIV56) showed organotypic brain slices were prone to 
structural defects caused from tissue stretching and neuronal loss. This 
resulted in loss of tissue architecture therefore it was concluded BOSCs may 
not provide an effective and useful system for the investigation of misfolded 
protein processing in vitro.  
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8.2 Introduction 
 
BOSCs provide easily accessible brain tissue models which retain functional 
synaptic circuitry along with tissue architecture and are therefore used to study 
neurodegenerative diseases and pathological processes (Harwell and 
Coleman 2016; Novotny et al. 2016; Wolf et al. 2015; Falsig et al. 2012; Falsig 
et al. 2008; Duff et al. 2002; Bruce, Malfroy, and Baudry 1996). In this chapter 
a BOSC model was established and characterised to ascertain its suitability in 
providing an in vitro system for studying and advancing our understanding of 
misfolded protein interactions in the brain. Over-time the original organotypic 
method using the roller-tube technique has evolved to a more sophisticated 
interface system (Gähwiler 1981; Hogue 1947), involving culturing tissue slices 
on a permeable membrane between an interface of air and culture medium 
referred to as the membrane interface method (Bahr 1995; Stoppini, Buchs, 
and Muller 1991). This method was used to establish BOSCs in this study. A 
majority of BOSC studies have focused on culturing isolated areas of the brain 
such as the hippocampus and the cerebellum (Harwell and Coleman 2016; 
Novotny et al. 2016; Wolf et al. 2015; Falsig et al. 2012) and limited studies 
exist which culture whole brain slices (Staal et al. 2011). Both whole brain and 
hippocampal slices were cultured in this study from WT, 101LL and PrP-/- mice. 
Brain slices were obtained from postnatal Day 6 pups as at this time point 
tissues showed a high degree of plasticity and were not as susceptible to 
mechanical damage during the sectioning stage (Cho, Wood, and Bowlby 
2007). Cultures were characterised using immunohistochemistry in 
conjunction with IMARIS software analysis. The main focus of this study was 
to develop a working organotypic culturing system, explore cellular populations 
present and finally challenge organotypic slices with misfolded PrP fibrils. 
Unfortunately, initial characterisation results showed tissue architecture 
degradation, astrocytic scarring, and neuronal loss were evident in BOSC 
models from early time points in culture therefore, this culturing system was 
deemed not suitable for future fibril challenge experiments.  
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8.3 Results 
 
8.3.1 Brain sectioning using the Mcilwain tissue chopper  
 
Day 6 postnatal pup brains were processed as described in Materials and 
Methods (2.6). After incubation in oxygenated artificial cerebrospinal fluid 
(aCSF), a buffer solution used for maintaining oxygen supply to the exposed 
brain region, the brain sample was placed on the Mcilwain tissue chopper as 
shown in Figure 8.1 and whole brain coronal sections were cut at 400μm 
thickness. The freshly prepared slices were then separated into either whole 
brain or hippocampal slices. Slices were placed on sterile 0.4µm pore 
membrane inserts containing culture medium, and were incubated for a 
selected number of weeks.  
 
 
 
 
 
 
 
 
 
Figure 8.1: Illustration of the organotypic modelling set-up for culturing brain 
slices in vitro using the membrane interface method. (A) Mcilwain tissue 
chopper set-up for slicing brains. (B) Millipore insert that tissue was placed on 
and (C) Schematic representation of the membrane interface system.  
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8.3.2 Immunolabelling and imaging of whole organotypic brain slices 
 
Whole brain organotypic slices established from Day 6 WT, 101LL and PrP-/- 
pup brains were maintained in culture for approximately three to eight weeks. 
Tissues were then fixed and immunolabelled with specific markers for neurons, 
astrocytes and PrPC protein (Materials and Methods, 2.6).                                          
In all immunolabelled experiments, the entire tissue slice was imaged by 
combining multiple images together using the Zeiss LSM710 confocal 
microscope. As shown in Figure 8.2, tiled imaging allowed for entire slices to 
be displayed which was advantageous for morphological characterisation. 
Additionally, neuronal and astrocytic cell populations were confirmed by 
immunolabelling and PrPC protein was detectable however, tissue stretching 
was evident in whole brain slices. A clear reduction in neuronal and astrocytic 
immunolabelling coincided with these atypically stretched areas. These results 
suggested cellular degradation alongside architectural displacement of the 
brain slice was occurring over-time in these cultures. Tissue stretching was 
evident in all BOSC genotypes (Figure 8.3) suggesting these abnormalities 
were not specific to one genotype. Comparison of replicate tissue sections also 
demonstrated that all regions were sensitive to stretching in all genotypes 
examined. Further investigation using long-term culture studies (DIV56) 
showed brain slices were susceptible to neuronal and therefore architectural 
loss (data not included). As neuronal loss was evident at DIV56 in culture, 
earlier time points were investigated to determine if these defects developed 
in slices cultured over shorter periods of time. Additionally although tiled 
imaging was advantageous for producing images of the entire brain slice 
sections, the resolution was poor making tissue morphological characterisation 
analysis difficult. To counteract this images were taken at higher magnification 
and higher resolution. High resolution imaging allowed improved analysis of 
cellular immunolabelling (Figure 8.4).  
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This highlighted that even as early as DIV23 in culture, brain slices were 
susceptible to neuronal tissue stretching. High resolution images also 
displayed high signal intensities for GFAP (astrocytic) immunolabelling at the 
edges of tissue slices which was common to both genotypes and present in 
both short and long-term tissue slice cultures (data not shown, see Figure 8.9)  
for similar hippocampal related scarring). These observations suggested 
tissue scarring was occurring in response to the initial slicing of the brain 
tissue. High magnification imaging also allowed the detection of microglial 
populations previously difficult to locate using low power tiled imaging. Iba1 
and CD11b immunolabelling confirmed microglia were present and distributed 
throughout organotypic tissue slices (data not shown). These cells types 
appeared hypertrophic suggesting they were in an activated state. This 
activation may be in response to damage introduced during the chopping of 
brain tissue during initial preparation steps. IMARIS software was used to 
examine immunolabelled images using similar protocols described for primary 
hippocampal neuronal analysis (Materials and Methods, 2.2.9). Due to the 
thickness of slices and uneven tissue mounting, accurate analysis proved 
difficult however, Z stack confocal imaging helped overcome this obstacle. 
IMARIS Z stack analysis showed no significant differences were apparent in 
neuronal or microglial immunolabelling between similarly aged slices from WT 
and 101LL genotypes (Figure 8.5). These similarities confirmed earlier 
observations that slices from both genotypes were responding similarly to 
culturing conditions. In conclusion, whole brain slice cultures supported 
neuronal, astrocyte and microglial populations of cells along with expressing 
detectable amounts of PrPC. However, sections were prone to tissue stretching 
resulting in degradation of random areas of brain slice which occurred in all 
genotypes and became more pronounced over-time in culture. For the aims of 
this study whole brain organotypic slice culturing will not provide a suitable in 
vitro model for fibril challenge experiments.  
 
 
 
 
 
259 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.2: Multiple image tiling allowed for entire tissues to be imaged. 
Immunolabelling and image tiling were used to investigate what cells were 
present in organotypic slices and also to examine entire brain slice architecture 
in culture. Immunolabelling for neurons (MAP2/Green); astrocytes 
(GFAP/Red); PrPC (6H4/White) and nuclear (DAPI/Blue) confirmed the 
presence of these cells and proteins within slices. Tiled images show tissue 
stretching and degradation was evident in many areas including the 
hippocampus, thalamus and hypothalamus. Both neuronal and astrocytic 
populations were absent in these areas suggesting a loss of these cell types 
within stretched areas. DIV37 WT brain slice coronal section (400µm), Scale 
Bar 1000μm. 
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Figure 8.3: Tissue stretching was evident in all BOSC genotypes. Neuronal 
marker MAP2 was used to monitor tissue changes in organotypic slices to 
identify if tissue stretching was area and or genotype specific. Tiled images of 
replicate brain slices,  (A-A1) WT DIV37, (B-B1) 101LL DIV41 and (C-C1)       
PrP-/- DIV42 immunolabelled with neuronal marker MAP2 (Green). All 
genotypes showed brain slice stretching was present and comparisons of 
neuronal architecture between duplicate brain slices showed tissue stretching 
was not specific to brain area for example in panel (A-A1) WT DIV37, slice 
defects were present in the hippocampus and thalamus areas in image on left 
however, section on right displayed limited stretching in these areas. 101LL 
DIV41 and PrP-/- DIV42 slices displayed similar contrasting results. Although 
timeframes were not identical, tissue stretching was occurring in all genotypes. 
Scale Bar 1000μm. 
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Figure 8.4: High resolution imaging was advantageous for investigating tissue 
degradation. Tissue architecture was studied using neuronal immunolabelling 
(MAP2/Green) to monitor neuronal degradation. Top image: Immunolabelling 
with neuronal marker MAP2 (Green), and bottom enlarged image. Tiled high 
resolution imaging of organotypic whole brain coronal sections was useful for 
investigating neuronal degradation which was evident in this brain slice, and 
tissue morphology changes. Images processed using IMARIS software, DIV23 
WT, Scale Bar 1000μm and 200μm. 
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Figure 8.5: Z stack images allowed for accurate immunolabelling analysis to 
be carried out in IMARIS. To allow for detailed analysis of organotypic brain 
slices and cellular populations present, Z stacks were created using the 
confocal LSM710 microscope which were then analysed using IMARIS. (A-A1) 
WT DIV37 and (B-B1) 101LL DIV41 slices immunolabelled with neuronal 
marker MAP2 (Green), microglial marker CD11b (White) and nuclear marker 
DAPI (Blue). (C) IMARIS analysis (Materials and Methods, 2.2.9) quantified 
cellular populations present in all images. Neuronal populations were present 
and microglia appeared to be in an activated state based on their hypertrophic 
morphology, in both WT and 101LL cultures. IMARIS analysis showed no 
significant differences in signal intensities were evident between WT and 
101LL immunolabelled neurons (P-Value 0.91) and microglia (P-Value 0.13), 
N=2, unpaired t test. Scale Bar 30μm. 
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8.3.3 Immunolabelling and imaging of hippocampal organotypic brain slices 
 
The experiments described so far have shown tissue stretching and defects 
were evident in whole organotypic brain slices. To investigate if isolated areas 
of the brain were more structurally stable in vitro, organotypic hippocampal 
sections from WT and 101LL brains were cultured (Materials and Methods, 
2.6). Hippocampal sections were more intact and showed limited stretching in 
comparison to whole brain cultures (Figure 8.6). However, these observations 
were carried out over shorter timeframes in culture (DIV6-DIV28) and by DIV13 
some neuronal loss was also evident in hippocampal slices. Higher 
magnification imaging confirmed substantial neuronal loss was evident by 
DIV28 suggesting that isolated brain structures were also susceptible to 
neuronal degradation and stretching over-time (Figure 8.7). As shown in 
Figure 8.8, hippocampal sections cultured for longer periods of time displayed 
a similar neuronal degradation pattern to whole brain organotypic slices and 
therefore long-term culturing of hippocampal slices was not further explored in 
this study (WT showed similar results, data not shown). One prominent feature 
evident in both full brain and hippocampal slice cultures was the presence of 
glial scarring which was investigated in detail in short-term cultured 
hippocampal slices using IMARIS filament tracer module (Materials and 
Methods, 2.2.9). GFAP immunolabelling confirmed glial scarring and IMARIS 
filament analysis showed astrocyte cells formed a protective barrier around the 
entire hippocampal tissue slice (Figure 8.9). In conclusion, tissue stretching 
was reduced in hippocampal slice cultures in comparison to whole brain slices 
however, substantial neuronal degradation was still evident over-time. 
Additionally, glial scarring formed an astrocytic envelope surrounding the 
entire hippocampal tissue slice which would be problematic for future fibril 
challenge experiments regarding fibril penetration into the brain slice.  
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Figure 8.6: Isolated hippocampal tissues were less prone to tissue stretching. 
Tissue morphology changes were monitored in hippocampal slices to access 
neuronal degradation over-time in these isolated sections. Tiled images of 
organotypic hippocampal slices were obtained from WT mice maintained in 
culture for 6, 13 and 28 days, immunolabelled with neuronal marker MAP2 
(Green), PrP marker 6H4 (White) and nuclear stain DAPI (Blue). Tissue 
structure was grossly maintained within the above timeframes and PrPC 
protein expression was detectable in all sections. Neuronal loss did appear 
evident over DIV13 and DIV28 timeframes. Additionally, some DAPI stained 
areas were out of the focus field of the confocal microscope, and this was a 
limiting factor associated with mounting organotypic membranes for imaging. 
WT hippocampi, Scale Bar 1000μm. 
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Figure 8.7: Neuronal loss was evident in isolated hippocampal slices. Tiled 
high magnification image of DIV28 WT organotypic hippocampal slice allowed 
for detailed analysis of tissue structure to be carried out. (A) Full                     
image of tissue section immunolabelled with neuronal marker                                             
MAP2 (Green). Red box indicates area of magnification. (B) Magnified area 
showed substantial neuronal loss was evident in the hippocampal slice.                                                           
(C) Merged image of additional markers (Astrocytes/GFAP/Red, 
PrPC/6H4/White, Nuclear/DAPI/Blue) confirmed neuronal loss observations 
were accurate and not due to mounting detection limitations. (D) Cross-
sections of hippocampal slice (Red box) showing absence of MAP2 
immunolabelling in top tissue section in comparison to detectable GFAP, 6H4 
and DAPI signals, which were visible on this plane. These analysis  suggested 
neuronal loss was occurring in hippocampal brain slices. Scale Bar (A) 700μm, 
(B)-(C) 200μm and (D) 500μm. 
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Figure 8.8: Long-term cultures are susceptible to neuronal degradation. 
Hippocampal slice cultures were maintained in culture for extended 
timeframes (DIV42), to investigate if isolated tissues would be susceptible to 
degradation over-time. 101LL hippocampal tissue immunolabelled with 
neuronal marker (MAP2/Green), astrocytic marker (GFAP/Red) and nuclear 
stain (DAPI/Blue). Tissues displayed neuronal loss was evident in large 
sections of the hippocampus, suggesting hippocampal cultures could not be 
maintained over longer time periods. Scale Bar 1000μm. 
 
 
 
 
Figure 8.9: Glial scarring was evident in hippocampal slices. To investigate if 
astrocytic scarring was evident from initial tissue processing, Z stacked images 
were created of WT DIV6 tissue sections immunolabelled with neuronal marker 
MAP2 (Green) and astrocytic marker GFAP (Red). IMARIS analysis was 
carried out using filament tracer and 3D constructs created displayed an 
envelope of astrocytes surrounding and enclosing neurons were present along 
the entire organotypic slice confirming glial scarring was occurring in 
hippocampal organotypic slices.  
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8.4 Discussion 
 
The overall aim of this study was to develop a representative model of the 
brain using organotypic brain slices to study neuron-glia interactions after 
challenge with misfolded PrP fibrils. BOSC cultures were therefore established 
and characterised from WT, 101LL and PrP-/- genotypes using 
immunohistochemistry in conjunction with IMARIS software analysis. Previous 
studies by other groups have focused on isolating and culturing specific 
regions of the brain (Harwell and Coleman 2016; Novotny et al. 2016; Wolf et 
al. 2015; Falsig et al. 2012) however, in this study both full brain and 
hippocampal organotypic slices were established and compared to determine 
suitability for future fibril challenge experiments.  
 
A number of brain slice isolation methods were investigated during the 
development of the organotypic culturing system to maximise the efficiency of 
the technique. Originally up to four pups were culled at one time and extracted 
brains were immersed in aCSF for approximately 20 minutes. This method 
resulted in obtaining approximately two tissue slices from each pup brain. The 
revised protocol (Materials and Methods, 2.6) focused on preparing one pup 
at a time, reduced tissue incubation time in aCSF from 20 to 3 minutes and 
used a dissection microscope for efficient separation of slices. These 
improvements resulted in obtaining approximately five tissue slices per brain, 
more than double the amount of the original protocol. Other preparative 
techniques may also be used to prepare tissue slices such as tissue 
embedding in low melting agarose which is then sliced on a vibratome (Elias 
and Kriegstein 2007). This method was not investigate here but could have the 
potential to reduce tissue stretching in brain slices cultures.    
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To avoid introducing any bias regarding tissue slice analysis multiple images 
of each tissue were taken using the Zeiss LSM710 confocal microscope which 
were then stitched together forming one entire image of the organotypic slice. 
This allowed for the entire organotypic tissue to be viewed and analysed after 
immunolabelling. Immunohistochemical analysis of whole organotypic brain 
sections established from WT, 101LL and PrP-/- genotypes confirmed cultures 
supported neuronal, astrocyte and microglial populations of cells, and also 
confirmed PrPC was present. Additionally, IMARIS analysis showed no 
significant differences were apparent between immunolabelled neuronal and 
microglial cell populations in both WT and 101LL cultures, which was similar 
to findings observed in Chapter 3 (Figure 3.11, 3.14) investigating genotype 
similarities between WT and 101LL primary hippocampal culture models.  
 
Hippocampal organotypic slice cultures displayed similar characteristics to 
whole brain slices for the presence of neurons, astrocytes and PrPC in both 
WT and 101LL cultures. However, morphological tissue abnormalities were 
noted between both whole slice and hippocampal slices. Whole organotypic 
brain slices were more prone to tissue stretching resulting in random areas of 
degradation in the tissue which was applicable to all genotypes investigated 
and became more pronounced over-time in culture. This may explain why the 
majority of published studies focus on culturing isolated areas of the brain 
rather than whole brain slices. Hippocampal sections did appear more 
structurally stable in culture and less susceptible to tissue stretching however, 
substantial neuronal loss and degradation was also noted in these isolated 
slices. Although neurons appeared viable in brain slices immunolabelled with 
MAP2 (Figure 8.6), only limited viability studies (LDH assay, data not shown) 
were carried out during characterisation to confirm these observations. Other 
studies have used the exclusion non-fluorescent dye propidium iodide (PI) to 
evaluate cell viability (Cater et al. 2007). PI can enter through damaged plasma 
membranes and on binding to nuclear DNA becomes intensely fluorescent. PI 
viability examinations were not carried out in this study.  
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IMARIS characterisation of organotypic slices was difficult due to the thickness 
of the organotypic tissues. Thicker slices were difficult to image on the confocal 
and low resolution tiled images obtained could not be analysed accurately in 
IMARIS. Additionally, mounting tissues on glass slides resulted in producing 
irregular plains of view which could not be imaged by confocal microscopy. 
Careful mounting and replacing standard slides with concave mounting slides 
reduced these complications to an extent. Capturing Z stack confocal images 
of organotypic slices also improved IMARIS analysis of cultures however, this 
was a timely and costly process. An alternative method of tissue processing 
using a microtome (Au - Brachmann and Au - Tucker 2011) produces thinner 
slices which could be easily imaged after immunolabelling by confocal 
microscopy, therefore improving the quality of images obtained for IMARIS 
analysis, and this method could be used in future studies. IMARIS analysis of 
Z stacked hippocampal slice images showed slices were surrounded by an 
envelope of astrocytic cells. These glial scars inflicted by tissue processing as 
a result of astrocyte activation and proliferation were unavoidable and 
presented a physical astrocytic barrier which would be difficult to penetrate for 
future challenge experiments involving the addition of recombinant PrP fibrils 
to the brain slices. Additionally, microglial cells appeared hypertrophic (Figure 
8.5) indicating these glial cells were also responding to cellular damage 
induced by tissue processing. Astrocytes and microglia are known to respond 
to CNS damage in the form of increased proliferation at the site of injury (Hill 
et al. 2014). This response was a limiting factor of the slice culture method and 
for this particular study it would be difficult to distinguish between glial 
response associated with tissue processing and that associated with fibril 
challenge.  
 
 
 
 
 
270 
 
The development of organotypic brain slice cultures has revolutionized many 
experimental studies and has provided many suitable models for studying  
neuronal injury (Yu and Barclay Morrison 2010), neuronal protection (Noraberg 
et al. 2005; McKinney et al. 1997), oligodendrocyte differentiation (Hill et al. 
2014) and stroke (McManus et al. 2004; Kristensen, Noraberg, and Zimmer 
2001). In the majority of these studies however, brain slices used were 
maintained in culture for short periods of time, for example, oligodendrocyte 
studies used slices cultured for 5-7 days (Hill et al. 2014); neuronal protection 
studies used 14 day old cultures (McKinney et al. 1997) and neuronal injury 
studies used 22 day old slices (Yu and Barclay Morrison 2010). These data 
suggest maintaining BOSCs over a shorter timeframe may be advantageous 
for carrying out some experimental studies and this observation was already 
concluded based on results shown in Figure 8.6.  
 
In conclusion, organotypic brain slice culturing of hippocampal slices may be 
advantageous for culturing tissue slices over very short periods of time 
however, not for prolonged incubation periods. A combination of experimental 
findings described in this chapter including, neuronal degradation, tissue 
stretching, astrocytic scarring, microglial activation, technicalities of mounting 
and cost of Z stack imaging emphasised that BOSCs did not provide a suitable 
in vitro model system for studying abnormal protein interactions. The method 
described in this chapter could be developed and optimised further however, 
due to time constraints this was not a feasible option. Additionally, primary 
hippocampal neuronal cultures described in Chapter 3 provided a suitable 
alternative in vitro model for studying cellular interactions after fibril challenge, 
therefore, for the overall aims of this thesis primary hippocampal neuronal 
cultures were be the only in vitro system used for fibril challenge experiments. 
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Appendices 
 
Figure 3.a: B27 supplemented media supported neuronal viability, and minimal 
levels of LDH were found in 101LL cultures. Comparisons were carried out of 
two commercial media supplements, B27 and GS21 to ascertain which one 
would support better neuronal growth and viability. Additionally, LDH release 
was measured in 101LL cultures to monitor cellular viability over-time. (A) LDH 
was measured in the supernatant of primary cultures prepared from WT mice 
at 0, 3, 7 and 10 days in vitro (DIV) and was used to monitor cellular viability 
over-time using both supplements. (B) LDH was measured in the supernatant 
of primary cultures prepared from 101LL mice at 0, 3, 7 and 8 days in vitro 
(DIV). As shown in (A), at DIV10 GS21 supplement did not support long-term 
cellular viability in comparison to B27 based on LDH release readings 
therefore, B27 was used in future culture experiments. Cell viability was 
maintained in 101LL cultures up to DIV8 as shown in (B) however, cytotoxicity 
readings were elevated at DIV0. Individual sample readings also confirmed 
viability was reproducible in cultures. Fluorescent values were normalized to 
Triton X-100 treated lysis cells that represent the maximum amount of LDH 
available for release. WT and 101LL cells plated at 400,000 cells per well on 
PLL 6 well plate, Graph mean plus standard deviation, n=3 triplicate technical 
replicates, unpaired t test, P-Value <0.0001.  
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Figure 3.b: Primary cultures were viable up to 20 days in vitro. LDH analysis 
was used to explore stress levels associated with neuronal growth over an 
extended timeframe in culture. Cytotoxicity readings were elevated at DIV0 but 
then reduced and stabilised. A gradual increase in cytotoxicity from DIV10 up 
to DIV20 was occurring however approximately 84% of cells were still viable 
at this time point. Fluorescent values were normalized to Triton X-100 treated 
lysis cells that represent the maximum amount of LDH available for release. 
101LL cells plated at 150,000 cells per well on PDL/Fibronectin glass 
coverslips, Graph mean plus standard deviation, n=3 triplicate technical 
replicates, unpaired t test.  
 
 
 
Figure 3.c: PrPC abundance increased over-time in culture. To investigate if 
PrPC levels were increasing with neuronal development over-time, 
immunolabelling of cultures using a PrPC antibody was carried out at DIV3, 6, 
8, 10 and 16. Images show PrPC (7A12/White) immunolabelling amplified over-
time suggesting PrPC was increasing with neuronal developed. 101LL cultures 
1500,000 cells, plated on PDL/Fibronectin glass coverslips, Scale Bar 30µm.  
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Figure 3.d: Organelle associations were dominant with neuronal cell 
populations. To investigate if organelles essential for endolysosomal protein 
processing were detectable in cultures and to ascertain where these domains 
were located, dual-immunolabelling investigations were carried out. (A) Early 
endosomes (EEA1/Red), (B) Late endosomes (Rab9/Red) and (C) Lysosomes 
(LAMP1/Red) co-labelled with antibody for PrPC (6H4/White). (A1, B1, C1) 
Organelles plus  neuronal marker (MAP2/Green). Immunolabelling of neuronal 
populations confirmed majority of organelles were associated with these cell 
types. WT cultures, Scale bar 10µm, Zeiss LSM 710. 
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Figure 3.e: Monitoring stress levels in cultures lacking PrPC expression. LDH 
cytotoxicity assay was used to measure cellular stress levels of PrP-/- primary 
hippocampal cultures after challenge with increasing concentrations of H2O2 
(0, 10, 100, 300µM) to examine if PrPC was needed for neuroprotection. 
Culture supernatants were sampled at 0, 2, 4, 6 and 24hrs for LDH activity. 
Over 50% of cells were viable at 100µM H2O2 in PrP-/- primary hippocampal 
cultures indicating that PrPC may not be actively involved in neuroprotection 
as WT and 101LL cultures displayed a significant reduction in cell viability at 
these parameters (Figure 3.17). Fluorescent values were normalized to Triton 
X-100 treated lysis cells that represent the maximum amount of LDH available 
for release then the % of viable cells were calculated by % LDH release value 
minus 100. PrP-/- cells plated at 150,000 cells per well on PDL/Fibronectin 
glass coverslips, Graph mean plus standard deviation, n= 2 duplicate technical 
replicates. 
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Figure 4.a: Mass spectrometry confirmed recombinant PrP purity. Total Ion 
Current (TIC) histograms were plotted as intensity versus time (minutes) and 
full mass spectrum plot below as intensity versus m/z (mass-to-charge ratio). 
Data in TIC plot confirmed protein fraction was relatively pure and mass 
spectrum confirmed predicted PrP protein ion to mass profile was present.   
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Full Mass Spectrum of PrP 
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Figure 5.a: Fibrils did not induce cellular cytotoxicity after initial challenge. 
Immunolabelling using neuronal marker MAP2 was used to investigate if fibrils 
were inducing neurotoxicity in cultures. (A) Control unchallenged WT cultures 
stained with neuronal marker (MAP2/ Green) and (B) Challenged WT cultures 
after 6 hours. (C) IMARIS statistics based on intensity mean of MAP2 signal. 
No obvious neuronal changes were evident between unchallenged and 
challenged cultures and this observation was confirmed by IMARIS analysis 
which showed no significant differences (P-Value 0.48) were evident between 
both groups. WT cultures 30,000 cells, challenged with 7.5µg/ml WT fibrils for 
6 hours, Scale Bar 50µm. Graph mean plus standard deviation, n=3, n= data 
intensity sum of individual wells, unpaired t test. 
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Figure 5.b: Microglia response to fibril challenge. Immunolabelling was used 
to investigate if microglial cell morphology was changing in response to fibril 
insult. (A-B) Images showing complete microglial cell (CD11b/Green) and fibril 
(Red) interactions and (A1-A2; B1-B2) show enlarged images of WT and 
101LL microglia including PrPC (6H4/White) labelling. Microglia appeared to 
be in an activated state, based on immunolabelling results showing cell bodies 
were large and processes were short and thick, a phenotype correlated with 
microglial activation in response to neuronal injury. Enlarged images indicated 
microglial were associated with smaller sized fibrils suggesting phagocytosis 
may be occurring and this was evident in both genotypes. Cultures 75,000 
cells, challenged with 7.5µg/ml WT fibrils, Scale bar (A-B) 5µm, (A1-A2;         
B1-B2) 3µm, Confocal LSM710. 
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Figure 5.c: Limited fibrils were targeted to lipid-raft domains. To address 
possible routes of fibril internalisation into cells a marker for labelling lipid-rafts 
was used to investigate localisation of fibrils within these microdomains which 
would provide a viable route for fibril internalisation. (A, A1,A2) WT and            
(B, B1,B2) 101LL fibril-challenged cultures (WT Fibrils/Yellow) labelled with 
lipid-raft marker Cholera toxin Subunit B (Ctx/Green) and 6H4 (PrPC/White). 
Limited fibril localisation within these domains was evident in both genotypes 
suggesting this was not a main route of entry into cells. Cultures 75,000 cells, 
challenged with 7.5µg/ml WT fibrils, Scale bar 5µm, Confocal LSM710. 
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Figure 5.d: Fibrils were targeted to lysosomal organelles in astrocytes. To 
examine if fibrils were been targeted to lysosomal domains in glial cells for 
degradation, dual-labelling of astrocytic populations and lysosomal markers 
was carried out in WT challenged cultures. (A-A1) WT cultures challenged with 
WT fibrils (Yellow/Arrows), lysosomal marker LAMP1 (Red), astrocytes 
(GFAP/Green), PrPC (6H4/White) and DAPI (Nuclear/Blue). (A2-A3) IMARIS 
reconstructions of fibrils and organelle interactions. Fibril lysosomal 
interactions were evident in glial cells and IMARIS reconstruction confirmed 
fibrils were embedded in these acidic structures in WT cultures. Astrocytes 
appeared hypertrophic and therefore, were in an activated state. Assuming the 
neighbouring cell shown here is a neuron, astrocytes were internalising fibrils 
beside neuronal cell bodies suggesting a glial neuroprotective response was 
evident in WT cultures. WT Cultures 30,000 cells, challenged with 30µg/ml WT 
fibrils for 24-hours, Scale bar 5µm, Confocal LSM710. 
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Figure 5.e: Fibrils were targeted to lysosomes in WT cultures. To examine if 
fibrils were been trafficked to lysosomal domains, WT and 101LL cultures were 
labelled with a lysosomal marker to examine if lysosomal degradation 
pathways were operative in these genotypes. (A-B) WT and (C-D) 101LL 
cultures challenged with WT fibrils (Yellow), labelled with Lysosomal marker 
LAMP2 (Red), and DAPI (Nuclear/Blue). Lysosomal labelling in WT cultures 
showed WT fibrils were present in lysosomal acidic organelle domains, and 
this was not evident in 101LL cultures. WT and 101LL cultures 30,000 cells, 
challenged with 30µg/ml WT fibrils for 24-hours, Scale bar 10µm, Confocal 
LSM710. 
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Figure 5.f: Fibril challenge did not change detectable PrPC levels. Levels of 
normal PrPC in WT and 101LL cultures were compared using IMARIS software 
before and after fibril-challenged to investigate if conformational changes of 
the normal PrPC to the abnormal form was occurring. No significant differences 
in PrPC levels (based on 6H4 immunolabelling) were noted in either WT or 
101LL cultures suggesting no conformational changes were taking place within 
the 24-hour timeframe. WT and 101LL cultures 30,000 cells, challenged with 
30µg/ml WT fibrils for 24-hours. Graph mean plus standard deviation, WT 
minus fibrils n=9, WT plus fibrils n=21, 101LL minus fibrils n=6 and 101LL plus 
fibrils n=14, n= data intensity sum of individual wells, unpaired t test. 
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Figure 5.g: Fibril processing by autophagy was evident in WT challenged 
cultures. To ascertain if autophagy processing of fibrils was occurring in WT 
and 101LL cultures, the autophagosome marker p62 was used to label 
challenged cultures. (A-A1; B-B1) WT cultures challenged with 101L fibrils 
(Yellow), autophagosome marker p62 (Red) and DAPI (Blue). (C-C1) 101LL 
cultures challenged with 101L fibrils (Yellow/Arrows). Autophagosome labelling 
showed WT fibrils were present in these spherical structures however, no fibril 
associations were noted in 101LL cultures indicating an autophagy pathway 
was only activated in WT cultures. WT and 101LL cultures 30,000 cells, 
challenged with 30µg/ml 101L fibrils for 24 hours, Scale bar 10µm, Confocal 
LSM710. 
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Figure 6.a: Miru identified similar clusters of genes between in vivo and in vitro 
system comparisons, Cluster 025 (Green) 11 genes, Cluster 038 (Grey) 9 
genes, Cluster 041 (Brown) 9 genes and Cluster 067 (Maroon) 8 genes 
showed similar normalised expression intensity values across both systems 
and genotypes. GO enrichment (DAVID) for Cluster 025 identified protein 
transport, proteolysis, response to metal ion and lipid metabolic processes, 
Cluster 038 enrichment was associated with protein targeting to mitochondria, 
intracellular protein transport, tumor necrosis factor-mediated signalling 
pathway, Cluster 041 was enriched for proteolysis, G-protein coupled receptor 
signalling pathway, myeloid cell differentiation and Cluster 067 was enriched 
for cell surface receptor signalling pathway, actin cytoskeleton organisation, 
regulation of canonical Wnt signalling pathway. Normalised expression 
intensity values are shown on the y axis. 
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Figure 6.b: Heatmap showing ANOVA P-Values for the association between 
principal components and categorical experimental variables. Where different 
values of categorical variables (e.g. different treatment conditions) are 
associated with large changes in the data, these P-Values are expected to be 
significant for early components responsible for large proportions of variance. 
 
 
Contrast  
 
Gene  
 
LogFC  
 
P-Value 
 
FDR 
Unchallenged 101LL 
vs WT 
 
Tnfaip2 
Tgfbi 
 
2.30 
3.91 
 
3.51E-06 
4.15E-06 
0.02 
0.02 
WT Plus Fibrils vs 
WT 
 
Tnfaip2 
Tgfbi 
0.81 
2.65 
 
0.11 
0.0001 
0.11 
0.002 
101LL Plus Fibrils vs 
101LL 
Tnfaip2 
Tgfbi 
-1.06 
-1.01 
 
0.0007 
0.08 
0.02 
0.24 
 
Table 6.a: RNA-seq analysis identified two DEGs in unchallenged 101LL vs 
WT comparison namely Tnfaip2 and Tgfbi, which showed an increase in 
expression in 101LL cultures. After challenge, Tnfaip2 expression was 
significantly reduced in 101LL cultures and Tgfbi expression was significantly 
increased in WT cultures. Tgfbi and Tnfaip2 expression was reduced in 101LL 
and WT challenged cultures however, this observation was not significant.  
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Figure 6.c: Prnp expression profile showed this gene was highly variable in 
unchallenged and challenged 101LL cultures (purple and green) and was 
highly consistent in unchallenged and challenged WT cultures (pink and 
orange). Expression increased subtly but significantly in challenged WT 
cultures (LogFC 0.20, P-Value 0.004, FDR 0.02) after fibril challenge and no 
significant changes in were noted in 101LL challenged cultures (LogFC -0.33, 
P-Value 0.36, FDR 0.59).  
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DAVID GO enrichment 
(Biological Process Cluster 
0073) 
Gene Count P-Value Benjamini 
Phosphorylation 6 2.6E-3 4.7E-1 
Protein phosphorylation 5 1.3E-2 7.9E-1 
Negative regulation of axon 
extension 
2 3.2E-2 9.2E-1 
Protein autophosphorylation 3 3.5E-2 8.8E-1 
Antigen processing and 
presentation 
2 8.3E-2 9.8E-1 
 
DAVID GO enrichment 
(Biological Process) 
Gene Count P-Value Benjamini 
Ion transmembrane transport 2 4.3E-2 9.9E-1 
Response to stimulus 2 5.8E-2 9.7E-1 
 
Figure 6.d: Miru identified genes clusters specific to 101LL response to         
fibril challenge. Cluster 0073 was identified and genes associated with this 
cluster were predominantly up-regulated in 101LL fibril challenge cultures in 
comparison to other groups. Cluster 0128 showed the opposite result and were 
only down-regulated in 101LL fibril challenge cultures. Readings based on 
mean counts per million (normalised expressed intensity values). Class viewer 
scaling was raw, class plot was mean line. GO enrichment for Cluster 0073 
(48 genes) using DAVID showed challenged cultures were associated with 
only five biological processes, and top two were related to phosphorylation. 
Genes associated with phosphorylation were Flt3, Ak8, Camk1g, Cdk5, Cdkl3 
and Mapk15. GO enrichment for Cluster 0128 (33 DEGs) using DAVID showed 
response to stimulus (Asic3 and Stat1) which was previously shown to be 
associated with down-regulated genes in 101LL challenged cultures.  
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DAVID GO enrichment 
(Biological Process Cluster 
0001) 
Gene count P-Value Benjamini 
Glycolytic process - chemical 
reactions resulting in the 
breakdown of a carbohydrate into 
pyruvate 
13 1.3E-9 2.8E-6 
Gluconeogenesis - formation of 
glucose from noncarbohydrate 
precursors, such as pyruvate, 
amino acids and glycerol 
9 1.6E-6 1.7E-3 
Metabolic process 37 3.7E-6 2.8E-3 
Chemical synaptic transmission 19 2.4E-5 1.3E-2 
Apoptotic process 38 1.4E-4 5.9E-2 
Carbohydrate metabolic process 19 2.5E-4 8.8E-2 
 
Figure 6.e: Miru identified generic gene clusters in response to fibril challenge. 
Cluster0001 and 0002 were identified in Miru and genes associated with 
these clusters were up-regulated in both WT and 101LL fibril-challenged 
cultures in comparison to untreated cells. Readings based on mean counts per 
million (normalised expressed intensity values). Class viewer scaling was 
raw, class plot was mean line. GO enrichment for Cluster 0001 (791 genes) 
using DAVID showed glycolytic process to be a top hit. GO enrichment for 
Cluster 0002 (263 genes) showed challenged cultures were associated with 
response to stimulus. 
DAVID GO enrichment 
(Biological Process 0002) 
Gene count P-Value Benjamini 
Response to mechanical stimulus 6 5.6E-4 4.3E-1 
Cellular amino acid biosynthetic 
process 
4 2.3E-3 6.9E-1 
Response to drug 11 3.6E-3 7.0E-1 
Apoptotic process 5 5.7E-3 7.6E-1 
tRNA aminoacylation from protein 
translation 
4 6.6E-3 7.4E-1 
Nervous system development 10 2.0E-2 9.7E-1 
